PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 16581019-7 2006 Furthermore, the inhibition of KCC2 function with furosemide directly induced EPSP-spike (E-S) potentiation, an important component of LTP in hippocampus. Furosemide 50-60 solute carrier family 12 member 5 Rattus norvegicus 31-35 16303857-7 2006 The increase in PRC caused by an intraperitoneal injection of furosemide (40 mg/kg) was comparable in WT and A1AR-/- mice, and it was accompanied by similar transient increases in blood pressure, heart rate, and activity. Furosemide 62-72 adenosine A1 receptor Mus musculus 109-113 16675646-0 2006 Visual compatibility of furosemide with phenylephrine and vasopressin. Furosemide 24-34 arginine vasopressin Homo sapiens 58-69 16612254-6 2006 RESULTS: Placental production of IL-10 was not affected by clonidine, but decreased significantly after incubation of the tissue with diazoxide, hydralazine or furosemide. Furosemide 160-170 interleukin 10 Homo sapiens 33-38 16628676-2 2006 The objective of this work was to study, in rats with acute extrahepatic cholestasis, the cortical renal expression of the organic anion transporter 1 (OAT1) and the organic anion transporter 3 (OAT3), in association with the pharmacokinetics and renal excretion of furosemide (FS). Furosemide 278-280 solute carrier family 22 member 6 Rattus norvegicus 123-150 16628676-2 2006 The objective of this work was to study, in rats with acute extrahepatic cholestasis, the cortical renal expression of the organic anion transporter 1 (OAT1) and the organic anion transporter 3 (OAT3), in association with the pharmacokinetics and renal excretion of furosemide (FS). Furosemide 278-280 solute carrier family 22 member 6 Rattus norvegicus 152-156 16628676-2 2006 The objective of this work was to study, in rats with acute extrahepatic cholestasis, the cortical renal expression of the organic anion transporter 1 (OAT1) and the organic anion transporter 3 (OAT3), in association with the pharmacokinetics and renal excretion of furosemide (FS). Furosemide 278-280 solute carrier family 22 member 8 Rattus norvegicus 166-193 16628676-2 2006 The objective of this work was to study, in rats with acute extrahepatic cholestasis, the cortical renal expression of the organic anion transporter 1 (OAT1) and the organic anion transporter 3 (OAT3), in association with the pharmacokinetics and renal excretion of furosemide (FS). Furosemide 278-280 solute carrier family 22 member 8 Rattus norvegicus 195-199 16628676-12 2006 In conclusion, acute obstructive jaundice is associated with an upregulation of OAT1 and OAT3, which might explain, at least in part, the increased systemic and renal elimination of FS. Furosemide 182-184 solute carrier family 22 member 6 Rattus norvegicus 80-84 16628676-12 2006 In conclusion, acute obstructive jaundice is associated with an upregulation of OAT1 and OAT3, which might explain, at least in part, the increased systemic and renal elimination of FS. Furosemide 182-184 solute carrier family 22 member 8 Rattus norvegicus 89-93 16612254-8 2006 There was a stepwise reduction in production of TNF-alpha and IL-6 with increasing doses of diazoxide, hydralazine and furosemide by placentas and PBMCs from these women with normal pregnancies. Furosemide 119-129 tumor necrosis factor Homo sapiens 48-57 16612254-8 2006 There was a stepwise reduction in production of TNF-alpha and IL-6 with increasing doses of diazoxide, hydralazine and furosemide by placentas and PBMCs from these women with normal pregnancies. Furosemide 119-129 interleukin 6 Homo sapiens 62-66 16612254-9 2006 CONCLUSION: Our data suggest that the antihypertensive drugs clonidine and hydralazine can stimulate production of the circulating anti-inflammatory cytokine IL-10, whereas furosemide and diazoxide inhibit the production of this cytokine and the proinflammatory cytokines TNF-alpha and IL-6 by placentas and PBMCs. Furosemide 173-183 tumor necrosis factor Homo sapiens 272-281 16612254-9 2006 CONCLUSION: Our data suggest that the antihypertensive drugs clonidine and hydralazine can stimulate production of the circulating anti-inflammatory cytokine IL-10, whereas furosemide and diazoxide inhibit the production of this cytokine and the proinflammatory cytokines TNF-alpha and IL-6 by placentas and PBMCs. Furosemide 173-183 interleukin 6 Homo sapiens 286-290 16106034-1 2005 Acute administration of loop diuretics like furosemide leads to a stimulation of renin secretion, an effect thought to result from inhibition of Na-K-2Cl cotransporter (NKCC2)-mediated salt transport at the luminal surface of the macula densa (MD). Furosemide 44-54 solute carrier family 12, member 1 Mus musculus 169-174 16222701-1 2006 In this study, we demonstrated that the specific inhibitors of the Na+/K+/Cl- cotransporter (NKCC1), bumetanide and furosemide, inhibited extracellular regulated kinase (ERK) phosphorylation in Balb/c 3T3 fibroblasts, stimulated with a variety of mitogens. Furosemide 116-126 mitogen-activated protein kinase 1 Homo sapiens 138-168 16222701-1 2006 In this study, we demonstrated that the specific inhibitors of the Na+/K+/Cl- cotransporter (NKCC1), bumetanide and furosemide, inhibited extracellular regulated kinase (ERK) phosphorylation in Balb/c 3T3 fibroblasts, stimulated with a variety of mitogens. Furosemide 116-126 mitogen-activated protein kinase 1 Homo sapiens 170-173 16222701-5 2006 Several additional lines of evidence supported the above conclusion: (i) furosemide inhibits phosphorylation of MAPK kinase (MEK) induced by receptor tyrosine kinase (RTK) ligands, such as PDGF, FGF, and EGF. Furosemide 73-83 mitogen-activated protein kinase kinase 7 Homo sapiens 125-128 16222701-5 2006 Several additional lines of evidence supported the above conclusion: (i) furosemide inhibits phosphorylation of MAPK kinase (MEK) induced by receptor tyrosine kinase (RTK) ligands, such as PDGF, FGF, and EGF. Furosemide 73-83 ret proto-oncogene Homo sapiens 141-165 16222701-5 2006 Several additional lines of evidence supported the above conclusion: (i) furosemide inhibits phosphorylation of MAPK kinase (MEK) induced by receptor tyrosine kinase (RTK) ligands, such as PDGF, FGF, and EGF. Furosemide 73-83 ret proto-oncogene Homo sapiens 167-170 16222701-5 2006 Several additional lines of evidence supported the above conclusion: (i) furosemide inhibits phosphorylation of MAPK kinase (MEK) induced by receptor tyrosine kinase (RTK) ligands, such as PDGF, FGF, and EGF. Furosemide 73-83 epidermal growth factor Homo sapiens 204-207 16222701-6 2006 (ii) Furosemide also inhibited ERK phosphorylation, induced by thrombin, a GPCR. Furosemide 5-15 mitogen-activated protein kinase 1 Homo sapiens 31-34 16222701-6 2006 (ii) Furosemide also inhibited ERK phosphorylation, induced by thrombin, a GPCR. Furosemide 5-15 coagulation factor II, thrombin Homo sapiens 63-71 16222701-7 2006 (iii) Furosemide inhibited MEK and ERK phosphorylation even when ERK phosphorylation was induced by direct activation of protein kinase C (PKC) by TPA, which bypasses early steps of the mitogenic cascade. Furosemide 6-16 mitogen-activated protein kinase kinase 7 Homo sapiens 27-30 16222701-7 2006 (iii) Furosemide inhibited MEK and ERK phosphorylation even when ERK phosphorylation was induced by direct activation of protein kinase C (PKC) by TPA, which bypasses early steps of the mitogenic cascade. Furosemide 6-16 mitogen-activated protein kinase 1 Homo sapiens 35-38 16222701-7 2006 (iii) Furosemide inhibited MEK and ERK phosphorylation even when ERK phosphorylation was induced by direct activation of protein kinase C (PKC) by TPA, which bypasses early steps of the mitogenic cascade. Furosemide 6-16 mitogen-activated protein kinase 1 Homo sapiens 65-68 16464787-0 2006 Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure. Furosemide 55-65 aquaporin 2 Homo sapiens 18-29 16464787-4 2006 We tested the hypothesis that U-AQP2 increases after a single intravenous dose of furosemide in CHF patients. Furosemide 82-92 aquaporin 2 Homo sapiens 32-36 16464787-8 2006 RESULTS: Furosemide increased U-AQP2 (140 %), urine volume (280 %), C(H2O) (95 %) and FE(Na) by a factor of 15 (p<0.008 for all), and also AVP (51 %), PRC, Ang II (86 %) and Aldo (59 %) (p<0.021 for all). Furosemide 9-19 aquaporin 2 Homo sapiens 32-36 16464787-8 2006 RESULTS: Furosemide increased U-AQP2 (140 %), urine volume (280 %), C(H2O) (95 %) and FE(Na) by a factor of 15 (p<0.008 for all), and also AVP (51 %), PRC, Ang II (86 %) and Aldo (59 %) (p<0.021 for all). Furosemide 9-19 angiotensinogen Homo sapiens 159-165 16464787-10 2006 CONCLUSIONS: In CHF, furosemide increased the vasopressin level, which stimulated water reabsorption via the APQ2 water channels. Furosemide 21-31 arginine vasopressin Homo sapiens 46-57 16531376-4 2006 Furosemide was considered appropriate when the primary or secondary ED or hospital diagnoses included congestive heart failure (CHF) or pulmonary edema, or the BNP was > 400. Furosemide 0-10 natriuretic peptide B Homo sapiens 160-163 16452663-8 2006 Bumetanide and furosemide, which inhibit Cl- influx through the Na(+)-K(+)-Cl- cotransporter isoform-1 (NKCC-1) and efflux through the K(+)-Cl- cotransporter isoform-2, were unable to inhibit the first rise in [Cl-]i, yet entirely prevented the secondary rise in [Cl-]i during reoxygenation. Furosemide 15-25 solute carrier family 12, member 2 Mus musculus 64-102 16452663-8 2006 Bumetanide and furosemide, which inhibit Cl- influx through the Na(+)-K(+)-Cl- cotransporter isoform-1 (NKCC-1) and efflux through the K(+)-Cl- cotransporter isoform-2, were unable to inhibit the first rise in [Cl-]i, yet entirely prevented the secondary rise in [Cl-]i during reoxygenation. Furosemide 15-25 solute carrier family 12, member 2 Mus musculus 104-110 16715419-6 2006 The bleeding volume, homologous blood transfusion volume, furosemide dose, and corrected KCl volume were all significantly less in the hANP group. Furosemide 58-68 natriuretic peptide A Homo sapiens 135-139 16239278-7 2005 Furosemide (100 microm), a pharmacological compound known to block the activity of the neurone-specific K(+)-Cl- cotransporter, KCC2, reversed IPSC polarity and shifted E(IPSC) towards its theoretical value. Furosemide 0-10 solute carrier family 12 member 5 Rattus norvegicus 128-132 16412259-6 2005 The established cell line (NE-MD) showed a time-dependent increase in signals of the nNOS protein when they were incubated with 12 microM furosemide (an inhibitor of Na(+)-K(+)-2Cl(-) symporter) for 5 h. In conclusion, this newly developed macula densa cell line will be useful in studies of the TGF stem. Furosemide 138-148 nitric oxide synthase 1, neuronal Mus musculus 85-89 15976003-0 2005 Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. Furosemide 50-60 prostaglandin E receptor 4 (subtype EP4) Mus musculus 34-37 16157691-4 2005 In the current work, we provide additional insight in these regards by showing in mouse that the administration of either furosemide or an H(2)O-rich diet, which are predicted to alter NKCC2 expression in the TAL, exerts differential effects on mRNA levels for the variants, increasing those of A (furosemide) but decreasing those of F and AF (furosemide or H(2)O). Furosemide 122-132 solute carrier family 12, member 1 Mus musculus 185-190 16157691-4 2005 In the current work, we provide additional insight in these regards by showing in mouse that the administration of either furosemide or an H(2)O-rich diet, which are predicted to alter NKCC2 expression in the TAL, exerts differential effects on mRNA levels for the variants, increasing those of A (furosemide) but decreasing those of F and AF (furosemide or H(2)O). Furosemide 122-132 talipes Mus musculus 209-212 16157691-4 2005 In the current work, we provide additional insight in these regards by showing in mouse that the administration of either furosemide or an H(2)O-rich diet, which are predicted to alter NKCC2 expression in the TAL, exerts differential effects on mRNA levels for the variants, increasing those of A (furosemide) but decreasing those of F and AF (furosemide or H(2)O). Furosemide 298-308 solute carrier family 12, member 1 Mus musculus 185-190 16157691-4 2005 In the current work, we provide additional insight in these regards by showing in mouse that the administration of either furosemide or an H(2)O-rich diet, which are predicted to alter NKCC2 expression in the TAL, exerts differential effects on mRNA levels for the variants, increasing those of A (furosemide) but decreasing those of F and AF (furosemide or H(2)O). Furosemide 298-308 solute carrier family 12, member 1 Mus musculus 185-190 16011733-7 2005 In treated group: cardiac dimensions were reduced with left ventricular fractional shortening significantly increased in combination group (from 22.4 to 28%); captopril + furosemide animals had highest heart rate and lowest systolic and diastolic blood pressures; body and heart weight were reduced, but kidney weight was significantly increased with furosemide (1.7 g in control vs. 2 g in capto + furo); plasma renin activity and angiotensin 1 were greatly increased, and moderately stimulated in control. Furosemide 171-181 renin Rattus norvegicus 413-418 15917300-9 2005 Treatment of the gland with furosemide, a blocker of the NKCC1 cotransporter, reduced the plateau phase of fluid flow by approximately 30%. Furosemide 28-38 solute carrier family 12, member 2 Mus musculus 57-62 15917300-13 2005 Blocking NKCC1 with furosemide reduced the amount of shrinkage by approximately 50%. Furosemide 20-30 solute carrier family 12, member 2 Mus musculus 9-14 16174750-5 2005 In Atp6v1b1(-/-) mice, the normal urinary acidification induced by a lumen-negative potential in response to furosemide infusion is abolished. Furosemide 109-119 ATPase, H+ transporting, lysosomal V1 subunit B1 Mus musculus 3-11 15961422-11 2005 Together with the earlier evidence on the dependence of post-furosemide medullary hypoperfusion on angiotensin II, the study exposes its interaction with PG in the control of medullary circulation. Furosemide 61-71 angiotensinogen Rattus norvegicus 99-113 15937522-4 2005 Everolimus also attenuated the stimulation of renocortical COX-2 expression by furosemide (12 mg day(-1) for 7 days; s.c. via osmotic minipumps), by low salt intake (0.02% NaCl, wt wt(-1)) or by a combination of low salt intake with the AT(1)-receptor antagonist valsartan (30 mg kg(-1) day(-1); oral). Furosemide 79-89 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 59-64 15967872-2 2005 Furosemide-induced diuresis and acute oral captopril stimulated the renal vein/contralateral renin ratios to 4.3:1 and 6.5:1 in patients 1 and 2, respectively. Furosemide 0-10 renin Homo sapiens 93-98 15976003-10 2005 The furosemide-induced increase in plasma renin concentration was significantly decreased in EP4-/- mice and to a lesser degree also in IP-/- mice. Furosemide 4-14 prostaglandin E receptor 4 (subtype EP4) Mus musculus 93-96 15976003-11 2005 Pharmacologic inhibition of EP4 receptors in furosemide-treated WT mice with the specific antagonist ONO-AE3-208 mimicked the changes in renin mRNA expression, plasma renin concentration, diuresis, and sodium excretion seen in EP4-/- mice. Furosemide 45-55 prostaglandin E receptor 4 (subtype EP4) Mus musculus 28-31 15976003-11 2005 Pharmacologic inhibition of EP4 receptors in furosemide-treated WT mice with the specific antagonist ONO-AE3-208 mimicked the changes in renin mRNA expression, plasma renin concentration, diuresis, and sodium excretion seen in EP4-/- mice. Furosemide 45-55 prostaglandin E receptor 4 (subtype EP4) Mus musculus 227-230 15528393-8 2005 Sodium depletion with furosemide and low-sodium diet produced a strong sodium appetite and induced Fos-ir in SFO and MnPO. Furosemide 22-32 FBJ osteosarcoma oncogene Mus musculus 99-102 15912074-0 2005 The effect of furosemide infusion on serum epidermal growth factor concentration after acute lung injury. Furosemide 14-24 epidermal growth factor Homo sapiens 43-66 15912074-4 2005 The current study was undertaken to clarify whether furosemide attenuates the inflammatory response by changing the epidermal growth factor level in patients with acute lung injury. Furosemide 52-62 epidermal growth factor Homo sapiens 116-139 15952020-5 2005 Compared with reported plasma concentration achieved during treatment, only furosemide would have the potential to inhibit TPMT also in vivo, whereas the IC50 values of the other agents are far above the corresponding plasma levels. Furosemide 76-86 thiopurine S-methyltransferase Homo sapiens 123-127 15952020-6 2005 CONCLUSIONS: Our ex vivo study revealed that only furosemide has the potential to inhibit TPMT activity in patients with IBD. Furosemide 50-60 thiopurine S-methyltransferase Homo sapiens 90-94 15977143-3 2005 DRS "F-0" was started after intravenous administration of diethylene-triamine- pentaacetic acid (DTPA) mixed with furosemide. Furosemide 114-124 sushi repeat containing protein X-linked Homo sapiens 0-3 15656876-6 2005 Per 40 mg day(-1) of furosemide, urinary calcium was increased by 17% (P < 0.05) and plasma PTH levels were increased by 28% (P = 0.04). Furosemide 21-31 parathyroid hormone Homo sapiens 95-98 15623552-7 2005 Treatment with furosemide, which decreases inner-medullary NaCl, reduces inner-medullary Pax2 mRNA and protein. Furosemide 15-25 paired box 2 Mus musculus 89-93 16095054-0 2005 Urinary excretion of aquaporin-2 after furosemide and felodipine in healthy humans. Furosemide 39-49 aquaporin 2 Homo sapiens 21-32 16095054-5 2005 We sought to test the hypotheses that urinary excretion of aquaporin-2 (U-AQP2) increases after a single intravenous dose of furosemide, and that U-AQP2 decreases after a single oral dose of felodipine. Furosemide 125-135 aquaporin 2 Homo sapiens 59-70 16095054-17 2005 CONCLUSIONS: Furosemide treatment increased U-AQP2, AVP, and the activity of the renin-angiotensin-aldosterone system. Furosemide 13-23 aquaporin 2 Homo sapiens 46-50 16095054-5 2005 We sought to test the hypotheses that urinary excretion of aquaporin-2 (U-AQP2) increases after a single intravenous dose of furosemide, and that U-AQP2 decreases after a single oral dose of felodipine. Furosemide 125-135 aquaporin 2 Homo sapiens 74-78 16095054-17 2005 CONCLUSIONS: Furosemide treatment increased U-AQP2, AVP, and the activity of the renin-angiotensin-aldosterone system. Furosemide 13-23 renin Homo sapiens 81-86 16095054-10 2005 RESULTS: Furosemide treatment increased U-AQP2 (202%), urine volume (214%), and FENa by a factor of 11, (p < 0.001 for all), whereas CH2O and GFR were unchanged. Furosemide 9-19 aquaporin 2 Homo sapiens 42-46 16095054-12 2005 Furosemide treatment increased AVP (18%), PRC (60%), ang II (100%), and aldo (98%) (p < 0.032); ANP was decreased by 29% (p < 0.001), whereas there was no change in BNP. Furosemide 0-10 angiotensinogen Homo sapiens 53-59 16095054-12 2005 Furosemide treatment increased AVP (18%), PRC (60%), ang II (100%), and aldo (98%) (p < 0.032); ANP was decreased by 29% (p < 0.001), whereas there was no change in BNP. Furosemide 0-10 natriuretic peptide B Homo sapiens 171-174 15175220-3 2004 Using exogenously expressed KCC2 protein, we first examined the interaction of cations at the transport site of KCC2 by monitoring furosemide-sensitive (86)Rb(+) influx as a function of external Rb(+) concentration at different fixed external cation concentrations (Na(+), Li(+), K(+), Cs(+), and NH(4)(+)). Furosemide 131-141 solute carrier family 12 member 5 Homo sapiens 112-116 15564765-8 2004 The abundance of NKCC2 and NCC is increased by furosemide and hydrochlorothiazide, respectively. Furosemide 47-57 solute carrier family 12 member 1 Homo sapiens 17-22 15564765-8 2004 The abundance of NKCC2 and NCC is increased by furosemide and hydrochlorothiazide, respectively. Furosemide 47-57 solute carrier family 12 member 3 Homo sapiens 27-30 15564765-10 2004 In the proximal tubule, the abundance of OAT1 is increased by chronic treatment with furosemide or hydrochlorothiazide. Furosemide 85-95 solute carrier family 22 member 6 Homo sapiens 41-45 15175220-10 2004 Consistent with KCC2-mediated NH(4)(+) transport, pH(i) recovery in KCC2-expressing cells could be inhibited by furosemide (200 microM) or removal of external [Cl(-)]. Furosemide 112-122 solute carrier family 12 member 5 Homo sapiens 16-20 15175220-3 2004 Using exogenously expressed KCC2 protein, we first examined the interaction of cations at the transport site of KCC2 by monitoring furosemide-sensitive (86)Rb(+) influx as a function of external Rb(+) concentration at different fixed external cation concentrations (Na(+), Li(+), K(+), Cs(+), and NH(4)(+)). Furosemide 131-141 solute carrier family 12 member 5 Homo sapiens 28-32 15175220-10 2004 Consistent with KCC2-mediated NH(4)(+) transport, pH(i) recovery in KCC2-expressing cells could be inhibited by furosemide (200 microM) or removal of external [Cl(-)]. Furosemide 112-122 solute carrier family 12 member 5 Homo sapiens 68-72 15314687-7 2004 Amiloride or furosemide reduced BP in CD ET-1 KO mice on a normal or high-Na diet and prevented excessive Na retention in salt-loaded CD ET-1 KO mice. Furosemide 13-23 endothelin 1 Mus musculus 41-45 15450096-4 2004 Here we demonstrate that isolated CA1 neurons of these mice showed furosemide-sensitivity of GABA-evoked currents, confirming the functional expression of alpha6 subunit. Furosemide 67-77 carbonic anhydrase 1 Mus musculus 34-37 15364336-2 2004 BACKGROUND: Furosemide activates the renin-angiotensin-aldosterone system in patients with congestive heart failure (CHF). Furosemide 12-22 renin Homo sapiens 37-42 15283765-6 2004 (4) cBS is caused by mutations in the chloride channel ClC-Kb with similar clinical characteristics as seen under combination of thiazides and furosemide, (5) GS is caused by mutations in the thiazide-sensitive sodium-chloride cotransporter NCCT resembling the effect of long-term thiazide administration. Furosemide 143-153 chloride voltage-gated channel Kb Homo sapiens 55-61 15283765-7 2004 CONCLUSION: The combination of pharmacology and genetics suggests a new terminology for the above described SLTs: Furosemide-like-SLT for HPS caused by NKCC2-mutations, furosemide/amiloride-like-SLT for HPS caused by ROMK-mutations, furosemide/thiazide-like-SLT for HPS + SND, thiazide/furosemide-like-SLT for cBS, and thiazide-like-SLT for GS. Furosemide 114-124 solute carrier family 12 member 1 Homo sapiens 152-157 15283765-7 2004 CONCLUSION: The combination of pharmacology and genetics suggests a new terminology for the above described SLTs: Furosemide-like-SLT for HPS caused by NKCC2-mutations, furosemide/amiloride-like-SLT for HPS caused by ROMK-mutations, furosemide/thiazide-like-SLT for HPS + SND, thiazide/furosemide-like-SLT for cBS, and thiazide-like-SLT for GS. Furosemide 114-124 potassium inwardly rectifying channel subfamily J member 1 Homo sapiens 217-221 15314687-7 2004 Amiloride or furosemide reduced BP in CD ET-1 KO mice on a normal or high-Na diet and prevented excessive Na retention in salt-loaded CD ET-1 KO mice. Furosemide 13-23 endothelin 1 Mus musculus 137-141 15223304-5 2004 Furosemide, which inhibits the NKCC-1 and KCC2 cotransporters, and bumetanide, a more specific NKCC-1 inhibitor, enhanced ATP recovery when measured 3 h after OGD. Furosemide 0-10 solute carrier family 12 member 2 Homo sapiens 31-37 15223304-5 2004 Furosemide, which inhibits the NKCC-1 and KCC2 cotransporters, and bumetanide, a more specific NKCC-1 inhibitor, enhanced ATP recovery when measured 3 h after OGD. Furosemide 0-10 solute carrier family 12 member 5 Homo sapiens 42-46 15223304-6 2004 Furosemide and bumetanide also attenuated area CA1 neuronal injury after OGD. Furosemide 0-10 carbonic anhydrase 1 Homo sapiens 47-50 15023890-0 2004 Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Furosemide 78-88 natriuretic peptide B Canis lupus familiaris 0-25 15149320-8 2004 In contrast, rofecoxib attenuated the furosemide-induced rise of PRA and of renin mRNA, both in the absence and in the presence of CsA. Furosemide 38-48 renin Rattus norvegicus 76-81 15149320-11 2004 Since the furosemide-induced stimulation of the renin system is not attenuated by CsA but by COX-2 inhibition, we speculate that extrarenal COX-2-derived prostanoids may be involved in the stimulation of the renin system by CsA and by loop diuretics. Furosemide 10-20 renin Rattus norvegicus 48-53 15149320-11 2004 Since the furosemide-induced stimulation of the renin system is not attenuated by CsA but by COX-2 inhibition, we speculate that extrarenal COX-2-derived prostanoids may be involved in the stimulation of the renin system by CsA and by loop diuretics. Furosemide 10-20 cytochrome c oxidase II, mitochondrial Rattus norvegicus 93-98 15149320-11 2004 Since the furosemide-induced stimulation of the renin system is not attenuated by CsA but by COX-2 inhibition, we speculate that extrarenal COX-2-derived prostanoids may be involved in the stimulation of the renin system by CsA and by loop diuretics. Furosemide 10-20 cytochrome c oxidase II, mitochondrial Rattus norvegicus 140-145 15149320-11 2004 Since the furosemide-induced stimulation of the renin system is not attenuated by CsA but by COX-2 inhibition, we speculate that extrarenal COX-2-derived prostanoids may be involved in the stimulation of the renin system by CsA and by loop diuretics. Furosemide 10-20 renin Rattus norvegicus 208-213 14985360-9 2004 Inhibition of insulin-induced swelling by furosemide largely abolished activation of beta(1) integrin and phosphorylation of Src, but not of PKB. Furosemide 42-52 insulin Homo sapiens 14-21 14985360-9 2004 Inhibition of insulin-induced swelling by furosemide largely abolished activation of beta(1) integrin and phosphorylation of Src, but not of PKB. Furosemide 42-52 SRC proto-oncogene, non-receptor tyrosine kinase Rattus norvegicus 125-128 15075186-8 2004 In furosemide-induced alkalotic rats, NBCn1 protein abundance was decreased in both the IM and inner stripe of outer medulla (ISOM) as determined by immunoblotting and immunohistochemistry. Furosemide 3-13 solute carrier family 4 member 7 Rattus norvegicus 38-43 15089816-12 2004 Non-adherence with furosemide was less common among those who died and appeared to occur at different time points from non-adherence with ACE inhibitor treatment, which was slightly more common in all outcome groups. Furosemide 19-29 angiotensin I converting enzyme Homo sapiens 138-141 15023890-0 2004 Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Furosemide 52-62 natriuretic peptide B Canis lupus familiaris 0-25 15180925-7 2004 Despite the abrogation of glomerular filtration, detected by inulin clearance measurements, renocortical COX-2 mRNA abundance was stimulated by furosemide treatment (3.2-fold) or low-salt diet (2.9-fold) to similar degrees compared with the intact contralateral kidney (2.7-fold for both treatments), whereas a high-salt diet did not significantly suppress COX-2 mRNA in the macula densa region of either kidney. Furosemide 144-154 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 105-110 15180925-7 2004 Despite the abrogation of glomerular filtration, detected by inulin clearance measurements, renocortical COX-2 mRNA abundance was stimulated by furosemide treatment (3.2-fold) or low-salt diet (2.9-fold) to similar degrees compared with the intact contralateral kidney (2.7-fold for both treatments), whereas a high-salt diet did not significantly suppress COX-2 mRNA in the macula densa region of either kidney. Furosemide 144-154 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 357-362 15180925-8 2004 Renin mRNA expression was regulated strictly in parallel in both kidneys, a low-salt diet or furosemide treatment stimulating and a high-salt diet suppressing it. Furosemide 93-103 renin Rattus norvegicus 0-5 15149320-7 2004 Basal as well as furosemide-induced stimulation of plasma renin activity (PRA) and of renal renin mRNA was further enhanced by CsA. Furosemide 17-27 renin Rattus norvegicus 58-63 15149320-7 2004 Basal as well as furosemide-induced stimulation of plasma renin activity (PRA) and of renal renin mRNA was further enhanced by CsA. Furosemide 17-27 renin Rattus norvegicus 92-97 15086907-2 2004 We showed previously that parathyroidectomy protected against the development of furosemide-induced nephrocalcinosis in young rats, indicating a possible role for parathyroid hormone (PTH) in its pathogenesis. Furosemide 81-91 parathyroid hormone Rattus norvegicus 163-182 15023890-3 2004 The objective of this study was to test the hypothesis that exogenous BNP enhances the renal diuretic and natriuretic actions of furosemide (Fs) and retards the activation of aldosterone in a model of CHF. Furosemide 129-139 natriuretic peptide B Canis lupus familiaris 70-73 15023890-3 2004 The objective of this study was to test the hypothesis that exogenous BNP enhances the renal diuretic and natriuretic actions of furosemide (Fs) and retards the activation of aldosterone in a model of CHF. Furosemide 141-143 natriuretic peptide B Canis lupus familiaris 70-73 15023890-8 2004 Similarly, urinary sodium excretion was higher in the Fs+BNP group. Furosemide 54-56 natriuretic peptide B Canis lupus familiaris 57-60 15007654-3 2004 Contrastingly, we have shown earlier that the abundance of the major ion transporter of the TAL, the furosemide-sensitive Na-K-2Cl cotransporter (NKCC2) was increased when related to kidney function in the hypothyroid organism. Furosemide 101-111 solute carrier family 12 member 1 Rattus norvegicus 146-151 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 34-39 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 46-51 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 46-51 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 46-51 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 46-51 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 46-51 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 46-51 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 46-51 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 46-51 15039295-10 2004 Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence. Furosemide 407-417 solute carrier family 22 member 6 Homo sapiens 46-51 14610216-8 2004 hOAT1 and hOAT3, but not hOAT2 and hOAT4 mediated the uptake of furosemide. Furosemide 64-74 solute carrier family 22 member 6 Homo sapiens 0-5 15005740-0 2004 Investigation into the mechanisms by which nedocromil sodium, frusemide and bumetanide inhibit the histamine-induced itch and flare response in human skin in vivo. Furosemide 62-71 itchy E3 ubiquitin protein ligase Homo sapiens 117-121 15005740-8 2004 RESULTS: In study 1, nedocromil sodium, frusemide and bumetanide reduced itch scores by 36%, 48% and 34%, respectively, and flare areas by 17%, 26% and 15% respectively (all P<0.05). Furosemide 40-49 itchy E3 ubiquitin protein ligase Homo sapiens 73-77 15005740-12 2004 CONCLUSION: This study has provided evidence to support the hypothesis that nedocromil sodium, frusemide and bumetanide inhibit sensory nerve activation to reduce the itch and flare responses induced by histamine in human skin in vivo. Furosemide 95-104 itchy E3 ubiquitin protein ligase Homo sapiens 167-171 14684611-7 2004 Acute treatment with specific V1 or V2 receptor agonists resulted in specific increases in medullary COX-2, which was prevented by furosemide. Furosemide 131-141 cytochrome c oxidase II, mitochondrial Rattus norvegicus 101-106 14610216-8 2004 hOAT1 and hOAT3, but not hOAT2 and hOAT4 mediated the uptake of furosemide. Furosemide 64-74 solute carrier family 22 member 8 Homo sapiens 10-15 14592462-9 2003 Purified Na+/K+ ATPase only presented ouabain-induced phosphoprotein, indicating that furosemide-induced phosphorylation is not related to this enzyme and appears to correspond to a new member of P-type ATPases associated with the second Na+ pump. Furosemide 86-96 dynein axonemal heavy chain 8 Homo sapiens 16-22 14670634-1 2004 The present study investigates co-localization of AT(1A) receptor subtype and Fos protein in neuronal populations of the lamina terminalis (LT) that have been recruited during acute Na(+) and water depletion mediated by furosemide injections. Furosemide 220-230 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 78-81 14670634-3 2004 As expected, furosemide treatment dramatically increased the density of Fos-immunoreactive neuronal population in all the regions of the LT compared to control (saline-injected animals). Furosemide 13-23 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 72-75 14756687-9 2004 After high-dose furosemide, plasma renin activity increased in both groups of lambs, although the effects were greater in 1-week-old lambs. Furosemide 16-26 renin Ovis aries 35-40 14992282-7 2004 On the other hand, DIDS, furosemide, and bumetanide prevented CGC death induced by K5 and St. Furosemide 25-35 keratin 5 Homo sapiens 83-92 15489025-3 2004 Additionally, we investigated if moxonidine into the LPBN would modify furosemide+captopril-induced c-fos expression in the forebrain. Furosemide 71-81 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 100-105 12897087-0 2003 Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney. Furosemide 75-85 solute carrier family 22 member 6 Rattus norvegicus 17-44 14510783-7 2003 Facilitation by 100 pm Ang II was inhibited by 100 microm frusemide. Furosemide 58-67 angiotensinogen Homo sapiens 23-29 14507972-10 2003 This BDNF-induced effect correlates with the existing level of furosemide-sensitive K+-Cl- transport activity in the postsynaptic cell. Furosemide 63-73 brain-derived neurotrophic factor Rattus norvegicus 5-9 12759757-0 2003 Parallel down-regulation of chloride channel CLC-K1 and barttin mRNA in the thin ascending limb of the rat nephron by furosemide. Furosemide 118-128 chloride voltage-gated channel Ka Rattus norvegicus 45-51 12759757-0 2003 Parallel down-regulation of chloride channel CLC-K1 and barttin mRNA in the thin ascending limb of the rat nephron by furosemide. Furosemide 118-128 barttin CLCNK type accessory subunit beta Rattus norvegicus 56-63 12759757-2 2003 The aim of the present study was to investigate the influence of the loop diuretic furosemide on the gene expression of the kidney chloride channel ClC-K1 and its recently described functional subunit barttin. Furosemide 83-93 chloride voltage-gated channel Ka Rattus norvegicus 148-154 12759757-2 2003 The aim of the present study was to investigate the influence of the loop diuretic furosemide on the gene expression of the kidney chloride channel ClC-K1 and its recently described functional subunit barttin. Furosemide 83-93 barttin CLCNK type accessory subunit beta Rattus norvegicus 201-208 12759757-7 2003 In furosemide-treated rats ClC-K1 mRNA decreased to half in the inner medulla. Furosemide 3-13 chloride voltage-gated channel Ka Rattus norvegicus 27-33 12759757-9 2003 Under furosemide treatment barttin mRNA was regulated in parallel with ClC-K1 mRNA. Furosemide 6-16 barttin CLCNK type accessory subunit beta Rattus norvegicus 27-34 12759757-9 2003 Under furosemide treatment barttin mRNA was regulated in parallel with ClC-K1 mRNA. Furosemide 6-16 chloride voltage-gated channel Ka Rattus norvegicus 71-77 12759757-12 2003 Microdissection of the inner medullary collecting duct and thin limb of Henle"s loop followed by real-time PCR revealed that CLC-K1 and barttin mRNA regulation in inner medulla was limited to the thin limb; mRNA levels in collecting ducts were not affected by furosemide treatment. Furosemide 260-270 chloride voltage-gated channel Ka Rattus norvegicus 125-131 12759757-12 2003 Microdissection of the inner medullary collecting duct and thin limb of Henle"s loop followed by real-time PCR revealed that CLC-K1 and barttin mRNA regulation in inner medulla was limited to the thin limb; mRNA levels in collecting ducts were not affected by furosemide treatment. Furosemide 260-270 barttin CLCNK type accessory subunit beta Rattus norvegicus 136-143 12759757-13 2003 Our findings imply that during furosemide treatment selective down-regulation of ClC-K1 and barttin mRNAs in thin limb plays a role in maintaining salt and water homeostasis. Furosemide 31-41 chloride voltage-gated channel Ka Rattus norvegicus 81-87 12759757-13 2003 Our findings imply that during furosemide treatment selective down-regulation of ClC-K1 and barttin mRNAs in thin limb plays a role in maintaining salt and water homeostasis. Furosemide 31-41 barttin CLCNK type accessory subunit beta Rattus norvegicus 92-99 12915681-10 2003 Furosemide increased PAI-1 antigen [27.8 ng/ml (20.6, 35.0), P = 0.002 vs. 19.3 ng/ml (13.4, 25.2) baseline], even in the presence of candesartan [27.2 ng/ml (16.5, 37.8), P = 0.042 vs. baseline] or spironolactone [27.3 ng/ml (17.9, 36.8), P = 0.015 vs. baseline]. Furosemide 0-10 serpin family E member 1 Homo sapiens 21-26 12915681-11 2003 However, coadministration of AT(1) and aldosterone receptor antagonists prevented the furosemide-induced increase in PAI-1 [19.2 ng/ml (9.8, 28.6), P = 0.974 vs. baseline, P < 0.05 vs. candesartan, spironolactone or furosemide alone]. Furosemide 86-96 serpin family E member 1 Homo sapiens 117-122 12922924-6 2003 We tested the hypothesis that the selective adenosine A(1) receptor antagonist FK838 is orally active and causes diuresis and natriuresis, but maintains glomerular filtration rate in normal rats or in rats with furosemide resistance. Furosemide 211-221 adenosine A1 receptor Rattus norvegicus 44-67 12922924-13 2003 This study shows that the adenosine A(1) receptor antagonist FK838 is orally active and causes potent diuresis and natriuresis and maintains glomerular filtration rate in normal or furosemide-resistant rats. Furosemide 181-191 adenosine A1 receptor Rattus norvegicus 26-49 12897087-9 2003 Although OAT1 protein abundance in cortical homogenates was increased by furosemide infusion (271 +/- 35 vs 100 +/- 15%, P < 0.05), Na-K-ATPase alpha1 subunit protein abundance was not affected (113 +/- 14 vs 100 +/- 8%, P = 0.42). Furosemide 73-83 solute carrier family 22 member 6 Rattus norvegicus 9-13 12897087-12 2003 CONCLUSION: Chronic furosemide or hydrochlorothiazide infusion caused increases in OAT1 protein abundance in rat kidney. Furosemide 20-30 solute carrier family 22 member 6 Rattus norvegicus 83-87 12840061-6 2003 HEK/EP1 [Ca2+]i responses were observed mainly in preparations from rabbits on a low-salt diet and were completely inhibited by either a selective COX-2 inhibitor or an EP1 antagonist, and also by 100 microM luminal furosemide. Furosemide 216-226 prostaglandin E receptor 1 Homo sapiens 0-7 12704183-6 2003 Active E217betaG transport by MRP2 was significantly stimulated by the organic anions indomethacin, furosemide, and probenecid and by several conjugated bile acids. Furosemide 100-110 ATP binding cassette subfamily C member 2 Homo sapiens 30-34 12840061-6 2003 HEK/EP1 [Ca2+]i responses were observed mainly in preparations from rabbits on a low-salt diet and were completely inhibited by either a selective COX-2 inhibitor or an EP1 antagonist, and also by 100 microM luminal furosemide. Furosemide 216-226 prostaglandin E receptor 1 Homo sapiens 4-7 12441308-5 2003 A high-salt diet reduced expression of COX-2, whereas a low-salt diet, furosemide infusion, and renal artery stenosis stimulated COX-2 expression. Furosemide 71-81 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 129-134 12595280-3 2003 The pattern of Fos-ir in the brain after furosemide was similar to that seen after peripheral injection of ANG II. Furosemide 41-51 FBJ osteosarcoma oncogene Mus musculus 15-18 12798820-10 2003 Plasma renin activity was upregulated by ramipril or ramipril plus furosemide but not influenced by infarction or furosemide alone. Furosemide 67-77 renin Rattus norvegicus 7-12 12798820-10 2003 Plasma renin activity was upregulated by ramipril or ramipril plus furosemide but not influenced by infarction or furosemide alone. Furosemide 114-124 renin Rattus norvegicus 7-12 12798820-11 2003 CONCLUSIONS: Furosemide and ramipril significantly reduced cardiac ACE and remodeling. Furosemide 13-23 angiotensin I converting enzyme Rattus norvegicus 67-70 12441308-6 2003 Additional angiotensin-converting enzyme inhibition led to further increases in renocortical COX-2 expression by 62, 136, 300, 50, and 70% for a high-, normal-, and low-salt diet, furosemide infusion, and renal artery stenosis, respectively. Furosemide 180-190 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 93-98 12388138-6 2003 The prolactin effect on iodide uptake into cultured mammary tissues was abolished by pendrin transport inhibitors, including DIDS, furosemide, and probenecid. Furosemide 131-141 solute carrier family 26, member 4 Mus musculus 85-92 12620696-6 2003 After furosemide, in 67% of patients, decreases in SBP (166 +/- 5 to 134 +/- 5 mm Hg; P <.001), DBP (82 +/- 4 to 71 +/- 4 mm Hg; P =.004), and MAP (111 +/- 3 to 92 +/- 3 mm Hg; P <.001), were associated with increases in PRA (2.1 +/- 1.2 to 5.1 +/- 1.8 ng/mL/h; P =.01) and SA (4.8 +/- 1.0 to 9.4 +/- 1.4 ng/dL; P =.01) and with decreases in ANP (101 +/- 28 to 58 +/- 11 pg/mL; P =.01) and body weight (77.5 +/- 3.6 to 76.4 +/- 3.3 kg; P =.02), findings consistent with volume mediated/salt sensitive hypertension. Furosemide 6-16 selenium binding protein 1 Homo sapiens 51-54 12620696-6 2003 After furosemide, in 67% of patients, decreases in SBP (166 +/- 5 to 134 +/- 5 mm Hg; P <.001), DBP (82 +/- 4 to 71 +/- 4 mm Hg; P =.004), and MAP (111 +/- 3 to 92 +/- 3 mm Hg; P <.001), were associated with increases in PRA (2.1 +/- 1.2 to 5.1 +/- 1.8 ng/mL/h; P =.01) and SA (4.8 +/- 1.0 to 9.4 +/- 1.4 ng/dL; P =.01) and with decreases in ANP (101 +/- 28 to 58 +/- 11 pg/mL; P =.01) and body weight (77.5 +/- 3.6 to 76.4 +/- 3.3 kg; P =.02), findings consistent with volume mediated/salt sensitive hypertension. Furosemide 6-16 D-box binding PAR bZIP transcription factor Homo sapiens 99-102 14596865-4 2003 By using the high cellular resolution of the in situ hybridization histochemistry (ISHH), we investigated whether a furosemide-induced fluid and electrolyte depletion might modify both putative GABAergic and glutamatergic systems within the LT. We show that acute furosemide treatment (4 h) significantly reduced the expression of GAD67 mRNA, the active holoenzyme predictive of GABA synthesis, within the SFO. Furosemide 116-126 glutamate decarboxylase 1 Homo sapiens 331-336 12388392-6 2003 Semiquantitative immunoblotting revealed that the abundances of thick ascending limb Na(+)-K(+)-2Cl(-) cotransporter and all three subunits of the epithelial Na(+) channel (ENaC) were increased by furosemide infusion. Furosemide 197-207 sodium channel epithelial 1 subunit gamma Rattus norvegicus 147-171 12388392-6 2003 Semiquantitative immunoblotting revealed that the abundances of thick ascending limb Na(+)-K(+)-2Cl(-) cotransporter and all three subunits of the epithelial Na(+) channel (ENaC) were increased by furosemide infusion. Furosemide 197-207 sodium channel epithelial 1 subunit gamma Rattus norvegicus 173-177 12472779-6 2003 Rats with Li nephropathy were treated with furosemide (3 mg/kg body weight), which blocks the activity of rBSC1, and changes in urine concentration, plasma AVP, medullary accumulation of Li ions, and apical AQP2 expression were determined. Furosemide 43-53 solute carrier family 12 member 1 Rattus norvegicus 106-111 14580937-4 2003 Our results show that beta-endorphin knockout (KO) and heterozygous (HT) mutant mice consume approximately a 50% less 2% NaCl solution compared with wild type mice (WT), after furosemide and low sodium diet treatment. Furosemide 176-186 pro-opiomelanocortin-alpha Mus musculus 22-36 14596865-6 2003 The hydromineral challenge did not alter the expression of GAD65 and type 2 vesicular glutamate transporter (vGlut2) mRNA in all the structures of the LT. Furosemide treatment was associated with a reduction in the population of GAD67-containing neurons in the periphery of the SFO and dorsal part of the MnPO. Furosemide 155-165 glutamate decarboxylase 1 Homo sapiens 229-234 12608533-0 2003 Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Furosemide 69-79 ATP binding cassette subfamily C member 2 Rattus norvegicus 10-14 12608533-1 2003 PURPOSE: This study assesses the impact of rat multidrug resistance-associated protein 2 (Mrp2) on the biliary excretion and oral absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats (EHBR). Furosemide 144-154 ATP binding cassette subfamily C member 2 Rattus norvegicus 47-88 12608533-1 2003 PURPOSE: This study assesses the impact of rat multidrug resistance-associated protein 2 (Mrp2) on the biliary excretion and oral absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats (EHBR). Furosemide 144-154 ATP binding cassette subfamily C member 2 Rattus norvegicus 90-94 12372766-8 2002 UT-B1 protein expression in rat kidney medulla was downregulated greatly by long-term [deamino-Cys(1),D-Arg(8)]vasopressin infusion and moderately by furosemide treatment. Furosemide 150-160 solute carrier family 14 member 1 (Kidd blood group) Rattus norvegicus 0-5 12393866-3 2002 The chloride channel inhibitor furosemide prevented intracellular alkalinization, Bax translocation, cytochrome c release, and cell death. Furosemide 31-41 BCL2 associated X, apoptosis regulator Homo sapiens 82-85 12393866-3 2002 The chloride channel inhibitor furosemide prevented intracellular alkalinization, Bax translocation, cytochrome c release, and cell death. Furosemide 31-41 cytochrome c, somatic Homo sapiens 101-113 12393866-4 2002 Translocation of full-length Bid to the mitochondria was also prevented by furosemide. Furosemide 75-85 BH3 interacting domain death agonist Homo sapiens 29-32 12393866-10 2002 Furosemide only delayed full-length Bid depletion and tBid accumulation. Furosemide 0-10 BH3 interacting domain death agonist Homo sapiens 36-39 12393866-13 2002 It is concluded that with either staurosporine or TNF a furosemide-sensitive change in pH(i) is linked to Bax translocation, cytochrome c release, and cell killing. Furosemide 56-66 tumor necrosis factor Homo sapiens 50-55 12393866-13 2002 It is concluded that with either staurosporine or TNF a furosemide-sensitive change in pH(i) is linked to Bax translocation, cytochrome c release, and cell killing. Furosemide 56-66 BCL2 associated X, apoptosis regulator Homo sapiens 106-109 12393866-13 2002 It is concluded that with either staurosporine or TNF a furosemide-sensitive change in pH(i) is linked to Bax translocation, cytochrome c release, and cell killing. Furosemide 56-66 cytochrome c, somatic Homo sapiens 125-137 12115021-14 2002 Furosemide exhibited an anti-inflammatory effect through inhibition of production and release of cytokines interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha from peripheral mononuclear cells, which may have a beneficial effect on local inflamed tissue imbalance in the ratio of different cytokines, thus improving the sensitivity of target cells to endogenous glucocorticosteroids. Furosemide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 127-164 12432442-7 2002 Responses of both plasma renin activity and serum aldosterone level following the furosemide upright provocation were blunted in the hyperkalemic acute phase, but recovered in the normokalemic convalescent phase. Furosemide 82-92 renin Homo sapiens 25-30 12361471-8 2002 However, incubation of the epithelial cells in Cl(-)free medium or with a blocker of the Na(+)-K(+)-2Cl(-) cotransporter (Furosemide) reduced the effect of PAF. Furosemide 122-132 PCNA clamp associated factor Homo sapiens 156-159 12115021-4 2002 In neonates, after administration of furosemide, the urinary excretion of endothelin-1 and aldosterone increased markedly, and it is known that endothelin may release ANF and aldosterone in a dose-dependent manner. Furosemide 37-47 endothelin 1 Homo sapiens 74-86 12130981-9 2002 In the atrial natriuretic peptide group, extravascular lung water was significantly (p <.05) lower and Pao2 was significantly (p <.05) higher than in the control and furosemide groups, respectively. Furosemide 172-182 natriuretic peptide A Canis lupus familiaris 7-33 12115021-4 2002 In neonates, after administration of furosemide, the urinary excretion of endothelin-1 and aldosterone increased markedly, and it is known that endothelin may release ANF and aldosterone in a dose-dependent manner. Furosemide 37-47 natriuretic peptide A Homo sapiens 167-170 12115021-6 2002 Because the concomitant use of ANF and furosemide appeared to be diuretically effective in newborns after cardiac surgery, one may suggest that furosemide competes with ANF for its effects on the adrenals. Furosemide 144-154 natriuretic peptide A Homo sapiens 31-34 12323126-3 2002 Furthermore, there is also evidence that furosemide induces prostaglandin synthesis, blocks the sodium-calcium pump, producing relaxation of the smooth muscle that narrows the airway and causes reduced nerve responsiveness to the Neurokinin A produced in acute asthma attacks. Furosemide 41-51 tachykinin precursor 1 Homo sapiens 230-242 12358151-9 2002 However, peripheral plasma renin activity (PRA) increased normally after the patient resumed an upright posture following furosemide administration. Furosemide 122-132 renin Homo sapiens 27-32 11996409-6 2002 The aim of our study was to examine the influence of furosemide and spironolactone on leukocyte migration through endothelial cell monolayers (ECM). Furosemide 53-63 multimerin 1 Homo sapiens 143-146 11864976-2 2002 Simultaneous treatment of the cells with wortmannin, cycloheximide, furosemide, cyclosporin A, or decylubiquinone prevented the release of cytochrome c and significantly reduced the loss of viability. Furosemide 68-78 cytochrome c, somatic Homo sapiens 139-151 11864976-5 2002 The increase in the content of Bax was followed by the translocation of this protein from the cytosol to the mitochondria, an event that was inhibited by furosemide, a chloride channel inhibitor. Furosemide 154-164 BCL2 associated X, apoptosis regulator Homo sapiens 31-34 11996409-10 2002 Furosemide (76 +/- 7.2%) and spironolactone (70 +/- 7.7%) were able to inhibit PMNL migration through ECM significantly, when both cell types were treated simulating the situation after an iv injection. Furosemide 0-10 multimerin 1 Homo sapiens 102-105 11996409-11 2002 Furosemide and spironolactone were identified as potent inhibitors of leukocyte migration through ECM. Furosemide 0-10 multimerin 1 Homo sapiens 98-101 12005183-4 2002 DIDS inhibited 10 nM ET-1-induced increase in cell count and [3H]-thymidine incorporation into VSMC in a concentration-dependent manner, whereas other Cl- channel blockers including IAA-94, NPPB, DPC, SITS and furosemide did not produce these effects. Furosemide 210-220 endothelin 1 Rattus norvegicus 21-25 11961000-0 2002 Low tonicity mediates a downregulation of cyclooxygenase-1 expression by furosemide in the rat renal papilla. Furosemide 73-83 prostaglandin-endoperoxide synthase 1 Rattus norvegicus 42-58 11961000-3 2002 Furosemide increased Cox-2 mRNA expression approximately twofold in the cortex, but it left Cox-1 mRNA expression unaltered there. Furosemide 0-10 cytochrome c oxidase II, mitochondrial Rattus norvegicus 21-26 11961000-3 2002 Furosemide increased Cox-2 mRNA expression approximately twofold in the cortex, but it left Cox-1 mRNA expression unaltered there. Furosemide 0-10 cytochrome c oxidase I, mitochondrial Rattus norvegicus 92-97 11961000-5 2002 In the inner medulla, however, furosemide decreased Cox-1 and Cox-2 mRNA levels to approximately 30% and 60% of their control levels, respectively. Furosemide 31-41 cytochrome c oxidase I, mitochondrial Rattus norvegicus 52-57 11961000-5 2002 In the inner medulla, however, furosemide decreased Cox-1 and Cox-2 mRNA levels to approximately 30% and 60% of their control levels, respectively. Furosemide 31-41 cytochrome c oxidase II, mitochondrial Rattus norvegicus 62-67 11961000-8 2002 Furosemide lowered urine osmolality from 1550 mosmol/kg to 480 mosmol/kg; therefore, further consideration was given to the influence of tonicity as a possible mediator of the effects of furosemide on the Cox expression. Furosemide 187-197 coproporphyrinogen oxidase Rattus norvegicus 205-208 12013228-4 2002 CZE-LIF and MECC-LIF are thereby shown to permit unambiguous recognition of furosemide in urines collected after ingestion of therapeutic doses of this drug. Furosemide 76-86 LIF interleukin 6 family cytokine Homo sapiens 4-7 12013228-4 2002 CZE-LIF and MECC-LIF are thereby shown to permit unambiguous recognition of furosemide in urines collected after ingestion of therapeutic doses of this drug. Furosemide 76-86 LIF interleukin 6 family cytokine Homo sapiens 17-20 12013228-9 2002 CZE-LIF and CE-MS2 with injection of plain or diluted urine represent simple, rapid and attractive urinary screening and confirmation assays for furosemide in patient urines. Furosemide 145-155 LIF interleukin 6 family cytokine Homo sapiens 4-7 11967238-5 2002 We have tested whether the stimulation of COX-2 expression by short- and long-term unilateral renal artery stenosis, low salt, and furosemide treatment depends on co-expression of NOS1. Furosemide 131-141 prostaglandin-endoperoxide synthase 2 Mus musculus 42-47 11703026-6 2001 RESULTS: Furosemide treatment significantly decreased plasma Cl concentration and significantly increased plasma renin activity and aldosterone concentration. Furosemide 9-19 renin Canis lupus familiaris 113-118 11788444-9 2002 The effects of luminal ANG II were furosemide sensitive and abolished by the AT(1) receptor blocker candesartan. Furosemide 35-45 angiogenin Homo sapiens 23-26 11807827-6 2002 In Balb/c 3T3 fibroblasts stimulated with FGF, bumetanide, and furosemide inhibited 50-60% of the ERK 1/2 phosphorylation. Furosemide 63-73 mitogen-activated protein kinase 3 Homo sapiens 98-105 11849395-5 2002 RESULTS: In situ hybridization analysis and RNase protection assay of the total kidney revealed a down-regulation of CLC-K2 mRNA in the high salt diet rats and an up-regulation of CLC-K2 mRNA in furosemide treated rats, which were restricted to the outer medulla. Furosemide 195-205 chloride voltage-gated channel Kb Rattus norvegicus 180-186 11849395-7 2002 Using RT-PCR and real time PCR, the changing levels of CLC-K2 mRNA after furosemide treatment or high salt diet were restricted to the mTAL, whereas CLC-K2 mRNA levels in cTAL and OMCD were not changed in furosemide or high salt rats compared to time paired controls. Furosemide 73-83 chloride voltage-gated channel Kb Rattus norvegicus 55-61 11849395-7 2002 Using RT-PCR and real time PCR, the changing levels of CLC-K2 mRNA after furosemide treatment or high salt diet were restricted to the mTAL, whereas CLC-K2 mRNA levels in cTAL and OMCD were not changed in furosemide or high salt rats compared to time paired controls. Furosemide 205-215 chloride voltage-gated channel Kb Rattus norvegicus 55-61 11812667-7 2002 RESULTS: N-ANF showed the closest correlations to clinical and echocardiographic measures of heart failure severity, e.g. NYHA functional class, furosemide dose, exercise tolerance, systolic and diastolic function. Furosemide 145-155 natriuretic peptide A Homo sapiens 11-14 11851355-8 2002 Combination therapy with furosemide is less efficient with regard to collagen content and MMP-2 (active form) reduction but did not worsen beneficial effects of ramipril on LV function and mortality rate. Furosemide 25-35 matrix metallopeptidase 2 Rattus norvegicus 90-95 11592951-3 2001 Rats subjected to various chronic treatments were found to preferentially decrease kidney AT(4) receptor density (furosemide, puromycin aminonucleoside, nitro-L-arginine methyl ester), decrease kidney AT(1) receptor density (bilateral ureteral obstruction), or increase kidney AT(1) receptor distribution in the inner medulla (water diuresis). Furosemide 114-124 leucyl and cystinyl aminopeptidase Homo sapiens 90-104 11703026-8 2001 A significant interaction between a low Na diet and furosemide administration resulted in the lowest plasma Cl concentrations, highest plasma renin activities, and highest plasma aldosterone concentrations. Furosemide 52-62 renin Canis lupus familiaris 142-147 11703026-9 2001 CONCLUSIONS AND CLINICAL RELEVANCE: In healthy dogs, feeding a low Na diet and administering furosemide resulted in an additive effect on plasma Cl concentration, renin activity, and aldosterone concentration, which may be an important consideration for treating dogs with cardiac disease. Furosemide 93-103 renin Canis lupus familiaris 163-168 11849618-3 2001 In view of the fact that some drugs such as furosemide, diclofenac and mefenamic acid, based on the structural similarities to thyroxine could compete for binding to thyroxine binding globulin (TBG) and appears that there are some structural similarities between tamoxifen and thyroxine, one can hypothesize that tamoxifen is also able to compete for TBG binding and thereby affecting thyroid function tests. Furosemide 44-54 serpin family A member 7 Homo sapiens 166-192 11849618-3 2001 In view of the fact that some drugs such as furosemide, diclofenac and mefenamic acid, based on the structural similarities to thyroxine could compete for binding to thyroxine binding globulin (TBG) and appears that there are some structural similarities between tamoxifen and thyroxine, one can hypothesize that tamoxifen is also able to compete for TBG binding and thereby affecting thyroid function tests. Furosemide 44-54 serpin family A member 7 Homo sapiens 194-197 11849618-3 2001 In view of the fact that some drugs such as furosemide, diclofenac and mefenamic acid, based on the structural similarities to thyroxine could compete for binding to thyroxine binding globulin (TBG) and appears that there are some structural similarities between tamoxifen and thyroxine, one can hypothesize that tamoxifen is also able to compete for TBG binding and thereby affecting thyroid function tests. Furosemide 44-54 serpin family A member 7 Homo sapiens 351-354 11849618-4 2001 DESIGN AND METHODS: In this study, we designed an in vitro binding assay as well as computational methods using MOPAC 7 package for evaluation of competitive potency of tamoxifen for TBG binding in comparison with well-known TBG competitors (including furosemide, mefenamic acid and diclofenac). Furosemide 252-262 serpin family A member 7 Homo sapiens 183-186 11719734-0 2001 Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Furosemide 15-25 renin Homo sapiens 53-58 11549664-0 2001 Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. Furosemide 89-99 renin Homo sapiens 63-68 11719734-0 2001 Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Furosemide 15-25 prostaglandin-endoperoxide synthase 2 Homo sapiens 88-104 11719734-3 2001 Plasma renin activity increased 2 to 3 times over baseline with a low-sodium diet and 5 times over baseline 30 minutes after intravenous furosemide; it was still elevated nearly 5 times on day 9. Furosemide 137-147 renin Homo sapiens 7-12 11719734-7 2001 We have concluded that low-sodium and furosemide-stimulated renin and aldosterone secretion is completely blocked in healthy volunteers during COX-2 inhibition with rofecoxib, suggesting that intact COX-2 is of major importance for stimulation of the renin system under these conditions in man. Furosemide 38-48 renin Homo sapiens 60-65 11719734-7 2001 We have concluded that low-sodium and furosemide-stimulated renin and aldosterone secretion is completely blocked in healthy volunteers during COX-2 inhibition with rofecoxib, suggesting that intact COX-2 is of major importance for stimulation of the renin system under these conditions in man. Furosemide 38-48 prostaglandin-endoperoxide synthase 2 Homo sapiens 199-204 11719734-7 2001 We have concluded that low-sodium and furosemide-stimulated renin and aldosterone secretion is completely blocked in healthy volunteers during COX-2 inhibition with rofecoxib, suggesting that intact COX-2 is of major importance for stimulation of the renin system under these conditions in man. Furosemide 38-48 renin Homo sapiens 251-256 11703585-6 2001 RESULTS: Induction of COX-2 mRNA expression due to furosemide was paralleled by increased renal excretion of prostanoids. Furosemide 51-61 cytochrome c oxidase II, mitochondrial Rattus norvegicus 22-27 11703585-9 2001 Moreover, the COX-2 inhibitor rofecoxib dose-dependently attenuated diuresis and saluresis, as well as the stimulation of the renin system induced by furosemide. Furosemide 150-160 cytochrome c oxidase II, mitochondrial Rattus norvegicus 14-19 11703585-9 2001 Moreover, the COX-2 inhibitor rofecoxib dose-dependently attenuated diuresis and saluresis, as well as the stimulation of the renin system induced by furosemide. Furosemide 150-160 renin Rattus norvegicus 126-131 11489390-0 2001 A spectrophotometric-partial least squares (PLS-1) method for the simultaneous determination of furosemide and amiloride hydrochloride in pharmaceutical formulations. Furosemide 96-106 plastin 1 Homo sapiens 44-49 11489390-1 2001 A numerical method, based on the use of spectrophotometric data coupled to PLS-1 multivariate calibration, is reported for the simultaneous determination of furosemide and amiloride hydrochloride in synthetic samples and commercial tablets. Furosemide 157-167 plastin 1 Homo sapiens 75-80 11763992-8 2001 Serum creatinine transiently decreased rather than increased 14 days after cisplatin and furosemide administration, while NAG excretion increased 3 days after cisplatin and furosemide administration. Furosemide 173-183 N-acetyl-alpha-glucosaminidase Homo sapiens 122-125 11763992-11 2001 Moreover, the first course morning cisplatin and furosemide treatment was associated with less change in NAG excretion (less kidney toxicity) than the first course of evening cisplatin and furosemide treatment. Furosemide 49-59 N-acetyl-alpha-glucosaminidase Homo sapiens 105-108 11763992-12 2001 The second course evening cisplatin and furosemide treatment was associated with an increase in NAG excretion compared to the first course of treatment, while morning cisplatin and furosemide treatment in the second course showed less change in NAG excretion compared to the first course. Furosemide 40-50 N-acetyl-alpha-glucosaminidase Homo sapiens 96-99 11763992-12 2001 The second course evening cisplatin and furosemide treatment was associated with an increase in NAG excretion compared to the first course of treatment, while morning cisplatin and furosemide treatment in the second course showed less change in NAG excretion compared to the first course. Furosemide 181-191 N-acetyl-alpha-glucosaminidase Homo sapiens 245-248 11549664-0 2001 Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. Furosemide 89-99 renin Homo sapiens 63-68 11549664-3 2001 This study aims to validate the accuracy and efficacy of the basal plasma aldosterone concentration (picomoles per liter) to PRA (nanograms per liter/sec) ratio and of combined stimulation of PRA by the furosemide and upright posture test in screening for aldosterone-producing adenoma in hypertensives with PRA less than 0.28 ng/liter.sec (1 ng/ml.h). Furosemide 203-213 S100 calcium binding protein A6 Homo sapiens 192-195 11549664-3 2001 This study aims to validate the accuracy and efficacy of the basal plasma aldosterone concentration (picomoles per liter) to PRA (nanograms per liter/sec) ratio and of combined stimulation of PRA by the furosemide and upright posture test in screening for aldosterone-producing adenoma in hypertensives with PRA less than 0.28 ng/liter.sec (1 ng/ml.h). Furosemide 203-213 S100 calcium binding protein A6 Homo sapiens 192-195 11725383-0 2001 The influence of inhaled furosemide on adverse effects of ACE-inhibitors in airways. Furosemide 25-35 angiotensin I converting enzyme Felis catus 58-61 11443066-6 2001 The oocyte K-Cl cotransporter was sensitive to several inhibitors, including loop diuretics, with apparent half-maximal inhibition values of 200 and 500 microM for furosemide and bumetanide, respectively. Furosemide 164-174 solute carrier family 12 member 6 L homeolog Xenopus laevis 11-29 11423756-6 2001 Responses of both plasma renin activity and serum aldosterone level to the furosemide-posture challenge were blunted. Furosemide 75-85 renin Homo sapiens 25-30 11510880-4 2001 TSC mRNA increased during furosemide treatment 1.75-fold versus control but was not affected by a high- or a low-salt diet. Furosemide 26-36 solute carrier family 12 member 3 Rattus norvegicus 0-3 11510880-5 2001 The mRNA for the alpha-subunit of ENaC increased with the low-salt diet (about 1.5-fold) and with furosemide (about 2.1-fold) in all kidney zones, but did not change with the high-salt diet. Furosemide 98-108 sodium channel epithelial 1 subunit gamma Rattus norvegicus 34-38 11510880-6 2001 Dietary salt loading down-regulated CIC-K2 mRNA in the outer medulla 0.6-fold versus control whilst furosemide treatment, but not the low-salt diet, increased ClC-K2 mRNA in the outer (1.6-fold) and inner medulla (2.0-fold). Furosemide 100-110 chloride voltage-gated channel Kb Rattus norvegicus 159-165 11249848-10 2001 These studies indicate that the mBSC1-A4 isoform of the SLC12A1 gene encodes a hypotonically activated, cAMP- and furosemide-sensitive Na(+)-Cl(-) cotransporter. Furosemide 114-124 brain size control 1 Mus musculus 32-37 11249848-10 2001 These studies indicate that the mBSC1-A4 isoform of the SLC12A1 gene encodes a hypotonically activated, cAMP- and furosemide-sensitive Na(+)-Cl(-) cotransporter. Furosemide 114-124 solute carrier family 12, member 1 Mus musculus 56-63 11526200-9 2001 A classic loop diuretic, furosemide (10 mg/kg ip), markedly increased renal medullary Po(2) levels from 22.5 to 52.2 mmHg, which was accompanied by a significant reduction of HIF-1alpha transcripts in renal medullary tissue. Furosemide 25-35 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 175-185 11181077-4 2001 Bumetanide and furosemide, NKCC inhibitors, significantly inhibited the Pin-induced increased [K(+)](i) and apoptosis, whereas K(ATP) inhibitors (glibenclamide and tolbutamide) had no effects. Furosemide 15-25 dynein light chain LC8-type 1 Homo sapiens 72-75 11725383-11 2001 CONCLUSION: The results showed the protective effect of inhaled furosemide against the respiratory adverse effects induced by ACE-inhibitors administration. Furosemide 64-74 angiotensin I converting enzyme Felis catus 126-129 11410710-15 2001 Thus, in cultured normal and KCC1-transfected cells, K-Cl COT shows significant differences from erythrocytes, and NEM and cell swelling open furosemide-sensitive and Cl-independent K/Rb channels. Furosemide 142-152 solute carrier family 12 member 4 Homo sapiens 29-33 11050128-9 2000 KCC2 inhibition by furosemide caused a change in the intracellular Cl(-) concentration that depended on the concentration of pipette Cl(-); in recordings with low pipette Cl(-), furosemide lowered intracellular Cl(-), whereas in recordings with elevated pipette Cl(-), furosemide raised intracellular Cl(-). Furosemide 19-29 solute carrier family 12 member 5 Rattus norvegicus 0-4 11095476-3 2000 After repeated EE administration, renin stimulation was induced by a single oral dose of 40 mg furosemide, followed by 50 mg captopril, 12 h later. Furosemide 95-105 renin Homo sapiens 34-39 11135058-0 2001 Furosemide stimulates macula densa cyclooxygenase-2 expression in rats. Furosemide 0-10 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 35-51 11135058-8 2001 Furosemide led to a fivefold and threefold increase of plasma renin activity and renocortical renin mRNA level, respectively. Furosemide 0-10 renin Rattus norvegicus 62-67 11135058-8 2001 Furosemide led to a fivefold and threefold increase of plasma renin activity and renocortical renin mRNA level, respectively. Furosemide 0-10 renin Rattus norvegicus 94-99 11135058-10 2001 Moreover, the percentage of juxtaglomerular apparatuses immunopositive for COX-2 increased threefold in response to furosemide compared with vehicle-infused animals. Furosemide 116-126 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 75-80 11369814-2 2001 The effects of torasemide and furosemide on cell growth induced by angiotensin II (Ang II) were investigated in cultured vascular smooth muscle cells (VSMCs) obtained from the aorta of adult spontaneously hypertensive rats (SHR). Furosemide 30-40 angiotensinogen Rattus norvegicus 67-81 11369814-2 2001 The effects of torasemide and furosemide on cell growth induced by angiotensin II (Ang II) were investigated in cultured vascular smooth muscle cells (VSMCs) obtained from the aorta of adult spontaneously hypertensive rats (SHR). Furosemide 30-40 angiotensinogen Rattus norvegicus 83-89 11369815-1 2001 BACKGROUND: The direct effects of torasemide and furosemide on vasoconstriction and increases in intracellular free calcium concentration ([Ca(2+)]i) induced by endothelin-1 (ET-1) were investigated in the aorta of spontaneously hypertensive rats (SHR). Furosemide 49-59 endothelin 1 Rattus norvegicus 161-173 11369815-1 2001 BACKGROUND: The direct effects of torasemide and furosemide on vasoconstriction and increases in intracellular free calcium concentration ([Ca(2+)]i) induced by endothelin-1 (ET-1) were investigated in the aorta of spontaneously hypertensive rats (SHR). Furosemide 49-59 endothelin 1 Rattus norvegicus 175-179 11369815-4 2001 RESULTS: ET-1-induced vasoconstriction was reduced in a dose-dependent way by torasemide and furosemide (IC(50) values: 4.3+/-1.4x10(-5) and 9.8+/-5.6 x10(-5) M, respectively). Furosemide 93-103 endothelin 1 Rattus norvegicus 9-13 11369815-6 2001 Furosemide inhibited the initial rise in [Ca(2+)]i induced by ET-1, with no effect on the second rise. Furosemide 0-10 endothelin 1 Rattus norvegicus 62-66 11050128-9 2000 KCC2 inhibition by furosemide caused a change in the intracellular Cl(-) concentration that depended on the concentration of pipette Cl(-); in recordings with low pipette Cl(-), furosemide lowered intracellular Cl(-), whereas in recordings with elevated pipette Cl(-), furosemide raised intracellular Cl(-). Furosemide 178-188 solute carrier family 12 member 5 Rattus norvegicus 0-4 11050128-9 2000 KCC2 inhibition by furosemide caused a change in the intracellular Cl(-) concentration that depended on the concentration of pipette Cl(-); in recordings with low pipette Cl(-), furosemide lowered intracellular Cl(-), whereas in recordings with elevated pipette Cl(-), furosemide raised intracellular Cl(-). Furosemide 178-188 solute carrier family 12 member 5 Rattus norvegicus 0-4 11046100-5 2000 Furosemide administration increased plasma renin activity from 1.0 +/- 0.2 to 4.5 +/- 1.2 ng of angiotensin I/ml/h and there was no effect of HOE 140 (from 1.1 +/- 0.2 to 3.9 +/- 0.8 ng of angiotensin I/ml/h). Furosemide 0-10 renin Homo sapiens 43-48 11057431-6 2000 RESULTS: Before stimulation with frusemide, the plasma renin in Group A was 0.79 +/- 0.13 ng angiotensin l/ml per h, while in Group B the corresponding figure was 1.73 +/- 0.38 ng angiotensin l/ml per h. This difference was statistically significant (P= 0.0127). Furosemide 33-42 renin Homo sapiens 55-60 11046100-5 2000 Furosemide administration increased plasma renin activity from 1.0 +/- 0.2 to 4.5 +/- 1.2 ng of angiotensin I/ml/h and there was no effect of HOE 140 (from 1.1 +/- 0.2 to 3.9 +/- 0.8 ng of angiotensin I/ml/h). Furosemide 0-10 angiotensinogen Homo sapiens 96-109 11046100-5 2000 Furosemide administration increased plasma renin activity from 1.0 +/- 0.2 to 4.5 +/- 1.2 ng of angiotensin I/ml/h and there was no effect of HOE 140 (from 1.1 +/- 0.2 to 3.9 +/- 0.8 ng of angiotensin I/ml/h). Furosemide 0-10 angiotensinogen Homo sapiens 189-202 11054013-5 2000 In conclusion, furosemide could represent a valid therapeutic aid in the prevention of nasosinusal polyps. Furosemide 15-25 activation induced cytidine deaminase Homo sapiens 62-65 11022906-1 2000 A simplified high-performance liquid chromatographic procedure is described for the determination of furosemide (4-chloro-N-furfuryl-5-sulphamoylanthranillic acid), which makes use of UV detection, a C18, reversed-phase column, and micellar mobile phases of sodium dodecyl sulphate (SDS) and 1-propanol at pH 3 buffered with phosphate system. Furosemide 101-111 Bardet-Biedl syndrome 9 Homo sapiens 200-203 10991988-4 2000 p-[(14)C]Aminohippurate (PAH) uptake by rOAT1-expressing oocytes was inhibited in the presence of a thiazide (chlorothiazide, cyclothiazide, hydrochlorothiazide), a loop diuretic (bumetanide, ethacrynic acid, furosemide), or a carbonic anhydrase inhibitor (acetazolamide, ethoxzolamide, methazolamide). Furosemide 209-219 solute carrier family 22 member 6 Rattus norvegicus 40-45 10991988-10 2000 Although the loop diuretics had little trans-stimulation effect on [(14)C]PAH efflux via rOAT1, the rOAT1-mediated furosemide uptake was observed. Furosemide 115-125 solute carrier family 22 member 6 Rattus norvegicus 100-105 11012899-8 2000 CsA also increased by 38% the ouabain-resistant furosemide-sensitive component (Or-Fs) of 86Rb+ influx, reflecting the Na+-K+-Cl- cotransport activity and stimulated the basolateral efflux of 36Cl- from mTAL cells grown on filters. Furosemide 48-58 excision repaiross-complementing rodent repair deficiency, complementation group 8 Mus musculus 0-3 10996478-13 2000 However, ALT activity was significantly increased 5 h following FS administration. Furosemide 64-66 glutamic pyruvic transaminase, soluble Mus musculus 9-12 10913127-3 2000 KCC1 and KCC4 exhibit differential sensitivity to transport inhibitors, such that KCC4 is much less sensitive to bumetanide and furosemide. Furosemide 128-138 solute carrier family 12 (potassium/chloride transporter), member 4 L homeolog Xenopus laevis 0-4 10942735-4 2000 Injection of Xenopus oocytes with KCC2 cRNA induced a 20-fold increase in Cl(-)-dependent, furosemide-sensitive K(+) uptake. Furosemide 91-101 solute carrier family 12 member 5 L homeolog Xenopus laevis 34-38 10988115-8 2000 In addition, inhalation of furosemide attenuated the activity of RARs. Furosemide 27-37 arginyl-tRNA synthetase 1 Rattus norvegicus 65-69 10988115-9 2000 These findings indicate that SARs are sensitized and RARs desensitized by inhalation of furosemide. Furosemide 88-98 arginyl-tRNA synthetase 1 Rattus norvegicus 53-57 10975299-5 2000 Baseline renin production was elevated, although the renin response to furosemide was similar in chronic furosemide-treated and vehicle-treated lambs. Furosemide 71-81 renin Ovis aries 53-58 10786260-8 2000 Seventy-six percent of patients identified by physicians as CHF patients who were taking digoxin and furosemide were treated with an ACE inhibitor. Furosemide 101-111 angiotensin I converting enzyme Homo sapiens 133-136 10910438-14 2000 The DDAVP-frusemide test revealed that the release of AQP2 into urine is not caused by hypertonicity of tubular fluid. Furosemide 10-19 aquaporin 2 Homo sapiens 54-58 10930521-2 2000 The Na+-ATPase, insensitive to ouabain, but sensitive to furosemide, is stimulated by Ang-(1-7) (68% by 10(-9) M), in a dose-dependent manner. Furosemide 57-67 angiogenin Sus scrofa 86-94 10910000-2 2000 Furosemide decreased the plasma concentration of hypoxanthine by 39% and increased plasma renin activity (PRA) and the plasma concentration of protein by 3.4-fold and 9%, respectively, at 90 minutes after administration. Furosemide 0-10 renin Homo sapiens 90-95 10856393-5 2000 Three patients restarted furosemide for ankle edema and 1 for blood pressure levels >180/100 mm Hg. Furosemide 25-35 ankyrin repeat and LEM domain containing 1 Homo sapiens 40-57 10799304-7 2000 Treating rats with furosemide, a diuretic which decreases the kidney interstitium osmolarity without affecting vasopressin levels, led to decreased levels of the UT-A2 protein. Furosemide 19-29 arginine vasopressin Rattus norvegicus 111-122 10799304-7 2000 Treating rats with furosemide, a diuretic which decreases the kidney interstitium osmolarity without affecting vasopressin levels, led to decreased levels of the UT-A2 protein. Furosemide 19-29 solute carrier family 14 member 2 Homo sapiens 162-167 10988347-3 2000 Furosemide (100 microM) and 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB; 300 microM) completely inhibited PAF (10 microM)-induced increase in short-circuit current (Isc) across the mucosa, indicating that PAF caused a Cl(-) secretion in the rat colon. Furosemide 0-10 PCNA clamp associated factor Rattus norvegicus 109-112 10988347-3 2000 Furosemide (100 microM) and 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB; 300 microM) completely inhibited PAF (10 microM)-induced increase in short-circuit current (Isc) across the mucosa, indicating that PAF caused a Cl(-) secretion in the rat colon. Furosemide 0-10 PCNA clamp associated factor Rattus norvegicus 208-211 10862634-14 2000 With the ammonium chloride test as the gold standard for diagnosis of distal RTA, the frusemide test showed a sensitivity of 1.0 (95% CI, 0.69-1.0) and a specificity of 0.89 (95% CI, 0.78-0.96) for the diagnosis of distal RTA. Furosemide 86-95 MAS related GPR family member F Homo sapiens 77-80 10862634-14 2000 With the ammonium chloride test as the gold standard for diagnosis of distal RTA, the frusemide test showed a sensitivity of 1.0 (95% CI, 0.69-1.0) and a specificity of 0.89 (95% CI, 0.78-0.96) for the diagnosis of distal RTA. Furosemide 86-95 MAS related GPR family member F Homo sapiens 222-225 10793196-1 2000 The purpose of this study was to determine whether the loop diuretics furosemide, bumetanide and ethacrynic acid, which block the KCC1 potassium-chloride transporter in the kidney loop of Henle and the KCC2 potassium-chloride transporter in neuronal membranes, would prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Furosemide 70-80 solute carrier family 12 member 4 Rattus norvegicus 130-134 10793196-1 2000 The purpose of this study was to determine whether the loop diuretics furosemide, bumetanide and ethacrynic acid, which block the KCC1 potassium-chloride transporter in the kidney loop of Henle and the KCC2 potassium-chloride transporter in neuronal membranes, would prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Furosemide 70-80 solute carrier family 12 member 5 Rattus norvegicus 202-206 10845684-10 2000 P-glycoprotein and an efflux pump for furosemide were functionally present. Furosemide 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 10760499-13 2000 We conclude that the receptor-mediated action of angiotensin II is in some way involved in the activation of the pathway that occurs in the SFO, OVLT, SON, and magnocellular region of the paraventricular nucleus (PVN) in response to furosemide treatment. Furosemide 233-243 angiotensinogen Rattus norvegicus 49-63 10760499-14 2000 It is possible that the furosemide-induced activation in the SON and PVN is not due to direct actions of angiotensin II on angiotensin receptors in those structures, but instead occurs synaptically as a result of inputs from the SFO and OVLT, which have themselves been activated directly by angiotensin II. Furosemide 24-34 angiotensinogen Rattus norvegicus 105-119 10760498-6 2000 In both experiments, the furosemide-treated rats had significantly more Fos-positive cell nuclei than vehicle-treated rats in the subfornical organ (SFO), organum vasculosum lamina terminalis (OVLT), supraoptic nuclei (SON), and magnocellular region of the paraventricular nuclei (PVN) - areas previously shown to be activated by hypovolemia or peripheral angiotensin. Furosemide 25-35 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 72-75 10760498-7 2000 In the short-survival experiment, the furosemide-treated rats had more Fos-positive cell nuclei in the nucleus of the solitary tract (NTS) and in the dorsal horn of the spinal cord at spinal levels T(11), T(12), and T(13). Furosemide 38-48 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 71-74 10760499-14 2000 It is possible that the furosemide-induced activation in the SON and PVN is not due to direct actions of angiotensin II on angiotensin receptors in those structures, but instead occurs synaptically as a result of inputs from the SFO and OVLT, which have themselves been activated directly by angiotensin II. Furosemide 24-34 angiotensinogen Rattus norvegicus 292-306 10760498-12 2000 In this experiment, furosemide administration increased the number of Fos-positive cells in the SFO, OVLT, SON and PVN, but not in the caudal thoracic spinal cord or NTS. Furosemide 20-30 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 70-73 10760498-15 2000 It is hypothesized that activation in these forebrain regions depends on the action of angiotensin II that is generated after furosemide treatment. Furosemide 126-136 angiotensinogen Rattus norvegicus 87-101 10760499-17 2000 Thus, the present results also suggest that the central blockade of the formation of angiotensin II or blockade of the actions of angiotensin II prevents in some way the activation of the renal afferent pathway mediated by the renal nerves (the direct pathway) in response to the actions of furosemide. Furosemide 291-301 angiotensinogen Rattus norvegicus 85-99 10760499-6 2000 In the first experiment, furosemide injection was preceded by treatment with a dose of Captopril, CAP, (an angiotensin-converting enzyme (ACE) inhibitor) that blocks the peripheral but not the central formation of angiotensin II. Furosemide 25-35 angiotensin I converting enzyme Rattus norvegicus 107-136 10760499-6 2000 In the first experiment, furosemide injection was preceded by treatment with a dose of Captopril, CAP, (an angiotensin-converting enzyme (ACE) inhibitor) that blocks the peripheral but not the central formation of angiotensin II. Furosemide 25-35 angiotensin I converting enzyme Rattus norvegicus 138-141 10760499-7 2000 In the second experiment, furosemide injection was preceded by treatment with a higher dose of CAP; this dosage blocks the peripheral and central formation of angiotensin II. Furosemide 26-36 angiotensinogen Rattus norvegicus 159-173 10760499-11 2000 Rats receiving furosemide plus the low CAP dose showed more Fos-positive cells than control rats in the subfornical organ (SFO), organum vasculosum lamina terminalis (OVLT), supraoptic nucleus (SON), magnocellular region of the paraventricular nucleus, nucleus of the solitary tract (NTS), and caudal thoracic/rostral lumbar spinal cord dorsal horn. Furosemide 15-25 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 60-63 10760499-17 2000 Thus, the present results also suggest that the central blockade of the formation of angiotensin II or blockade of the actions of angiotensin II prevents in some way the activation of the renal afferent pathway mediated by the renal nerves (the direct pathway) in response to the actions of furosemide. Furosemide 291-301 angiotensinogen Rattus norvegicus 130-144 10577572-11 1999 Frusemide significantly increased mean plasma renin activity (days 0 and 42), and the mean aldosterone concentration (day 42) in comparison with placebo, whereas candoxatril caused no significant changes in any of the hormonal parameters assessed. Furosemide 0-9 renin Homo sapiens 46-51 10727523-9 2000 Probenecid, sulfinpyrazone, indomethacin, furosemide, and penicillin G all significantly increased MRP2-ATPase activity, whereas these compounds acted more as ATPase inhibitors on MRP1. Furosemide 42-52 ATP binding cassette subfamily C member 2 Homo sapiens 99-103 10727523-9 2000 Probenecid, sulfinpyrazone, indomethacin, furosemide, and penicillin G all significantly increased MRP2-ATPase activity, whereas these compounds acted more as ATPase inhibitors on MRP1. Furosemide 42-52 ATP binding cassette subfamily C member 1 Homo sapiens 180-184 11125222-8 2000 Likewise, a reduction of insulin-induced swelling by the loop diuretics furosemide and bumetanide cause insulin resistance shown by the levels of cell swelling, MAP-kinase activation and proteolysis control. Furosemide 72-82 insulin Homo sapiens 25-32 10604960-7 2000 The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system). Furosemide 17-27 renin Rattus norvegicus 69-74 10604960-7 2000 The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system). Furosemide 17-27 renin Rattus norvegicus 156-161 10604960-7 2000 The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system). Furosemide 131-141 renin Rattus norvegicus 69-74 10604960-7 2000 The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system). Furosemide 131-141 renin Rattus norvegicus 156-161 11041285-10 2000 A strong immunostaining for FKBP-12, a tacrolimus-binding protein, was observed in the medulla of the kidneys of rats treated with tacrolimus either with or without furosemide. Furosemide 165-175 FKBP prolyl isomerase 1A Rattus norvegicus 28-35 10690296-3 1999 RESULTS: Bradykinin and thapsigargin significantly decreased the MQAE fluorescence intensity, which indicates increased [Cl-]i; these changes were reversed by removal of extracellular chloride (Cl-o) and were significantly inhibited by Cl(-)-channel inhibitor N-phenylanthranilic acid but not by Na(+)-K(+)-Cl- cotransport inhibitor furosemide. Furosemide 333-343 kininogen 1 Homo sapiens 9-19 10750752-7 2000 The dosage of furosemide was significantly lower and the urine volume was significantly larger in the hANP group. Furosemide 14-24 natriuretic peptide A Homo sapiens 102-106 10681377-8 2000 Plasma renin activity was increased by the bolus and the infusion of furosemide, even in the presence of 121 ml/h of fluid replacement. Furosemide 69-79 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 7-12 10703687-5 2000 RESULTS: No significant differences between groups were detected at baseline except that patients with higher ACE inhibitor doses were more likely to take nitrates, beta-blockers and amiodarone, received higher furosemide doses and had higher serum gamma-glutamyl transferase levels. Furosemide 211-221 angiotensin I converting enzyme Homo sapiens 110-113 10567922-7 2000 Furthermore, the two specific inhibitors of the Na(+)/K(+)/Cl(-) cotransporter activity; bumetanide and furosemide inhibited the clonogenic efficiency in the NKCC1 transfected cells. Furosemide 104-114 solute carrier family 12, member 2 Mus musculus 158-163 10842416-6 2000 The changes in the ETK (erythrocyte transketolase activity in whole blood) and a-ETK (ETK activity coefficient) during the hospital stay correlated with the cumulative dosage of furosemide adjusted for the duration of the therapy (r = 0.36, p < 0.001 and r = - 0.28, p > 0.03). Furosemide 178-188 EPH receptor A3 Homo sapiens 19-22 10842416-6 2000 The changes in the ETK (erythrocyte transketolase activity in whole blood) and a-ETK (ETK activity coefficient) during the hospital stay correlated with the cumulative dosage of furosemide adjusted for the duration of the therapy (r = 0.36, p < 0.001 and r = - 0.28, p > 0.03). Furosemide 178-188 EPH receptor A3 Homo sapiens 81-84 10842416-6 2000 The changes in the ETK (erythrocyte transketolase activity in whole blood) and a-ETK (ETK activity coefficient) during the hospital stay correlated with the cumulative dosage of furosemide adjusted for the duration of the therapy (r = 0.36, p < 0.001 and r = - 0.28, p > 0.03). Furosemide 178-188 EPH receptor A3 Homo sapiens 81-84 10577447-8 1999 Frusemide reduced plasma concentrations of atrial natriuretic factor and increased plasma renin activity. Furosemide 0-9 renin Homo sapiens 90-95 10619350-9 1999 RESULTS: There was a significant reduction in levels of TNF-alpha and IL-6 at a furosemide concentration of 0.5 x 10(-2) M and a reduction in IL-8 levels at 10(-2) M. This inhibition was comparable to that found with equivalent molar concentrations of hydrocortisone. Furosemide 80-90 tumor necrosis factor Homo sapiens 56-65 10619350-9 1999 RESULTS: There was a significant reduction in levels of TNF-alpha and IL-6 at a furosemide concentration of 0.5 x 10(-2) M and a reduction in IL-8 levels at 10(-2) M. This inhibition was comparable to that found with equivalent molar concentrations of hydrocortisone. Furosemide 80-90 interleukin 6 Homo sapiens 70-74 10525077-7 1999 CeOAT1 exhibits broad specificity, accepting anions such as folate, indomethacin, furosemide, probenecid, and benzylpenicillin as substrates. Furosemide 82-92 MFS domain-containing protein Caenorhabditis elegans 0-6 10497143-8 1999 UGT1A8, but not UGT1A10, catalyzed the glucuronidation of opioids, bile acids, fatty acids, retinoids, and clinically useful drugs, such as ciprofibrate, furosemide, and diflunisal. Furosemide 154-164 UDP glucuronosyltransferase family 1 member A8 Homo sapiens 0-6 10604545-7 1999 AT II markedly increased by the stimulation test using furosemide (1 mg/kg i.v.). Furosemide 55-65 angiotensinogen Homo sapiens 0-5 10513831-3 1999 In eight healthy subjects, injection of furosemide increased plasma renin activity (PRA) with little or no change in blood pressure or heart rate. Furosemide 40-50 renin Homo sapiens 68-73 10233039-6 1999 Plasma levels of aldosterone and plasma renin activity are substantially increased 3 h after furosemide treatment, and so the NaCl appetite cannot result simply from progressively increasing levels of these hormones. Furosemide 93-103 renin Rattus norvegicus 40-45 10510146-0 1999 The effect of nitric oxide inhibition on the renin response to frusemide, in man. Furosemide 63-72 renin Homo sapiens 45-50 10543284-3 1999 The aim of this study was to assess whether pretreatment with nebulized Fur (40 mg) was able to modulate PAF-induced systemic and respiratory effects in asthma. Furosemide 72-75 PCNA clamp associated factor Homo sapiens 105-108 10543284-7 1999 Although Fur did not alter PAF-induced systemic and respiratory effects, it did partially inhibit (63%; p<0.04) the increments of uLTE4 levels shown after PAF inhalation. Furosemide 9-12 PCNA clamp associated factor Homo sapiens 158-161 10347194-6 1999 The expression of mouse KCC3 in Xenopus laevis oocytes reveals the expected functional characteristics of a K+Cl- cotransporter: Cl--dependent uptake of 86Rb+ which is strongly activated by cell swelling and weakly sensitive to furosemide. Furosemide 228-238 solute carrier family 12, member 6 Mus musculus 24-28 10347239-5 1999 By making alpha1/alpha6 chimeras we have identified a transmembrane region (209-279) responsible for the high furosemide sensitivity of alpha6beta3gamma2s receptors. Furosemide 110-120 adrenoceptor alpha 1D Homo sapiens 10-23 10510146-6 1999 L-NMMA completely blocked the renin rise following the bolus of frusemide (1.18+/-0.196 vs 1.96+/-0.333 ng ml-1 h-1 P<0.01). Furosemide 64-73 renin Homo sapiens 30-35 10510146-7 1999 Phenylephrine 0.5 microg kg-1 min-1 produced very similar haemodynamic effects to L-NMMA, and also suppressed the renin response to frusemide (1.43+/-0.290 vs 2.67+/-0.342 ng ml-1 h-1 P<0. Furosemide 132-141 CD59 molecule (CD59 blood group) Homo sapiens 30-35 10510146-7 1999 Phenylephrine 0.5 microg kg-1 min-1 produced very similar haemodynamic effects to L-NMMA, and also suppressed the renin response to frusemide (1.43+/-0.290 vs 2.67+/-0.342 ng ml-1 h-1 P<0. Furosemide 132-141 renin Homo sapiens 114-119 10464063-5 1999 The ATPase-dependent Na(+) pump and Na(+)-K(+)-2Cl(-) co-transport activities were assessed from Na(+)-loaded red blood cells by using nystatine, in the presence of furosemide and ouabain, as appropriate. Furosemide 165-175 dynein axonemal heavy chain 8 Homo sapiens 4-10 9950961-9 1999 Like rat OAT1 organic anion transporter, hPAHT was inhibited by furosemide, indomethacin, probenecid, and alpha-ketoglutarate. Furosemide 64-74 solute carrier family 22 member 6 Homo sapiens 9-13 10187864-8 1999 An increased initial uptake rate of 86Rb was seen in clones with high KCC3 expression, which was dependent on extracellular Cl- but not Na+ and was inhibitable by the loop diuretic agent furosemide. Furosemide 187-197 solute carrier family 12 member 6 Homo sapiens 70-74 9950961-9 1999 Like rat OAT1 organic anion transporter, hPAHT was inhibited by furosemide, indomethacin, probenecid, and alpha-ketoglutarate. Furosemide 64-74 solute carrier family 22 member 6 Homo sapiens 41-46 10077374-8 1999 Intolerance to ACE inhibitor was defined as hypotension (<95 mmHg systolic blood pressure or a decrease exceeding 25 mmHg in systolic blood pressure) leading to oliguria (<0.5 ml/kg per h) which was unresponsive to intravenous furosemide (20 mg). Furosemide 233-243 angiotensin I converting enzyme Homo sapiens 15-18 10100306-0 1999 Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum. Furosemide 17-27 solute carrier family 6 member 2 Rattus norvegicus 0-3 10100306-5 1999 RESULTS: Net secretion from rat intestine of over 3-fold was observed for 20 microM furosemide. Furosemide 84-94 solute carrier family 6 member 2 Rattus norvegicus 9-12 10100306-6 1999 Net secretion of furosemide by Caco-2 cells was over 300% greater than for intestinal segments (10-fold vs. 3-fold). Furosemide 17-27 solute carrier family 6 member 2 Homo sapiens 0-3 9887087-6 1999 hOAT1-mediated PAH uptake was inhibited by bulky inorganic anions, various xenobiotics, and endogenous substances, including benzylpenicillin, furosemide, indomethacin, probenecid, phenol red, urate, and alpha-ketoglutarate. Furosemide 143-153 solute carrier family 22 member 6 Homo sapiens 0-5 10713865-1 1999 Five years ago, our in vitro and in vivo studies demonstrated for the first time that diuretic agents such as furosemide, hydrochlorothiazide, amiloride, triamterene and spironolactone inhibit carbonic anhydrase (CA) I, II and renal CA IV by a direct mechanism of action. Furosemide 110-120 carbonic anhydrase 1 Homo sapiens 193-218 10713865-1 1999 Five years ago, our in vitro and in vivo studies demonstrated for the first time that diuretic agents such as furosemide, hydrochlorothiazide, amiloride, triamterene and spironolactone inhibit carbonic anhydrase (CA) I, II and renal CA IV by a direct mechanism of action. Furosemide 110-120 carbonic anhydrase 4 Homo sapiens 233-238 9928060-0 1998 Effect of sodium depletion by frusemide on tissue concentrations and metabolism of VIP. Furosemide 30-39 vasoactive intestinal peptide Homo sapiens 83-86 19281395-1 1999 A furosemide-sensitive Na-K-Cl cotransporter (NKCC2 isoform) accounts for almost all luminal NaCl reabsorption in the thick ascending limb of Henle"s loop (TALH). Furosemide 2-12 solute carrier family 12 member 1 Rattus norvegicus 46-51 10954127-6 1999 Furosemide and indapamide, diuretics known to have vasodilating effects, induce the fall of blood pressure that parallels the decrease of CA I activity. Furosemide 0-10 carbonic anhydrase 1 Homo sapiens 138-142 9914266-5 1999 In each case, recordings from the CA1 region showed that reduction of [Cl-]o to 21 mM reversibly blocked the bursting within 1 h. Similar to previous observations with furosemide treatment, low-[Cl-]o medium blocked spontaneous hypersynchronous discharges without reducing synaptic hyperexcitability (i.e., hyperexcitable field responses evoked by electrical stimulation). Furosemide 168-178 carbonic anhydrase 1 Rattus norvegicus 34-37 9929566-2 1999 Acute administration of the loop diuretic furosemide significantly reduced AR, SMIT and BGT gene expression in the inner and outer medulla compared with controls. Furosemide 42-52 aldo-keto reductase family 1 member B1 Rattus norvegicus 75-77 9929566-2 1999 Acute administration of the loop diuretic furosemide significantly reduced AR, SMIT and BGT gene expression in the inner and outer medulla compared with controls. Furosemide 42-52 solute carrier family 5 member 3 Rattus norvegicus 79-83 9862246-0 1998 Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle. Furosemide 0-9 angiotensinogen Homo sapiens 19-33 9862246-3 1998 Since angiotensin II is a highly potent vasoconstrictor involved in the pathophysiology of these diseases, we have investigated the effect of frusemide on the contraction elicited by angiotensin II on human internal mammary artery (IMA) and saphenous vein (SV). Furosemide 142-151 angiotensinogen Homo sapiens 183-197 9862246-7 1998 RESULTS: Frusemide induced a concentration-dependent decrease of the contraction elicited by angiotensin II on IMA and SV. Furosemide 9-18 angiotensinogen Homo sapiens 93-107 9862246-8 1998 On both vessels, the inhibitory effect on the maximal contraction to angiotensin II was significant with concentrations of frusemide from 10(-5) to 10(-3) M. Angiotensin II potency (pD2) was only reduced by 10(-3) M frusemide. Furosemide 123-132 angiotensinogen Homo sapiens 69-83 9862246-8 1998 On both vessels, the inhibitory effect on the maximal contraction to angiotensin II was significant with concentrations of frusemide from 10(-5) to 10(-3) M. Angiotensin II potency (pD2) was only reduced by 10(-3) M frusemide. Furosemide 123-132 angiotensinogen Homo sapiens 158-172 9862246-8 1998 On both vessels, the inhibitory effect on the maximal contraction to angiotensin II was significant with concentrations of frusemide from 10(-5) to 10(-3) M. Angiotensin II potency (pD2) was only reduced by 10(-3) M frusemide. Furosemide 216-225 angiotensinogen Homo sapiens 69-83 9862246-8 1998 On both vessels, the inhibitory effect on the maximal contraction to angiotensin II was significant with concentrations of frusemide from 10(-5) to 10(-3) M. Angiotensin II potency (pD2) was only reduced by 10(-3) M frusemide. Furosemide 216-225 angiotensinogen Homo sapiens 158-172 9862246-10 1998 Bumetanide was less potent than frusemide in inhibiting angiotensin II-induced contractions in both IMA and SV. Furosemide 32-41 angiotensinogen Homo sapiens 56-70 9862246-11 1998 CONCLUSIONS: Frusemide, at concentrations in the therapeutic range (10(-5) M), inhibits angiotensin II-induced contraction on human isolated IMA and SV. Furosemide 13-22 angiotensinogen Homo sapiens 88-102 9767530-6 1998 Addition of furosemide, but not chlorothiazide, to animals on the 8.0% NaCl diet further augmented steady-state mRNA levels of THP. Furosemide 12-22 uromodulin Rattus norvegicus 127-130 9864275-12 1998 When the natriuresis was expressed relative to UFURV (i.e., the natriuretic efficiency), we found that natriuretic efficiency of furosemide was significantly increased in untreated CBL rats (+59%). Furosemide 129-139 Cbl proto-oncogene Rattus norvegicus 181-184 9864275-13 1998 However, the natriuretic efficiency of furosemide was normalized in CBL rats treated with canrenoate. Furosemide 39-49 Cbl proto-oncogene Rattus norvegicus 68-71 9864275-14 1998 The urinary excretion of furosemide was unchanged in untreated CBL rats, but it was significantly increased in cirrhotic rats treated with canrenoate (+43%). Furosemide 25-35 Cbl proto-oncogene Rattus norvegicus 63-66 9832372-4 1998 The photodegradation product of furosemide glucuronide was hydrolyzed to one of the photodegradation products of furosemide by beta-glucuronidase, indicating that the photodegradation product of furosemide glucuronide possessed a glucuronic acid moiety. Furosemide 32-42 glucuronidase beta Homo sapiens 127-145 9767530-7 1998 CONCLUSIONS: An increase in dietary salt and the loop diuretic, furosemide, increased expression of THP in the rat. Furosemide 64-74 uromodulin Rattus norvegicus 100-103 9716718-3 1998 Both the sodium- and chloride-dependent betaine transporter (BGT) and sodium-dependent myo-inositol transporter (SMIT) were expressed preferentially in macula densa cells and for both mRNAs the signal intensity was visibly reduced by furosemide. Furosemide 234-244 solute carrier family 6 member 12 Rattus norvegicus 9-59 9716718-3 1998 Both the sodium- and chloride-dependent betaine transporter (BGT) and sodium-dependent myo-inositol transporter (SMIT) were expressed preferentially in macula densa cells and for both mRNAs the signal intensity was visibly reduced by furosemide. Furosemide 234-244 solute carrier family 5 member 3 Rattus norvegicus 70-111 9716718-3 1998 Both the sodium- and chloride-dependent betaine transporter (BGT) and sodium-dependent myo-inositol transporter (SMIT) were expressed preferentially in macula densa cells and for both mRNAs the signal intensity was visibly reduced by furosemide. Furosemide 234-244 solute carrier family 5 member 3 Rattus norvegicus 113-117 9716718-4 1998 The enzymes aldose reductase (which mediates the conversion of glucose to sorbitol) and sorbitol dehydrogenase (which converts sorbitol into fructose) were expressed not only in macula densa cells but also in the surrounding tubular cells, and the expression was insensitive to furosemide. Furosemide 278-288 aldo-keto reductase family 1 member B1 Rattus norvegicus 12-28 9665357-4 1998 RESULTS: In the 8 hours after furosemide ingestion there were increases in levels of plasma cholesterol (10.1%; P = .001), high-density lipoprotein cholesterol (9.0%; P = .006), and apolipoprotein B (9.8%; P = .003). Furosemide 30-40 apolipoprotein B Homo sapiens 182-198 9737091-3 1998 Therefore, we assessed the effects of meloxicam, a selective inhibitor of COX-2, and indomethacin, an unselective inhibitor of COX-1 and COX-2, on furosemide stimulated plasma renin activity (PRA). Furosemide 147-157 renin Homo sapiens 176-181 9737091-13 1998 CONCLUSION: Meloxicam inhibited furosemide stimulated renin release, suggesting that in man COX-2 is responsible for prostaglandin synthesis mediating renin release. Furosemide 32-42 renin Homo sapiens 54-59 9737091-13 1998 CONCLUSION: Meloxicam inhibited furosemide stimulated renin release, suggesting that in man COX-2 is responsible for prostaglandin synthesis mediating renin release. Furosemide 32-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 9737091-13 1998 CONCLUSION: Meloxicam inhibited furosemide stimulated renin release, suggesting that in man COX-2 is responsible for prostaglandin synthesis mediating renin release. Furosemide 32-42 renin Homo sapiens 151-156 9735929-0 1998 Renin-aldosterone system can respond to furosemide in patients with hyperkalemic hyporeninism. Furosemide 40-50 renin Homo sapiens 0-5 9735929-10 1998 Plasma atrial natriuretic peptide (ANP) fell with furosemide in 8 of 8 responders and in 1 of the 2 nonresponders in whom it was measured. Furosemide 50-60 natriuretic peptide A Homo sapiens 7-33 9735929-10 1998 Plasma atrial natriuretic peptide (ANP) fell with furosemide in 8 of 8 responders and in 1 of the 2 nonresponders in whom it was measured. Furosemide 50-60 natriuretic peptide A Homo sapiens 35-38 9682923-1 1998 A furosemide-sensitive Na-K-Cl cotransporter (NKCC2 isoform) accounts for almost all luminal NaCl reabsorption in the thick ascending limb of Henle"s loop (TALH). Furosemide 2-12 solute carrier family 12 member 1 Rattus norvegicus 46-51 9696953-4 1998 RESULTS: PRA, AII and PA increased significantly after furosemide administration whereas ACTH and potassium did not. Furosemide 55-65 angiotensinogen Homo sapiens 14-17 9608012-1 1998 Micropuncture studies of single nephrons have shown that macula densa solute reabsorption via a furosemide-sensitive pathway activates nitric oxide (NO) generation via neuronal NO synthase (nNOS). Furosemide 96-106 nitric oxide synthase 1 Rattus norvegicus 190-194 9696953-7 1998 CONCLUSION: These results suggest that, in contrast to cimetidine, the inhibitory effect of omeprazole on AII-stimulated aldosterone production following dosing with furosemide is negligible. Furosemide 166-176 angiotensinogen Homo sapiens 106-109 9514615-3 1998 Mutual displacement experiments indicated that furosemide and valproic acid share a common high affinity binding site on human serum albumin (HSA). Furosemide 47-57 albumin Homo sapiens 127-140 9622326-6 1998 Frusemide significantly affected the right atrial and pulmonary artery pressure and ANP responses to exercise. Furosemide 0-9 natriuretic peptide A Equus caballus 84-87 9622326-7 1998 Fluid administration decreased plasma total protein concentrations at rest and during running and abolished the effects of frusemide on the haemodynamic and ANP responses to exercise. Furosemide 123-132 natriuretic peptide A Equus caballus 157-160 9683914-8 1998 In order to differentiate the potential role of elevated renin in the down-regulation of pulmonary ACE, additional rats (n = 12) were treated with furosemide that resulted in a 8-fold rise in plasma renin activity, but only in a marginal decrease of pulmonary ACE mRNA levels and activity (-10% vs. sham (n = 8), P-value n.s.). Furosemide 147-157 renin Rattus norvegicus 199-204 9523993-1 1998 The binding conformations of oxyphenbutazone (OXY), Nepsilon-dansyl-L-lysine (DNS-LYS), and furosemide (FU) to human serum albumin (HSA) have been investigated by molecular dynamics (MD) calculations and transferred nuclear Overhauser effect (TRNOE) measurements. Furosemide 92-102 albumin Homo sapiens 117-136 9596069-5 1998 Simultaneous infusion of the diuretic agent furosemide prevented the AVP-induced decrease in the 117-kD band. Furosemide 44-54 arginine vasopressin Rattus norvegicus 69-72 9596069-7 1998 However, when AVP-treated rats were infused with furosemide for 5 d, the 117-kD band was markedly accentuated, whereas the 97-kD band was unchanged. Furosemide 49-59 arginine vasopressin Rattus norvegicus 14-17 9518596-6 1998 Moreover, the proportion of neurons changing sensitivity to AII after one application of Aldo was increased in the furosemide group (44.2% vs. 20.4%, p=0.0123). Furosemide 115-125 angiotensinogen Homo sapiens 60-63 10323004-7 1997 The changes indicate that Ca2+ may play an important role in the mechanism of the furosemide test. Furosemide 82-92 LOW QUALITY PROTEIN: carbonic anhydrase 2 Cavia porcellus 26-29 9502574-2 1998 Two genes, the gene encoding the furosemide-sensitive apical Na-K-2Cl cotransporter (NKCC2) and the gene encoding the luminal inwardly-rectifying potassium channel Kir 1.1 (ROMK), have been reported to cause the neonatal subtype of Bartter syndrome. Furosemide 33-43 solute carrier family 12 member 1 Homo sapiens 85-90 9374636-6 1997 Both furosemide [inhibition constant (Ki) approximately 25 microM] and bumetanide (Ki approximately 55 microM) inhibited the NEM-stimulated 86Rb influx in the KCC2-9 cells. Furosemide 5-15 solute carrier family 12 member 5 Homo sapiens 159-163 9365820-2 1997 injection of 2 mg/kg of furosemide resulted in a sustained increase in heart rate and an age-dependent increase in plasma renin activity. Furosemide 24-34 renin Ovis aries 122-127 9439444-5 1997 Similar cascade effects on furosemide binding in the presence of CMPF were also originated by other long-chain (C18) fatty acids, linoleate and stearate, although to a lesser extent. Furosemide 27-37 Bardet-Biedl syndrome 9 Homo sapiens 112-115 9388483-0 1997 Angiotensin II mediates cell hypertrophy in vascular smooth muscle cultures from hypertensive Ren-2 transgenic rats by an amiloride- and furosemide-sensitive mechanism. Furosemide 137-147 angiotensinogen Rattus norvegicus 0-14 9388483-3 1997 In both SD- and TGR-VSMC, AII increased both cell size, by a furosemide- and amiloride-sensitive mechanism, and Na+/K+/2Cl- cotransport activity, by an amiloride-sensitive mechanism. Furosemide 61-71 angiotensinogen Rattus norvegicus 26-29 9371207-0 1997 Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma. Furosemide 65-74 tachykinin precursor 1 Homo sapiens 11-23 9371207-0 1997 Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma. Furosemide 65-74 tachykinin precursor 1 Homo sapiens 25-28 9371207-2 1997 A randomised, double blind, placebo controlled study was performed to investigate the effect of the potent loop diuretic, frusemide, administered by inhalation on the bronchoconstrictor response to neurokinin A (NKA) and histamine in 11 asthmatic subjects. Furosemide 122-131 tachykinin precursor 1 Homo sapiens 198-210 9371207-2 1997 A randomised, double blind, placebo controlled study was performed to investigate the effect of the potent loop diuretic, frusemide, administered by inhalation on the bronchoconstrictor response to neurokinin A (NKA) and histamine in 11 asthmatic subjects. Furosemide 122-131 tachykinin precursor 1 Homo sapiens 212-215 9371207-5 1997 RESULTS: Compared with placebo, inhaled frusemide reduced the airway responsiveness to NKA in all the subjects studied, the geometric mean (range) values for PC20NKA increasing significantly (p < 0.001) from 130.3 (35.8-378.8) to 419.9 (126.5-1000) micrograms/ml after placebo and frusemide, respectively. Furosemide 40-49 tachykinin precursor 1 Homo sapiens 87-90 9371207-7 1997 CONCLUSIONS: The decrease in airway responsiveness to NKA after administration of frusemide by inhalation suggests that this drug may interfere with the activation of neurotransmission in human asthma. Furosemide 82-91 tachykinin precursor 1 Homo sapiens 54-57 9247750-5 1997 PRA and PRC respond appropriately to physiologic stimuli in pre-eclampsia except for impaired renin release following frusemide, possibly due to prostacyclin deficiency. Furosemide 118-127 renin Homo sapiens 94-99 9174082-11 1997 Frusemide gave a similar pattern of staining to desoxycorticosterone, stimulating c-fos expression in the same regions but to a lesser extent. Furosemide 0-9 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 82-87 9210443-2 1997 Both drugs were extracted from human plasma with ethyl acetate; furosemide was extracted at pH 1 and amiloride at pH 12. Furosemide 64-74 alanine--glyoxylate and serine--pyruvate aminotransferase Homo sapiens 92-96 9186867-7 1997 In other animals furosemide, a diuretic acting on macula densa cells, activated renin synthesis to a level similar to that found in the ramipril-treated group. Furosemide 17-27 renin Rattus norvegicus 80-85 9186867-8 1997 Addition of L-NAME to the furosemide-treated rats suppressed the increases in renin mRNA levels, total renin content and renin secretion, suggesting that NO acts on renin activation by a mechanism independent of angiotensin II. Furosemide 26-36 renin Rattus norvegicus 78-83 9186867-8 1997 Addition of L-NAME to the furosemide-treated rats suppressed the increases in renin mRNA levels, total renin content and renin secretion, suggesting that NO acts on renin activation by a mechanism independent of angiotensin II. Furosemide 26-36 renin Rattus norvegicus 103-108 9186867-8 1997 Addition of L-NAME to the furosemide-treated rats suppressed the increases in renin mRNA levels, total renin content and renin secretion, suggesting that NO acts on renin activation by a mechanism independent of angiotensin II. Furosemide 26-36 renin Rattus norvegicus 103-108 9186867-8 1997 Addition of L-NAME to the furosemide-treated rats suppressed the increases in renin mRNA levels, total renin content and renin secretion, suggesting that NO acts on renin activation by a mechanism independent of angiotensin II. Furosemide 26-36 renin Rattus norvegicus 103-108 8941932-7 1996 Phosphorylation of HSP25 after the 20-minute furosemide diuresis was increased in KC rats. Furosemide 45-55 heat shock protein family B (small) member 1 Rattus norvegicus 19-24 9170004-0 1997 Role of kinins in basal and furosemide-stimulated renin secretion. Furosemide 28-38 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 50-55 9170004-7 1997 Injection of furosemide (2 mg/kg) caused a sustained increase i plasma renin activity from 6.7 +/- 1.6 to 15.9 +/- 3.3 ng/ml/2h (P < 0.01), a transient increase in mean arterial pressure from 72 +/- 3 to 78 +/- 3 mmHg (P < 0.05), and a sustained increase in heart rate from 228 +/- 8 to 253 +/- 6 bpm (P < 0.01). Furosemide 13-23 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 71-76 9088586-7 1997 RESULTS: Plasma renin activity (PRA) was significantly (P < 0.01) increased after prior treatment with frusemide compared with placebo at all time points. Furosemide 106-115 renin Homo sapiens 16-21 9088586-12 1997 It is hypothesised that this effect of frusemide may be due to RAS activation with ANG II mediated pulmonary vasoconstriction. Furosemide 39-48 angiotensinogen Homo sapiens 83-89 8996639-5 1996 Other ionic flux inhibitors 4,4"-diisothiocyanostilbene-2,2"-disulfonic acid (DIDS) and furosemide slightly inhibited the pHi recovery from an acid load. Furosemide 88-98 glucose-6-phosphate isomerase Rattus norvegicus 122-125 9136670-2 1997 To this end the renin system in male Sprague Dawley rats was stimulated by unilateral renal artery clipping (0.2 mm clip), by furosemide (60 mg/kg per diem) or isoproterenol (160 microg/kg per diem), and by ingestion of a low-salt diet (0.02%), or was suppressed by setting a contralateral renal artery clip (0.2-mm clip) or by ingestion of a high-salt diet (4%). Furosemide 126-136 renin Rattus norvegicus 16-21 9136670-4 1997 Renin gene expression was stimulated four- to fivefold by renal artery clipping and isoproterenol infusion, two- to three-fold by furosemide and a low-salt diet, and about four-fold by losartan. Furosemide 130-140 renin Rattus norvegicus 0-5 9196851-2 1997 During ACE inhibition, the rise in heart rate and decrease in renal blood flow in response to furosemide did not occur, and the natriuretic and diuretic responses to furosemide were attenuated by approximately two-thirds. Furosemide 94-104 angiotensin-converting enzyme Ovis aries 7-10 9196851-2 1997 During ACE inhibition, the rise in heart rate and decrease in renal blood flow in response to furosemide did not occur, and the natriuretic and diuretic responses to furosemide were attenuated by approximately two-thirds. Furosemide 166-176 angiotensin-converting enzyme Ovis aries 7-10 9196851-4 1997 Therefore, the cardiovascular, renal, and endocrine responses to furosemide in conscious lambs were significantly altered by ACE inhibition. Furosemide 65-75 angiotensin-converting enzyme Ovis aries 125-128 8930208-7 1996 M17055 and furosemide, but not trichlormethiazide, significantly increased the proportion of cardiac V3 myosin of SHR by enhancing the gene expression of beta-myosin heavy chain. Furosemide 11-21 myosin heavy chain 7 Rattus norvegicus 154-177 8912747-5 1996 However, the increase in PaO2 (to 386.3 +/- 67.5 mm Hg) after infusion of ANP was significantly higher than the increase in PaO2 (to 275.9 +/- 63.3 mm Hg) after furosemide treatment, and in the no treatment control (to 171.1 +/- 31.5 mm Hg). Furosemide 161-171 natriuretic peptides A Sus scrofa 74-77 8872956-3 1996 We investigated the localization of BGT-1 mRNA and its acute regulation by NaCl and furosemide administration. Furosemide 84-94 solute carrier family 6 member 12 Rattus norvegicus 36-41 8872956-8 1996 Intraperitoneal administration of NaCl rapidly increased the signal in the MTAL, and furosemide prevented the increase in BGT-1 mRNA by NaCl loading. Furosemide 85-95 solute carrier family 6 member 12 Rattus norvegicus 122-127 8928409-3 1996 During dynamic testing of the response of plasma renin activity and aldosterone to the administration of furosemide and a vertical position in diabetics a significantly reduced response was recorded as compared with non-diabetic hypertonic subjects. Furosemide 105-115 renin Homo sapiens 49-54 8794909-11 1996 Furosemide, which non-competitively inhibits the GABAA receptor, showed 700-fold selectivity for alpha 6 beta 3 gamma 2 receptors over alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing receptors and exhibited selectivity for alpha 4 beta 3 gamma 2 receptors (> 50-fold). Furosemide 0-10 adrenoceptor alpha 1D Homo sapiens 135-142 8864301-0 1996 Expression of Fos in rat brain in relation to sodium appetite: furosemide and cerebroventricular renin. Furosemide 63-73 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 14-17 8864301-3 1996 Some rats had access to distilled water, and others had no fluids available during the 24 h. All of the furosemide-treated rats showed Fos-IR in both the subfornical organ (SFO) and around the organum vasculosum laminae terminalis (OVLT). Furosemide 104-114 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 135-138 8765998-2 1996 Stimulation of the renin system was achieved by unilateral renal artery clipping (2-kidney/1-clip rats), treatment with the angiotensin II (ANG II) antagonist losartan (40 mg/kg), application of furosemide (12 mg x kg-1 x day-1) and a low-sodium diet (0.02% w/w Na+), which increased renin mRNA levels to 464%, 495%, 309% and 219% of those of control animals, respectively. Furosemide 195-205 renin Rattus norvegicus 19-24 9240763-8 1996 The insulin-mediated increase in Vt was abolished by ouabain and furosemide. Furosemide 65-75 insulin Oryctolagus cuniculus 4-11 8706303-12 1996 Residents receiving frusemide had higher PTH than other residents (medians 6.95 vs 3.45 pmol/l, CI 1.9-4.2 pmol/l, P < 0.0001). Furosemide 20-29 parathyroid hormone Homo sapiens 41-44 8738111-0 1996 Captopril increases renin release stimulated by furosemide and hypotension in isolated perfused guinea pig kidneys. Furosemide 48-58 renin Cavia porcellus 20-25 8738111-3 1996 Captopril increased on a dose dependent basis renin release induced by 0.1 mg/ml furosemide; 5.8 +/- 1.3 ng/ml/hr at 0 mg/ml of captopril vs. 8.8 +/- 1.6 ng/ml/hr at 0.01 mg/ml (p < 0.05) and 11.8 +/- 2.4 ng/ml/hr at 0.1 mg/ml (p < 0.01), 15-20 min after furosemide infusion. Furosemide 81-91 renin Cavia porcellus 46-51 8706303-13 1996 In linear modelling, the most important predictor of the natural logarithm of PTH was daily frusemide dose, adjusted R2 (Ra2) = 31.8%, F = 39.3, P < 0.001. Furosemide 92-101 parathyroid hormone Homo sapiens 78-81 8706303-13 1996 In linear modelling, the most important predictor of the natural logarithm of PTH was daily frusemide dose, adjusted R2 (Ra2) = 31.8%, F = 39.3, P < 0.001. Furosemide 92-101 ribonucleotide reductase regulatory subunit M2 Homo sapiens 121-124 8706303-16 1996 However, the daily frusemide dose is a more important predictor of PTH in this population. Furosemide 19-28 parathyroid hormone Homo sapiens 67-70 8648902-4 1996 Renin secretion was increased in isolated afferent arterioles after in vivo treatment with the diuretic furosemide (+300%) or in vitro treatment with the adenylyl cyclase activator forskolin (+50%), indicating that this vascular preparation responds appropriately to regulators of the renin-angiotensin system. Furosemide 104-114 renin Rattus norvegicus 0-5 8866635-1 1996 RESULTS: Incubation in vitro of human recombinant and erythrocyte (RBC) thiopurine methyl transferase (TPMT) with furosemide, bendroflumethiazide and trichlormethiazide demonstrated inhibition of both enzyme preparations, with IC50 values of 170 microM, 360 microM and 1 mM, respectively. Furosemide 114-124 thiopurine S-methyltransferase Homo sapiens 103-107 8894667-6 1996 Thus we studied the response of the renin-angiotensin-aldosterone system to sodium depletion using a single dose of furosemide. Furosemide 116-126 renin Homo sapiens 36-41 8894667-13 1996 During sodium depletion with furosemide, renin as well as aldosterone levels rose significantly in 1 parent and a sibling, respectively. Furosemide 29-39 renin Homo sapiens 41-46 8770946-5 1996 TGF blockade did not alter baseline diameter of either arteriole, but significantly blunted the mid-afferent vasoconstriction evoked by 10 nM Ang II (44 +/- 7% inhibition by papillectomy; 43 +/- 10% inhibition by furosemide). Furosemide 213-223 angiotensinogen Rattus norvegicus 142-148 8950280-7 1996 Both down-regulation and inhibition of PKC dramatically reduced the furosemide-sensitive Na+/K+/Cl- cotransport, as r fell to 0.239 and 0.032 in bradykinin-stimulated cells after H-7 and 24-h PMA treatments, respectively. Furosemide 68-78 kininogen 1 Homo sapiens 145-155 9163007-7 1996 Heterogeneity of the peritoneal GAA and GSA transport dynamics in the control series of the experiments, as well as in the series with furosemide, may be related to the physico-chemical differences (e.g. molecular mass) of the analysed derivates. Furosemide 135-145 alpha glucosidase Homo sapiens 32-35 8594886-8 1995 Treatment of rats with furosemide for 5 days increased expression of TSC message within the DCT but did not induce its expression elsewhere. Furosemide 23-33 solute carrier family 12 member 3 Rattus norvegicus 69-72 8992496-4 1996 10 day gavage with indapamide, amiloride and cicletanine, as well as angiotensin-converting enzyme (ACE) inhibitor perindopril and calcium channel blockers nifedipine and verapamil decreases capillary permeability, whereas furosemide, hydrochlorothiazide, ACE inhibitor captopril and calcium channel blocker clentiazem do not modify or increase EB extravasation. Furosemide 223-233 angiotensin I converting enzyme Rattus norvegicus 100-103 8594873-5 1995 Furosemide treatment resulted in a marked increase of both NOS and renin levels compared with controls (P < 0.05). Furosemide 0-10 renin Rattus norvegicus 67-72 8594876-4 1995 Furosemide infusion increased plasma renin activity (PRA) from 8.8 +/- 1.4 to 41 +/- 5.2 ng angiotensin I (ANG I).h-1.ml-1 and renin mRNA levels from 112 +/- 8 of standard to 249 +/- 18% of standard. Furosemide 0-10 renin Rattus norvegicus 37-42 8594876-4 1995 Furosemide infusion increased plasma renin activity (PRA) from 8.8 +/- 1.4 to 41 +/- 5.2 ng angiotensin I (ANG I).h-1.ml-1 and renin mRNA levels from 112 +/- 8 of standard to 249 +/- 18% of standard. Furosemide 0-10 renin Rattus norvegicus 127-132 8594876-5 1995 After treatment with indomethacin, the furosemide-induced increases in renin mRNA levels was attenuated to 190 +/- 11% of standard. Furosemide 39-49 renin Rattus norvegicus 71-76 8594876-6 1995 After injections of L-NAME, both the furosemide-induced increases of renin mRNA levels and of PRA were reduced to 126 +/- 14% of standard and 22 +/- 5 ng ANG I.h-1.ml-1, respectively. Furosemide 37-47 renin Rattus norvegicus 69-74 8553380-2 1995 Results obtained were as follows: (1) GAA synthesis was significantly suppressed with 1 mM GM; (2) GM-induced decrease in GAA synthesis was recognized during incubation longer than 15 min; (3) furosemide significantly enhanced the suppression of GAA synthesis by GM. Furosemide 193-203 alpha glucosidase Rattus norvegicus 38-41 8553380-2 1995 Results obtained were as follows: (1) GAA synthesis was significantly suppressed with 1 mM GM; (2) GM-induced decrease in GAA synthesis was recognized during incubation longer than 15 min; (3) furosemide significantly enhanced the suppression of GAA synthesis by GM. Furosemide 193-203 alpha glucosidase Rattus norvegicus 122-125 8553380-2 1995 Results obtained were as follows: (1) GAA synthesis was significantly suppressed with 1 mM GM; (2) GM-induced decrease in GAA synthesis was recognized during incubation longer than 15 min; (3) furosemide significantly enhanced the suppression of GAA synthesis by GM. Furosemide 193-203 alpha glucosidase Rattus norvegicus 122-125 8708993-5 1995 The mean renal clearance of frusemide was 90.2 +/- 16.9 mL min-1 during the first period and 91.5 +/- 29.3 mL min-1 in the remaining period, during which the stimulation of urine production was absent. Furosemide 28-37 CD59 molecule (CD59 blood group) Homo sapiens 59-64 7583049-0 1995 Furosemide treatment alters the distribution of kallikrein gene expression in kidneys of mice. Furosemide 0-10 kallikrein 1-related peptidase b9 Mus musculus 48-58 8589285-6 1995 Therapeutic conclusions can be drawn from the observation that both losartan and hydralazine/furosemide reduced osteopontin expression, macrophage infiltration, transforming growth factor-beta expression, and interstitial fibrosis, but did not prevent the decrease in GFR. Furosemide 93-103 secreted phosphoprotein 1 Rattus norvegicus 112-123 7583049-4 1995 Although the overall level of kallikrein gene expression was significantly greater in kidneys from furosemide-treated mice than in any other group, there was no detectable change in renal kallikrein gene expression in the submandibular glands after any of the treatments. Furosemide 99-109 kallikrein 1-related peptidase b9 Mus musculus 30-40 7586717-11 1995 In the group that received frusemide and the low sodium diet, VIP in the lung was significantly lower than the low sodium (P < 0.005) and normal sodium (P < 0.0001) groups. Furosemide 27-36 vasoactive intestinal peptide Rattus norvegicus 62-65 7657791-2 1995 To investigate the physiological role of the SMIT, we sought to determine its localization by in situ hybridization and its acute regulation by NaCl and furosemide administration. Furosemide 153-163 solute carrier family 5 member 3 Rattus norvegicus 45-49 8586834-2 1995 METHODS: We artificially activated the renin-angiotensin-aldosterone system by two means: by pretreatment with frusemide (40 mg/day orally for 2 days) and by administering exogenous angiotensin II (1 ng/kg per min intravenously). Furosemide 111-120 renin Homo sapiens 39-44 7607716-0 1995 Effects of furosemide and verapamil on the NaCl dependency of macula densa-mediated renin secretion. Furosemide 11-21 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 84-89 8584500-1 1995 This investigation aimed at examing the hypothesis that furosemide elicits renal sympathoexcitation through stimulation of renal renin release, which in turn produces increased plasma angiotensin II levels, causing centrally mediated sympathoexcitation. Furosemide 56-66 angiotensinogen Rattus norvegicus 184-198 7543251-0 1995 Selective neuronal nitric oxide synthase inhibition blocks furosemide-stimulated renin secretion in vivo. Furosemide 59-69 renin Rattus norvegicus 81-86 7543251-3 1995 To test whether neuronal NOS mediates renin secretion, renin was stimulated by either the renal baroreceptor or the diuretic furosemide (acting through the macula densa pathway). Furosemide 125-135 renin Rattus norvegicus 55-60 7654491-8 1995 The non-renal clearance of frusemide (36.7 +/- 21.0 vs 15.2 +/- 13.4 ml min-1, P = 0.0068) was also decreased. Furosemide 27-36 CD59 molecule (CD59 blood group) Homo sapiens 72-77 7607716-5 1995 Addition of 50 mumol/L furosemide to the luminal fluid caused renin secretion to become essentially independent of macula densa NaCl concentration. Furosemide 23-33 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 62-67 7594440-2 1995 METHODS: Endogenous levels of angiotensin II in the rats were increased either by unilateral 0.2-mm renal artery clips or by subcutaneous infusions of frusemide (12 mg/day) and by low-sodium diet. Furosemide 151-160 angiotensinogen Rattus norvegicus 30-44 7589163-0 1995 Furosemide inhibits bradykinin-induced contraction of human bronchi: role of thromboxane A2 receptor antagonism. Furosemide 0-10 kininogen 1 Homo sapiens 20-30 7543396-0 1995 Effect of blockade of nitric oxide synthesis on the renin secretory response to frusemide in conscious rabbits. Furosemide 80-89 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 52-57 7543396-3 1995 In the present study, we investigated the effect of inhibiting nitric oxide synthase on the renin secretory response to frusemide, which stimulates renin secretion by blocking Na(+)-K(+)-2Cl- co-transport in the macula densa. Furosemide 120-129 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 92-97 7543396-3 1995 In the present study, we investigated the effect of inhibiting nitric oxide synthase on the renin secretory response to frusemide, which stimulates renin secretion by blocking Na(+)-K(+)-2Cl- co-transport in the macula densa. Furosemide 120-129 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 148-153 7543396-9 1995 Inhibition of nitric oxide synthase with NG-nitro-L-arginine methyl ester increased mean arterial pressure by 9 mmHg, decreased heart rate and plasma renin activity, and markedly suppressed the renin response to frusemide (from 4.6 +/- 0.7 to 7.6 +/- 1.7, 4.7 +/- 1.0 and 4.6 +/- 0.7 pmol 2 h-1 ml-1 at 15, 30 and 45 min respectively). Furosemide 212-221 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 194-199 7752314-5 1995 Five years postoperatively, ambulation and furosemide administration under low sodium diet stimuli remarkably enhanced plasma renin activity and plasma aldosterone concentration in the aldosterone-producing adenoma enucleation group (p < 0.001), almost similar to that of normal subjects but increment magnitudes were slight (p < 0.05 to < 0.01) in the adrenalectomy group. Furosemide 43-53 renin Homo sapiens 126-131 7651759-4 1995 Plasma renin activity was elevated by furosemide treatment. Furosemide 38-48 renin Rattus norvegicus 7-12 7589163-2 1995 Furosemide 10(-4) to 10(-3) M concentration dependently inhibited bradykinin- and the stable TP receptor agonist U-46619-induced contraction of human isolated small airways. Furosemide 0-10 kininogen 1 Homo sapiens 66-76 7589163-4 1995 Such an inhibition of TP receptors could a least partly explain the inhibitory effect of furosemide on bradykinin-induced contraction, and could be one of the mechanisms of the protective effect of furosemide in asthma. Furosemide 89-99 kininogen 1 Homo sapiens 103-113 7589163-4 1995 Such an inhibition of TP receptors could a least partly explain the inhibitory effect of furosemide on bradykinin-induced contraction, and could be one of the mechanisms of the protective effect of furosemide in asthma. Furosemide 198-208 kininogen 1 Homo sapiens 103-113 7600440-0 1995 Renal and renin responses to furosemide in conscious lambs during postnatal maturation. Furosemide 29-39 renin Ovis aries 10-15 7758515-9 1995 Furosemide-induced diuresis resulted in normal rises of plasma renin activity in both patients; however, plasma aldosterone levels increased only in the boy and not in his sister. Furosemide 0-10 renin Homo sapiens 63-68 7538611-0 1995 Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1. Furosemide 48-58 insulin-like growth factor 1 Rattus norvegicus 91-96 7538611-0 1995 Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1. Furosemide 48-58 insulin-like growth factor binding protein 1 Rattus norvegicus 101-108 7752176-3 1995 Nifedipine and furosemide reduced blood pressure to the same extent (-14 to -15 mm Hg for supine SBP and -9 to -10 mm Hg for supine DBP, both P < 0.0001). Furosemide 15-25 selenium binding protein 1 Homo sapiens 97-100 7752176-3 1995 Nifedipine and furosemide reduced blood pressure to the same extent (-14 to -15 mm Hg for supine SBP and -9 to -10 mm Hg for supine DBP, both P < 0.0001). Furosemide 15-25 D-box binding PAR bZIP transcription factor Homo sapiens 132-135 7864228-2 1995 We found that an injection of furosemide (10 mg/kg) produced a transient marked increase in urine output, a moderate 7-10% reduction in blood volume, and a three- to fourfold rise in plasma vasopressin from 1.6 +/- 0.2 to 5.6 +/- 1.0 pmol/l. Furosemide 30-40 arginine vasopressin Rattus norvegicus 190-201 7864228-5 1995 However, the lines describing the relationship of log plasma vasopressin to plasma volume and plasma sodium in the rats treated with furosemide for 32 h lay to the left of the same relationships in the rats treated for 8 h or the sham-treated controls. Furosemide 133-143 arginine vasopressin Rattus norvegicus 61-72 7599693-3 1995 Oral administration of furosemide, 40 mg for 2 days, under mild salt restriction (50 mEq NaCl/day) for 6 days stimulated the renin-angiotensin system resulting in significant increases in plasma renin activity (PRA) (1.84 +/- 0.12 vs. 1.05 +/- 0.17 ng/l/s; P < 0.01), plasma angiotensin II concentration, and plasma aldosterone concentration (PAC). Furosemide 23-33 renin Homo sapiens 125-130 7599693-3 1995 Oral administration of furosemide, 40 mg for 2 days, under mild salt restriction (50 mEq NaCl/day) for 6 days stimulated the renin-angiotensin system resulting in significant increases in plasma renin activity (PRA) (1.84 +/- 0.12 vs. 1.05 +/- 0.17 ng/l/s; P < 0.01), plasma angiotensin II concentration, and plasma aldosterone concentration (PAC). Furosemide 23-33 renin Homo sapiens 195-200 7599693-3 1995 Oral administration of furosemide, 40 mg for 2 days, under mild salt restriction (50 mEq NaCl/day) for 6 days stimulated the renin-angiotensin system resulting in significant increases in plasma renin activity (PRA) (1.84 +/- 0.12 vs. 1.05 +/- 0.17 ng/l/s; P < 0.01), plasma angiotensin II concentration, and plasma aldosterone concentration (PAC). Furosemide 23-33 angiotensinogen Homo sapiens 278-292 7600440-2 1995 To test the hypothesis that the renal and renin responses to furosemide are altered during postnatal maturation, experiments were carried out in conscious chronically instrumented newborn lambs (11 +/- 3 days, n = 7) and older lambs (28 +/- 3 days, n = 6), at least 5 days after surgery under halothane anesthesia for placement of catheters. Furosemide 61-71 renin Ovis aries 42-47 7584692-10 1995 After the administration of furosemide 4 patients in Group I were unable to increase aldosterone (2.8 +/- 0.9 ng/dl) secretion in spite of marked elevation of plasma renin activity (28 +/- 7 ng/ml/h), suggesting an impairment of 11-hydroxylase in the zona glomerulosa. Furosemide 28-38 renin Homo sapiens 166-171 7589049-9 1995 The cumulative urinary electrolyte excretion after concomitant administration of meloxicam and furosemide is somewhat lower than after administration of furosemide alone, in particular for the period 0-8 h after administration of furosemide. Furosemide 95-105 period circadian regulator 2 Homo sapiens 193-203 7900569-8 1995 A case with a high level of plasma renin and aldosterone activity temporarily induced by furosemide was reported. Furosemide 89-99 renin Homo sapiens 35-40 8641327-8 1995 The total body clearance of furosemide in the volunteers was 138 ml x min(-1) and this was much lower in the CAPD patients (61.9 ml x min(-1)) in whom the renal clearance was negligible. Furosemide 28-38 CD59 molecule (CD59 blood group) Homo sapiens 70-76 8641327-8 1995 The total body clearance of furosemide in the volunteers was 138 ml x min(-1) and this was much lower in the CAPD patients (61.9 ml x min(-1)) in whom the renal clearance was negligible. Furosemide 28-38 CD59 molecule (CD59 blood group) Homo sapiens 134-140 7810602-6 1994 An NMDG-Cl- dependent NH4(+)-induced fall in pHi was reduced approximately 33% by 10 mM Ba+, approximately 84% by 0.1 mM bumetanide, and 100% by 1.5 mM furosemide, whereas 1 mM hydrochlorothiazide had no effect; inhibition by Ba+ was observed even in the presence of 0.1 mM verapamil added to block both K+ channels and K+/NH4+ antiport. Furosemide 152-162 glucose-6-phosphate isomerase Rattus norvegicus 45-48 7495050-2 1995 Following the retaining of sinus rhythm with the help of lanicor, nitrosorbide and lasix patients of group 1 exhibited increased Vs, Vd, Vcf, EF against decreased left atrial size and left atrial index. Furosemide 83-88 DiGeorge syndrome chromosome region Homo sapiens 137-140 7996475-8 1994 Thus the hemodynamic effects, and in particular the direct early dilator effect, of furosemide may be explained in part by an enhanced endothelial synthesis and release of bradykinin and related kinins, which in turn stimulates endothelial autacoid formation via B2 kinin receptor activation. Furosemide 84-94 kininogen 1 Bos taurus 172-182 7977842-3 1994 Rats treated jointly with furosemide and low-dose captopril had exaggerated increases in plasma renin activity and angiotensin I but equivalent increases in plasma aldosterone compared with rats treated with either agent alone. Furosemide 26-36 renin Rattus norvegicus 96-101 7977842-4 1994 Treatment with furosemide plus low-dose captopril increased plasma vasopressin but not plasma oxytocin. Furosemide 15-25 arginine vasopressin Rattus norvegicus 67-78 7977842-5 1994 The administration of a higher dose of captopril (100 mg/kg) with furosemide, a combination of drugs that does not stimulate fluid intake (29), further increased plasma renin activity and angiotensin I but prevented the rise in plasma vasopressin. Furosemide 66-76 renin Rattus norvegicus 169-174 7977842-5 1994 The administration of a higher dose of captopril (100 mg/kg) with furosemide, a combination of drugs that does not stimulate fluid intake (29), further increased plasma renin activity and angiotensin I but prevented the rise in plasma vasopressin. Furosemide 66-76 arginine vasopressin Rattus norvegicus 235-246 8035168-6 1994 Luminal furosemide (10(-4) M) reduced the initial rate of cell acidification by 70% and the fall in steady state pHi by 35%. Furosemide 8-18 glucose-6-phosphate isomerase Rattus norvegicus 113-116 7958753-5 1994 In furosemide-treated animals, plasma aldosterone concentrations correlated positively with PRA (r = 0.85; n = 64; P < 0.01) and negatively with plasma sodium concentrations (r = -0.80; n = 64; P < 0.01), suggesting that in sodium-depleted camels the nexus between the renin-angiotensin system and aldosterone was restored. Furosemide 3-13 renin Camelus bactrianus 275-280 7928730-6 1994 The amount of the decrease in 2f1-f2 emission amplitude after furosemide injection was approximately independent of frequency and consistent for the middle frequency ratios and intensity levels (f2/f1 approximately equal to 1.3, L1 x L2 approximately equal to 55 x 50 dB SPL). Furosemide 62-72 sphingosine-1-phosphate lyase 1 Homo sapiens 271-274 8062074-5 1994 Rats with CeA or BST lesions also showed significant decreases in their intake of 2% NaCl after furosemide depletion, while intakes of the sham lesion groups remained unchanged. Furosemide 96-106 carcinoembryonic antigen gene family 4 Rattus norvegicus 10-13 7515562-4 1994 Na(+)-H+ antiport activity, estimated from the Na(+)-induced initial rate of pHi recovery of Na(+)-depleted acidified cells in the presence of 0.1 mM furosemide to inhibit Na(+)-K(+)-2Cl- cotransport, was inhibited by 300 mM urea and 10(-8) M arginine vasopressin (AVP) in an additive manner. Furosemide 150-160 glucose-6-phosphate isomerase Rattus norvegicus 77-80 8054254-6 1994 The frusemide-induced rise in plasma renin activity was significantly less with paracetamol than placebo at 60 min (4.3 +/- 2.9 vs 2.7 +/- 1.9 ng ml-1 h-1, P < 0.01; 95% confidence interval of the difference 0.4 to 2.7). Furosemide 4-13 renin Homo sapiens 37-42 8033511-3 1994 The aim of this study was to determine whether the plasma active renin concentration could be stimulated in women with pre-eclampsia by intravenous frusemide, which stimulates renin acutely through a prostacyclin-mediated mechanism. Furosemide 148-157 renin Homo sapiens 65-70 8033511-3 1994 The aim of this study was to determine whether the plasma active renin concentration could be stimulated in women with pre-eclampsia by intravenous frusemide, which stimulates renin acutely through a prostacyclin-mediated mechanism. Furosemide 148-157 renin Homo sapiens 176-181 8033511-11 1994 After frusemide, plasma active renin concentration rose significantly in non-pregnant (P = 0.002) and normal pregnant (P = 0.008) women, but not in women with pre-eclampsia. Furosemide 6-15 renin Homo sapiens 31-36 7863230-6 1994 Volume depletion after furosemide injection, also accompanied by increased levels of angiotensin II, resulted in elevation of PTH(1-84) in controls, cirrhotics, patients with glomerulonephritis without the nephrotic syndrome, but not in nephrotic patients. Furosemide 23-33 angiotensinogen Homo sapiens 85-99 7943288-2 1994 This study shows that when furosemide- and bumetanide-inhibitable 86Rb+ uptake is measured in the skeletal muscle-like BC3H1 cell line, insulin and insulin-like growth factor I (IGF-I) activate a loop diuretic-sensitive K+ and Cl- transport system but have no effect on Na(+)-K(+)-ATPase. Furosemide 27-37 insulin-like growth factor 1 Mus musculus 148-176 7943288-2 1994 This study shows that when furosemide- and bumetanide-inhibitable 86Rb+ uptake is measured in the skeletal muscle-like BC3H1 cell line, insulin and insulin-like growth factor I (IGF-I) activate a loop diuretic-sensitive K+ and Cl- transport system but have no effect on Na(+)-K(+)-ATPase. Furosemide 27-37 insulin-like growth factor 1 Mus musculus 178-183 8067387-7 1994 When the Na(+)-K(+)-2Cl- cotransporter in the luminal membrane of the MTAL was blocked by 10(-4) mol/l furosemide, the insulin-mediated increase in Vte was also abolished. Furosemide 103-113 insulin Oryctolagus cuniculus 119-126 8026000-0 1994 Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Furosemide 73-83 angiotensinogen Homo sapiens 18-32 8026000-0 1994 Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Furosemide 73-83 angiotensin I converting enzyme Homo sapiens 99-102 8026000-1 1994 BACKGROUND: Contrary to expectation, most studies have demonstrated that initiation of an angiotensin-converting enzyme (ACE) inhibitor in conventional doses in patients with heart failure reduces the diuretic efficacy of furosemide. Furosemide 222-232 angiotensin I converting enzyme Homo sapiens 90-119 8026000-1 1994 BACKGROUND: Contrary to expectation, most studies have demonstrated that initiation of an angiotensin-converting enzyme (ACE) inhibitor in conventional doses in patients with heart failure reduces the diuretic efficacy of furosemide. Furosemide 222-232 angiotensin I converting enzyme Homo sapiens 121-124 8026000-14 1994 CONCLUSIONS: Intense although transient ACE inhibition with captopril enhances the diuretic effects of furosemide during long-term ACE inhibition. Furosemide 103-113 angiotensin I converting enzyme Homo sapiens 40-43 8026000-14 1994 CONCLUSIONS: Intense although transient ACE inhibition with captopril enhances the diuretic effects of furosemide during long-term ACE inhibition. Furosemide 103-113 angiotensin I converting enzyme Homo sapiens 131-134 8038908-4 1994 Postural stimulation with or without furosemide administration increased 18-oxoF, 18-OH-F, aldosterone and plasma renin activity (PRA). Furosemide 37-47 renin Homo sapiens 114-119 7526657-3 1994 Furosemide inhibited anti-IgE-induced histamine release. Furosemide 0-10 immunoglobulin heavy constant epsilon Homo sapiens 26-29 7526657-4 1994 Preincubation of the cells with the drug, prior to anti-IgE stimulation, significantly reduced furosemide"s inhibitory effect. Furosemide 95-105 immunoglobulin heavy constant epsilon Homo sapiens 56-59 8035168-10 1994 Addition of furosemide to the lumen abolished net ammonium absorption and caused pHi to increase abruptly (dpHi/dt = 0.8 U/min) to 7.0. Furosemide 12-22 glucose-6-phosphate isomerase Rattus norvegicus 81-84 8016771-0 1994 Effect of inhaled frusemide on responses of airways to bradykinin and adenosine 5"-monophosphate in asthma. Furosemide 18-27 kininogen 1 Homo sapiens 55-65 8058474-4 1994 In non-clipped animals furosemide increased PRA from 10 to 47 ng angiotensin I.h-1.ml-1 and raised renin mRNA levels in both kidneys 2.5-fold. Furosemide 23-33 renin Rattus norvegicus 99-104 8065467-7 1994 We conclude that the later generalized vasoconstriction following furosemide involves regional specific stimulation of angiotensin II and alpha-adrenoceptors. Furosemide 66-76 angiotensinogen Rattus norvegicus 119-133 8016771-3 1994 The effect of inhaled frusemide on bronchoconstriction induced by inhaled bradykinin, which is thought to cause bronchoconstriction via neural mechanisms, was studied and compared with the effects of adenosine 5"-monophosphate (AMP) which probably produces its airway effects by augmenting mast cell mediator release and interfering with neural pathways. Furosemide 22-31 kininogen 1 Homo sapiens 74-84 8016771-13 1994 CONCLUSIONS: These data suggest that inhaled frusemide affords protection against bradykinin-induced bronchoconstriction which is comparable to that against AMP, supporting a common mechanism of action for frusemide. Furosemide 45-54 kininogen 1 Homo sapiens 82-92 8016771-10 1994 For bradykinin the geometric mean PC20 values following pretreatment with inhaled frusemide and matched placebo were 13.22 (2.53- > 16.0) and 2.52 (0.45-5.61) mg/ml respectively (95% CI 0.43 to 1.01). Furosemide 82-91 kininogen 1 Homo sapiens 4-14 8016771-11 1994 Frusemide afforded 5.45 and 5.24 fold protection against AMP and bradykinin-induced bronchoconstriction respectively. Furosemide 0-9 kininogen 1 Homo sapiens 65-75 8136154-7 1994 Incubation with furosemide (10(-4) M) for 30 min caused a marked reduction in both basal and arachidonic acid-stimulated production of PGE2 and PGF2 alpha but did not reduce production of 6-keto-PGF1 alpha and PGD2. Furosemide 16-26 prostaglandin D2 synthase Homo sapiens 210-214 8065233-0 1994 Effect of angiotensin II type 1 receptor antagonist on urinary prostaglandin E2 excretion following furosemide in rats. Furosemide 100-110 angiotensin II receptor, type 1b Rattus norvegicus 10-40 7880980-8 1994 The greater metabolic activity of furosemide in liver may also be supported by the result that the amount of hepatic cytochrome P-450 (0.7013 versus 0.5186 nmol/mg protein) and the weights of liver (3.52 versus 2.93% of body weight) were significantly greater in SHRs of 16 weeks of age than in age-matched Wistar rats. Furosemide 34-44 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 117-133 8019837-5 1994 Assessment of the curve parameters collectively revealed that at 5 mg/kg, both furosemide (FUR) and ethacrynic acid (EA) reduced Cl penetration into CSF by one quarter; at 50 mg/kg, these loop agents decreased Cl uptake by about a third. Furosemide 91-94 colony stimulating factor 2 Rattus norvegicus 149-152 8047284-5 1994 In adult CP, the KCl cotransport inhibitor, furosemide (1 mM), decreased K efflux by 23% or 65%, respectively, when aCSF had Cl or NO3 as the main anion. Furosemide 44-54 NBL1, DAN family BMP antagonist Homo sapiens 131-134 24233289-4 1994 A three-factor, three-level factorial design allowed us to establish a calibration matrix of the three diuretics that covered the three ranges from 10 to 40, 1.5 to 6, and 0.1 to 0.4 muM for furosemide, piretanide, and triamterene, respectively. Furosemide 191-201 latexin Homo sapiens 183-186 8296708-0 1994 Interaction of intravenous atrial natriuretic factor with furosemide in patients with heart failure. Furosemide 58-68 natriuretic peptide A Homo sapiens 27-52 7954537-4 1994 Both torasemide and furosemide increased plasma renin activity and aldosterone concentration, but only torasemide significantly inhibited aldosterone-receptor binding in rat kidney. Furosemide 20-30 renin Rattus norvegicus 48-53 8019837-5 1994 Assessment of the curve parameters collectively revealed that at 5 mg/kg, both furosemide (FUR) and ethacrynic acid (EA) reduced Cl penetration into CSF by one quarter; at 50 mg/kg, these loop agents decreased Cl uptake by about a third. Furosemide 79-89 colony stimulating factor 2 Rattus norvegicus 149-152 8141403-5 1994 It is concluded that the integrity of renin-angiotensin mechanisms is necessary for the rapid ingestion of water and saline after furosemide and captopril and that arterial pressure modulates the behavioral responses. Furosemide 130-140 renin Rattus norvegicus 38-43 8065233-1 1994 The present study was undertaken to examine an effect of an angiotensin II type 1 (AT1) receptor antagonist on urinary prostaglandin E2 (PGE2) excretion following furosemide, a loop diuretic, in rats. Furosemide 163-173 angiotensin II receptor, type 1b Rattus norvegicus 60-96 8065233-2 1994 Furosemide (30 mg/kg) was given orally with or without pretreatment with derapril (30 mg/kg), an angiotensin converting enzyme inhibitor, TCV-116 (1 mg/kg), an AT1 receptor antagonist, or losartan (10 mg/kg), another AT1 receptor antagonist. Furosemide 0-10 angiotensin II receptor, type 1a Rattus norvegicus 160-163 8065233-7 1994 As TCV-116 and losartan are selective AT1 receptor antagonists, the effect of furosemide on renal PGE2 production, as reflected by the urinary PGE2, might be mediated by an activation of AT1 receptors. Furosemide 78-88 angiotensin II receptor, type 1a Rattus norvegicus 38-41 8065233-7 1994 As TCV-116 and losartan are selective AT1 receptor antagonists, the effect of furosemide on renal PGE2 production, as reflected by the urinary PGE2, might be mediated by an activation of AT1 receptors. Furosemide 78-88 angiotensin II receptor, type 1a Rattus norvegicus 187-190 8288156-5 1993 In the present study, the effects of furosemide on the activities of the hexokinase, phosphofructokinase and pyruvate kinase were examined. Furosemide 37-47 hexokinase 1 Homo sapiens 73-83 8146012-9 1994 The dB-cAMP-induced secretion of Ox2- and Cl- were fully abolished by serosal furosemide (10(-4) M) and partially inhibited (35%) by 5 x 10(-4) M mucosal NPPB [5-nitro-2-(3-phenylpropylamino)-benzoic acid], a putative Cl- channel blocker. Furosemide 78-88 OX-2 membrane glycoprotein Oryctolagus cuniculus 33-36 8179835-3 1993 Also, the renin-aldosterone stimulation testing on this patient performed by sodium restricted diet and furosemide, upright position and by angiotensin converting enzyme inhibition (captopril, 50 mg) showed the blunted renin and aldosterone responses to each of these stimuli, almost no changes from baseline renin and aldosterone levels, it was concluded that the underlying defect responsible for hyperkalemia in this case was hyporeninemic hypoaldosteronism and this was aggravated by other factors or drugs affecting potassium homeostasis. Furosemide 104-114 renin Homo sapiens 10-15 8179835-3 1993 Also, the renin-aldosterone stimulation testing on this patient performed by sodium restricted diet and furosemide, upright position and by angiotensin converting enzyme inhibition (captopril, 50 mg) showed the blunted renin and aldosterone responses to each of these stimuli, almost no changes from baseline renin and aldosterone levels, it was concluded that the underlying defect responsible for hyperkalemia in this case was hyporeninemic hypoaldosteronism and this was aggravated by other factors or drugs affecting potassium homeostasis. Furosemide 104-114 renin Homo sapiens 219-224 8179835-3 1993 Also, the renin-aldosterone stimulation testing on this patient performed by sodium restricted diet and furosemide, upright position and by angiotensin converting enzyme inhibition (captopril, 50 mg) showed the blunted renin and aldosterone responses to each of these stimuli, almost no changes from baseline renin and aldosterone levels, it was concluded that the underlying defect responsible for hyperkalemia in this case was hyporeninemic hypoaldosteronism and this was aggravated by other factors or drugs affecting potassium homeostasis. Furosemide 104-114 renin Homo sapiens 219-224 8011564-4 1993 The transient systemic arterial constriction and small increase in systemic blood pressure that follows intravenous furosemide probably results from the release of renin and subsequent activation of angiotensin. Furosemide 116-126 renin Homo sapiens 164-169 8288156-9 1993 The concentration of furosemide required to inhibit phosphofructokinase in muscle was lower than that required to inhibit the activity of this enzyme in the liver or to inhibit the activities of hexokinase and pyruvate kinase in both muscle and liver. Furosemide 21-31 hexokinase 1 Homo sapiens 195-205 8392557-13 1993 However, angiotensin II is an important mediator of renal vasoconstriction during furosemide infusion. Furosemide 82-92 angiotensinogen Rattus norvegicus 9-23 8271212-3 1993 To this end we investigated the effects of frusemide and bumetanide, two different inhibitors of the macula densa Na(+)-K(+)-2Cl- cotransport, on pressure-dependent renin release from isolated perfused rat kidneys. Furosemide 43-52 renin Rattus norvegicus 165-170 8271212-10 1993 The vasorelaxant effects of frusemide and bumetanide were paralleled by an increase of renin secretion to a maximum of 21 +/- 4 (ng Ang I h-1) min-1 g-1 (n = 10). Furosemide 28-37 renin Rattus norvegicus 87-92 8271212-11 1993 On a molar basis bumetanide was twice as potent as frusemide in stimulating renin secretion. Furosemide 51-60 renin Rattus norvegicus 76-81 8400079-4 1993 The third objective was to determine the modulating action of continuous low-dose atrial natriuretic factor (ANF) administration during acute CHF upon these biologic responses, testing the hypothesis that exogenous low-dose ANF would prevent activation of the RAAS and enhance the natriuretic action of furosemide. Furosemide 303-313 natriuretic peptide A Canis lupus familiaris 224-227 8400079-7 1993 Low-dose exogenous ANF and furosemide (Group 3; N = 6) in acute CHF were associated with a maintenance of GFR, no activation of the RAAS, and potentiation of furosemide-induced natriuresis. Furosemide 158-168 natriuretic peptide A Canis lupus familiaris 19-22 8400079-9 1993 Low-dose ANF in acute CHF with furosemide maintains GFR, attenuates activation of the RAAS, and potentiates natriuresis. Furosemide 31-41 natriuretic peptide A Canis lupus familiaris 9-12 8396158-1 1993 It has been reported that the urinary excretions of chloride (Cl), potassium (K), and magnesium (Mg), but not sodium (Na), after furosemide, a loop diuretic, were decreased by pretreatment with lisinopril, an ACE inhibitor in hypertensive subjects. Furosemide 129-139 angiotensin I converting enzyme Homo sapiens 209-212 7910062-0 1993 Correlation between renin responsiveness to furosemide and antihypertensive effect of captopril in patients with normal-renin essential hypertension. Furosemide 44-54 renin Homo sapiens 20-25 7910062-1 1993 The relationship between renin responsiveness to furosemide and the antihypertensive effect of captopril in patients with normal-renin essential hypertension were studied in 23 patients including nine men (mean age, 41 years) and 14 women (mean age, 40 years). Furosemide 49-59 renin Homo sapiens 25-30 7910062-6 1993 These data suggest that renin responsiveness to a single intravenous dose of furosemide can be a useful test for predicting the therapeutic response to captopril in patients with normal-renin essential hypertension. Furosemide 77-87 renin Homo sapiens 24-29 7910062-6 1993 These data suggest that renin responsiveness to a single intravenous dose of furosemide can be a useful test for predicting the therapeutic response to captopril in patients with normal-renin essential hypertension. Furosemide 77-87 renin Homo sapiens 186-191 8255723-0 1993 Furosemide stimulates renin expression in the kidneys of salt-supplemented rats. Furosemide 0-10 renin Rattus norvegicus 22-27 8255723-5 1993 Plasma renin activities increased from 2.9 +/- 0.5 ng angiotensin I h-1 ml-1 in controls to 10.6 +/- 2.2 ng angiotensin I h-1 ml-1 in furosemide-treated rats. Furosemide 134-144 renin Rattus norvegicus 7-12 8255723-6 1993 In parallel, kidney areas immunoreactive for renin increased by 80% and the renal content of renin mRNA increased by 120% in the animals receiving furosemide. Furosemide 147-157 renin Rattus norvegicus 45-50 8255723-6 1993 In parallel, kidney areas immunoreactive for renin increased by 80% and the renal content of renin mRNA increased by 120% in the animals receiving furosemide. Furosemide 147-157 renin Rattus norvegicus 93-98 8255723-7 1993 Under the assumption that the effects seen on renal renin expression were primarily due to the inhibition of TALH and macula densa function by furosemide, our findings suggest that salt transport across the TALH and macula densa exerts a negative control function not only on the secretion but also on the expression of renin in the kidney. Furosemide 143-153 renin Rattus norvegicus 52-57 8219659-10 1993 Following furosemide angiotensin II increased significantly even after cilazapril pretreatment. Furosemide 10-20 angiotensinogen Homo sapiens 21-35 8219659-13 1993 The study shows that (a) cilazapril increases furosemide-induced natriuresis irrespective of salt intake, (b) antinatriuresis is not affected by cilazapril, and (c) angiotensin II levels rise after furosemide on cilazapril in therapeutic doses. Furosemide 198-208 angiotensinogen Homo sapiens 165-179 8498970-11 1993 The vascular renin-angiotensin system is subject to the action of a number of drugs and chemicals, most notably specific inhibitors of the angiotensin-converging enzyme and drugs affecting kidney function (furosemide) and/or vessel tone (propranolol). Furosemide 206-216 renin Homo sapiens 13-18 8389946-2 1993 In this study we examined acid-base composition and ATPase enzyme activities in medullary thick ascending limb of Henle"s loop (MTAL) and collecting tubule (CCT and MCT) after seven days of chronic furosemide therapy. Furosemide 198-208 FLVCR heme transporter 2 Rattus norvegicus 157-160 8478172-8 1993 Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours. Furosemide 13-23 O-GlcNAcase Homo sapiens 59-88 8478172-8 1993 Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours. Furosemide 13-23 O-GlcNAcase Homo sapiens 90-93 8478172-8 1993 Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours. Furosemide 13-23 alkaline phosphatase, placental Homo sapiens 99-119 8478172-8 1993 Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours. Furosemide 13-23 alkaline phosphatase, placental Homo sapiens 121-124 8478172-8 1993 Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours. Furosemide 13-23 alkaline phosphatase, placental Homo sapiens 228-231 8482447-6 1993 RESULTS: Serosal addition of endothelin 1 evoked a sustained increase in short-circuit current that was significantly reduced by tetrodotoxin or atropine, and virtually abolished by a selective endothelin A receptor antagonist (BQ-123), furosemide, piroxicam, d,I-verapamil, or removal of serosal calcium. Furosemide 237-247 endothelin 1 Rattus norvegicus 29-41 8482447-6 1993 RESULTS: Serosal addition of endothelin 1 evoked a sustained increase in short-circuit current that was significantly reduced by tetrodotoxin or atropine, and virtually abolished by a selective endothelin A receptor antagonist (BQ-123), furosemide, piroxicam, d,I-verapamil, or removal of serosal calcium. Furosemide 237-247 endothelin receptor type A Rattus norvegicus 194-215 8466703-8 1993 The renin response to sodium and volume depletion induced by the low sodium diet and furosemide correlated significantly (P < .001) with the subsequent blood pressure response to the low sodium diet. Furosemide 85-95 renin Homo sapiens 4-9 8471406-1 1993 A combination of dietary sodium restriction (40 mmol day-1) and frusemide pretreatment has been used to activate the renin angiotensin system (RAS) in order to characterise the haemodynamic and hormonal responses to enalapril in young normotensives. Furosemide 64-73 renin Homo sapiens 117-122 8495989-1 1993 Single dose of frusemide 0.1 mg/kg orally was administered in 10 rabbits pretreated with soluble insulin 4 IU intravenously. Furosemide 15-24 insulin Oryctolagus cuniculus 97-104 1493659-10 1992 Reduced sensitivity of cardiopulmonary baroreceptors and lowered production of ANF due to structural cardiac changes could represent, according to most opinions, the main factors responsible for the prevailing sympathetic activation and hydro-saline retention in CHF. Furosemide 237-242 natriuretic peptide A Homo sapiens 79-82 7506186-5 1993 Furosemide-induced increases in plasma renin activity and aldosterone levels were blunted, and urinary excretion of prostaglandin E2 was markedly reduced by nimesulide. Furosemide 0-10 renin Homo sapiens 39-44 8425246-2 1993 Treatment with epinephrine, calcium chloride, sodium bicarbonate, and furosemide reduced K+ to 6.5 mEq.L-1 within 30 min and myocardial performance was enhanced with amrinone and cardiac rhythm was controlled with A-V segmental pacing. Furosemide 70-80 immunoglobulin kappa variable 1-16 Homo sapiens 103-106 1436675-11 1992 ANGII and norepinephrine, but not AVP, was also reduced after treatment with furosemide. Furosemide 77-87 angiotensinogen Rattus norvegicus 0-5 1341182-13 1992 CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema. Furosemide 12-22 LDL receptor related protein associated protein 1 Homo sapiens 46-49 1341182-13 1992 CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema. Furosemide 12-22 WBP2 N-terminal like Homo sapiens 51-55 1341182-13 1992 CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema. Furosemide 12-22 caspase recruitment domain family member 16 Homo sapiens 61-64 1341182-13 1992 CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema. Furosemide 12-22 WBP2 N-terminal like Homo sapiens 69-73 1341182-13 1992 CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema. Furosemide 12-22 caspase recruitment domain family member 16 Homo sapiens 74-77 1436675-0 1992 Effect of furosemide treatment on the central and peripheral pressor responses to cholinergic and adrenergic agonists, angiotensin II, hypertonic solution and vasopressin. Furosemide 10-20 angiotensinogen Rattus norvegicus 119-133 1436675-0 1992 Effect of furosemide treatment on the central and peripheral pressor responses to cholinergic and adrenergic agonists, angiotensin II, hypertonic solution and vasopressin. Furosemide 10-20 arginine vasopressin Rattus norvegicus 159-170 1436675-8 1992 Treatment with furosemide reduced the pressor response induced by carbachol, norepinephrine and ANGII i.c.v., but no change was observed in the pressor response to i.c.v. Furosemide 15-25 angiotensinogen Rattus norvegicus 96-101 1523447-3 1992 The best-fit Cox regression model identified six significant predictors of infiltration (P less than .05): catheter material, age, anatomic insertion site, hyperalimentation, and use of furosemide and dopamine. Furosemide 186-196 cytochrome c oxidase subunit 8A Homo sapiens 13-16 1436675-12 1992 These results show that the treatment with furosemide impairs the pressor responses induced by central or peripheral administration of adrenergic agonist or ANGII, as well as those induced by central cholinergic activation. Furosemide 43-53 angiotensinogen Rattus norvegicus 157-162 1436675-13 1992 The results suggest that the treatment with furosemide impairs central and peripheral pressor responses mediated by sympathetic activation and ANGII, but not those produced by AVP. Furosemide 44-54 angiotensinogen Rattus norvegicus 143-148 1473090-8 1992 Compared to data derived from the literature, the solute-free water generation during administration of furosemide (CH2O/GFR) was significantly reduced in patients with CF (6.8 +/- 1.5%) as compared with healthy subjects (13.3 +/- 6.1%). Furosemide 104-114 Rap guanine nucleotide exchange factor 5 Homo sapiens 116-124 1572111-1 1992 Furosemide causes not only natriuresis, but a rapid (5-10 min) increase in plasma renin activity. Furosemide 0-10 renin Homo sapiens 82-87 1572111-3 1992 Drugs like indomethacin abolish the renin increment and could potentially affect both mechanisms: they inhibit cyclooxygenase but could also compete with furosemide for transport into the tubular lumen, reducing furosemide concentration at its site of action. Furosemide 154-164 renin Homo sapiens 36-41 1572111-3 1992 Drugs like indomethacin abolish the renin increment and could potentially affect both mechanisms: they inhibit cyclooxygenase but could also compete with furosemide for transport into the tubular lumen, reducing furosemide concentration at its site of action. Furosemide 212-222 renin Homo sapiens 36-41 1290347-10 1992 It has also been found that the decrease in the intravascular fluid volume induced by furosemide administration resulted in the reduction of ANP concentration in plasma. Furosemide 86-96 natriuretic peptide A Homo sapiens 141-144 1633064-0 1992 Captopril augments both basal and frusemide-induced natriuresis in normal man by suppression of circulating angiotensin II. Furosemide 34-43 angiotensinogen Homo sapiens 108-122 1633064-10 1992 Captopril augmented frusemide-induced natriuresis and again this effect was reversed by angiotensin II reinfusion. Furosemide 20-29 angiotensinogen Homo sapiens 88-102 1393272-6 1992 Frusemide increased AVP levels to 134.1 +/- 73.6 pg ml-1 (P less than 0.05) and lignocaine totally prevented this increase, e.g. mean AVP levels of 2.7 pg ml-1. Furosemide 0-9 vasopressin-neurophysin 2-copeptin Oryctolagus cuniculus 20-23 1393272-12 1992 It is concluded that in healthy rabbits lignocaine reduces baseline secretion of AVP and its antidiuretic effect; in addition, lignocaine prevents the rise in AVP induced by frusemide. Furosemide 174-183 vasopressin-neurophysin 2-copeptin Oryctolagus cuniculus 159-162 1576058-2 1992 We therefore measured lymphocyte free Mg2+ concentrations in patients with congestive cardiac failure treated with loop diuretics or a frusemide/amiloride mixture (Frumil) and compared them with control subjects. Furosemide 135-144 mucin 7, secreted Homo sapiens 38-41 1552700-6 1992 When the apical Na-K-2Cl cotransport was blocked by furosemide or bumetanide, a net K secretion occurred (-1.1 +/- 0.2 pmol/min), which was significantly decreased by PAF (-0.06 +/- 0.3 pmol/min). Furosemide 52-62 patchy fur Mus musculus 167-170 1295687-0 1992 Effect of vasopressin on brain swelling at the cellular level: do astrocytes exhibit a furosemide--vasopressin-sensitive mechanism for volume regulation? Furosemide 87-97 arginine vasopressin Homo sapiens 99-110 1812004-5 1991 Higher doses of torasemide (10 mg/kg) and furosemide (100 mg/kg) increased both plasma renin activity and aldosterone concentration in normotensive rats in a similar manner. Furosemide 42-52 renin Rattus norvegicus 87-92 1623899-5 1992 Metamizole significantly reduced furosemide clearance (175 vs 141 ml.min-1), furosemide-stimulated plasma renin activity (1.42 vs 0.79 ng AI.ml-1.h-1) and the urinary excretion of prostacyclin metabolites and of prostaglandin F2 alpha (by 70-81%). Furosemide 77-87 renin Homo sapiens 106-111 1316586-7 1992 To clarify mechanisms involved in the effect of frusemide on plasma PTH values, seven normal subjects were studied for 24 h before and for 24 h after oral administration of 80 mg frusemide. Furosemide 48-57 parathyroid hormone Homo sapiens 68-71 1316586-1 1992 It has been suggested that frusemide affects plasma parathyroid hormone (PTH) concentrations. Furosemide 27-36 parathyroid hormone Homo sapiens 52-71 1316586-1 1992 It has been suggested that frusemide affects plasma parathyroid hormone (PTH) concentrations. Furosemide 27-36 parathyroid hormone Homo sapiens 73-76 1316586-3 1992 The rate of increase of plasma PTH observed with progression of renal failure was faster in patients who received frusemide as compared to patients who did not receive the drug. Furosemide 114-123 parathyroid hormone Homo sapiens 31-34 1316586-4 1992 The slope of the regression line of PTH on CCr was steeper (P less than 0.02) for patients with frusemide (n = 40, slope -0.34) than without frusemide (n = 37, slope -0.20). Furosemide 96-105 parathyroid hormone Homo sapiens 36-39 1316586-4 1992 The slope of the regression line of PTH on CCr was steeper (P less than 0.02) for patients with frusemide (n = 40, slope -0.34) than without frusemide (n = 37, slope -0.20). Furosemide 141-150 parathyroid hormone Homo sapiens 36-39 2022640-6 1991 The stimulation of the furosemide-sensitive influx by Ha-ras is paralleled by an increase in mean cell volume which can be inhibited by furosemide. Furosemide 23-33 Harvey rat sarcoma virus oncogene Mus musculus 54-60 1935501-0 1991 Verapamil and furosemide prevent cholecystokinin-induced translocation of immunoglobulins in rat intestine. Furosemide 14-24 cholecystokinin Rattus norvegicus 33-48 1935501-3 1991 The effect of CCK on the translocation of immunoglobulins, albumin, and electrolytes is reduced by the prior injection of the calcium-channel blocker verapamil and the chloride-channel blocker furosemide. Furosemide 193-203 cholecystokinin Rattus norvegicus 14-17 1822524-4 1991 About 96% of Cd2+ uptake was inhibited by DIDS (4,4"-diisothiocyanatostilbene-2,2"-disulphonic acid) with IC50 (concentration giving 50% of maximal inhibition) of 0.3 microM and by furosemide with IC50 of 500 microM and was resistant to ouabain and amiloride. Furosemide 181-191 CD2 molecule Homo sapiens 13-16 1666052-2 1991 This study was to determine whether antagonism of Na+/K+/Cl- co-transport by loop diuretics (furosemide or bumetanide) and thereby Cl- entry could block ACTH secretion. Furosemide 93-103 pro-opiomelanocortin-alpha Mus musculus 153-157 1666052-7 1991 Forskolin did not affect the activity of the Na+/K+/Cl- co-transporter but both basal and forskolin-stimulated secretion of ACTH were inhibited by furosemide (IC50 of 5 x 10(-4) M; maximal inhibition: 50%). Furosemide 147-157 pro-opiomelanocortin-alpha Mus musculus 124-128 1655330-0 1991 Plasma and tissue kallikrein-kinin systems during acute administration of frusemide in normotensive and hypertensive humans. Furosemide 74-83 kallikrein related peptidase 4 Homo sapiens 18-28 1655330-5 1991 Frusemide increased plasma pre-kallikrein, angiotensin II and aldosterone concentrations and plasma renin activity, whereas the plasma level of tissue kallikrein remained unchanged. Furosemide 0-9 kallikrein related peptidase 4 Homo sapiens 31-41 1655330-5 1991 Frusemide increased plasma pre-kallikrein, angiotensin II and aldosterone concentrations and plasma renin activity, whereas the plasma level of tissue kallikrein remained unchanged. Furosemide 0-9 angiotensinogen Homo sapiens 43-57 1655330-5 1991 Frusemide increased plasma pre-kallikrein, angiotensin II and aldosterone concentrations and plasma renin activity, whereas the plasma level of tissue kallikrein remained unchanged. Furosemide 0-9 renin Homo sapiens 100-105 1655330-8 1991 Frusemide increased the urine volume and the excretion of Na+, K+, Mg2+, Cl-, aldosterone, prostaglandin E2 and tissue kallikrein. Furosemide 0-9 kallikrein related peptidase 4 Homo sapiens 119-129 1655330-12 1991 Thus, acute administration of frusemide to hypertensive patients and normal subjects increased the plasma level of pre-kallikrein, possibly indicating less activation to kallikrein and subsequently less kinin generation in the blood stream. Furosemide 30-39 kallikrein related peptidase 4 Homo sapiens 119-129 1655330-12 1991 Thus, acute administration of frusemide to hypertensive patients and normal subjects increased the plasma level of pre-kallikrein, possibly indicating less activation to kallikrein and subsequently less kinin generation in the blood stream. Furosemide 30-39 kallikrein related peptidase 4 Homo sapiens 170-180 1655330-16 1991 Urinary excretion of kallikrein is reduced in patients with primary hypertension after the administration of frusemide, apparently without affecting the renal excretory response. Furosemide 109-118 kallikrein related peptidase 4 Homo sapiens 21-31 1853956-11 1991 At the doses studied, hydrochlorothiazide was also more potent than furosemide in increasing plasma renin activity, increasing sodium excretion, and decreasing lithium excretion. Furosemide 68-78 renin Homo sapiens 100-105 1941559-5 1991 The contents of hepatic cytochrome P-450 (1.29 versus 2.15 nmol/mg protein) and the weights of liver and stomach increased significantly in PB-treated rats, suggesting that the metabolizing enzymes for furosemide are induced by pretreatment with PB. Furosemide 202-212 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 24-40 1907105-9 1991 Administration of the renin inhibitor CGP 29287 (1 mg/kg) to furosemide-pretreated conscious marmosets lowered blood pressure and increased renal blood flow. Furosemide 61-71 renin Callithrix jacchus 22-27 1924052-6 1991 The increase in plasma renin activity after frusemide was inhibited by ketoprofen on both Day 1 and Day 5. Furosemide 44-53 renin Homo sapiens 23-28 1924052-7 1991 These results suggest that ketoprofen reduces the diuresis and renin release induced by frusemide, but that the reduction in diuretic response may become less important after their repeated coadministration. Furosemide 88-97 renin Homo sapiens 63-68 1873917-5 1991 During furosemide infusion, PAI, PAII, PRA, as well as UV-AI and UV-AII increased. Furosemide 7-17 serpin family E member 1 Homo sapiens 28-31 1873917-5 1991 During furosemide infusion, PAI, PAII, PRA, as well as UV-AI and UV-AII increased. Furosemide 7-17 NLR family pyrin domain containing 3 Homo sapiens 34-37 2022640-6 1991 The stimulation of the furosemide-sensitive influx by Ha-ras is paralleled by an increase in mean cell volume which can be inhibited by furosemide. Furosemide 136-146 Harvey rat sarcoma virus oncogene Mus musculus 54-60 2022640-7 1991 A rapid stimulation of the furosemide-sensitive Rb+ influx is also observed after addition of bombesin to growth-arrested cells. Furosemide 27-37 gastrin releasing peptide Homo sapiens 94-102 2022640-8 1991 Furosemide inhibits the mitogenic response after expression of Ha-ras or addition of bombesin. Furosemide 0-10 Harvey rat sarcoma virus oncogene Mus musculus 63-69 2022640-8 1991 Furosemide inhibits the mitogenic response after expression of Ha-ras or addition of bombesin. Furosemide 0-10 gastrin releasing peptide Homo sapiens 85-93 2022640-9 1991 Both the Ha-ras and the bombesin-induced stimulation of the furosemide-sensitive Rb+ transport can be blocked by protein kinase C depletion or the protein kinase C inhibitor staurosporine. Furosemide 60-70 Harvey rat sarcoma virus oncogene Mus musculus 9-15 2022640-9 1991 Both the Ha-ras and the bombesin-induced stimulation of the furosemide-sensitive Rb+ transport can be blocked by protein kinase C depletion or the protein kinase C inhibitor staurosporine. Furosemide 60-70 gastrin releasing peptide Homo sapiens 24-32 2022640-10 1991 In contrast to bombesin-induced phosphatidylinositol-4,5-bisphosphate hydrolysis which is down-modulated by Ha-ras, the stimulation of the furosemide-sensitive Rb+ influx by bombesin is elevated in Ha-ras-expressing cells. Furosemide 139-149 gastrin releasing peptide Homo sapiens 174-182 2022640-10 1991 In contrast to bombesin-induced phosphatidylinositol-4,5-bisphosphate hydrolysis which is down-modulated by Ha-ras, the stimulation of the furosemide-sensitive Rb+ influx by bombesin is elevated in Ha-ras-expressing cells. Furosemide 139-149 Harvey rat sarcoma virus oncogene Mus musculus 198-204 1831170-2 1991 Dopamine (DA) infusion enhanced the diuresis, natriuresis and kaliuresis evoked by furosemide, but this increase was significantly lower in the presence of SCH 23390, a selective DA1-dopaminergic antagonist. Furosemide 83-93 RT1 class II, locus Da Rattus norvegicus 179-182 1780509-5 1991 Urinary kallikrein in hypertense non-diabetic patients who are not treated with diuretics (furosemide) has a behaviour as in normal controls, but it is much higher in patients treated with captopril, being this finding of great importance since it can suggest new therapeutic approaches to diabetic nephropathy. Furosemide 91-101 kallikrein related peptidase 4 Homo sapiens 8-18 1986589-2 1991 This study assesses the predictive diagnostic value of furosemide-131I-hippuran renography after angiotensin-converting enzyme (ACE) inhibition in patients with and without RVH. Furosemide 55-65 angiotensin I converting enzyme Homo sapiens 128-131 1986589-15 1991 CONCLUSION: Furosemide-131I-hippuran renography with ACE inhibition is highly predictive in identifying patients with RVH. Furosemide 12-22 angiotensin I converting enzyme Homo sapiens 53-56 1864454-2 1991 Prostaglandin E1 also increased the total serum protein and serum albumin concentrations, and reduced creatinine clearance and plasma renin activity following frusemide loading. Furosemide 159-168 renin Homo sapiens 134-139 1832596-4 1991 After upright posture and furosemide administration plasma ANP was decreased (p less than 0.01) in patients with low renin and, less markedly, with normal renin essential hypertension, however not in IHA and APA. Furosemide 26-36 natriuretic peptide A Homo sapiens 59-62 1832596-4 1991 After upright posture and furosemide administration plasma ANP was decreased (p less than 0.01) in patients with low renin and, less markedly, with normal renin essential hypertension, however not in IHA and APA. Furosemide 26-36 renin Homo sapiens 117-122 1832596-5 1991 In about half of the patients with low renin essential hypertension, unchanged PRA after upright posture and furosemide administration was associated with increased plasma Aldo and decreased ANP levels. Furosemide 109-119 natriuretic peptide A Homo sapiens 191-194 1831170-9 1991 It is possible that endogenous DA, stimulating DA1 receptors in the rat kidney may be an important factor involved in the Na+, K+ and water excretion evoked by furosemide. Furosemide 160-170 RT1 class II, locus Da Rattus norvegicus 47-50 1831170-8 1991 Our data show that renal responses to furosemide are attenuated by the DA1-dopaminergic antagonist. Furosemide 38-48 RT1 class II, locus Da Rattus norvegicus 71-74 1830313-6 1991 The only significant treatment effect was observed for high-density-lipoprotein3 cholesterol concentration (HDL3 cholesterol concentration), which was higher when patients were on furosemide therapy (p less than 0.05). Furosemide 180-190 HDL3 Homo sapiens 108-112 1943567-1 1991 Assessment of vasopressin by radioimmunoassay has shown an increase in its blood concentration and a disturbed reaction of the vasopressinergic structures of the hypothalamus to metoclopramide, furosemide, insulin hypoglycemia, and exercise. Furosemide 194-204 arginine vasopressin Homo sapiens 14-25 2242386-4 1990 Furosemide, an inhibitor of Na+, K+, Cl- co-transport, reduced the 86Rb+ influx and the effect was partly additive to the effect of 2 mM Ba2+. Furosemide 0-10 bone area 2 Mus musculus 137-140 1964125-7 1990 After furosemide ANF and cGMP decreased slightly in both groups whereas AII and Aldo increased; AVP increased in the controls, but not in the cirrhotic patients. Furosemide 6-16 natriuretic peptide A Homo sapiens 17-20 1823389-0 1991 Evaluation of insulin-induced changes in the renal response to furosemide in normal subjects. Furosemide 63-73 insulin Homo sapiens 14-21 1823389-2 1991 We analyzed the response of the kidney to furosemide in 5 healthy men, in the presence of both normal physiological serum insulin levels and levels at the upper limit of the physiological range, obtained by the hyperinsulinemic-euglycemic clamp technique. Furosemide 42-52 insulin Homo sapiens 122-129 1823389-3 1991 After furosemide administration, glomerular filtration rate, urine flow, urine sodium excretion, free water clearance, urine pH, plasma renin activity and plasma aldosterone exhibited the same behavior in the presence of both serum insulin concentrations. Furosemide 6-16 insulin Homo sapiens 232-239 1823389-4 1991 The rise in urinary potassium excretion following furosemide administration was significantly lower in the presence of high insulin concentrations. Furosemide 50-60 insulin Homo sapiens 124-131 1823389-6 1991 Thus, in conditions in which natriuresis is mildly stimulated, as in the case of the administration of low doses of furosemide, insulin does not affect the rate of renal sodium reabsorption. Furosemide 116-126 insulin Homo sapiens 128-135 1784627-6 1991 Plasma renin activity (PRA) increased following furosemide administration in animals on an NSD and an LSD, but not in those on an HSD. Furosemide 48-58 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 7-12 1784627-11 1991 In animals on an LSD, the increase in furosemide response appears to be associated with changes in the activity of the renin-angiotensin system and in rabbits on an HSD, the decrease in furosemide effect is probably the net result of several factors. Furosemide 38-48 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 119-124 2242386-5 1990 When the islets were preincubated with Ba2+ (2 mM) the specific effect of 1 mM furosemide on the 86Rb+ influx was reduced, whereas, in acute experiments, Ba2+ (2 mM) did not affect the specific effect of furosemide on 86Rb+ influx. Furosemide 79-89 bone area 2 Mus musculus 39-42 2242386-5 1990 When the islets were preincubated with Ba2+ (2 mM) the specific effect of 1 mM furosemide on the 86Rb+ influx was reduced, whereas, in acute experiments, Ba2+ (2 mM) did not affect the specific effect of furosemide on 86Rb+ influx. Furosemide 204-214 bone area 2 Mus musculus 39-42 2242386-6 1990 86Rb+ efflux from preloaded islets was significantly reduced by 2 mM Ba2+ and during the first 5 min of ion efflux the effect of the combination of 2 mM Ba2+ and 1 mM furosemide was stronger than the effect of Ba2+ alone. Furosemide 167-177 bone area 2 Mus musculus 69-72 2221139-2 1990 Intraperitoneal injection of the angiotensin-converting enzyme inhibitor captopril at 1.7 mg/mouse (high dose) decreased the Na intake of the Na-depleted (furosemide-treated) mice by 80-85%. Furosemide 155-165 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 33-62 2087934-0 1990 Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients. Furosemide 82-92 renin Homo sapiens 7-12 2087934-0 1990 Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients. Furosemide 82-92 kallikrein related peptidase 4 Homo sapiens 34-44 2087934-1 1990 The responsiveness of renin-angiotensin and kallikrein-kinin systems to furosemide challenge has been investigated in forty-six diabetic patients (34 NIDDM/12 IDDM), subdivided into Group I (uncomplicated DM), Group II (DM with hypertension), Group III (DM with nephropathy), Group IV (DM with hypertension and nephropathy) and a control group of 10 healthy volunteers. Furosemide 72-82 renin Homo sapiens 22-27 2087934-2 1990 Plasma renin activity (PRA) was estimated by radioimmunoassay in blood samples drawn before and 10 min after furosemide administration (0.5 mg/kg i.v.). Furosemide 109-119 renin Homo sapiens 7-12 2087934-6 1990 Both PRA and kallikrein levels increased after furosemide in controls while in diabetics this response was severely blunted. Furosemide 47-57 kallikrein related peptidase 4 Homo sapiens 13-23 2167800-10 1990 After frusemide there was a small transient increase in excretion of active kallikrein 1-2 h after dosing which coincided with the maximum diuresis and natriuresis. Furosemide 6-15 kallikrein related peptidase 4 Homo sapiens 76-86 2403378-8 1990 CEF free fraction (fp) in isolated human serum albumin (CEF fp = 7.7%) was increased by drugs which bind to Site I: sulfisoxazole (CEF fp = 68.1%), warfarin (CEF fp = 56.0%) and furosemide (CEF fp = 55.0%). Furosemide 178-188 albumin Homo sapiens 41-54 2203682-5 1990 Renin release in intact hydropenic rats was not altered by diuretic therapy, but furosemide increased plasma renin activity in hydropenic as well as in volume-expanded rats. Furosemide 81-91 renin Rattus norvegicus 109-114 2203682-6 1990 This demonstrates the importance of furosemide inhibition of transport in the macula densa for its renin secretory action. Furosemide 36-46 renin Rattus norvegicus 99-104 2253658-0 1990 Effect of furosemide on angiotensin II-mediated prostaglandin I2 production in hypertensive subjects. Furosemide 10-20 angiotensinogen Homo sapiens 24-38 2118863-13 1990 Furosemide (50 micrograms/ml) stimulated the release of active and inactive renins significantly at 20 and 40 min (p less than 0.05 vs. control) but did not affect the release of either renin at 60 min. Furosemide 0-10 renin Rattus norvegicus 76-81 1694396-3 1990 Furosemide could in principle decrease the basolateral membrane Cl- conductance (Gcl), increase the basolateral membrane K+ conductance, or have a combined effect. Furosemide 0-10 germ cell-less 2, spermatogenesis associated Homo sapiens 81-84 1694396-5 1990 Furosemide increased Rb by 22%, which indicates that furosemide reduces basolateral membrane Gcl. Furosemide 0-10 germ cell-less 2, spermatogenesis associated Homo sapiens 93-96 2199209-1 1990 Recent studies have shown that inhaled frusemide exerts a protective effect against various bronchoconstrictor stimuli in asthma including exercise, fog and allergen. Furosemide 39-48 zinc finger protein, FOG family member 1 Homo sapiens 149-152 2160342-4 1990 Renin was responsive to posture, low sodium diet, saline infusion and frusemide, but relatively unresponsive to raising or lowering circulating levels of angiotensin II. Furosemide 70-79 renin Homo sapiens 0-5 2319462-10 1990 This blunted response presumably occurs because of a reduction in the amount of pharmacologically active drug due to albumin-furosemide binding. Furosemide 125-135 albumin Rattus norvegicus 117-124 2319462-11 1990 Consequently, albumin-furosemide binding in the renal tubule may contribute to the diuretic resistance in nephrotic syndrome. Furosemide 22-32 albumin Rattus norvegicus 14-21 2106127-4 1990 Parathyroid hormone concentrations were high in furosemide-treated patients (0.95 +/- 0.15 ng/mL) compared with patients not treated with furosemide and receiving either moderate (0.49 +/- 0.05 ng/mL) or low (0.42 +/- 0.07 ng/mL) phosphorus intakes. Furosemide 48-58 parathyroid hormone Homo sapiens 0-19 2083062-1 1990 The study has been performed in an attempt to provide further data on the supposed direct action of insulin on the kidney, based on the assumption that any effect of insulin on sodium reabsorption via co-transport should shift the dose-response curve to the furosemide administration. Furosemide 258-268 insulin Homo sapiens 100-107 2083062-1 1990 The study has been performed in an attempt to provide further data on the supposed direct action of insulin on the kidney, based on the assumption that any effect of insulin on sodium reabsorption via co-transport should shift the dose-response curve to the furosemide administration. Furosemide 258-268 insulin Homo sapiens 166-173 1694396-5 1990 Furosemide increased Rb by 22%, which indicates that furosemide reduces basolateral membrane Gcl. Furosemide 53-63 germ cell-less 2, spermatogenesis associated Homo sapiens 93-96 2203383-2 1990 It is possible that these factors may play a role in changes in insulin sensitivity in vivo produced by such diverse conditions as treatment with furosemide, thyroid status or catecholamine status. Furosemide 146-156 insulin Homo sapiens 64-71 2185908-18 1990 Furosemide has two documented metabolites--furosemide glucuronide and saluamine (CSA). Furosemide 0-10 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 81-84 2178660-9 1990 Both nonsteroidal agents inhibited equally the rise in renin activity seen after frusemide. Furosemide 81-90 renin Homo sapiens 55-60 2319462-0 1990 Intratubular albumin blunts the response to furosemide-A mechanism for diuretic resistance in the nephrotic syndrome. Furosemide 44-54 albumin Rattus norvegicus 13-20 2319462-4 1990 After addition of albumin to furosemide perfusate, fractional loop chloride reabsorption was 45 +/- 1%; a value greater (P less than .01) than that observed in furosemide perfused loop segments, but less (P less than .05) than that observed in control loop segments. Furosemide 160-170 albumin Rattus norvegicus 18-25 2319462-9 1990 Thus, albumin in renal tubule fluid attenuates the effect of furosemide on loop segment chloride reabsorption in the rat. Furosemide 61-71 albumin Rattus norvegicus 6-13 2253658-4 1990 The rises in urinary 6-keto-PGF1 alpha and PGE2, and plasma AII after furosemide were prevented by the captopril pretreatment. Furosemide 70-80 angiotensinogen Homo sapiens 60-63 2253658-6 1990 The data indicate that the effect of furosemide on PGI2 production, as reflected by the urinary excretion of 6-keto-PGF1 alpha, was mediated by an action of AII. Furosemide 37-47 angiotensinogen Homo sapiens 157-160 2253658-1 1990 The role of angiotensin II (AII) in Prostaglandin I2 (PGI2) production following furosemide has been examined in a placebo-controlled, cross-over study. Furosemide 81-91 angiotensinogen Homo sapiens 12-26 2253658-1 1990 The role of angiotensin II (AII) in Prostaglandin I2 (PGI2) production following furosemide has been examined in a placebo-controlled, cross-over study. Furosemide 81-91 angiotensinogen Homo sapiens 28-31 2253658-3 1990 Urinary excretion of 6-keto-PGF1 alpha (a metabolite of PGI2) and PGE2, PRA and AII was increased following furosemide without captopril pretreatment. Furosemide 108-118 angiotensinogen Homo sapiens 80-83 34988469-7 2021 We found that furosemide sensitive sodium transport (NKCC2) is only increased during late pregnancy, thiazide sensitive sodium transport (NDCBE/pendrin) is increased in all stages of pregnancy, and that benzamil sensitive sodium transport (ENaC) is increased beginning in mid-pregnancy. Furosemide 14-24 solute carrier family 12 member 1 Rattus norvegicus 53-58 2136743-4 1990 The infusion of furosemide increased urine volume, sodium excretion, osmolal clearance, and PRA, but decreased circulating ANP levels and urinary clearance and fractional excretion of AVP. Furosemide 16-26 arginine vasopressin Homo sapiens 184-187 2266774-0 1990 Disproportional release of differently glycosylated forms of human renin by furosemide. Furosemide 76-86 renin Homo sapiens 67-72 2266774-7 1990 These results provide evidence for the presence of differently glycosylated forms of AR and PR in human plasma and suggest the preferential release of AR-III with the acute stimulation of renin, by furosemide. Furosemide 198-208 renin Homo sapiens 188-193 3184174-2 1988 Furosemide-sensitive cation effluxes from cells with nearly normal membrane potential and pH were lower in NO3- media than in Cl- media; they were reduced when pH was lowered in Cl- media. Furosemide 0-10 NBL1, DAN family BMP antagonist Homo sapiens 107-110 8418022-0 1993 Time course of stimulation of renal renin messenger RNA by furosemide. Furosemide 59-69 renin Rattus norvegicus 36-41 8418022-3 1993 In the first series, Sprague-Dawley rats received furosemide (10 mg/kg) intraperitoneally and a low sodium diet (0.05% sodium); renin secretion was significantly stimulated at 8 or 16 hours after treatment, but renin mRNA levels did not change. Furosemide 50-60 renin Rattus norvegicus 128-133 8418022-6 1993 In additional animals, the response of renin mRNA 4 hours after furosemide was found not to be potentiated by the converting enzyme inhibitor quinapril (5 mg/kg). Furosemide 64-74 renin Rattus norvegicus 39-44 34851962-9 2021 RESULTS: By including 13 studies with 422 participants, the meta-analysis revealed that furosemide with albumin co-administration increased urine output by 31.45 ml/hour and increased urine excretion by 1.76 mEq/hour in comparison to furosemide treatment alone. Furosemide 234-244 albumin Homo sapiens 104-111 34851962-10 2021 The diuretic effect of albumin and furosemide co-administration was better in participants with low baseline serum albumin levels (< 2.5 g/dL) and high prescribed albumin infusion doses (> 30 g), and the effect was more significant within 12 hours after administration. Furosemide 35-45 albumin Homo sapiens 115-122 34851962-10 2021 The diuretic effect of albumin and furosemide co-administration was better in participants with low baseline serum albumin levels (< 2.5 g/dL) and high prescribed albumin infusion doses (> 30 g), and the effect was more significant within 12 hours after administration. Furosemide 35-45 albumin Homo sapiens 163-170 34851962-12 2021 CONCLUSION: Co-administration of furosemide with albumin might enhance diuresis and natriuresis effects than furosemide treatment alone but with high heterogeneity in treatment response. Furosemide 33-43 albumin Homo sapiens 49-56 34851962-13 2021 According to the present meta-analysis, combination therapy might provide advantages compared to the furosemide therapy alone in patients with baseline albumin levels lower than 2.5 g/dL or in patients receiving higher albumin infusion doses or in patients with impaired renal function. Furosemide 101-111 albumin Homo sapiens 152-159 34851962-13 2021 According to the present meta-analysis, combination therapy might provide advantages compared to the furosemide therapy alone in patients with baseline albumin levels lower than 2.5 g/dL or in patients receiving higher albumin infusion doses or in patients with impaired renal function. Furosemide 101-111 albumin Homo sapiens 219-226 9691010-2 1998 In addition, the expression of the furosemide-sensitive type 1 Na-K-2Cl cotransporter (BSC-1) and the natriuretic response to an intravenous test dose furosemide (7.5 mg/kg) during acute V2-receptor blockade was measured. Furosemide 35-45 solute carrier family 12 member 1 Rattus norvegicus 87-92 34599018-10 2021 Of those, the increases of plasma kynurenic acid exposure are comparable to the increases of furosemide by OAT1/3 inhibition. Furosemide 93-103 potassium two pore domain channel subfamily K member 3 Homo sapiens 107-113 34107482-4 2021 Incomplete dRTA (idRTA) is defined as impaired urinary acidification that does not lead to overt metabolic acidosis and therefore can be diagnosed if patients fail to adequately acidify urine after an ammonium chloride (NH4Cl) challenge or furosemide and fludrocortisone test. Furosemide 240-250 rta Drosophila melanogaster 11-15 34114742-1 2021 AIM: The phosphorylation level of the furosemide-sensitive Na+ -K+ -2Cl- cotransporter (NKCC2) in the thick ascending limb (TAL) is used as a surrogate marker for NKCC2 activation and TAL function. Furosemide 38-48 solute carrier family 12, member 1 Mus musculus 88-93 34288546-6 2021 Patients treated with furosemide plus HSS compared with controls treated with furosemide alone showed a comparable degree of reduction in the serum levels of interleukin (IL)-6, soluble suppression of tumorigenicity 2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP) in the "between-group" analysis. Furosemide 78-88 interleukin 6 Homo sapiens 158-176 35392272-0 2022 The Acute Effects of Furosemide on Na-K-Cl Cotransporter-1, Fetuin-A and Pigment Epithelium-Derived Factor in the Guinea Pig Cochlea. Furosemide 21-31 alpha-2-HS-glycoprotein Cavia porcellus 60-68 35508593-3 2022 METHODS: Physiologically based pharmacokinetic models were constructed for four OAT1/3 substrates in healthy individuals: acyclovir, meropenem, furosemide, and ciprofloxacin. Furosemide 144-154 solute carrier family 22 member 6 Homo sapiens 80-86 35557955-0 2022 Multiple Poses and Thermodynamics of Ligands Targeting Protein Surfaces: The Case of Furosemide Binding to mitoNEET in Aqueous Solution. Furosemide 85-95 CDGSH iron sulfur domain 1 Homo sapiens 107-115 35557955-6 2022 This is the X-ray structure of furosemide bound to oxidized mitoNEET. Furosemide 31-41 CDGSH iron sulfur domain 1 Homo sapiens 60-68 35557955-7 2022 Here we employ an enhanced sampling approach, Localized Volume-based Metadynamics, developed by some of us, to identify binding poses of furosemide to human mitoNEET protein in solution. Furosemide 137-147 CDGSH iron sulfur domain 1 Homo sapiens 157-165 35631326-5 2022 LOS and FUR showed the high affinity for human serum albumin, and the binding reactions between them were spontaneous and exothermic. Furosemide 8-11 albumin Homo sapiens 47-60 35635321-7 2022 One proposed role of NHE3 relates to furosemide-induced urinary acidification. Furosemide 37-47 solute carrier family 9 (sodium/hydrogen exchanger), member 3 Mus musculus 21-25 35635321-10 2022 Compared to vehicle, chronic furosemide treatment in control mice resulted in greater NKCC2 and lower Npt2a abundances, effects that were absent in NHE3TAL-KO mice. Furosemide 29-39 solute carrier family 12, member 1 Mus musculus 86-91 35635321-10 2022 Compared to vehicle, chronic furosemide treatment in control mice resulted in greater NKCC2 and lower Npt2a abundances, effects that were absent in NHE3TAL-KO mice. Furosemide 29-39 solute carrier family 34 (sodium phosphate), member 1 Mus musculus 102-107 35635321-11 2022 In summary, NHE3 in the TAL plays a role for the sustained acidification effect of furosemide. Furosemide 83-93 solute carrier family 9 (sodium/hydrogen exchanger), member 3 Mus musculus 12-16 35392272-0 2022 The Acute Effects of Furosemide on Na-K-Cl Cotransporter-1, Fetuin-A and Pigment Epithelium-Derived Factor in the Guinea Pig Cochlea. Furosemide 21-31 pigment epithelium-derived factor Cavia porcellus 73-106 35392272-11 2022 Furosemide induced an increased staining intensity of Fetuin-A at 120 min. Furosemide 0-10 alpha-2-HS-glycoprotein Cavia porcellus 54-62 35392272-14 2022 Furosemide induced an increased staining intensity of PEDF in type I neurons and pillar cells after 120 min. Furosemide 0-10 pigment epithelium-derived factor Cavia porcellus 54-58 35392272-17 2022 Fetuin-A and PEDF are present in many cells of the cochlea and probably increase after furosemide exposure, possibly as an otoprotective response. Furosemide 87-97 alpha-2-HS-glycoprotein Cavia porcellus 0-8 35392272-17 2022 Fetuin-A and PEDF are present in many cells of the cochlea and probably increase after furosemide exposure, possibly as an otoprotective response. Furosemide 87-97 pigment epithelium-derived factor Cavia porcellus 13-17 2686391-0 1989 Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure. Furosemide 51-61 angiotensin I converting enzyme Homo sapiens 65-94 35239032-5 2022 We conducted a systematic review with the objective of evaluating the change in urine volume and urine sodium excretion after treatment with furosemide only versus furosemide with albumin in edematous patients with NS. Furosemide 164-174 albumin Homo sapiens 180-187 35239032-6 2022 OBJECTIVES: (1) To evaluate efficacy of furosemide alone versus furosemide with albumin in the treatment of nephrotic edema in adults and children. Furosemide 64-74 albumin Homo sapiens 80-87 35163352-13 2022 The NKCC1 inhibitor furosemide showed a weaker effect on ejection fraction in isolated renal lymphatics of PAN vs controls. Furosemide 20-30 solute carrier family 12 member 2 Rattus norvegicus 4-9 35163352-14 2022 High sodium within the renal interstitium following proteinuric injury is associated with impaired renal lymphatic pumping that may, in part, involve the SPAK-NKCC1-eNOS pathway, which may contribute to sodium retention and reduce lymphatic responsiveness to furosemide. Furosemide 259-269 serine threonine kinase 39 Rattus norvegicus 154-158 35163352-14 2022 High sodium within the renal interstitium following proteinuric injury is associated with impaired renal lymphatic pumping that may, in part, involve the SPAK-NKCC1-eNOS pathway, which may contribute to sodium retention and reduce lymphatic responsiveness to furosemide. Furosemide 259-269 solute carrier family 12 member 2 Rattus norvegicus 159-164 35163352-14 2022 High sodium within the renal interstitium following proteinuric injury is associated with impaired renal lymphatic pumping that may, in part, involve the SPAK-NKCC1-eNOS pathway, which may contribute to sodium retention and reduce lymphatic responsiveness to furosemide. Furosemide 259-269 nitric oxide synthase 3 Rattus norvegicus 165-169 2677316-0 1989 Caffeine potentiates the renin response to furosemide in rats. Furosemide 43-53 renin Rattus norvegicus 25-30 2532921-4 1989 Frusemide increased natriuresis (UNaV), kaliuresis (UKV), inulin clearance and plasma renin activity (PRA) and ramipril pretreatment significantly enhanced these effects suggesting that the acute generation of angiotensin II (AII) may attenuate these actions of intravenous frusemide. Furosemide 0-9 angiotensinogen Homo sapiens 210-224 2532921-4 1989 Frusemide increased natriuresis (UNaV), kaliuresis (UKV), inulin clearance and plasma renin activity (PRA) and ramipril pretreatment significantly enhanced these effects suggesting that the acute generation of angiotensin II (AII) may attenuate these actions of intravenous frusemide. Furosemide 274-283 angiotensinogen Homo sapiens 210-224 2532921-15 1989 AII may therefore inhibit the rise in urinary dopamine excretion after frusemide. Furosemide 71-80 angiotensinogen Homo sapiens 0-3 2586018-0 1989 Interference of different ACE-inhibitors with the diuretic action of furosemide and hydrochlorothiazide. Furosemide 69-79 angiotensin I converting enzyme Homo sapiens 26-29 2615191-6 1989 In further studies, the effects of ouabain (10(-3) M), furosemide (10(-4) M) or acidosis (pH 7.0 rather than the usual pH 7.4) on TAL transport activity and adenine nucleotide levels were compared. Furosemide 55-65 leucine rich repeat and sterile alpha motif containing 1 Homo sapiens 130-133 2615191-8 1989 Addition of ouabain or furosemide reduced CH2O and TAL necrosis in parallel while acidosis had no effect on CH2O during perfusion. Furosemide 23-33 leucine rich repeat and sterile alpha motif containing 1 Homo sapiens 51-54 2553866-3 1989 When the effect of rANP was investigated on in vitro 22Na+ uptake into isolated cerebral capillaries, 10(-7) M rANP significantly inhibited the uptake in the presence of 1.0 mM ouabain, 1.0 mM furosemide, and 2.0 mM LiCl in the uptake buffer, a finding suggesting a specific inhibitory effect of rANP on amiloride-sensitive Na+ transport. Furosemide 193-203 natriuretic peptide A Rattus norvegicus 111-115 2553866-3 1989 When the effect of rANP was investigated on in vitro 22Na+ uptake into isolated cerebral capillaries, 10(-7) M rANP significantly inhibited the uptake in the presence of 1.0 mM ouabain, 1.0 mM furosemide, and 2.0 mM LiCl in the uptake buffer, a finding suggesting a specific inhibitory effect of rANP on amiloride-sensitive Na+ transport. Furosemide 193-203 natriuretic peptide A Rattus norvegicus 111-115 2677316-6 1989 We therefore wanted to determine if: 1) adenosine modulates furosemide-induced renin release and 2) sodium-chloride reabsorption at the macula densa is essential for adenosine actions. Furosemide 60-70 renin Rattus norvegicus 79-84 2677316-9 1989 In the vehicle group, furosemide increased urinary volume, sodium and potassium excretion and increased plasma renin activity from 6 +/- 1 to 45 +/- 11 ngAl/ml/hr. Furosemide 22-32 renin Rattus norvegicus 111-116 2677316-10 1989 Caffeine and 1,3-dipropyl-8-(p-sulfophenyl)xanthine potentiated the increase in plasma renin activity produced by furosemide (to 120 +/- 15 and 147 +/- 21 ng Al/ml/hr, respectively), whereas having no significant effects on urinary volume, sodium excretion or blood pressure. Furosemide 114-124 renin Rattus norvegicus 87-92 2677316-11 1989 These results suggest that furosemide-induced renin release in vivo is restrained by endogenous adenosine. Furosemide 27-37 renin Rattus norvegicus 46-51 2809941-5 1989 Compared to a group of similarly fed VLBW infants without BPD and not treated with the diuretic, the furosemide-treated infants excreted a larger percent of the calcium intake in the urine but had similar total urinary calcium and phosphorus losses (mg/kg/day) and serum calcium, phosphorus, alkaline phosphatase, and parathyroid hormone (PTH) levels. Furosemide 101-111 parathyroid hormone Homo sapiens 318-337 2732945-5 1989 Angiotensin II blockade with saralasin (2 micrograms/kg/min) prevented the fall in medullary plasma flow in indomethacin-treated rats during furosemide infusion but did not alter mean arterial pressure, inulin clearance or total renal blood flow. Furosemide 141-151 angiotensinogen Rattus norvegicus 0-14 2534930-0 1989 [Effect of furosemide on the plasma level of atrial natriuretic peptide (ANP) in healthy persons and in patients with uncomplicated primary arterial hypertension]. Furosemide 11-21 natriuretic peptide A Homo sapiens 45-71 2534930-0 1989 [Effect of furosemide on the plasma level of atrial natriuretic peptide (ANP) in healthy persons and in patients with uncomplicated primary arterial hypertension]. Furosemide 11-21 natriuretic peptide A Homo sapiens 73-76 2534930-4 1989 A significant decrease in ANP plasma levels was noted in all examined individuals following furosemide administration in all time intervals comparing with baseline values. Furosemide 92-102 natriuretic peptide A Homo sapiens 26-29 2534930-5 1989 An increase in 1-minute urine output and 1-minute sodium excretion with the urine significantly correlated with plasma ANP decrease during 90 minutes following furosemide administration. Furosemide 160-170 natriuretic peptide A Homo sapiens 119-122 2534930-6 1989 The obtained results suggest that furosemide inhibits ANP secretion in the patients with uncomplicated primary hypertension similarly to healthy individuals. Furosemide 34-44 natriuretic peptide A Homo sapiens 54-57 2498379-7 1989 The binding of T4 to apoA-I was reduced by known inhibitors of T4 binding to serum proteins (diclofenac = mefenamic acid = furosemide = 8-anilinonaphthalene sulfonic acid much greater than dilantin greater than heparin greater than barbital) and by lipids (unsaturated fatty acids greater than cholesterol = cholesterol esters = phospholipids greater than saturated fatty acids = diglycerides = triglycerides). Furosemide 123-133 apolipoprotein A1 Homo sapiens 21-27 2498384-8 1989 In contrast, furosemide, the drug most highly reactive with TBG, was only 0.11 +/- 0.03% (n = 7) as potent as T4, followed by meclofenamic acid greater than mefenamic acid greater than fenclofenac greater than flufenamic acid greater than diflunisal greater than milrinone. Furosemide 13-23 serpin family A member 7 Homo sapiens 60-63 2539125-3 1989 This action of ANP was mimicked by 8-bromo-cGMP and completely diminished by furosemide. Furosemide 77-87 natriuretic peptide A Bos taurus 15-18 2792351-4 1989 It was also found that furosemide and ethacrynic acid by binding to human serum albumin molecule produce its conformational alterations. Furosemide 23-33 albumin Homo sapiens 80-87 2655691-9 1989 Significant increments in plasma renin activity, which were suppressed by all treatments, were observed after frusemide. Furosemide 110-119 renin Homo sapiens 33-38 2655691-13 1989 In the presence of frusemide, indomethacin had more anti-natriuretic and renin-suppressing effect than ibuprofen. Furosemide 19-28 renin Homo sapiens 73-78 2792172-2 1989 Decreased renal sensitivity to frusemide was found in only one patient, who also had hypovolaemia and an activated renin-angiotensin-aldosterone system. Furosemide 31-40 renin Homo sapiens 115-120 2645910-3 1989 Reduction of renal perfusion pressure, intravenous infusion of furosemide, and captopril administration cause a greater increase in renin release from innervated kidneys than from denervated kidneys. Furosemide 63-73 renin Homo sapiens 132-137 2543544-2 1989 Hyporeninemic hypoaldosteronism was disclosed on the basis of a lack of response of plasma renin activity to furosemide administration or tilting with marked hypotension and a subnormal response of aldosterone to furosemide stimulation, tilting, angiotensin II infusion and ACTH administration, as well as increased vascular responsiveness to angiotensin II infusion. Furosemide 109-119 renin Homo sapiens 4-9 2543544-2 1989 Hyporeninemic hypoaldosteronism was disclosed on the basis of a lack of response of plasma renin activity to furosemide administration or tilting with marked hypotension and a subnormal response of aldosterone to furosemide stimulation, tilting, angiotensin II infusion and ACTH administration, as well as increased vascular responsiveness to angiotensin II infusion. Furosemide 213-223 renin Homo sapiens 4-9 2566466-8 1989 Although the fraction unbound of furosemide was unchanged between treatments (0.770 for treatment I vs. 0.695% for treatment II), the renal and secretion clearances of furosemide were reduced by about 30% in the presence of angiotensin II. Furosemide 168-178 angiotensinogen Rattus norvegicus 224-238 2655681-8 1989 Plasma renin activity was increased acutely by both doses of frusemide and by bumetanide (2.5 mg) compared with placebo and to bumetanide (250 micrograms). Furosemide 61-70 renin Homo sapiens 7-12 2655681-10 1989 Angiotensin II was increased significantly 30 min after frusemide 100 mg and bumetanide 2.5 mg, and by all four treatments at 50 min when compared with placebo. Furosemide 56-65 angiotensinogen Homo sapiens 0-14 2655681-14 1989 Frusemide 100 mg and bumetanide 2.5 mg have the same effects on the renal vasculature and the renin-angiotensin-prostaglandin system. Furosemide 0-9 renin Homo sapiens 94-99 2655681-15 1989 Under the conditions of this study, frusemide 10 mg had different effects on plasma renin activity than bumetanide 250 micrograms. Furosemide 36-45 renin Homo sapiens 84-89 2521333-0 1989 Atrial natriuretic factor inhibits isoproterenol- and furosemide-stimulated renin release in humans. Furosemide 54-64 renin Homo sapiens 76-81 2521333-4 1989 Atrial natriuretic factor abolished the rise in plasma renin activity caused by isoproterenol (p = 0.003) and significantly (p = 0.048) attenuated the rise in plasma renin activity after a bolus injection of furosemide. Furosemide 208-218 renin Homo sapiens 55-60 2521333-4 1989 Atrial natriuretic factor abolished the rise in plasma renin activity caused by isoproterenol (p = 0.003) and significantly (p = 0.048) attenuated the rise in plasma renin activity after a bolus injection of furosemide. Furosemide 208-218 renin Homo sapiens 166-171 2510079-4 1989 Furosemide injection resulted in increases of all variables, albeit that PAI and PAII were elevated to a lesser extent then PRA. Furosemide 0-10 serpin family E member 1 Homo sapiens 73-76 3061717-0 1988 Effects of frusemide and captopril on the relationship between biologically and immunologically active renin in human plasma. Furosemide 11-20 renin Homo sapiens 103-108 2919032-9 1989 This was confirmed by the exaggerated response to frusemide reflected by urinary flow measurements in patients with a creatinine clearance of 10 ml min-1 or less. Furosemide 50-59 CD59 molecule (CD59 blood group) Homo sapiens 148-153 2654919-3 1989 An acute furosemide test made it possible to establish 3 types of responses of vasopressin secretion in such patients: normal, paradoxical and areactive. Furosemide 9-19 arginine vasopressin Homo sapiens 79-90 2787038-3 1989 The effects of CGRP were nearly abolished in chloride-free solutions or after treatment with furosemide. Furosemide 93-103 calcitonin related polypeptide alpha Homo sapiens 15-19 3073092-3 1988 So, for instance, drugs that increase prostaglandins synthesis as colchicine or furosemide inhibit insulin secretion while non steroid anti-inflammator drugs, mainly salicylates, which inhibit cyclo-oxygenase, enhance the insulin response to various stimuli. Furosemide 80-90 insulin Homo sapiens 99-106 2972152-1 1988 The effects of an oral water load and iv administration of isotonic glucose, hypertonic saline, mannitol and furosemide on release of human atrial natriuretic peptide (hANP) were examined in normal subjects to determine the main factors causing its release. Furosemide 109-119 natriuretic peptide A Homo sapiens 168-172 3148912-3 1988 The addition of albumin (45 g/l) abolished the furosemide response whereas the nitroglycerin response was unaffected. Furosemide 47-57 albumin Oryctolagus cuniculus 16-23 3148912-4 1988 Similarly the pronounced effect of nitroglycerin on electrically evoked contractions was unaffected by the presence of albumin whereas the furosemide effect was weakened by albumin. Furosemide 139-149 albumin Oryctolagus cuniculus 173-180 2855542-2 1988 Each measurement was repeated before and after stimulation of renin activity induced by furosemide. Furosemide 88-98 renin Homo sapiens 62-67 2972152-5 1988 The plasma hANP level decreased from 17.3 +/- 2.5 to 9.0 +/- 2.5 ng/l after injection of 40 mg of furosemide. Furosemide 98-108 natriuretic peptide A Homo sapiens 11-15 3220046-5 1988 However, plasma renin activity (PRA) was normal or slightly high, and responded normally to furosemide-upright stimulation and fluorohydrocortisone suppression. Furosemide 92-102 renin Homo sapiens 16-21 3064599-12 1988 In conclusion, furosemide modulates coronary reserve, and it is likely that this is because furosemide mediates activation of renin-angiotensin system, thus reducing the vasodilatory capacity of the coronary arteries. Furosemide 15-25 renin Homo sapiens 126-131 3238049-6 1988 GRP-induced Isc increases were halved by serosal furosemide (0.3 mM) and reduced by 65% and 90% in tissue bathing solutions lacking Cl- or Cl- and HCO3-, respectively. Furosemide 49-59 gastrin releasing peptide Homo sapiens 0-3 3134540-0 1988 Effect of cyclooxygenase inhibition on the pulmonary vasodilator response to furosemide. Furosemide 77-87 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 10-24 3134540-11 1988 We conclude that: 1) the vasodilatory activity of furosemide is mediated by increased production and not decreased metabolism of an endogenous cyclooxygenase product; 2) the effect of prostacyclin on vascular reactivity is similar to that of furosemide; and 3) local formation of prostacyclin by vascular tissue most likely mediates the vascular activity of furosemide. Furosemide 50-60 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 143-157 2967740-9 1988 A single oral dose of the diuretic furosemide increased angiotensin I significantly from 21 (+/- 1) to 32 (+/- 1.7) pmol/L (n = 5); P less than 0.001), whereas angiotensin II remained unchanged, 6.6 (+/- 0.5) vs 6.4 (+/- 0.4) pmol/L (n = 5). Furosemide 35-45 angiotensinogen Homo sapiens 56-69 2967740-9 1988 A single oral dose of the diuretic furosemide increased angiotensin I significantly from 21 (+/- 1) to 32 (+/- 1.7) pmol/L (n = 5); P less than 0.001), whereas angiotensin II remained unchanged, 6.6 (+/- 0.5) vs 6.4 (+/- 0.4) pmol/L (n = 5). Furosemide 35-45 angiotensinogen Rattus norvegicus 160-174 3284821-0 1988 Role of angiotensin II in renal prostaglandin E2 production after furosemide administration. Furosemide 66-76 angiotensinogen Homo sapiens 8-22 3284821-1 1988 The role of plasma angiotensin II (Ang II) in furosemide-stimulated renal prostaglandin E2 (PGE2) production was evaluated in eight healthy subjects. Furosemide 46-56 angiotensinogen Homo sapiens 19-33 3284821-1 1988 The role of plasma angiotensin II (Ang II) in furosemide-stimulated renal prostaglandin E2 (PGE2) production was evaluated in eight healthy subjects. Furosemide 46-56 angiotensinogen Homo sapiens 35-41 3284821-5 1988 Urinary PGE2 excretion, PRA, and Ang II increased after furosemide administration without captopril pretreatment, and there was a significant correlation between the increment in Ang II and that in urinary PGE2 excretion. Furosemide 56-66 angiotensinogen Homo sapiens 33-39 3284821-5 1988 Urinary PGE2 excretion, PRA, and Ang II increased after furosemide administration without captopril pretreatment, and there was a significant correlation between the increment in Ang II and that in urinary PGE2 excretion. Furosemide 56-66 angiotensinogen Homo sapiens 179-185 3284821-8 1988 These results suggest that Ang II may play an important role in furosemide-stimulated PGE2 production. Furosemide 64-74 angiotensinogen Homo sapiens 27-33 3386517-1 1988 We have studied the effects of two diuretics, selective for renal cortical (furosemide) and inner medullary (vasopressin antagonist) water handling, in rat kidney at 1.5 T and find that furosemide completely dissipates the cortical-inner medullary T2 gradient whereas the vasopressin antagonist has little effect. Furosemide 186-196 arginine vasopressin Rattus norvegicus 109-120 3386517-1 1988 We have studied the effects of two diuretics, selective for renal cortical (furosemide) and inner medullary (vasopressin antagonist) water handling, in rat kidney at 1.5 T and find that furosemide completely dissipates the cortical-inner medullary T2 gradient whereas the vasopressin antagonist has little effect. Furosemide 186-196 arginine vasopressin Rattus norvegicus 272-283 3064599-12 1988 In conclusion, furosemide modulates coronary reserve, and it is likely that this is because furosemide mediates activation of renin-angiotensin system, thus reducing the vasodilatory capacity of the coronary arteries. Furosemide 92-102 renin Homo sapiens 126-131 2832173-6 1988 Addition of frusemide to enalapril therapy resulted in a greater fall in mean blood pressure (87 +/- 5 mmHg to 79 +/- 4 mmHg; P less than 0.01) and an increase in cardiac output (3.1 +/- 1.1 l min-1 to 3.6 +/- 1.0 l min-1; P less than 0.02). Furosemide 12-21 CD59 molecule (CD59 blood group) Homo sapiens 193-198 3341836-1 1988 Thirty-five patients with severe chronic congestive heart failure that was refractory to conventional therapy were given high dosages of furosemide (250 to 4000 mg/d) because of significantly reduced renal function (mean endogenous creatinine clearance, 0.53 mL/s/1.73 m2 [32 mL/min/1.73 m2]). Furosemide 137-147 CD59 molecule (CD59 blood group) Homo sapiens 279-284 3277563-3 1988 We studied the renin-aldosterone response to intravenous furosemide (60 mg) and upright posture and the renin response to converting enzyme inhibition (captopril, 50 mg) and upright posture in five patients with SLE and hyperkalemia (group 1) and five normokalemic patients with SLE (group 2). Furosemide 57-67 renin Homo sapiens 15-20 2832173-6 1988 Addition of frusemide to enalapril therapy resulted in a greater fall in mean blood pressure (87 +/- 5 mmHg to 79 +/- 4 mmHg; P less than 0.01) and an increase in cardiac output (3.1 +/- 1.1 l min-1 to 3.6 +/- 1.0 l min-1; P less than 0.02). Furosemide 12-21 CD59 molecule (CD59 blood group) Homo sapiens 216-221 3060993-8 1988 It is proposed that activation of the sympathetic nervous system and/or the renin-angiotensin-aldosterone system may play a role in mediating the acute tolerance to furosemide diuresis. Furosemide 165-175 renin Homo sapiens 76-81 3276725-4 1988 Four of the 5 diabetic patients whose PRA failed to rise to the usual level after furosemide treatment attained a plasma prorenin level higher than any normal subject, suggesting that furosemide stimulated synthesis and secretion of prorenin, but that conversion of prorenin to active renin was impaired. Furosemide 184-194 renin Homo sapiens 124-129 2826469-11 1988 After exposure to fMLP, protein I-treated neutrophils underwent a furosemide-sensitive hyperpolarization rather than the usual depolarization. Furosemide 66-76 formyl peptide receptor 1 Homo sapiens 18-22 2826469-11 1988 After exposure to fMLP, protein I-treated neutrophils underwent a furosemide-sensitive hyperpolarization rather than the usual depolarization. Furosemide 66-76 annexin A2 Homo sapiens 24-33 2973989-0 1988 Frusemide pretreatment blunts the inhibition of renal tubular sodium reabsorption by ANF in man. Furosemide 0-9 natriuretic peptide A Homo sapiens 85-88 2973989-5 1988 In contrast, after frusemide pretreatment, ANF caused an increase in water excretion (urinary flow rate) but no change in sodium excretion. Furosemide 19-28 natriuretic peptide A Homo sapiens 43-46 3346341-4 1988 When the rate of 86Rb+ efflux (as a tracer for K+) was measured from each of the three cell lines, a furosemide- and TPA-inhibitable component of efflux was clearly evident in parental and TNR-9 cells but was virtually absent in TNR-2 cells. Furosemide 101-111 tenascin R Mus musculus 189-192 3346341-4 1988 When the rate of 86Rb+ efflux (as a tracer for K+) was measured from each of the three cell lines, a furosemide- and TPA-inhibitable component of efflux was clearly evident in parental and TNR-9 cells but was virtually absent in TNR-2 cells. Furosemide 101-111 tenascin R Mus musculus 229-232 3346341-5 1988 86Rb+ influx measurements indicated the presence in parental 3T3 cells and the TNR-9 line of a substantial furosemide-sensitive flux that could be inhibited by TPA. Furosemide 107-117 tenascin R Mus musculus 79-82 3346341-6 1988 In contrast, much less furosemide-sensitive influx was present in 3T3-TNR-2 cells and it was relatively unaffected by TPA. Furosemide 23-33 tenascin R Mus musculus 70-73 3346341-7 1988 In both parental 3T3 and 3T3-TNR-2 cells, most of the furosemide-sensitive 86Rb+ influx is dependent on extracellular Na+ and Cl-. Furosemide 54-64 tenascin R Mus musculus 29-32 2828800-4 1988 Administration of furosemide to rats for five days resulted in a profound diuresis (approximately equal to 350% increase in urine volume) accompanied by a significant increase in PBR density (43%) that was apparent by the fifth day of treatment. Furosemide 18-28 translocator protein Rattus norvegicus 179-182 2853446-2 1988 The role of the renin-angiotensin-aldosterone system in the development of tolerance to the diuretic effect of furosemide was investigated in 12 healthy male volunteers. Furosemide 111-121 renin Homo sapiens 16-21 2960866-5 1987 Intravenous injection of saline elevated circulating ANF, whereas acute volume depletion by hemorrhage, water deprivation and furosemide diuresis greatly lowered plasma ANF. Furosemide 126-136 natriuretic peptide A Rattus norvegicus 169-172 3506626-1 1987 Changes in plasma active and inactive renin and angiotensin II in response to tilt and intravenous frusemide were assessed in ten patients with essential hypertension, before treatment and again during chronic therapy with the alpha 1-adrenoceptor antagonist prazosin. Furosemide 99-108 renin Homo sapiens 38-43 3506626-1 1987 Changes in plasma active and inactive renin and angiotensin II in response to tilt and intravenous frusemide were assessed in ten patients with essential hypertension, before treatment and again during chronic therapy with the alpha 1-adrenoceptor antagonist prazosin. Furosemide 99-108 angiotensinogen Homo sapiens 48-62 3506626-3 1987 Both before and during prazosin, tilt and frusemide each led to significant elevation of plasma active renin (P less than 0.001) and angiotensin II (P less than 0.05). Furosemide 42-51 renin Homo sapiens 103-108 3506626-3 1987 Both before and during prazosin, tilt and frusemide each led to significant elevation of plasma active renin (P less than 0.001) and angiotensin II (P less than 0.05). Furosemide 42-51 angiotensinogen Homo sapiens 133-147 3506626-4 1987 Inactive renin tended to fall with tilt, and fell significantly following frusemide (P less than 0.05). Furosemide 74-83 renin Homo sapiens 9-14 2822455-2 1987 In the submitted paper the influence of therapeutic doses of the calmodulin inhibitor, trifluoperazine, on aldosterone and cortisol secretion stimulated by ACTH or by activation of endogenous angiotensin by furosemide was investigated in healthy subjects. Furosemide 207-217 calmodulin 1 Homo sapiens 65-75 2963164-9 1987 Pretreatment of rabbits with furosemide for two days before experiments resulted in greater basal renin release rates from microdissected afferent arterioles (1.70 +/- 0.35 ng AI.hr-1.Af-1/hr, N = 14). Furosemide 29-39 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 98-103 3653395-4 1987 Furosemide but not tetraethylammonium inhibited the gastrin-induced depolarization. Furosemide 0-10 gastrin Homo sapiens 52-59 3652622-7 1987 Indomethacin attenuated the natriuretic and renin responses to frusemide, but did not alter urine dopamine output. Furosemide 63-72 renin Homo sapiens 44-49 3555065-4 1987 Renin/aldosterone stimulation testing was performed by intravenous injection of 80 mg of furosemide followed by four hours of upright posture. Furosemide 89-99 renin Homo sapiens 0-5 2956192-4 1987 Volume contraction induced by furosemide treatment of chronic water restriction significantly reduced the circulating immunoreactive ANF. Furosemide 30-40 natriuretic peptide A Rattus norvegicus 133-136 3694431-5 1987 On the basis of the results, it was demonstrated that disposition of furosemide in man can be described by a two-compartment open model with the following average parameters: t1/2 alpha = 0.237 +/- 0.069 h, t1/2 beta = 1.29 +/- 0.20 h and Vss = 8.46 +/- 2.171. Furosemide 69-79 interleukin 1 receptor like 1 Homo sapiens 207-223 3296006-2 1987 PGI2 may mediate, in part, the early increment in plasma renin activity (PRA) after furosemide. Furosemide 84-94 renin Rattus norvegicus 57-62 3032710-1 1987 Renin secretion was stimulated in rats by adrenalectomy (ADX), by treatment with the converting enzyme inhibitor enalapril (MK 421), or by feeding a low salt diet plus furosemide treatment (FUR). Furosemide 168-178 renin Rattus norvegicus 0-5 3828657-10 1987 AII responses were totally inhibited by the chloride channel blocker, diphenylamine-2-carboxylate (DPC) while cotransport inhibitors e.g. piretanide and frusemide significantly reduced the size of AII responses in colon and jejunum. Furosemide 153-162 angiotensinogen Rattus norvegicus 0-3 3828657-10 1987 AII responses were totally inhibited by the chloride channel blocker, diphenylamine-2-carboxylate (DPC) while cotransport inhibitors e.g. piretanide and frusemide significantly reduced the size of AII responses in colon and jejunum. Furosemide 153-162 angiotensinogen Rattus norvegicus 197-200 3549504-5 1987 Serum renin and serum aldosterone correlated mutually before and after intravenous furosemide. Furosemide 83-93 renin Homo sapiens 6-11 3296006-3 1987 We hypothesized that thromboxane synthetase inhibition should direct prostaglandin endoperoxide metabolism toward PGI2, thereby enhancing the effects of furosemide on renin release. Furosemide 153-163 renin Rattus norvegicus 167-172 3549322-6 1987 These results suggest that urinary PGE2 excretion after frusemide administration may be reduced by propranolol and that the mechanism responsible for the effect of propranolol on the frusemide-induced renal PGE2 production may be, at least in part, secondary to inhibition of the renin-angiotensin system. Furosemide 183-192 renin Homo sapiens 280-285 3324714-0 1987 Diminution by captopril of the diuretic, natriuretic and kallikrein stimulating action of furosemide by reduction in its renal secretion. Furosemide 90-100 kallikrein related peptidase 4 Homo sapiens 57-67 3324714-6 1987 After furosemide injection changes in plasma aldosterone concentration paralleled changes in renal kallikrein and kinin excretion. Furosemide 6-16 kallikrein related peptidase 4 Homo sapiens 99-109 3324714-7 1987 However, after captopril there was a sharp dissociation between aldosterone, which was diminished by captopril continuously, and renal kallikrein and kinins, which were still stimulated by furosemide. Furosemide 189-199 kallikrein related peptidase 4 Homo sapiens 135-145 3324714-8 1987 These results suggest that renal kallikrein-kinin system is stimulated by furosemide directly and independently of aldosterone secretion. Furosemide 74-84 kallikrein related peptidase 4 Homo sapiens 33-43 3105853-0 1987 Effect of cyclooxygenase and thromboxane synthetase inhibition on furosemide-stimulated plasma renin activity. Furosemide 66-76 renin Rattus norvegicus 95-100 3105853-1 1987 We studied the effects of a specific thromboxane (TX) synthetase inhibitor (U-63,557A) and a cyclooxygenase inhibitor on furosemide-induced renin release. Furosemide 121-131 renin Rattus norvegicus 140-145 3105853-5 1987 Plasma renin activity was measured in blood samples collected 0, 10, 20, and 40 min after the injection of furosemide. Furosemide 107-117 renin Rattus norvegicus 7-12 3105853-7 1987 The results demonstrated that plasma renin activity rose with time following furosemide in the various groups of rats; indomethacin suppressed the furosemide-induced increments in plasma renin activity, while U-63,557A at doses of 4-8 mg X kg-1 augmented it. Furosemide 77-87 renin Rattus norvegicus 37-42 3105853-7 1987 The results demonstrated that plasma renin activity rose with time following furosemide in the various groups of rats; indomethacin suppressed the furosemide-induced increments in plasma renin activity, while U-63,557A at doses of 4-8 mg X kg-1 augmented it. Furosemide 147-157 renin Rattus norvegicus 37-42 3105853-7 1987 The results demonstrated that plasma renin activity rose with time following furosemide in the various groups of rats; indomethacin suppressed the furosemide-induced increments in plasma renin activity, while U-63,557A at doses of 4-8 mg X kg-1 augmented it. Furosemide 147-157 renin Rattus norvegicus 187-192 3105853-10 1987 Thus, these experiments suggest that thromboxane synthetase inhibition, within a narrow dosage range, potentiates furosemide-induced renin release while cyclooxygenase inhibition suppresses it. Furosemide 114-124 renin Rattus norvegicus 133-138 3326401-8 1987 In DI rats was found a paradoxical antidiuretic effect of furanthril after either an acute or chronic treatment, which was attributed to the per se stimulated renin-angiotensin system and suppressed PG-synthesis typical for these rats. Furosemide 58-68 renin Rattus norvegicus 159-164 3107857-9 1987 We conclude that intravenous frusemide administration to a rat reduces sympathetic vasoconstrictor responses of the ex vivo blood perfused tail artery segment by a diuresis-independent but prostaglandin and angiotensin II dependent release of another hormone from the kidney. Furosemide 29-38 angiotensinogen Rattus norvegicus 207-221 3644819-4 1987 The Ca2+ concentration in endolymph was abruptly increased by anoxia or the intravenous administration of 60 mg/kg furosemide and was slightly increased by the intravenous administration of 30 mg/kg furosemide or 100 mg/kg acetazolamide. Furosemide 115-125 LOW QUALITY PROTEIN: carbonic anhydrase 2 Cavia porcellus 4-7 3644819-4 1987 The Ca2+ concentration in endolymph was abruptly increased by anoxia or the intravenous administration of 60 mg/kg furosemide and was slightly increased by the intravenous administration of 30 mg/kg furosemide or 100 mg/kg acetazolamide. Furosemide 199-209 LOW QUALITY PROTEIN: carbonic anhydrase 2 Cavia porcellus 4-7 3328888-6 1987 The renin secretion rate was increased by furosemide but not by verapamil. Furosemide 42-52 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 4-9 3549580-0 1987 Acute effect of furosemide on renal kallikrein and prostaglandin systems in mild to moderate essential hypertension. Furosemide 16-26 kallikrein related peptidase 4 Homo sapiens 36-46 3549580-9 1987 In both H and N furosemide caused a significant rise of PRA1 (p less than 0.001 in H and p less than 0.01 in N) and PRA2 (p less than 0.001 in H and p less than 0.05 in N). Furosemide 16-26 Rab acceptor 1 Homo sapiens 56-60 3600908-4 1987 In the biopsy carried out after the cessation of furosemide intake, these morphological changes were markedly improved with a reduced activity of the renin-angiotensin system. Furosemide 49-59 renin Homo sapiens 150-155 3099310-3 1986 With the exception of HCT, the other drugs also suppressed the production of thromboxane A2 (IND greater than SPI greater than FUR); lipoxygenase formation of hydroxyeicosatetraenoic acid was also enhanced by SPI and IND. Furosemide 127-130 chromogranin A Homo sapiens 209-212 3099310-2 1986 All four compounds augmented the synthesis of prostaglandins (PGs) D2 (HCT,FUR), E2 (SPI) and I2 (FUR,IND), probably through facilitated reorientation of endoperoxide biotransformation. Furosemide 98-101 chromogranin A Homo sapiens 81-96 3553421-0 1987 System dynamics modeling of renin aldosterone and electrolyte changes induced by furosemide in hypertensive patients. Furosemide 81-91 renin Homo sapiens 28-33 3096336-9 1986 PB, 3-MC and PCN increased F-UDP-GT activity to 208%, 282% and 342% of vehicle-treated animals, respectively, while F pretreatment did not affect the conjugation of F. In comparison, 1-naphthol glucuronidation was preferentially induced by 3-MC (4.4-fold of control) while estrone glucuronidation was induced by PB and PCN (4.9- and 2.5-fold of control, respectively). Furosemide 27-28 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 29-35 2937798-0 1986 Effects of acute water load, hypertonic saline infusion, and furosemide administration on atrial natriuretic peptide and vasopressin release in humans. Furosemide 61-71 arginine vasopressin Homo sapiens 121-132 3528445-3 1986 Twenty children with chronic renal failure never had hyperkalemia, and both renin and aldosterone were normally stimulated by intravenous administration of furosemide, whereas three patients had moderate hyperkalemia (serum potassium concentration between 5.3 and 5.6 mEq/L) and failed to raise plasma renin activity and aldosterone values in response to furosemide. Furosemide 156-166 renin Homo sapiens 76-81 2944248-6 1986 In patients with RVH, inactive renin was markedly decreased by furosemide but unchanged by captopril, in spite of significant increase in active renin. Furosemide 63-73 renin Homo sapiens 31-36 2944248-8 1986 These data support the idea that in patients with RVH, the increase in active renin by furosemide is at least partly due to the activation of inactive renin. Furosemide 87-97 renin Homo sapiens 78-83 2944248-8 1986 These data support the idea that in patients with RVH, the increase in active renin by furosemide is at least partly due to the activation of inactive renin. Furosemide 87-97 renin Homo sapiens 151-156 3539582-0 1986 Changes in central and peripheral renin-angiotensin system after furosemide injection. Furosemide 65-75 renin Canis lupus familiaris 34-39 3539582-2 1986 Administration of furosemide induced marked increases in PRA, Ang I-ir, PAng II-ir and CSF Ang II-ir, however, neither plasma nor CSF angiotensinogen was changed. Furosemide 18-28 ANG Canis lupus familiaris 62-65 3539582-2 1986 Administration of furosemide induced marked increases in PRA, Ang I-ir, PAng II-ir and CSF Ang II-ir, however, neither plasma nor CSF angiotensinogen was changed. Furosemide 18-28 ANG Canis lupus familiaris 73-76 3023151-5 1986 In 27 DP, plasma renin activity (PRA) increased from 0.8 +/- 0.6 SD to 2.4 +/- 2.2 ng/ml/h (normal: 1.2 +/- 0.7 to 3.2 +/- 1.7 ng/ml/h) 2 hours after intravenous administration of furosemide (1 mg/kg) and assumption of the upright posture. Furosemide 180-190 renin Homo sapiens 17-22 3099700-2 1986 The sodium depletion (furosemide: 30 mg/kg/d for 2 days) was used to potentiate the contribution of the renin-angiotensin system in the blood pressure (BP) control. Furosemide 22-32 renin Callithrix jacchus 104-109 2874909-0 1986 Effects of furosemide and indapamide upon pancreatic insulin and somatostatin secretion in vitro. Furosemide 11-21 somatostatin Canis lupus familiaris 65-77 2874909-2 1986 To study if this was due to a direct effect on the endocrine pancreas, we examined the effects of furosemide and indapamide on the release of insulin and somatostatin from the isolated perfused pancreas of normal dogs. Furosemide 98-108 insulin Canis lupus familiaris 142-149 2874909-2 1986 To study if this was due to a direct effect on the endocrine pancreas, we examined the effects of furosemide and indapamide on the release of insulin and somatostatin from the isolated perfused pancreas of normal dogs. Furosemide 98-108 somatostatin Canis lupus familiaris 154-166 2874909-3 1986 Furosemide at concentrations ranging between 1-30 micrograms/ml inhibited insulin in a dose-dependent manner (2p less than 0.01) whereas the somatostatin secretion was left unchanged. Furosemide 0-10 insulin Canis lupus familiaris 74-81 2874909-5 1986 The results suggest, that furosemide and indapamide possess the ability to directly inhibit insulin secretion. Furosemide 26-36 insulin Canis lupus familiaris 92-99 3512619-9 1986 The brisk increment in plasma renin activity seen ten minutes after furosemide, as well as later values (30 and 240 min) were not changed by aspirin. Furosemide 68-78 renin Homo sapiens 30-35 3518770-7 1986 Plasma aldosterone concentrations were unchanged after either drug but plasma renin activity (PRA) was increased after frusemide 10 mg (4.42 +/- 1.01----8.50 +/- 1.90 ng A I ml-1 h-1 P less than 0.01) and 20 mg (4.01 +/- 0.72----7.81 +/- 2.27 ng A I ml-1 h-1 P less than 0.05). Furosemide 119-128 renin Homo sapiens 78-83 3735922-5 1986 The rise in electrolyte excretion following lasix administration was accompanied with a fall in Prl in hyperprolactinemic patients. Furosemide 44-49 prolactin Homo sapiens 96-99 3735922-6 1986 Following the chronic furosemide test, all patients showed a tendency to Prl rise, while the hyperprolactinemic patients also exhibited sodium retention. Furosemide 22-32 prolactin Homo sapiens 73-76 3019648-1 1986 Furosemide has been reported to have a suppressive effect on ADH-, PTH- and adrenaline-stimulated adenosine 3":5"-cyclic monophosphate (cAMP) production, but the effect on adrenocorticotropin (ACTH) action has not yet been elucidated. Furosemide 0-10 parathyroid hormone Rattus norvegicus 67-70 2425102-2 1986 Recently, we have shown that aprotinin, a kallikrein inhibitor, inhibits the stimulation of plasma renin activity (PRA) by either furosemide or a low sodium diet. Furosemide 130-140 renin Homo sapiens 99-104 3947689-0 1986 Plasma prolactin levels in full-term newborn infants with idiopathic edema: response to furosemide. Furosemide 88-98 prolactin Homo sapiens 7-16 2871955-6 1986 The co-administration of other potentially nephrotoxic agents (e.g., gentamicin), the diuretic frusemide, or inhibitors or suppressors of hepatic drug metabolism increases the degree of NAG enzymuria, whilst inducers of drug metabolism (e.g., phenobarbitone) have the reverse effect. Furosemide 95-104 O-GlcNAcase Rattus norvegicus 186-189 3529267-6 1986 TGF responses are inhibitable by furosemide, and the renin secretion produced by furosemide seems to be in part macula densa dependent. Furosemide 81-91 renin Homo sapiens 53-58 3893163-0 1985 Renin release in turtles: effects of volume depletion and furosemide administration. Furosemide 58-68 renin Rattus norvegicus 0-5 4052780-1 1985 Infusions of angiotensin II (AII) or carbachol (CBC) into the lateral ventricles of rats which had been depleted of sodium 4 h previously with either furosemide or polyethylene glycol produced significant changes in salt appetite and sodium and water balances relative to rats infused with saline vehicle. Furosemide 150-160 angiotensinogen Rattus norvegicus 13-27 4052780-1 1985 Infusions of angiotensin II (AII) or carbachol (CBC) into the lateral ventricles of rats which had been depleted of sodium 4 h previously with either furosemide or polyethylene glycol produced significant changes in salt appetite and sodium and water balances relative to rats infused with saline vehicle. Furosemide 150-160 angiotensinogen Rattus norvegicus 29-32 2867875-3 1985 Furosemide 1-O-acyl glucuronide (FG) was specifically hydrolyzed by beta-glucuronidase (BG) and was also labile to alkaline hydrolysis. Furosemide 0-10 glucuronidase, beta Rattus norvegicus 68-86 3519847-0 1986 [Furosemide stimulation of renin-secretion in essential hypertension]. Furosemide 1-11 renin Homo sapiens 27-32 3928488-4 1985 In furosemide-treated marmosets, CGP 29 287 lowered blood pressure and inhibited plasma renin activity during intravenous infusion and after intravenous bolus injection. Furosemide 3-13 renin Rattus norvegicus 88-93 3903651-3 1985 With a normal perfusate chloride the addition of furosemide 10(-4) M to the perfusate also led to an increase in renin and a reduction in tubule chloride reabsorption. Furosemide 49-59 renin Rattus norvegicus 113-118 3161339-7 1985 6-Aminonicotinamide also completely blocked furosemide-stimulated renin release without having any effect on glomerular filtration rate or furosemide-induced natriuresis. Furosemide 44-54 renin Rattus norvegicus 66-71 3161339-9 1985 We conclude that 6-aminonicotinamide interferes with renin release by nonfiltering kidneys and also inhibits furosemide-stimulated renin release but does not affect beta-adrenergic-stimulated renin secretion. Furosemide 109-119 renin Rattus norvegicus 131-136 3161339-9 1985 We conclude that 6-aminonicotinamide interferes with renin release by nonfiltering kidneys and also inhibits furosemide-stimulated renin release but does not affect beta-adrenergic-stimulated renin secretion. Furosemide 109-119 renin Rattus norvegicus 131-136 3893163-6 1985 In other studies 48 h of furosemide administration in awake turtles increased renin more than threefold (P less than 0.05) and were accompanied by concomitant reductions in plasma sodium and potassium (P less than 0.05). Furosemide 25-35 renin Rattus norvegicus 78-83 2579968-1 1985 The diuretic furosemide inhibits serum protein binding of T4 in equilibrium dialysis, dextran-charcoal, and competitive ligand binding separation systems and displaces [125I]T4 from isolated preparations of T4-binding globulin (TBG), prealbumin, and albumin. Furosemide 13-23 serpin family A member 7 Homo sapiens 207-226 3926510-10 1985 When compared with salt-insensitive patients, salt-sensitives had lower levels of urinary kallikrein excretion and a blunted kallikrein response to dietary sodium restriction and furosemide. Furosemide 179-189 kallikrein related peptidase 4 Homo sapiens 125-135 2579968-1 1985 The diuretic furosemide inhibits serum protein binding of T4 in equilibrium dialysis, dextran-charcoal, and competitive ligand binding separation systems and displaces [125I]T4 from isolated preparations of T4-binding globulin (TBG), prealbumin, and albumin. Furosemide 13-23 serpin family A member 7 Homo sapiens 228-231 2579968-4 1985 Binding of [14C]furosemide to TBG was inhibited by unlabeled T4, suggesting that furosemide and T4 share a common binding site. Furosemide 16-26 serpin family A member 7 Homo sapiens 30-33 2579968-7 1985 These studies demonstrate that furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower total T4 and T3 levels. Furosemide 31-41 serpin family A member 7 Homo sapiens 75-78 2984947-3 1985 The disulfonic stilbenes SITS and DIDS and the diuretic furosemide, agents known to interfere with anion transport and with the regulation of intracellular pH in other tissues, inhibited the water flow response to vasopressin and C1PhS-cAMP in a pH-dependent manner when added to the serosal bathing medium. Furosemide 56-66 arginine vasopressin Homo sapiens 214-225 3903529-0 1985 Sulindac and ibuprofen inhibit furosemide-stimulated renin release but not natriuresis in men on a normal sodium diet. Furosemide 31-41 renin Homo sapiens 53-58 3968633-0 1985 Early furosemide therapy of RDS. Furosemide 6-16 peripherin 2 Homo sapiens 28-31 4074410-6 1985 When the concentration of microinjected PAH was greater than or equal to 5 mmol/l, fractional recovery of [3H]-PAH from the micropunctured kidney was significantly decreased by torasemide from 252% (control) to 210% (P less than 0.005), by furosemide to 217% (P less than 0.005), and by probenecid to 205% (P less than 0.01). Furosemide 240-250 phenylalanine hydroxylase Rattus norvegicus 40-43 3896657-6 1985 Piretanide and furosemide both induced a short-term increase in plasma renin activity with a maximum about 4 hours after dosing which returned to initial levels after approximately 12 hours regardless of whether a single or twice daily dose had been given. Furosemide 15-25 renin Homo sapiens 71-76 3892078-2 1985 Acute administration of furosemide led to a significant increase in plasma renin activity, plasma noradrenaline levels and heart rate, and also to a slight rise of blood pressure. Furosemide 24-34 renin Canis lupus familiaris 75-80 3888240-1 1985 To examine the importance of acute frusemide-induced renin release in the production of the acute peripheral venous and arterial responses to frusemide in man, the effects of two drugs, previously described as inhibitors of acute frusemide-induced renin release, propranolol and digoxin, were examined. Furosemide 35-44 renin Homo sapiens 53-58 3888240-5 1985 The study provides further evidence of a relationship between acute frusemide-induced renin release and the acute peripheral vascular effects of frusemide in man. Furosemide 68-77 renin Homo sapiens 86-91 3888240-5 1985 The study provides further evidence of a relationship between acute frusemide-induced renin release and the acute peripheral vascular effects of frusemide in man. Furosemide 145-154 renin Homo sapiens 86-91 3897676-0 1985 [Responses of plasma bradykinin and the renin-angiotensin axis to furosemide in essential hypertension]. Furosemide 66-76 kininogen 1 Homo sapiens 21-31 3891172-3 1985 The daily maintenance dose of frusemide correlated closely and in a positive fashion with plasma levels of renin activity, angiotensin II and aldosterone (P less than 0.001), and to a lesser extent with plasma noradrenaline. Furosemide 30-39 renin Homo sapiens 107-112 3891172-3 1985 The daily maintenance dose of frusemide correlated closely and in a positive fashion with plasma levels of renin activity, angiotensin II and aldosterone (P less than 0.001), and to a lesser extent with plasma noradrenaline. Furosemide 30-39 angiotensinogen Homo sapiens 123-137 2982287-8 1985 Acetazolamide and vanadate were also found to strongly inhibit both Cl- and HCO3- -ATPase activities, whereas 10 microM 4-acetamido-4"-isothiocyanostilbene-2,2"-disulfonic acid, 1 mM furosemide, or 1 mM ouabain had little or no effect. Furosemide 183-193 dynein axonemal heavy chain 8 Homo sapiens 83-89 3881208-1 1985 Prostaglandin-dependent, frusemide-induced changes in renal plasma flow, glomerular filtration rate and plasma renin activity were measured in 14 patients with mild essential hypertension. Furosemide 25-34 renin Homo sapiens 111-116 3881302-4 1985 furosemide, which stimulates renal prostaglandin (PG) synthesis and renin release, to compare these vasoactive systems in 14 diabetic and 23 normal control subjects. Furosemide 0-10 renin Homo sapiens 68-73 4025007-4 1985 After furosemide, sodium excretion (NaE) increased less and changes in AVP, AII and Aldo were blunted in the patients. Furosemide 6-16 angiotensinogen Homo sapiens 76-79 3929754-1 1985 We tested the hypothesis that furosemide interferes with energy generation in the cochlea, and determined its effect on CO2 formation from glucose and glyceroaldehyde-3-phosphate dehydrogenase (GAPDH) activity by examining biochemical and histochemical changes in the cochlea, the kidney, and the liver. Furosemide 30-40 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 194-199 3929754-5 1985 We concluded that furosemide does interfere with energy generation in the cochlea, kidney, and liver as a result of its inhibition of GAPDH. Furosemide 18-28 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 134-139 3903529-6 1985 Mean plasma renin activity levels in the 4 h after furosemide increased significantly at all time points in comparison to basal values, but were significantly less for ibuprofen and sulindac groups in the first hour. Furosemide 51-61 renin Homo sapiens 12-17 3903529-5 1985 Mean basal plasma renin activity levels prior to furosemide administration on day 6 were significantly lower in the presence of ibuprofen (1.5 +/- 2.0 ng/ml/h;p less than 0.01) and sulindac (2,3 +/- 0.9 ng/ml/h; p less than 0.05), compared with placebo (3.3 +/- 1.1 ng/ml/h); the difference between the two NSAIDs was also significant (p less than 0.05). Furosemide 49-59 renin Homo sapiens 18-23 6389735-9 1984 In normal participants, plasma renin concentration determined by direct radioimmunoassay was increased by standing and furosemide injection. Furosemide 119-129 renin Homo sapiens 31-36 6509197-1 1984 The correlation was established between the increase in diuresis and natriuresis and fall of CSF pressure after intravenous injection of 10 mg/kg furosemide into dogs. Furosemide 146-156 colony stimulating factor 2 Canis lupus familiaris 93-96 3895336-3 1985 Captopril test, upright posture, and furosemide administration provoked in our patients changes of renin and prorenin similar to those found in normal and hypertensive subjects. Furosemide 37-47 renin Homo sapiens 99-104 3890391-9 1985 A significant increase of plasma renin activity was observed after furosemide. Furosemide 67-77 renin Homo sapiens 33-38 6498676-6 1984 However, the level rose in two of them when they were given furosemide, which suggests an osmoreceptor defect and a normal ADH response to volume change. Furosemide 60-70 arginine vasopressin Homo sapiens 123-126 6518981-4 1984 Changes in lacrimal peroxidase secretion were found after administration of atropine, aspirin, furosemide, indomethacine and pilocarpine. Furosemide 95-105 peroxidase 42-like Gossypium hirsutum 20-30 6594069-1 1984 Studies were conducted to investigate the interaction of renal prostaglandin E2 (PGE2) production and the renin-angiotensin system in the mechanism of furosemide-induced natriuresis. Furosemide 151-161 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 106-111 6594069-2 1984 In conscious rabbits with permanent urinary bladder cannulation, furosemide in vivo (10 mg/kg) increased urinary water, sodium, and PGE2 excretion and plasma renin activity (PRA) over 50 min. Furosemide 65-75 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 158-163 6085642-2 1984 When applied to digitoxin and frusemide, two drugs highly bound to bovine serum albumin, the fraction of drug unbound could be continuously varied over approximately a 30-fold range. Furosemide 30-39 albumin Rattus norvegicus 74-87 6487901-5 1984 This dose of frusemide inhibited the vasoconstrictor responses to both angiotensin II and noradrenaline (P less than 0.01, two way analysis of variance). Furosemide 13-22 angiotensinogen Rattus norvegicus 71-103 6487901-8 1984 completely prevented the inhibitory effect of frusemide on the responses to angiotensin II and noradrenaline. Furosemide 46-55 angiotensinogen Rattus norvegicus 76-90 6487901-9 1984 To test whether frusemide-induced increased endogenous levels of angiotensin II may be responsible for the effects of frusemide on the vasoconstrictor responses, a separate group of rats were not given frusemide but were infused with exogenous angiotensin II (12.5-25 ng kg-1 min-1). Furosemide 16-25 angiotensinogen Rattus norvegicus 65-79 6384651-4 1984 Patients with low-renin essential hypertension (LREH) had a significantly reduced excretion of both PGE2 and PGF2 alpha before and after administration of furosemide as compared to controls. Furosemide 155-165 renin Homo sapiens 18-23 6380995-2 1984 The APA activities increased after treatment with furosemide or captopril. Furosemide 50-60 glutamyl aminopeptidase Rattus norvegicus 4-7 6387403-3 1984 The decreased pressor sensitivity to infused angiotensin II seen in the patient with pseudo-Bartter"s syndrome was corrected with indomethacin and the enhanced pressor sensitivity seen in hyporeninaemic hypoaldosteronism was reversed with frusemide. Furosemide 239-248 angiotensinogen Homo sapiens 45-59 6090761-7 1984 Plasma renin activity was tripled and rose after furosemide. Furosemide 49-59 renin Homo sapiens 7-12 6517623-0 1984 [The effects of furosemide and reserpine on plasma concentrations of vasopressin and aldosterone]. Furosemide 16-26 arginine vasopressin Homo sapiens 69-80 6375797-0 1984 Frusemide releases renin in the rat kidney when prostacyclin synthesis is suppressed. Furosemide 0-9 renin Rattus norvegicus 19-24 6144266-5 1984 The final addition of the beta-1 adrenoceptor agonist, prenalterol, increased systemic arterial systolic pressure (p less than 0.05), cardiac output (p less than 0.05), and heart rate (p less than 0.01), and reduced systemic vascular resistance (p less than 0.01) in both groups; these changes were greatest in those pretreated with furosemide and isosorbide dinitrate. Furosemide 333-343 adrenoceptor beta 1 Homo sapiens 26-45 6383811-1 1984 Plasma renin substrate concentration was measured in 18, four-day-old pony foals after the administration of the natriuretic agent frusemide. Furosemide 131-140 renin Equus caballus 7-12 6375797-1 1984 The effect of inhibiting prostaglandin (PG) synthesis on basal and frusemide-stimulated renin secretion was examined in the rat isolated perfused kidney. Furosemide 67-76 renin Rattus norvegicus 88-93 6375797-7 1984 Although renin secretion was increased during frusemide infusion, there was no significant difference between control (1,806 +/- 384 ng angiotensin I (AI) min-1) and treated (2,310 +/- 554 ng AI min-1) rats (P greater than 0.05). Furosemide 46-55 renin Rattus norvegicus 9-14 6375797-9 1984 These results demonstrate that frusemide-stimulated renin secretion in the rat kidney does not require intact renal PGI2 synthesis and is independent of beta-adrenergic mechanisms. Furosemide 31-40 renin Rattus norvegicus 52-57 6399315-5 1984 Renin secretion and renal inner medullary blood flow (tissue clearance of 133Xe) were simultaneously measured before and after frusemide-induced renin release. Furosemide 127-136 renin Rattus norvegicus 145-150 6378806-5 1984 Such a stimulation of the renin-angiotensin-aldosterone system was greater with azosemide than with furosemide. Furosemide 100-110 renin Homo sapiens 26-31 6428443-3 1984 The early increase in plasma renin activity after frusemide was inhibited by indomethacin. Furosemide 50-59 renin Homo sapiens 29-34 6325474-0 1984 Effect of ouabain and furosemide on pepsinogen secretion by gastric glands in vitro. Furosemide 22-32 pepsin II-2/3 Oryctolagus cuniculus 36-46 6328073-6 1984 Plasma renin activity was normal but responded to a greater extent to furosemide plus upright posture. Furosemide 70-80 renin Homo sapiens 7-12 6425870-3 1984 The variations of these corresponding kinetic parameters (Km, Vmax, specific activities) must correspond to different inhibition mechanisms of furosemide, for example different site(s) of fixation in the area of the active site of UDPGT. Furosemide 143-153 UDP glucuronosyltransferase family 1 member A4 Homo sapiens 231-236 6425870-4 1984 Because these variations were not as classically described, we checked the impact of furosemide pretreatment on in vitro levels of different UDPGT activities. Furosemide 85-95 UDP glucuronosyltransferase family 1 member A4 Homo sapiens 141-146 6388913-0 1984 Synchronous changes in active and inactive renin secretion after furosemide in patients with primary aldosteronism. Furosemide 65-75 renin Homo sapiens 43-48 6363244-1 1983 We examined the renin-angiotensin-aldosterone system in seven patients with Shy-Drager syndrome by studying their response to the stimulation of 1 mg/kg furosemide injection followed by sitting for 1 hour. Furosemide 153-163 renin Homo sapiens 16-21 6587654-5 1984 In contrast, the diuretic effect of furosemide in vasopressin (2 U/kg)-infused (or dehydrated) rats was greatly inhibited by indomethacin. Furosemide 36-46 arginine vasopressin Rattus norvegicus 50-61 6363244-5 1983 The five patients who showed a low plasma renin activity response and a normal aldosterone response to furosemide administration also showed low plasma aldosterone response to angiotensin II. Furosemide 103-113 angiotensinogen Homo sapiens 176-190 6349901-1 1983 To examine the importance of angiotensin II formation in the production of frusemide"s acute peripheral venous and arterial responses, the effect of pretreatment with captopril was studied. Furosemide 75-84 angiotensinogen Homo sapiens 29-43 6668785-5 1983 The patients with an excessive response to lasix had a significantly lower baseline urine excretion of stable sodium, a higher sodium concentration in the red blood cells and, in cases of stable hypertension, a higher activity of plasma renin as well. Furosemide 43-48 renin Homo sapiens 237-242 6349901-3 1983 The study provides evidence that angiotensin II formation performs an essential role in the production of the acute vascular effects of frusemide in man. Furosemide 136-145 angiotensinogen Homo sapiens 33-47 6685566-8 1983 Furosemide might also act at the same tubular site or inhibit tubular secretion of the atrial natriuretic factor. Furosemide 0-10 natriuretic peptide A Rattus norvegicus 87-112 6352481-0 1983 Inhibition of furosemide-induced increases in plasma renin activity by amiloride. Furosemide 14-24 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 53-58 6352481-2 1983 Furosemide elicited a rapid and persistent rise in plasma renin activity (PRA), but pretreatment of the same rabbits with a 15-minute intravenous infusion of amiloride, which amounted to 1 mg/kg and commenced at 30 minutes before furosemide, completely prevented this rise. Furosemide 0-10 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 58-63 6345362-6 1983 A positive correlation (r = + 0.425; p less than 0.05) was found between plasma renin activity after intravenous furosemide and Lii-Nao countertransport in essential hypertension. Furosemide 113-123 renin Homo sapiens 80-85 6645209-4 1983 These data suggest that, in FHH, tubular calcium reabsorption is enhanced in the thick ascending limb of Henle"s loop, the site of action of furosemide. Furosemide 141-151 calcium sensing receptor Homo sapiens 28-31 6195464-6 1983 Twenty minutes after administration of furosemide, plasma renin activity was increased and remained elevated during the following 8 h. Heart rate and plasma noradrenaline concentration were unchanged after 20 min, but both increased gradually as blood pressure started to fall. Furosemide 39-49 renin Homo sapiens 58-63 6141075-13 1983 The present data also suggested that both furosemide and prostaglandins stimulated aldosterone secretion via the renin-angiotensin system, rather than by acting directly on the adrenal cortex. Furosemide 42-52 renin Canis lupus familiaris 113-118 6361711-0 1983 [Intra-erythrocytic sodium and plasma renin activity in primary arterial hypertension before and after furosemide therapy]. Furosemide 103-113 renin Homo sapiens 38-43 6350561-6 1983 Furosemide (10 mg/kg) in anaesthetized animals produced a similar diuresis and natriuresis response to conscious sheep, but plasma active renin increased by 270% and inactive renin decreased to zero. Furosemide 0-10 renin Ovis aries 138-143 6350561-6 1983 Furosemide (10 mg/kg) in anaesthetized animals produced a similar diuresis and natriuresis response to conscious sheep, but plasma active renin increased by 270% and inactive renin decreased to zero. Furosemide 0-10 renin Ovis aries 175-180 6350561-7 1983 In conscious sheep given an infusion of papaverine, furosemide also produced an increase in plasma active renin and a concurrent decrease in the inactive form. Furosemide 52-62 renin Ovis aries 106-111 6339312-11 1983 The diuretic response to furosemide and spironolactone was related to the activity of the renin-aldosterone system. Furosemide 25-35 renin Homo sapiens 90-95 6133986-3 1983 During the 39 month (range 28-48) period of antihypertensive treatment with metoprolol, hydralazine, and frusemide (furosemide) or thiazide, arterial blood pressure fell from 144/97 mm Hg (mean of all pretreatment values) to 128/84 mm Hg (mean of all post-treatment values), urinary albumin excretion from 977 micrograms/min to 433 micrograms/min, and GFR from 80 to 62 ml/min/1 . Furosemide 105-114 CD59 molecule (CD59 blood group) Homo sapiens 373-378 6133986-3 1983 During the 39 month (range 28-48) period of antihypertensive treatment with metoprolol, hydralazine, and frusemide (furosemide) or thiazide, arterial blood pressure fell from 144/97 mm Hg (mean of all pretreatment values) to 128/84 mm Hg (mean of all post-treatment values), urinary albumin excretion from 977 micrograms/min to 433 micrograms/min, and GFR from 80 to 62 ml/min/1 . Furosemide 116-126 CD59 molecule (CD59 blood group) Homo sapiens 373-378 6339312-13 1983 These results indicate that (a) at the dosages used in the study, spironolactone is more effective than furosemide in nonazotemic cirrhosis with ascites, and (b) the activity of the renin-aldosterone system influences the diuretic response to furosemide and spironolactone in these patients. Furosemide 243-253 renin Homo sapiens 182-187 6405027-2 1983 The clearance of renin was 0.61 +/- 0.19 ml/min in control experiments and increased significantly to 1.26 +/- 0.38 ml/min after furosemide. Furosemide 129-139 renin Canis lupus familiaris 17-22 6405027-3 1983 The fractional excretion of renin increased from 1.51 +/- 0.45% during control to 3.90 +/- 0.98% after furosemide. Furosemide 103-113 renin Canis lupus familiaris 28-33 6405027-4 1983 The rate of excretion of renin was increased 10-fold during furosemide diuresis associated with a 10-fold increase in plasma renin concentration. Furosemide 60-70 renin Canis lupus familiaris 25-30 6345888-4 1983 Intravenous or prolonged furosemide administration was shown to be the test of choice for the diagnosis of renin suppression. Furosemide 25-35 renin Homo sapiens 107-112 6343667-0 1983 Contributions of central sympathetic neural activity to furosemide-induced increases in plasma renin activity and noradrenaline. Furosemide 56-66 renin Homo sapiens 95-100 6187220-3 1983 Plasma renin activity (PRA) was increased by furosemide and also by the low-sodium diet. Furosemide 45-55 renin Rattus norvegicus 7-12 6187220-6 1983 These results suggest that furosemide and low-sodium diet act on the kidney to release renin via protease production. Furosemide 27-37 renin Rattus norvegicus 87-92 6187220-7 1983 Because SBTI affected neither PRA nor urinary kallikrein excretion stimulated by these sodium depletions, it is suggested that renal kallikrein may play an important role in the control of renin release stimulated by furosemide and by low-sodium diet. Furosemide 217-227 renin Rattus norvegicus 189-194 6188888-4 1983 Plasma renin concentration (PRC) prior to the administration of captopril was highest in the furosemide group, followed by the HCTZ, TCTZ, and control groups, in this order. Furosemide 93-103 renin Rattus norvegicus 7-12 6339771-5 1983 The administration of furosemide produced significant increases in plasma NE (142.4 +/- 23.7%, p less than 0.01), plasma renin activity (PRA) (158.6 +/- 26.3%, p less than 0.01) and HR (32.3 +/- 6.0 beats/min, p less than 0.01). Furosemide 22-32 renin Canis lupus familiaris 121-126 6354727-0 1983 Sequential changes in plasma renin activity and plasma catecholamines in mildly hypertensive patients during acute, furosemide-induced body-fluid loss. Furosemide 116-126 renin Homo sapiens 29-34 6662065-5 1983 The increasing edemas of the shank and a stasis ulcer which were the reason for the patients admission to the hospital could be treated successfully by Furosemid and Phenprocoumon within a period of 4 weeks. Furosemide 152-161 SH3 and multiple ankyrin repeat domains 2 Homo sapiens 29-34 6354727-1 1983 To evaluate the role of adrenergic mechanisms in the acute response of renin to furosemide, plasma renin activity (PRA) and plasma catecholamine concentrations were measured for 3 h after i.v. Furosemide 80-90 renin Homo sapiens 71-76 6354727-3 1983 Furosemide induced a prompt and long-lasting increase in renin, with PRA more than doubled at all times. Furosemide 0-10 renin Homo sapiens 57-62 6293314-2 1982 Furosemide (2 mg/kg) induced significant diuresis, natriuresis, an increase in renal blood flow (RBF), and a fivefold increase in renin secretory rate (RSR), but no changes in glomerular filtration rate (GFR). Furosemide 0-10 renin Canis lupus familiaris 130-135 6755768-5 1982 There is a tendency for furosemide to elevate serum aldosterone levels and renin activity regardless of the time of administration. Furosemide 24-34 renin Homo sapiens 75-80 6293314-11 1982 These results indicate that inhibition of renal Na+-K+-ATPase abolishes furosemide-induced renin secretion despite potentiation of the natriuretic effect of the diuretic. Furosemide 72-82 renin Canis lupus familiaris 91-96 6282524-0 1982 Canrenoate reversal of inhibitory effects of digoxin on basal and furosemide-stimulated renin secretion. Furosemide 66-76 renin Homo sapiens 88-93 6757970-2 1982 In each renin subgroup, the administration of furosemide and 2 hours upright posture induced marked increases in urinary excretion of PGE and sodium, and in plasma renin activity. Furosemide 46-56 renin Homo sapiens 8-13 6757970-2 1982 In each renin subgroup, the administration of furosemide and 2 hours upright posture induced marked increases in urinary excretion of PGE and sodium, and in plasma renin activity. Furosemide 46-56 renin Homo sapiens 164-169 7153909-3 1982 With intra-arterial administration of furosemide, short-term reversible elevation occurred of the low threshold sharply tuned ;tip" segment of the frequency threshold (;tuning") curve (f.t.c.) Furosemide 38-48 TOR signaling pathway regulator Homo sapiens 127-130 7153909-12 1982 It is concluded that the selective effects of furosemide on the tip segment of cochlear fibre f.t.c.s offer further evidence for a physiologically vulnerable ;second filter" in the cochlea. Furosemide 46-56 TOR signaling pathway regulator Homo sapiens 64-67 6291543-1 1982 Diethyldithiocarbamate (DTC) and carbon disulfide (CS2), at nearly equimolar oral dose levels, protected mice against liver damage induced by carbon tetrachloride, chloroform, bromotrichloromethane, thioacetamide, bromobenzene, furosemide, acetaminophen, dimethylnitrosamine and trichloroethylene, as evidenced by the suppression of elevations in plasma GPT activity and liver calcium content, and of histopathological alterations. Furosemide 228-238 calsyntenin 2 Mus musculus 51-54 6805839-0 1982 Inappropriate secretion of antidiuretic hormone treated with frusemide. Furosemide 61-70 arginine vasopressin Homo sapiens 27-47 6805839-5 1982 These findings add further weight to evidence that Frusemide is a good alternative for the treatment of patients with inappropriate secretion of antidiuretic hormone who cannot tolerate water restriction. Furosemide 51-60 arginine vasopressin Homo sapiens 145-165 7139885-8 1982 At the time papillary plasma flow was measured, extracellular fluid volume was similar among the four groups of dogs; however, plasma renin activity increased significantly in furosemide and ethacrynic acid dogs (P less than 0.01) and remained unchanged in normal and chlorothiazide dogs. Furosemide 176-186 renin Canis lupus familiaris 134-139 7184313-7 1982 Furosemide caused a statistically significant decrease of BAO at rest (p less than 0.02) and during exercise (p less than 0.01), this was due to a significant reduction in gastric juice volume (p less than 0.001) and in the second hour of furosemide action also to a decrease of HCI concentration (p less than 0.05). Furosemide 0-10 HEMC Homo sapiens 279-282 6282524-7 1982 This result indicates that furosemide stimulates renin release by affecting a biochemical system other than that affected by digoxin. Furosemide 27-37 renin Homo sapiens 49-54 7083731-3 1982 When hemodynamics returned to control after stopping nitroprusside, furosemide was given ase a 200-mg rapid infusion. Furosemide 68-78 arylsulfatase L Homo sapiens 89-92 6461704-5 1982 Continuous intravenous loading with saline and furosemide, although increasing renal renin levels, afforded as much protection as saline loading alone. Furosemide 47-57 renin Rattus norvegicus 85-90 7043184-4 1982 While the mean plasma aldosterone concentrations were normal, the mean plasma renin activity in response to furosemide stimulation was subnormal in subjects with hyperparathyroidism. Furosemide 108-118 renin Homo sapiens 78-83 6813454-0 1982 Active and inactive renin release from rabbit kidney cortex slices: effect of sodium concentration and of furosemide. Furosemide 106-116 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 20-25 6813454-19 1982 The action of furosemide on secretion of active and inactive renin in vivo is therefore secondary to altered renal function. Furosemide 14-24 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 61-66 6809473-2 1982 The serum clearance of furosemide (Cls) was between 140 and 201 ml min-1 and on the average the renal clearance was 60% of Cls. Furosemide 23-33 CD59 molecule (CD59 blood group) Homo sapiens 67-72 6809473-3 1982 During the initial 30 min period a maximum additional excretion rate of sodium of 3.3 mmol min-1 was reached at an excretion rate of 0.8 mg furosemide min-1. Furosemide 140-150 CD59 molecule (CD59 blood group) Homo sapiens 91-96 6809473-3 1982 During the initial 30 min period a maximum additional excretion rate of sodium of 3.3 mmol min-1 was reached at an excretion rate of 0.8 mg furosemide min-1. Furosemide 140-150 CD59 molecule (CD59 blood group) Homo sapiens 151-156 7045443-0 1982 Renin response to furosemide differs with the routes of administration in health men. Furosemide 18-28 renin Homo sapiens 0-5 7045443-12 1982 These findings suggest that the response of renin release to furosemide in healthy men differs with the routes of administration and renin release with p.o. Furosemide 61-71 renin Homo sapiens 44-49 7045443-12 1982 These findings suggest that the response of renin release to furosemide in healthy men differs with the routes of administration and renin release with p.o. Furosemide 61-71 renin Homo sapiens 133-138 6125538-1 1982 It has been demonstrated that somatostatin (SRIF) can suppress hypophyseal and extrahypophyseal hormones; moreover, many studies have shown that SRIF inhibits frusemide-induced hyperreninemia in normal man, and renin and aldosterone in renovascular hypertension, possibly through a beta-adrenergic block. Furosemide 159-168 renin Homo sapiens 182-187 6281634-11 1982 Potassium delays the increase of plasma renin activity after furosemide and propranolol inhibits the furosemide-induced renin release, both without impairing aldosterone secretion. Furosemide 101-111 renin Homo sapiens 40-45 7042955-9 1982 injection of furosemide, by decreasing cardiac preload, mainly due to venodilation, reduces cardiac output of renin-dependent hypertensive animals, whereas mean arterial blood pressure and heart rate remain unaltered. Furosemide 13-23 renin Rattus norvegicus 110-115 6281634-11 1982 Potassium delays the increase of plasma renin activity after furosemide and propranolol inhibits the furosemide-induced renin release, both without impairing aldosterone secretion. Furosemide 101-111 renin Homo sapiens 120-125 6750183-0 1982 [Urinary electrolyte excretion and plasma corticoid level at the furosemide administration test in low renin hypertension]. Furosemide 65-75 renin Homo sapiens 103-108 7033708-3 1982 Renin classification was determined after furosemide (80 mg) stimulation; control measurements were made after each patient had been off all medications for at least 1 week. Furosemide 42-52 renin Homo sapiens 0-5 6120716-5 1982 4 Intravenous frusemide caused immediate rises in plasma active, total and inactive renin, angiotensin II, and aldosterone, which then declined over 2 h despite increasing cumulative sodium losses. Furosemide 14-23 renin Homo sapiens 84-89 6120716-5 1982 4 Intravenous frusemide caused immediate rises in plasma active, total and inactive renin, angiotensin II, and aldosterone, which then declined over 2 h despite increasing cumulative sodium losses. Furosemide 14-23 angiotensinogen Homo sapiens 91-105 6120716-6 1982 5 Intravenous propranolol or metoprolol attenuated, without abolishing, these early increases in the components of the renin-angiotensin-aldosterone system after frusemide. Furosemide 162-171 renin Homo sapiens 119-124 6120716-9 1982 8 Also in contrast to earlier work, we found attenuation by both intravenous propranolol and metoprolol of the immediate rise in renin after intravenous frusemide. Furosemide 153-162 renin Homo sapiens 129-134 6120716-0 1982 Response of the renin-angiotensin-aldosterone system to upright tilting and to intravenous frusemide: effect of prior metoprolol and propranolol. Furosemide 91-100 renin Homo sapiens 16-21 6121670-2 1982 The effect of the diuretic drug furosemide was studied in detail on ouabain-insensitive, SCN- and OCN- -sensitive C1-/HCO-3-ATPase in homogenates from larval dragonfly rectum (Aeshna cyanea), frog (Rana temporaria) and mouse (Mus musculus) kidney. Furosemide 32-42 dynein, axonemal, heavy chain 8 Mus musculus 124-130 6749346-8 1982 The mechanism of this sustained renin response several days after cessation of diuretic therapy may be best explained by a prolonged action of furosemide or by partial ongoing volume depletion with reduced sodium load to the distal nephron. Furosemide 143-153 renin Homo sapiens 32-37 6121670-6 1982 Furosemide even at 10 mM concentration which completely inhibits the anion-dependent ATPase has only a little inhibitory effect on the Na+/K+-ATPase of the 3 tissues. Furosemide 0-10 dynein, axonemal, heavy chain 8 Mus musculus 85-91 6121670-8 1982 The data suggest that furosemide may affect an active chloride transport system involving a C1-/HCO-3-ATPase. Furosemide 22-32 dynein, axonemal, heavy chain 8 Mus musculus 102-108 7033292-8 1982 The intravenous infusion of furosemide, which is known to stimulate renin release via a cyclooxygenase-dependent mechanism, caused a three-to fourfold increase of urinary 6-keto-PGF(1alpha) excretion rate, concomitant with the elevation of plasma renin activity levels, in six healthy women. Furosemide 28-38 renin Homo sapiens 68-73 7033292-8 1982 The intravenous infusion of furosemide, which is known to stimulate renin release via a cyclooxygenase-dependent mechanism, caused a three-to fourfold increase of urinary 6-keto-PGF(1alpha) excretion rate, concomitant with the elevation of plasma renin activity levels, in six healthy women. Furosemide 28-38 renin Homo sapiens 247-252 7026766-5 1981 The initial decrease in conductance seen in furosemide-treated animals appears to be mediated via the renin-angiotensin system. Furosemide 44-54 renin Canis lupus familiaris 102-107 7057463-11 1982 Furosemide inhibition is of high affinity (K1/2 = 3 micrometer). Furosemide 0-10 keratin 1 Canis lupus familiaris 43-51 7029027-4 1981 Following stimulation with furosemide and ambulation, the levels of active renin increased but its responsiveness to the stimulus decreased with age in both groups. Furosemide 27-37 renin Homo sapiens 75-80 7028367-10 1981 The magnitude of the isoprenaline-induced changes in plasma active renin was similar to that in a previous study of frusemide diuresis, but the time course was quite different. Furosemide 116-125 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 67-72 7028367-11 1981 Inactive renin disappeared from plasma during frusemide diuresis. Furosemide 46-55 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 9-14 7031155-12 1981 We conclude that prostaglandins mediate baseline renin secretion and renin stimulation in response to furosemide. Furosemide 102-112 renin Homo sapiens 69-74 7026766-6 1981 In volume-repleted as well as volume-depleted animals, the plasma concentrations of renin and angiotensin II, but not antidiuretic hormone, were increased 10 min after furosemide administration. Furosemide 168-178 renin Canis lupus familiaris 84-108 7029027-6 1981 These data show that an acute stimulation with furosemide and ambulation affects mainly the active form of plasma renin, and that the effect of age on inactive plasma renin in normal subjects may be different from that in patients with essential hypertension. Furosemide 47-57 renin Homo sapiens 114-119 7026766-9 1981 When fluid losses were not replaced, plasma levels of angiotensin II and renin, as well as antidiuretic hormone, were increased 40 min after furosemide administration. Furosemide 141-151 renin Canis lupus familiaris 54-78 7315959-6 1981 Parathyroid hormone increased fractional calcium and magnesium reabsorption in Henle"s loop and the distal tubule in the presence of intraluminal furosemide. Furosemide 146-156 parathyroid hormone Rattus norvegicus 0-19 7021994-0 1981 Renin release after furosemide and ethacrynic acid in man. Furosemide 20-30 renin Homo sapiens 0-5 7021646-4 1981 Following stimulation with furosemide and ambulation, the levels of active renin increased but the responsiveness to stimulus decreased with age in both groups. Furosemide 27-37 renin Homo sapiens 75-80 7021646-5 1981 In contrast, inactive renin levels slightly increased after furosemide administration and ambulation, resulting in increased proportion of active to total renin. Furosemide 60-70 renin Homo sapiens 22-27 7021646-5 1981 In contrast, inactive renin levels slightly increased after furosemide administration and ambulation, resulting in increased proportion of active to total renin. Furosemide 60-70 renin Homo sapiens 155-160 7021646-6 1981 These data show that an acute stimulation with furosemide and ambulation affects mainly the active form of plasma renin, and the effect of age on inactive plasma renin in normal subjects may be different from that in patients with essential hypertension. Furosemide 47-57 renin Homo sapiens 114-119 7028226-1 1981 Dose-response relationships of furosemide to its diuretic and cardiovascular actions and its effects on plasma renin activity (PRA) were evaluated in unanesthetized rats. Furosemide 31-41 renin Rattus norvegicus 111-116 7028226-7 1981 Furosemide did not induce significant changes in blood pressure and heart rate, but it did alter the renin dependency of the blood pressure as assessed by Saralasin. Furosemide 0-10 renin Rattus norvegicus 101-106 7021994-2 1981 The mechanisms of renin release after furosemide (F) and ethacrynic acid (EA) in man were examined. Furosemide 38-48 renin Homo sapiens 18-23 7023561-0 1981 Renin responsiveness to furosemide in the homotransplanted kidney. Furosemide 24-34 renin Homo sapiens 0-5 7023561-1 1981 Plasma renin activity (PRA) was measured after repetitive furosemide stimulations in 16 normotensive homotransplanted patients who previously had bilateral nephrectomies. Furosemide 58-68 renin Homo sapiens 7-12 7023561-4 1981 These data indicate that the juxtaglomerular cell responsiveness to furosemide is quantitatively time dependent after transplantation, and it is a factor that should be considered in the evaluation of renin-angiotensin system in such patients. Furosemide 68-78 renin Homo sapiens 201-206 7040751-6 1981 PA responses to furosemide had significant positive correlation with those to angiotensin II. Furosemide 16-26 angiotensinogen Homo sapiens 78-92 7231484-0 1981 Furosemide in inappropriate secretion of antidiuretic hormone. Furosemide 0-10 arginine vasopressin Homo sapiens 41-61 7291040-5 1981 Circulating plasma levels of alpha-MSH in control animals were 2.5 +/- 0.4 x 10(-10) moles per 1, but were unchanged by dietary sodium restriction or by sodium loss induced by diuretic (LASIX) administration. Furosemide 186-191 proopiomelanocortin Rattus norvegicus 29-38 7018773-0 1981 Effects of furosemide-induced plasma volume reduction on plasma antidiuretic hormone in normal and hypertensive subjects. Furosemide 11-21 arginine vasopressin Homo sapiens 64-84 7018800-9 1981 In contrast, indomethacin pretreatment caused renin to rise in response to frusemide in spontaneously hypertensive rats (4.7 +/- 0.8 to 27.1 +/- 1.8 ng h-1 ml-1). Furosemide 75-84 renin Rattus norvegicus 46-51 7018800-11 1981 These findings suggest that a prostaglandin normally inhibits the renin response of spontaneously hypertensive rats to frusemide-induced volume contraction. Furosemide 119-128 renin Rattus norvegicus 66-71 6785094-4 1981 In normal men, furosemide (n = 9) within 15 min increased active renin from 29.9 +/- 5.8 to 82.4 +/- 14.8 microunits/ml (P less than 0.001), while inactive renin slightly but not significantly decreased from 136.3 +/- 29.9 to 121.1 +/- 19.2 microunits/ml; orthostasis (n = 15) within 4 h stimulated active renin (P less than 0.001) and slightly raised inactive renin (P less than 0.05). Furosemide 15-25 renin Homo sapiens 65-70 7018795-6 1981 Plasma active renin increased during frusemide diuresis but inactive renin disappeared from the circulation. Furosemide 37-46 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 14-19 7018795-9 1981 The peak of the frusemide-induced changes in renal function (urine flow, sodium and potassium excretion and creatinine clearance) preceded the maximum changes in the two forms of renin by 90 min. Furosemide 16-25 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 179-184 6785094-4 1981 In normal men, furosemide (n = 9) within 15 min increased active renin from 29.9 +/- 5.8 to 82.4 +/- 14.8 microunits/ml (P less than 0.001), while inactive renin slightly but not significantly decreased from 136.3 +/- 29.9 to 121.1 +/- 19.2 microunits/ml; orthostasis (n = 15) within 4 h stimulated active renin (P less than 0.001) and slightly raised inactive renin (P less than 0.05). Furosemide 15-25 renin Homo sapiens 156-161 7026261-1 1981 The role of the sympathetic nervous system in furosemide-induced renin release was investigated in six normal subjects. Furosemide 46-56 renin Homo sapiens 65-70 6785094-4 1981 In normal men, furosemide (n = 9) within 15 min increased active renin from 29.9 +/- 5.8 to 82.4 +/- 14.8 microunits/ml (P less than 0.001), while inactive renin slightly but not significantly decreased from 136.3 +/- 29.9 to 121.1 +/- 19.2 microunits/ml; orthostasis (n = 15) within 4 h stimulated active renin (P less than 0.001) and slightly raised inactive renin (P less than 0.05). Furosemide 15-25 renin Homo sapiens 156-161 6785094-4 1981 In normal men, furosemide (n = 9) within 15 min increased active renin from 29.9 +/- 5.8 to 82.4 +/- 14.8 microunits/ml (P less than 0.001), while inactive renin slightly but not significantly decreased from 136.3 +/- 29.9 to 121.1 +/- 19.2 microunits/ml; orthostasis (n = 15) within 4 h stimulated active renin (P less than 0.001) and slightly raised inactive renin (P less than 0.05). Furosemide 15-25 renin Homo sapiens 156-161 6785094-5 1981 Both furosemide and orthostasis increased (P less than 0.001 each) the proportion of active renin in normal persons. Furosemide 5-15 renin Homo sapiens 92-97 6785094-9 1981 The stimulation of active renin by furosemide and orthostasis is bound to the presence of the kidney. Furosemide 35-45 renin Homo sapiens 26-31 6258416-3 1981 Plasma renin activity increased with sodium depletion (30 mEq sodium intake for 3 days after furosemide treatment) from 1.26 +/- 0.07 to 3.26 +/- 0.48 ng/ml/hr (p less than 0.001). Furosemide 93-103 renin Homo sapiens 7-12 6111397-0 1981 [Renal excretion of kallikrein after water loading and administration of furosemide or the beta-adrenergic blocker, trimepranol. Furosemide 73-83 kallikrein related peptidase 4 Homo sapiens 20-30 7014479-2 1981 In renal patients furosemide elicited comparably high increment (delta) of EF osm, Na, and K in both the stage of renal insufficiency and at normal Cin. Furosemide 18-28 pyridoxal phosphatase Homo sapiens 148-151 6111403-9 1981 From these results it may be concluded that Na, K, ATPase -- which in kidney is a site of action for furosemide, a potent diuretic -- is unaffected in PE and PIH and, hence, treatment with diuretics -- is unaffected in PE and PIH and, hence, treatment with diuretics in such patients may be ineffective. Furosemide 101-111 TANK binding kinase 1 Homo sapiens 44-57 7026261-2 1981 After intravenous administration of furosemide, plasma renin concentrations increased more than two-fold within 15 min. Furosemide 36-46 renin Homo sapiens 55-60 6160345-0 1981 Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension. Furosemide 62-72 kallikrein related peptidase 4 Homo sapiens 15-25 6160345-2 1981 Furosemide therapy significantly reduced mean arterial pressure (108.6 +/- 2.4 vs. 101.0 +/- 2.7 mm Hg, p < 0.02) in association with a significant increase in 24 hr urinary kallikrein activity (7.9 +/- 1.8 vs. 13.4 +/- 2.8 esterase units/24 hr, p < 0.02). Furosemide 0-10 kallikrein related peptidase 4 Homo sapiens 177-187 6160345-4 1981 A significant (p < 0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide. Furosemide 205-215 kallikrein related peptidase 4 Homo sapiens 91-101 6160345-4 1981 A significant (p < 0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide. Furosemide 205-215 kallikrein related peptidase 4 Homo sapiens 144-154 7328628-5 1981 We took the furosemide-sensitive fluxes to be a measure of Na-K cotransport. Furosemide 12-22 TANK binding kinase 1 Homo sapiens 59-63 7267702-0 1981 Effect of free fatty acid concentration on furosemide binding to human serum albumin. Furosemide 43-53 albumin Homo sapiens 71-84 7267702-1 1981 The effect of varying concentrations of sodium oleate on the binding of furosemide to human serum albumin was investigated using continuous ultrafiltration. Furosemide 72-82 albumin Homo sapiens 92-105 7003179-0 1980 The effect of angiotensin II antagonist, Sar1-Ile8-angiotensin II, on furosemide-induced increase in plasma noradrenaline, renin activity and aldosterone in unanesthetized dogs. Furosemide 70-80 renin Canis lupus familiaris 123-128 6459589-0 1981 Response of peripheral plasma renin activity (PRA) to furosemide stimulation; reduction of the renal parenchyma as a limiting factor. Furosemide 54-64 renin Homo sapiens 30-35 7013722-8 1980 It is concluded that the stimulation of insulin and glucagon secretion observed in vitro with high furosemide concentrations (5 mmol/l) are not observed under usual therapeutic conditions. Furosemide 99-109 insulin Homo sapiens 40-47 7029689-3 1981 Renin activity was increased to varying levels by raising ureteric pressure and by the administration of different doses of furosemide. Furosemide 124-134 renin Canis lupus familiaris 0-5 7003179-2 1980 Furthermore, the role of the renin-angiotensin system in the increased sympathetic nerve activity induced by furosemide was assessed by using Sar1-Ile8-angiotensin II, an angiotensin II antagonist. Furosemide 109-119 renin Canis lupus familiaris 29-34 7003179-6 1980 There results suggest that an administration of furosemide induced the increase in PNA and the increase in PNA by furosemide might by mediated by the renin-angiotensin system. Furosemide 48-58 renin Canis lupus familiaris 150-155 7010287-5 1980 Furosemide increased cryorenin and trypsin-activated renin in parallel to active renin from 2.9 +/- 1.1 ng/ml/hr and a6.9 +/- 1.5 of PRA to 5.0 +/- 1.0 and 11.2 +/- 1.5 at 65 min, respectively (P less than 0.05). Furosemide 0-10 renin Homo sapiens 25-30 7003179-6 1980 There results suggest that an administration of furosemide induced the increase in PNA and the increase in PNA by furosemide might by mediated by the renin-angiotensin system. Furosemide 114-124 renin Canis lupus familiaris 150-155 7010287-5 1980 Furosemide increased cryorenin and trypsin-activated renin in parallel to active renin from 2.9 +/- 1.1 ng/ml/hr and a6.9 +/- 1.5 of PRA to 5.0 +/- 1.0 and 11.2 +/- 1.5 at 65 min, respectively (P less than 0.05). Furosemide 0-10 renin Homo sapiens 53-58 7010289-5 1980 In contrast, when indomethacin was given but the sodium retention prevented by concomitant administration of furosemide, the blunted vasopressor response to angiotensin II and the hyperreninemia were not corrected. Furosemide 109-119 angiotensinogen Homo sapiens 157-171 7005123-0 1980 Response of renin, aldosterone and antidiuretic hormone to furosemide and furosemide-triamterene combination. Furosemide 59-69 renin Homo sapiens 12-17 6996896-6 1980 A rise in plasma renin activity was observed 2 hr after an 80-mg dose of furosemide but not after indacrinone. Furosemide 73-83 renin Homo sapiens 17-22 7439260-4 1980 It is concluded that treatment with furosemide or bumetanide may cause hypocalcaemia, resulting in elevation of s-PTH. Furosemide 36-46 parathyroid hormone Homo sapiens 114-117 6108811-2 1980 The response of plasma renin activity to frusemide 40 mg given intravenously, was examined before and after oral propranolol 160 mg daily for 7 days in normal and hypertensive subjects. Furosemide 41-50 renin Homo sapiens 23-28 6108811-9 1980 Preservation of the renin stimulatory effect of frusemide during beta blockade confirms the value of this procedure in the investigation of mineralocorticoid and renovascular hypertension were discontinuation of treatment may be undesirable. Furosemide 48-57 renin Homo sapiens 20-25 7005123-0 1980 Response of renin, aldosterone and antidiuretic hormone to furosemide and furosemide-triamterene combination. Furosemide 59-69 arginine vasopressin Homo sapiens 35-55 7005123-0 1980 Response of renin, aldosterone and antidiuretic hormone to furosemide and furosemide-triamterene combination. Furosemide 74-84 renin Homo sapiens 12-17 7005123-0 1980 Response of renin, aldosterone and antidiuretic hormone to furosemide and furosemide-triamterene combination. Furosemide 74-84 arginine vasopressin Homo sapiens 35-55 7005123-8 1980 The results show a fast but transient response of the renin-aldosterone system after furosemide and the furosemide-triamterene combination which could not be correlated with the natriuretic effects. Furosemide 85-95 renin Homo sapiens 54-59 7005123-8 1980 The results show a fast but transient response of the renin-aldosterone system after furosemide and the furosemide-triamterene combination which could not be correlated with the natriuretic effects. Furosemide 104-114 renin Homo sapiens 54-59 7017323-0 1980 [Plasma renin activity in patients with acute renal failure treated with furosemide (author"s transl)]. Furosemide 73-83 renin Homo sapiens 8-13 6992754-4 1980 The concomitant rise in plasma renin level after furosemide was also blocked by indomethacin. Furosemide 49-59 renin Homo sapiens 31-36 6996879-6 1980 This was in contrast to the rapid rise seen in normal humans thus indicating a dissociation between the diuretic and renin-releasing activities of frusemide in acute nephritis. Furosemide 147-156 renin Homo sapiens 117-122 7004088-0 1980 Effects of clonidine, guanethidine and furosemide on the development of vasopressin hypertension in rat. Furosemide 39-49 arginine vasopressin Rattus norvegicus 72-83 6997818-6 1980 The fetal lamb also manifests a hypothalamus-posterior pituitary AVP response to furosemide that is proportional to the maturing renal renin response. Furosemide 81-91 vasopressin-neurophysin 2-copeptin Ovis aries 65-68 6997818-1 1980 Circulating arginine vasopressin (AVP) and plasma renin activity responses to furosemide (2 mg/kg) and acute hypertonic saline (10 mEq/kg) were studied in the fetal lamb from 100 days gestation to term. Furosemide 78-88 renin Ovis aries 50-55 6997818-6 1980 The fetal lamb also manifests a hypothalamus-posterior pituitary AVP response to furosemide that is proportional to the maturing renal renin response. Furosemide 81-91 renin Ovis aries 135-140 6996661-0 1980 Effect of propranolol on the renin response to frusemide in man. Furosemide 47-56 renin Homo sapiens 29-34 6996661-1 1980 The response of plasma renin activity (PRA) to frusemide, 40 mg given intravenously, was examined before and after oral propranolol 160 mg daily for seven days in normal and hypertensive subjects. Furosemide 47-56 renin Homo sapiens 23-28 6996661-5 1980 Stimulation of renin release by oral frusemide, examined in one subject, was also unaltered by propranolol therapy. Furosemide 37-46 renin Homo sapiens 15-20 6996661-8 1980 The fact that the renin stimulating effect of frusemide is preserved during beta blockade indicates that this procedure can be used in the investigation of hypertension even in those patients in whom discontinuation of beta blocking treatment may be undesirable. Furosemide 46-55 renin Homo sapiens 18-23 6993779-1 1980 Dissociation between plasma renin and catecholamines or aldosterone following furosemide. Furosemide 78-88 renin Homo sapiens 28-33 7428185-6 1980 Some patients with a raised blood pressure appear to have an enhanced adrenal corticosteroid response to frusemide; this probably reflects an increased sensitivity to angiotensin II. Furosemide 105-114 angiotensinogen Homo sapiens 167-181 6992087-4 1980 Furosemide administration also resulted in a significant increase from 4.41 +/- 2.00 to 9.70 +/- 2.32 ng/ml/hr (P less than 0.02) in plasma renin activity, from 1.17 +/- 0.22 to 1.68 +/- 0.36 ng/ml (P less than 0.025) in plasma aldosterone, from 0.93 +/- 0.16 to 1.53 +/- 0.35 microgram/12 hr (P less than 0.025) in urinary aldosterone, from 17.53 +/- 3.37 to 23.73 +/- 3.16 ng/12 hr (P less than 0.025) in prostaglandin E, and from 16.48 +/- 4.12 to 26.27 +/- 4.12 ng/12 hr (P less than 0.05) in prostaglandin F2 alpha. Furosemide 0-10 renin Homo sapiens 140-145 6992087-5 1980 It is concluded that the renin-angiotensin-aldosterone system of the neonate responds to acute furosemide challenge in spite of its high baseline activity, and its response may be mediated by increased renal prostaglandin production. Furosemide 95-105 renin Homo sapiens 25-30 6992087-0 1980 Furosemide-induced alterations in the electrolyte status, the function of renin-angiotensin-aldosterone system, and the urinary excretion of prostaglandins in newborn infants. Furosemide 0-10 renin Homo sapiens 74-79 6998800-0 1980 Effect of furosemide on insulin and glucagon responses to arginine in normal subjects. Furosemide 10-20 insulin Homo sapiens 24-31 6992087-1 1980 To assess the responsiveness of the renin-angiotensin-aldosterone system of the neonate to acute furosemide stimulation and the role of renal prostaglandins in mediating the response of the renin-angiotensin-aldosterone system, this study was carried out to determine simultaneously plasma renin activity, plasma aldosterone concentration, urinary aldosterone, prostaglandin E, and prostaglandin F2 alpha excretion along with determination of plasma electrolyte concentration and urinary electrolyte excretion. Furosemide 97-107 renin Homo sapiens 36-41 6998800-1 1980 This study aimed at evaluating the influence of furosemide upon insulin and glucagon responses to arginine in healthy subjects. Furosemide 48-58 insulin Homo sapiens 64-71 6998800-3 1980 The acute insulin response (mean change from 3-10 min) to the second arginine pulse was significantly inhibited by furosemide (mean increase: 14.8 +/- 3.0 microU/ml versus 11.7 +/- 2.5 microU/ml, p < 0.01). Furosemide 115-125 insulin Homo sapiens 10-17 6998800-7 1980 The effect of furosemide on insulin and glucagon secretion might be mediated through enhanced release of endogenous prostaglandin E. Furosemide 14-24 insulin Homo sapiens 28-35 6987603-2 1980 The baseline to peak plasma renin activity (PRA) response to furosemide increased from delta 3.0 +/- 1.3 ng/ml/hr (M and SEM) and 95--106 days of gestation to delta 18.4 +/- 4.0 (P less than 0.01) at 123--142 days and delta 33.6 +/- 6.5 (P less than 0.001) in the newborn. Furosemide 61-71 renin Ovis aries 28-33 6987415-7 1980 Of the 16 patients (all normotensive) who had 6-month followup tests 5 had elevated peripheral renin activity, probably owing to furosemide stimulation. Furosemide 129-139 renin Homo sapiens 95-100 6987603-4 1980 The newborn plasma aldosterone response to furosemide via the endogenous renin-angiotensin was delta 17.1 +/- 4.2 ng/dl (P less than 0.01); the fetal lamb plasma aldosterone level did not increase. Furosemide 43-53 renin Ovis aries 73-78 7004092-1 1980 The furosemide-induced increase in protein excretion, and its relations to 1) the size of protein molecules as reflected by three enzymes, and 2) glomerular filtration rate (GFR), plasma renin activity (PRA) and prostaglandin (PG) E2 and F2 alpha excretions were studied in 14 outpatients with normal renal function and 13 healthy males. Furosemide 4-14 renin Homo sapiens 187-192 6987097-6 1980 3) In low renin EH, the response of PNE to the stimulation of standing with furosemide was significantly greater than in normal renin EH (p less than 0.05). Furosemide 76-86 renin Homo sapiens 10-15 518220-3 1979 Renin status was categorized by (1) the intravenous furosemide test, (2) ambulation during placebo, and (3) ambulation during spironolactone and hydrochlorothiazide treatment. Furosemide 52-62 renin Homo sapiens 0-5 7014055-0 1980 Peripheral renin activity before and after furosemide in normotensives and hypertensives. Furosemide 43-53 renin Homo sapiens 11-16 7002508-3 1980 Both isoproterenol and furosemide stimulated release of renin in all age animals while propranolol supressed renin release. Furosemide 23-33 renin Sus scrofa 56-61 6991284-0 1980 [Mechanism of the stimulating effect of furosemide, ethacrynic acid and novurit on renin secretion by the kidneys]. Furosemide 40-50 renin Canis lupus familiaris 83-88 6989757-10 1980 Administration of furosemide was utilized to increase plasma renin activity (PRA) in another series of experiments. Furosemide 18-28 renin Canis lupus familiaris 61-66 393525-4 1979 It is concluded that furosemide induces a generalized activation of the renal PG system temporally related to the increase of renin release and natriuresis. Furosemide 21-31 renin Homo sapiens 126-131 518124-3 1979 In the present study, plasma renin concentration following intravenous administration of frusemide was measured in eleven subjects with moderate or severe lead poisoning of industrial origin. Furosemide 89-98 renin Homo sapiens 29-34 396070-5 1979 Plasma noradrenaline concentration and plasma renin concentration at rest supine and after acute stimulation, as induced by frusemide intravenously and ambulation, did not differ from reference values in the 40-year-old normotensive controls. Furosemide 124-133 renin Homo sapiens 46-51 396074-4 1979 Frusemide increased urinary kallikrein excretion in normotensive subjects and in patients with essential hypertension. Furosemide 0-9 kallikrein related peptidase 4 Homo sapiens 28-38 396074-5 1979 The stimulating effect of frusemide on urinary kallikrein was significantly diminished in patients with essential hypertension. Furosemide 26-35 kallikrein related peptidase 4 Homo sapiens 47-57 522308-1 1979 Renal prostaglandins and their relation to renin in rabbits treated with furosemide (author"s transl)]. Furosemide 73-83 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 43-48 393505-2 1979 The angiotensin II antagonist was infused at a rate of 600 ng/kg/min for 30 min 1.5 hrs after intravenous injection of 40 mg of furosemide. Furosemide 128-138 angiotensinogen Homo sapiens 4-18 474601-3 1979 High plasma renin substrate concentrations, and normal basal and furosemide-stimulated plasma renin activities and plasma renin concentrations which were present before surgery, decreased after adrenalectomy, and the hypertension diminished. Furosemide 65-75 renin Homo sapiens 94-99 474601-3 1979 High plasma renin substrate concentrations, and normal basal and furosemide-stimulated plasma renin activities and plasma renin concentrations which were present before surgery, decreased after adrenalectomy, and the hypertension diminished. Furosemide 65-75 renin Homo sapiens 94-99 467810-0 1979 Acetylsalicyclic acid restores acute insulin response reduced by furosemide in man. Furosemide 65-75 insulin Homo sapiens 37-44 467810-6 1979 Infusion of lysine acetylsalicylate (LAS), an inhibitor of endogenous PGE synthesis, completely reversed the inhibitory effect of furosemide on insulin secretion and also augmented acute insulin response to glucose (response before furosemide + LAS: 41 +/- 6 muU/ml; during furosemide + LAS: 50 +/- 7 muU/ml, N = 10, P less than 0.02). Furosemide 130-140 insulin Homo sapiens 144-151 467810-8 1979 These findings demonstrate that (1) furosemide inhibits glucose-induced acute insulin responses and (2) LAS completely reverses the inhibitory effect of furosemide and also accelerates glucose disposal. Furosemide 36-46 insulin Homo sapiens 78-85 467810-9 1979 It is suggested that furosemide acts via the release of endogenous PGEs, which are known to inhibit insulin responses in man. Furosemide 21-31 insulin Homo sapiens 100-107 501896-5 1979 In 13 normal subjects, in whom 40 mg of furosemide was injected intravenously, plasma angiotensin II concentration before and after 30 and 120 minutes in an upright position was 14.6 +/- 2.2, 56.6 +/- 5.7 and 74.3 +/- 9.0 pg/ml, respectively. Furosemide 40-50 angiotensinogen Homo sapiens 86-100 503889-0 1979 [Evaluation of the effect of intravenous furosemide on the plasma renin activity of renal vein blood in patients with renovascular hypertension]. Furosemide 41-51 renin Homo sapiens 66-71 479736-2 1979 The diuretic drug frusemide brought about a rapid increase in plasma renin activity and aldosterone concentration in serum. Furosemide 18-27 renin Rattus norvegicus 69-74 507503-0 1979 Effect of exercise, phenylbutazone, and furosemide on the plasma renin activity and angiotensin I in horses. Furosemide 40-50 renin Equus caballus 65-70 477626-1 1979 Intravenous infusion of somatostatin in mongrel dogs caused a significant decrease in the peripheral plasma renin activity (PRA) enhanced by pentobarbital sodium anesthesia or furosemide treatment. Furosemide 176-186 somatostatin Canis lupus familiaris 24-36 477626-1 1979 Intravenous infusion of somatostatin in mongrel dogs caused a significant decrease in the peripheral plasma renin activity (PRA) enhanced by pentobarbital sodium anesthesia or furosemide treatment. Furosemide 176-186 renin Canis lupus familiaris 108-113 477626-3 1979 Intrarenal arterial infusion of somatostatin decreased furosemide-enhanced PRA in renal vein by 24.0%, 16.6% and 8.6% in dose of 0.1, 0.5 and 1.0 microgram, respectively. Furosemide 55-65 somatostatin Canis lupus familiaris 32-44 471592-3 1979 Plasma renin activity (PRA) increases from 23 +/- 2.7 ng/ml/hr (M and SE) to 85.8 +/- 16.5 (P less than 0.05) during infusion of saralasin alone and remained at this level after injection of furosemide. Furosemide 191-201 renin Ovis aries 7-12 449254-2 1979 In essential hypertension mean basal (supine) and stimulated plasma renin activity (2 h upright posture + 40 mg furosemide intraveneously) decreased progressively with age. Furosemide 112-122 renin Homo sapiens 68-73 424524-0 1979 Effects of furosemide on renal venous plasma renin activity. Furosemide 11-21 renin Homo sapiens 45-50 489926-12 1979 Intravenous injection of furosemide (50 mg) in a female volunteer was followed by an immediate rise of urinary sodium, PGE2, PGF2 alpha and PGE2/PGF2 alpha ratio and plasma renin activity. Furosemide 25-35 renin Homo sapiens 173-178 449049-0 1979 Change in plasma renin substrate level after the intravenous furosemide administration. Furosemide 61-71 renin Homo sapiens 17-22 424524-4 1979 Acute stimulation of renin by furosemide does not increase the predictive value of renal venous renin measurements and may actually result in a higher percentage of false-negatives. Furosemide 30-40 renin Homo sapiens 21-26 761310-0 1979 Effects of digoxin and digoxin plus furosemide on plasma renin activity of hypertensive patients. Furosemide 36-46 renin Homo sapiens 57-62 760897-0 1979 A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin. Furosemide 37-46 renin Rattus norvegicus 71-76 760897-2 1979 2 Frusemide at concentrations of 1.5 and 7.5 mmol/l produced significant increases in renin release but had no effect at 0.15 mmol/l. Furosemide 2-11 renin Rattus norvegicus 86-91 282044-2 1978 The response of active and inactive plasma renin to orthostasis and frusemide and to inhibition of prostaglandin synthesis by indomethacin was tested in normal human volunteers. Furosemide 68-77 renin Homo sapiens 43-48 429554-4 1979 Plasma renin activity increased from a mean (+/-SEM) of 21.3+/-3.4 ng/ml per h in the 10 control lambs to 39.4+/-8.2 ng/ml per h at 8 min (P < 0.001) and remained high through 120 min after furosemide. Furosemide 193-203 renin Ovis aries 7-12 429554-11 1979 These data support the view that the observed AVP response to furosemide in the newborn lamb was mediated through the renin-angiotensin system. Furosemide 62-72 renin Ovis aries 118-123 763247-1 1979 In 10 healthy and 27 diabetic children aged 11--17 years plasma renin activity was determined in horizontal position (PRA-I) and after stimulation by furosemid and upright position (PRA-II). Furosemide 150-159 renin Homo sapiens 64-69 517244-6 1979 The present data show that basal level of urinary excretion of PGE and kallikrein was lower in essential hypertension than in normal subjects and that the release of renal kallikrein and PGE after the furosemide administration was also suppressed in patients with essential hypertension compared with that in normal subjects, suggesting that there exists, in this disease, an impaired defense mechanism against the renin-angiotensin-aldosterone system resulting in sodium retention. Furosemide 201-211 renin Homo sapiens 415-420 757587-2 1978 The binding to a biological macromolecule (human serum albumin, HSA) of small molecules (two drugs: warfarin and furosemide) has been studied by high-performance liquid chromatography. Furosemide 113-123 albumin Homo sapiens 49-62 757587-2 1978 The binding to a biological macromolecule (human serum albumin, HSA) of small molecules (two drugs: warfarin and furosemide) has been studied by high-performance liquid chromatography. Furosemide 113-123 albumin Homo sapiens 64-67 282041-7 1978 An acute stimulation induced by frusemide and ambulation led to a considerable rise in active renin and a slight, but significant, rise of inactive renin. Furosemide 32-41 renin Homo sapiens 94-99 282041-7 1978 An acute stimulation induced by frusemide and ambulation led to a considerable rise in active renin and a slight, but significant, rise of inactive renin. Furosemide 32-41 renin Homo sapiens 148-153 758231-6 1979 Similarly, furosemide stimulated the release of both active and inactive renin. Furosemide 11-21 renin Sus scrofa 73-78 397653-5 1979 Likewise, furosemide will stimulate renin release. Furosemide 10-20 renin Homo sapiens 36-41 545821-7 1979 Of the 16 patients (all normotensive) who had 6-month followup tests 5 had elevated peripheral renin activity, probably owing to furosemide stimulation. Furosemide 129-139 renin Homo sapiens 95-100 282044-4 1978 Active renin increased by orthostasis and frusemide and decreased by indomethacin. Furosemide 42-51 renin Homo sapiens 7-12 712172-0 1978 [Plasma renin activity in essential hypertension with respect to aging, hypertension severity and furosemide test (author"s transl)]. Furosemide 98-108 renin Homo sapiens 8-13 741539-4 1978 Elevation of renin activity in lymph is noted following infusion with either chlorothiazide or furosemide, while a reduction of renin activity in renal lymph is noted after mannitol infusion. Furosemide 95-105 renin Canis lupus familiaris 13-18 741062-1 1978 The effects of orthostatism and furosemide tests on different parameters of renin-angiotensin system have been studied in 14 normal human subjects. Furosemide 32-42 renin Homo sapiens 76-81 568077-0 1978 [Change in renin activity in the venous blood plasma of dogs under the influence of furosemide, novurit, ethacrynic acid and mannitol]. Furosemide 84-94 renin Canis lupus familiaris 11-16 637637-4 1978 Aldosterone responses in relation to changes in peripheral renin activity were found to be nearly random with both furosemide and with posture. Furosemide 115-125 renin Homo sapiens 59-64 713174-0 1978 [The influence of aging on renin release stimulated by furosemide and upright posture in essential hypertension (author"s transl)]. Furosemide 55-65 renin Homo sapiens 27-32 722978-0 1978 [Renin-angiotensin-aldosterone system and electrolytes metabolism on furosemide stimulation test (author"s transl)]. Furosemide 69-79 renin Homo sapiens 1-6 26691-3 1978 The mobile phase used for chromatography on a reversed-phase column (C15 hydrocarbon permanently bonded to silica particles) is sufficiently acidic to induce fluorescence of furosemide. Furosemide 174-184 placenta associated 8 Homo sapiens 69-72 720703-0 1978 [The responsiveness of plasma renin activity to furosemide administration in diabetic patients (author"s transl)]. Furosemide 48-58 renin Homo sapiens 30-35 657458-10 1978 Renin secretion was 118 +/- 62 ng/min during the control period and averaged 240 +/- 67 ng/min after ouabain plus furosemide. Furosemide 114-124 renin Ovis aries 0-5 657458-13 1978 Ouabain also blocks the normal stimulatory effects of furosemide on renin secretion. Furosemide 54-64 renin Ovis aries 68-73 713284-3 1978 The rise in plasma renin activity on standing or after frusemide was proportional to the resting level, and it was generally less in hypertensives, but small or absent responses were also seen in those with normal blood pressure. Furosemide 55-64 renin Homo sapiens 19-24 353767-6 1978 PRA also increased in relation to frusemide-induced fluid loss. Furosemide 34-43 S100 calcium binding protein A6 Homo sapiens 0-3 645884-1 1978 Under inactin anesthesia, intravenous infusion of [Sar1,Thr8]angiotensin II produced a hypotensive effect in young spontaneously hypertensive rats (SHR) treated with furosemide and in mature SH rats fed a low-sodium diet. Furosemide 166-176 angiotensinogen Rattus norvegicus 61-75 637637-1 1978 Seventy-nine patients with essential hypertension were evaluated for peripheral renin activity in response to injection of 60 mg of furosemide and to upright posture. Furosemide 132-142 renin Homo sapiens 80-85 699607-3 1978 In vivo stimulation of renal PG synthesis by arachidonic acid (C20:4) or furosemide increases renin release. Furosemide 73-83 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 94-99 398707-0 1978 [Reliability and diagnostic use of the furosemide test in the study of the renin-angiotensin-aldosterone system]. Furosemide 39-49 renin Homo sapiens 75-80 624779-2 1978 The mean prothrombin times after a single oral dose of 50 mg warfarin were 18.8 +/- 0.7 sec before and 19.6 +/- 1.7 sec during furosemide administration, and 18.3 +/- 1.4 sec before and 19.7 +/- 1.3 sec during bumetanide administration. Furosemide 127-137 coagulation factor II, thrombin Homo sapiens 9-20 581995-15 1978 It is concluded that the decrease in renal medullary hemodynamics of furosemide-treated rats is due to a stimulation of the renin-angiotensin system. Furosemide 69-79 renin Rattus norvegicus 124-129 699607-4 1978 PG synthesis inhibitors decrease basal renin release and reduce the renin release following stimulation with C20:4, furosemide and renal ischemia. Furosemide 116-126 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 68-73 202362-2 1977 The hypothesis that acetazolamide and parathyroid hormone (PTH), inhibit renal carbonic anhydrase by a cyclic adenosine 3",5"-monophosphate (cyclic AMP)-dependent mechanism was also tested.2In vitro, acetazolamide, frusemide and ethacrynic acid at high concentrations (10(-3)M) all produced some inhibition of basal and stimulated rat kidney plasma membrane adenylate cyclase. Furosemide 215-224 parathyroid hormone Rattus norvegicus 38-57 732253-3 1978 of colchicine or vinblastine to furosemide treated rats on a low salt diet resulted in a decrease of plasma renin as well as plasma angiotensinogen concentration during a 5 h observation period. Furosemide 32-42 renin Rattus norvegicus 108-113 732253-3 1978 of colchicine or vinblastine to furosemide treated rats on a low salt diet resulted in a decrease of plasma renin as well as plasma angiotensinogen concentration during a 5 h observation period. Furosemide 32-42 angiotensinogen Rattus norvegicus 132-147 215821-2 1978 b) Does AII mediate the antidiuresis induced by furosemide? Furosemide 48-58 angiotensinogen Rattus norvegicus 8-11 215821-6 1978 Furosemide led to a two-fold increase of AII plasma concentrations and a decrease of plasma sodium levels. Furosemide 0-10 angiotensinogen Rattus norvegicus 41-44 202362-2 1977 The hypothesis that acetazolamide and parathyroid hormone (PTH), inhibit renal carbonic anhydrase by a cyclic adenosine 3",5"-monophosphate (cyclic AMP)-dependent mechanism was also tested.2In vitro, acetazolamide, frusemide and ethacrynic acid at high concentrations (10(-3)M) all produced some inhibition of basal and stimulated rat kidney plasma membrane adenylate cyclase. Furosemide 215-224 parathyroid hormone Rattus norvegicus 59-62 599795-2 1977 Renin activity proved to be higher in double stimulation (in orthostatism after furosemide intake) than in orthostatism before the intake of the drug. Furosemide 80-90 renin Homo sapiens 0-5 591619-1 1977 Plasma renin activity (PRA) was stimulated by oral frusemide (60 mg) in 4 normal male subjects. Furosemide 51-60 renin Homo sapiens 7-12 599792-3 1977 Decrease of the renin-angiotensin-aldosterone system compensatory reaction and the prostaglandin F level in patients with stable, high arterial pressur in response to furosemide administration may be among the causes of the hypotensive and natriuretic effect of this preparation. Furosemide 167-177 renin Homo sapiens 16-21 905911-0 1977 The effect of furosemide on serum prolactin levels in the postpartum period. Furosemide 14-24 prolactin Homo sapiens 34-43 599795-0 1977 [Change in plasma renin activity in patients with hypertension and healthy persons after furosemide intake]. Furosemide 89-99 renin Homo sapiens 18-23 599795-1 1977 Blood plasma renin activity was studied by the radioimmune method in clino- and orthostatism in 36 males with hypertensive disease and in 15 healthy males before and after 3-day medication with furosemide in a daily dose of 120 mg under in-patient conditions. Furosemide 194-204 renin Homo sapiens 13-18 871171-0 1977 Effects of renal denervation on renin release in response to tilting and furosemide. Furosemide 73-83 renin Felis catus 32-37 873120-1 1977 The effect of furosemide on secretin-stimulated pancreatic secretion was examined in 12 normal subjects using a perfusion method to quantitate pancreatic output. Furosemide 14-24 secretin Homo sapiens 28-36 873120-3 1977 When a bolus injection of furosemide (20 mg) was given during continuous secretin infusion, mean secretory volume increased further to a maximum value of 110 +/- 14.7 ml per min. Furosemide 26-36 secretin Homo sapiens 73-81 328540-4 1977 A significant increase in plasma renin activity and a significantly greater increase in aldosterone excretion were found in the spironolactone/thiazide group compared to the furosemide group. Furosemide 174-184 renin Homo sapiens 33-38 876706-0 1977 The renin-angiotensin-aldosterone system in the newborn lamb: response to furosemide. Furosemide 74-84 renin Ovis aries 4-9 876706-2 1977 Plasma renin activity (PRA) increased within 8 min after furosemide from a baseline value of 12.6 +/- 3.5 ng/ml/hr (mean and SEM) to a level of 24.1 +/- 8.6 ng/ml/hr (P less than 0.05), and peaked 20 mins after the furosemide infusion at a level of 33.1 +/- 8.0 ng/ml/hr. Furosemide 57-67 renin Ovis aries 7-12 876706-2 1977 Plasma renin activity (PRA) increased within 8 min after furosemide from a baseline value of 12.6 +/- 3.5 ng/ml/hr (mean and SEM) to a level of 24.1 +/- 8.6 ng/ml/hr (P less than 0.05), and peaked 20 mins after the furosemide infusion at a level of 33.1 +/- 8.0 ng/ml/hr. Furosemide 215-225 renin Ovis aries 7-12 876706-5 1977 The results indicate that the renin-angiotensin-aldosterone system responds promptly to furosemide stimulation despite initially high PRA and aldosterone levels. Furosemide 88-98 renin Ovis aries 30-35 884392-0 1977 Intrarenal stimulation of renin secretion by frusemide in the isolated kidney of the rat. Furosemide 45-54 renin Rattus norvegicus 26-31 874065-0 1977 Inhibition of the renin-aldosterone response to furosemide by indomethacin. Furosemide 48-58 renin Homo sapiens 18-23 874065-2 1977 The increases in plasma renin activity and plasma and urinary aldosterone following acute furosemide challenge were markedly blunted in the presence of indomethacin. Furosemide 90-100 renin Homo sapiens 24-29 871171-1 1977 In anesthetized cats head-up tilting for 30 min and infusion of furosemide at 0.75 mg/kg in 30 min significantly raised renin release from the innervated kidney (increments of 90.7 +/- 21.4 ng/min on tilting and 105.4 +/- 26.4 ng/min after furosemide); a small and inconstant increase from the contralateral denervated kidney (increments of 16.8 +/- 16.0 and 16.3 +/- 17.7 ng/min, respectively) was abolished by acute bilateral adrenalectomy. Furosemide 64-74 renin Felis catus 120-125 884392-2 1977 Intrarenal infusion of frusemide markedly stimulated renin secretion in the isolated perfused kidney of the rat. Furosemide 23-32 renin Rattus norvegicus 53-58 884392-4 1977 Renin vales increased from 24+/-6 to 195+/-34 units of secretion rate (renin concentration (nmol angiotensin I/h per litre) X flow rate (ml/min)) following administration of frusemide for 8 min, compared with corresponding control values of 13 +/- 2 (P greater than 0.05) and 47 +/-18 (P less than 0.001). Furosemide 174-183 renin Rattus norvegicus 0-5 871171-2 1977 Larger doses of furosemide (6.0 mg/kg) could release renin from the denervated kidney also, but the response was still more marked on the innervated side especially in the early period of infusion (increments of 132.7 +/- 23.8 and 33.7 +/- 23.8 ng/min of innervated and denervated sides at 10 min). Furosemide 16-26 renin Felis catus 53-58 884392-4 1977 Renin vales increased from 24+/-6 to 195+/-34 units of secretion rate (renin concentration (nmol angiotensin I/h per litre) X flow rate (ml/min)) following administration of frusemide for 8 min, compared with corresponding control values of 13 +/- 2 (P greater than 0.05) and 47 +/-18 (P less than 0.001). Furosemide 174-183 renin Rattus norvegicus 71-76 884392-9 1977 These findings indicate the existence of an intrarenal site of action for frusemide on renin secretion. Furosemide 74-83 renin Rattus norvegicus 87-92 190262-8 1977 Four hours after administration of 80 mg of Lasix at 0800 h to 10 normal subjects, the ratios of DOC to B and S to F increased significantly (P less than .02), an effect possibly related to a decreased secretion of ACTH. Furosemide 44-49 proopiomelanocortin Homo sapiens 215-219 884392-12 1977 A direct effect of frusemide on the renin secreting cell is therefore suggested. Furosemide 19-28 renin Rattus norvegicus 36-41 870268-2 1977 With intraperitoneal furosemide, mean net ultrafilrate sodium concentration increased significantly to 121.2 mE1/l while ethacrynic acid had no such effect and both drugs affected dialyzate volume very slightly. Furosemide 21-31 small nucleolar RNA, H/ACA box 73a Mus musculus 109-112 1027472-0 1976 [Behavior of sodium and water excretion and of plasma renin activity (PRA) after administration of furosemide in patients with glomerulonephritis with various degrees of functional deficiency and arterial pressure levels]. Furosemide 99-109 renin Homo sapiens 54-59 844016-3 1977 The furosemide screening test for renovascular hypertension revealed elevated plasma renin activity (PRA) but an intravenous pyelogram revealed a right suprarenal mass and no evidence of renovascular compression. Furosemide 4-14 renin Homo sapiens 85-90 844250-4 1977 Frusemide, ethacrynic acid and bumetanide cause an immediate rise in renin secretion which is not inhibited either by DL-propranolol or by a bilateral ureterovenous anastomosis which prevents salt and water loss. Furosemide 0-9 renin Canis lupus familiaris 69-74 838842-7 1977 Overall, in the hypertensive patients, there was a significant positive correlation (r= +0.58; P less than 0.01) between PRR and the PRA response to furosemide. Furosemide 149-159 ATPase H+ transporting accessory protein 2 Homo sapiens 121-124 840860-0 1977 Renin secretion after papaverine and furosemide in conscious sheep. Furosemide 37-47 renin Ovis aries 0-5 1071582-0 1976 Stimulation of renin secretion by frusemide and diazoxide in the isolated rat kidney. Furosemide 34-43 renin Rattus norvegicus 15-20 1071582-2 1976 The effect of diazoxide (17-3 micronmol min-1 g-1) and frusemide (0-12 micronmol min-1 g-1) on renin secretion was examined in the isolated perfused rat kidney. Furosemide 55-64 renin Rattus norvegicus 95-100 1071628-10 1976 The diuresis and natriuresis induced by frusemide in rats was associated with increased urinary kallikrein excretion and acute rises in plasma renin. Furosemide 40-49 renin Rattus norvegicus 143-148 1071582-10 1976 These observations identify an intrarenal site of action for diazoxide and frusemide on renin secretion. Furosemide 75-84 renin Rattus norvegicus 88-93 1071587-8 1976 Frusemide effectively reduced blood pressure and renin at all phases. Furosemide 0-9 renin Rattus norvegicus 49-54 1071603-2 1976 Supine plasma renin activity and its responsiveness to erect posture and frusemide were reduced in fifty-one patients with essential hypertension, compared with fifty-one age- and sex-matched control subjects. Furosemide 73-82 renin Homo sapiens 14-19 12404-0 1976 [Cyclic AMP and plasma renin activity in renal vein blood after amitryptiline, theophylline, furosemide and beta adrenergic blocking substances (author"s transl)]. Furosemide 93-103 renin Homo sapiens 23-28 1001347-0 1976 Natriuresis and renin release by the denervated dog kidney during furosemide administration. Furosemide 66-76 renin Canis lupus familiaris 16-21 1005885-2 1976 Furosemide greatly inhibits platelet aggregation, with ADP, epinephrine, collagen, ristocetin, thrombin and serotonin. Furosemide 0-10 coagulation factor II, thrombin Homo sapiens 95-103 12404-1 1976 The influence of amitryptiline, theophylline and furosemide on the concentration of cyclic-AMP and plasma renin activity (PRA) was investigated in renal vein plasma. Furosemide 49-59 renin Homo sapiens 106-111 1053468-1 1976 Changes in arterial blood pressure, renal electrolyte excretion, and plasma renin activity in response to repeated doses of furosemide were measured in 12 patients with essential hypertension admitted to the medical service for electrolyte balance studies. Furosemide 124-134 renin Homo sapiens 76-81 824442-1 1976 The effects of furosemide on stimulation of renin secretion and urinary sodium excretion were studied in dogs pretreated with the prostaglandin synthetase inhibitors, indomethacin and meclofenamate. Furosemide 15-25 renin Canis lupus familiaris 44-49 824442-6 1976 Indomethacin apparently affects furosemide-induced renin secretion at both the vascular and macula densa sites. Furosemide 32-42 renin Canis lupus familiaris 51-56 1053468-7 1976 However, the average increase in plasma renin activity after repeated doses of furosemide was not statistically significant and no correlation was demonstrated between the level of plasma renin activity after furosemide and the blood pressure lowering effect of the drug. Furosemide 79-89 renin Homo sapiens 40-45 22216503-8 1976 At the time of peak diuresis, both drugs caused a significant reduction of euglobulin lysis time; levels of available plasmin were significantly lowered after frusemide, and levels of active plasmin were significantly raised after bumetanide. Furosemide 159-168 plasminogen Homo sapiens 118-125 956367-4 1976 The lowering effect of indomethacin on plasma renin activity is not specifically related to hemorrhage because it also prevented the increase in plasma renin activity elicited by 5 mg/kg of furosemide. Furosemide 190-200 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 46-51 956367-4 1976 The lowering effect of indomethacin on plasma renin activity is not specifically related to hemorrhage because it also prevented the increase in plasma renin activity elicited by 5 mg/kg of furosemide. Furosemide 190-200 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 152-157 937875-0 1976 The intravenous furosemide test: a simple way to evaluate renin responsiveness. Furosemide 16-26 renin Homo sapiens 58-63 965879-5 1976 After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide. Furosemide 24-33 prolactin Homo sapiens 62-71 965879-5 1976 After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide. Furosemide 24-33 prolactin Homo sapiens 194-203 965879-5 1976 After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide. Furosemide 295-304 prolactin Homo sapiens 194-203 937875-1 1976 To identify patients with low-renin hypertension, we measured plasma renin activity after the administration of 40 mg of furosemide intravenously and 30 minutes of upright posture in 127 normotensive subjects and 363 patients with essential hypertension. Furosemide 121-131 renin Homo sapiens 69-74 937875-2 1976 Plasma renin activity 30 minutes after intravenous furosemide was found to be closely correlated to the level found after either 2 or 4 h of standing or 3 days of a low-salt diet plus 2 h of upright posture. Furosemide 51-61 renin Homo sapiens 7-12 1264120-0 1976 Letter: Furosemide stimulation of peripheral renin in men and women. Furosemide 8-18 renin Homo sapiens 45-50 1263402-2 1976 Stimulation of the renin activity was achieved by orthostasis or by furosemide. Furosemide 68-78 renin Homo sapiens 19-24 987428-1 1976 Response of plasma renin activity to furosemide]. Furosemide 37-47 renin Homo sapiens 19-24 56589-3 1976 Injection of frusemide alone produced hyperreninaemia; but, under somatostatin, renin release was inhibited by 45%. Furosemide 13-22 somatostatin Homo sapiens 66-78 56589-3 1976 Injection of frusemide alone produced hyperreninaemia; but, under somatostatin, renin release was inhibited by 45%. Furosemide 13-22 renin Homo sapiens 43-48 1083996-0 1976 [Influence of furosemide and propranolol (beta blocking agent) on plasmatic renin liberation in dogs]. Furosemide 14-24 renin Canis lupus familiaris 76-81 938983-0 1976 Effects of furosemide and chlorothiazide on blood pressure and plasma renin activity. Furosemide 11-21 renin Homo sapiens 70-75 985607-12 1976 High concentrations of furosemide stimulated renin release by a direct intrarenal mechanism. Furosemide 23-33 renin Bos taurus 45-50 187035-1 1976 15-Hydroxyprostaglandin dehydrogenase was inhibited by xylocaine, furosemide, and ethacrynic acid, but was activated by imipramine and other related drugs. Furosemide 66-76 carbonyl reductase 1 Homo sapiens 0-37 1267539-5 1976 The excretion of furosemide by the kidney is competitively inhibited by p-aminohippuric acid (PAH). Furosemide 17-27 phenylalanine hydroxylase Rattus norvegicus 94-97 1267539-6 1976 The relative small inhibitory effect of PAH in young rats is caused by a smaller participation of tubular secretion in the renal excretion of furosemide in this age group. Furosemide 142-152 phenylalanine hydroxylase Rattus norvegicus 40-43 1001004-6 1976 Mannitol infusion was able to bring the insulin/inulin clearance ratio up the values of the sieving coefficient of insulin (insulin filtration rate) without modifying the permeability of the glomerular wall; saline infusion displayed a similar effect; furosemide, only a minute one although it induced a more marked polyuria. Furosemide 252-262 insulin Canis lupus familiaris 40-47 1022409-0 1976 The effect of furosemide stimulation on renin secretion and its application in examining activity of the renin-angiotensin system. Furosemide 14-24 renin Homo sapiens 40-45 1022409-0 1976 The effect of furosemide stimulation on renin secretion and its application in examining activity of the renin-angiotensin system. Furosemide 14-24 renin Homo sapiens 105-110 937140-5 1976 Furosemide 5 mg in hyperhydrated animals produced in the same period an excretion of 645 +/- 52 ng BR of Kal, which is 147% higher to that excreted by the hyperhydrated controls. Furosemide 0-10 kallikrein related-peptidase 5 like Rattus norvegicus 105-108 937140-6 1976 The same dose of furosemide in 2% NaCl loaded rats, produced an excretion of Kal equivalent to 1333 +/- 72 ng BR which is 180% greater than in controls similarly loaded. Furosemide 17-27 kallikrein related-peptidase 5 like Rattus norvegicus 77-80 937140-7 1976 Acetazoleamide 20 mg and furosemide 5 mg produced similar excretions of Kal even though natriuresis is greater tna kalliuresis is lesser in furosemide injected rats. Furosemide 25-35 kallikrein related-peptidase 5 like Rattus norvegicus 72-75 937140-8 1976 Evaluation of total kidney Kal has shown that a single (10 mg) or a series of furosemide injections (8 days 5 mg + 1 day 10 mg), brings about a significant (p is less than 0.001) decrease in renal Kal, but the increase of Kal excreted in the urine (120 min) is 3.5 times more (under a single injection) and 42 times more (under 9 injections) than the amount which disappears from the kidneys. Furosemide 78-88 kallikrein related-peptidase 5 like Rattus norvegicus 27-30 937140-8 1976 Evaluation of total kidney Kal has shown that a single (10 mg) or a series of furosemide injections (8 days 5 mg + 1 day 10 mg), brings about a significant (p is less than 0.001) decrease in renal Kal, but the increase of Kal excreted in the urine (120 min) is 3.5 times more (under a single injection) and 42 times more (under 9 injections) than the amount which disappears from the kidneys. Furosemide 78-88 kallikrein related-peptidase 5 like Rattus norvegicus 197-200 937140-8 1976 Evaluation of total kidney Kal has shown that a single (10 mg) or a series of furosemide injections (8 days 5 mg + 1 day 10 mg), brings about a significant (p is less than 0.001) decrease in renal Kal, but the increase of Kal excreted in the urine (120 min) is 3.5 times more (under a single injection) and 42 times more (under 9 injections) than the amount which disappears from the kidneys. Furosemide 78-88 kallikrein related-peptidase 5 like Rattus norvegicus 197-200 937140-9 1976 Apparently furosemide not only stimulates Kal excretion, but also Kal synthesis in the kidney. Furosemide 11-21 kallikrein related-peptidase 5 like Rattus norvegicus 42-45 937140-9 1976 Apparently furosemide not only stimulates Kal excretion, but also Kal synthesis in the kidney. Furosemide 11-21 kallikrein related-peptidase 5 like Rattus norvegicus 66-69 1249195-8 1976 When furosemide was administered intravenously under this condition, both plasma ADH and PRA increased to 3.1 +/- 0.5 muU/ml and 15.5 +/- 1.6 ng/ml with 11.2 +/- 1.1% decrease in plasma volume. Furosemide 5-15 arginine vasopressin Homo sapiens 81-84 1022409-1 1976 The response of plasma renin concentration [PRC] to Furosemide administration and orthostasis stimulation was studied in 9 healthy volunteers and in 30 patients with essential hypertension. Furosemide 52-62 renin Homo sapiens 23-28 1182938-2 1975 Experiments were undertaken to investigate further the effect of furosemide on renin secretion in the anesthetized dog. Furosemide 65-75 renin Canis lupus familiaris 79-84 1053607-6 1975 Ten patients dropped out voluntarily and 39 were controlled for an additional four weeks at a dose of 20 mg bid furosemide. Furosemide 112-122 BH3 interacting domain death agonist Homo sapiens 108-111 183224-3 1976 Both acetaminophen and furosemide decreased the concentrations of cytochrome P-450 and cytochrome b5 in microsomes, and the activity of microsomal ethylmorphine N-demethylase and aniline hydroxylase. Furosemide 23-33 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 66-100 1257693-0 1976 Unimpeded plasma renin increase after intravenous furosemide during saline replacement. Furosemide 50-60 renin Homo sapiens 17-22 1257693-1 1976 The effect on plasma renin activity of intravenous furosemide combined with saline replacement of the volume depletion was studied in twelve patients with insignificant heart disease. Furosemide 51-61 renin Homo sapiens 21-26 1192694-0 1975 Effect of intravenous frusemide on plasma renin concentration: suppression of response in hypertension. Furosemide 22-31 renin Homo sapiens 42-47 1182938-4 1975 Furosemide, in a dose of 5 mg/kg, increased renin secretion and decreased renal resistance in dogs with a nonfiltering kidney. Furosemide 0-10 renin Canis lupus familiaris 44-49 1192694-2 1975 Intravenous frusemide produced in normal subjects a prompt rise of plasma renin concentration which correlated with urinary sodium. Furosemide 12-21 renin Homo sapiens 74-79 1192694-4 1975 The renin response to frusemide was suppressed in patients with primary hyperaldosteronism. Furosemide 22-31 renin Homo sapiens 4-9 1182938-6 1975 However, following dilation of the intact filtering kidney with acetylcholine, furosemide caused an increase in renin secretion. Furosemide 79-89 renin Canis lupus familiaris 112-117 1192694-6 1975 In patients with low-renin hypertension and normal renin essential hypertension, the renin response to frusemide was similarly suppressed. Furosemide 103-112 renin Homo sapiens 21-26 1182938-8 1975 Following propranolol treatment, furosemide increased renin secretion in the filtering kidney but had no effect on renal resistance. Furosemide 33-43 renin Canis lupus familiaris 54-59 1192694-8 1975 Suppression of the renin response to frusemide is therefore a feature of hypertension not confined to patients with primary hyperaldosteronism and low-renin hypertension. Furosemide 37-46 renin Homo sapiens 19-24 1192694-8 1975 Suppression of the renin response to frusemide is therefore a feature of hypertension not confined to patients with primary hyperaldosteronism and low-renin hypertension. Furosemide 37-46 renin Homo sapiens 151-156 1182938-9 1975 These experiments indicate that furosemide stimulates renin secretion by both the macula densa and the baroreceptor mechanisms. Furosemide 32-42 renin Canis lupus familiaris 54-59 1150481-4 1975 In the patients who were given substitution therapy with hydrocortisone, studies of plasma renin and aldosterone revealed impairment of plasma aldosterone response to salt restriction, orthostatism and furosemide-induced diuresis combined with postural change. Furosemide 202-212 renin Homo sapiens 91-96 1179572-2 1975 Peripheral plasma renin activity was elevated following furosemide challenge, and there was increased renal vein renin activity on the affected side with suppression of renin secretion from the contralateral kidney. Furosemide 56-66 renin Homo sapiens 18-23 1105697-3 1975 Furosemide alone resulted in a significant blood pressure fall with a rise in plasma renin and urinary aldosterone with a marked increase in urinary sodium loss. Furosemide 0-10 renin Homo sapiens 85-90 1138585-1 1975 A standardized test for renin responsiveness, employing the dual stimulus of upright posture and the loop diuretic furosemide, was applied to 19 hypertensive patients in the untreated state and during therapy with the antihypertensive agents guanethidine and methyldopa. Furosemide 115-125 renin Homo sapiens 24-29 1155613-5 1975 The addition of furosemide (from 10 minus 5 to 10 minus 3 M) stimulated renin secretion. Furosemide 16-26 renin Rattus norvegicus 72-77 172005-0 1975 [Effect of furosemide and ACTH on plasma renin, aldosterone and cortisol levels in normal man]. Furosemide 11-21 renin Homo sapiens 41-46 802648-0 1975 Effect of oxprenolol on catecholamines and plasma renin activity: acute response to frusemide in hypertensive patients. Furosemide 84-93 renin Homo sapiens 50-55 802648-11 1975 Oxprenolol suppressed the response of noradrenaline and plasma renin activity to frusemide in all cases. Furosemide 81-90 renin Homo sapiens 63-68 1168122-2 1975 They were divided into two groups according to the change in plasma-renin activity in response to furosemide administration: those with and those without response to stimulation, and sub-groups with low, normal or high plasma-renin activity (low renin hypertension; normal renin hypertension; high renin hypertension). Furosemide 98-108 renin Homo sapiens 68-73 1149327-0 1975 Abolition of the renin-releasing action of frusemide by acute renal denervation in dogs. Furosemide 43-52 renin Canis lupus familiaris 17-22 1149327-2 1975 The effects of infusions of frusemide at low (0.05-0.1 mg.kg-1.min-1) and high (0.5-2.0 mg.kg-1.min-1) rates were studied on renin secretion and urinary outputs of sodium and potassium in anaesthetized dogs in which one kidney was removed and the remaining kidney was either innervated or denervated. Furosemide 28-37 renin Canis lupus familiaris 125-130 1149327-7 1975 High rates of infusion of frusemide caused an immediate increase in renin secretion from innervated kidneys which was not related to urinary losses. Furosemide 26-35 renin Canis lupus familiaris 68-73 1149327-11 1975 Denervation of the kidney abolished the renin-releasing action of frusemide at both low and high infusion rates even when the sodium deficit amounted to 4.3 mmol.kg-1. Furosemide 66-75 renin Canis lupus familiaris 40-45 1149327-13 1975 Constriction of the aorta producing a fall of 10-30 mmHg in perfusion pressure raised the rate of renin secretion from denervated kidneys to control levels and partially restored the renin-releasing action of frusemide at high infusion rates. Furosemide 209-218 renin Canis lupus familiaris 98-103 1149327-13 1975 Constriction of the aorta producing a fall of 10-30 mmHg in perfusion pressure raised the rate of renin secretion from denervated kidneys to control levels and partially restored the renin-releasing action of frusemide at high infusion rates. Furosemide 209-218 renin Canis lupus familiaris 183-188 1149327-15 1975 The findings indicate that frusemide has a site of action apart from the macula densa in mediating renin release. Furosemide 27-36 renin Canis lupus familiaris 99-104 1159891-0 1975 [Effect of furosemide and d-1-propranolol on glomerular filtration and renin secretin in rats]. Furosemide 11-21 secretin Rattus norvegicus 77-85 1233219-0 1975 Effects of metoprolol and propranolol on furosemide-stimulated renin release in healthy subjects. Furosemide 41-51 renin Homo sapiens 63-68 1233219-1 1975 The effects of single doses of the beta1-receptor antagonist metoprolol (40 mg orally), propranolol (40 mg orally) and placebo were compared on furosemide-stimulated plasma renin activity (PRA) in seven healthy subjects. Furosemide 144-154 renin Homo sapiens 173-178 1129331-6 1975 Stimulation of renin secretion occurred after furosemide in indomethacin-treated animals. Furosemide 46-56 renin Canis lupus familiaris 15-20 1223821-1 1975 In 22 patients with chronic cor pulmonale syndrome plasma renin activity (PRA) was determined at rest and after stimulation by means of intravenous injection of furosemide. Furosemide 161-171 renin Homo sapiens 58-63 1135521-0 1975 Marked elevation of plasma renin activity during post diuretic sodium conservation in furosemide stimulated subjects. Furosemide 86-96 renin Homo sapiens 27-32 1186924-0 1975 Inhibition of furosemide-induced renin release by vasoconstrictors. Furosemide 14-24 renin Homo sapiens 33-38 164581-7 1975 With Furosemid treatment the activities of beta-glucuronidase and cathepsin D increased in the lysosomal supernatant and the lysosomal sediment of the 1-year old rats, whereas the activities of the collagenolytic enzyme increased in the lysosomal sediment of the same group. Furosemide 5-14 glucuronidase, beta Rattus norvegicus 43-61 164581-7 1975 With Furosemid treatment the activities of beta-glucuronidase and cathepsin D increased in the lysosomal supernatant and the lysosomal sediment of the 1-year old rats, whereas the activities of the collagenolytic enzyme increased in the lysosomal sediment of the same group. Furosemide 5-14 cathepsin D Rattus norvegicus 66-77 172003-3 1975 The sodium depletion induced by furosemide during continuous ACTH infusion increases plasma renin activity but does not change PA. Furosemide 32-42 proopiomelanocortin Homo sapiens 61-65 172003-3 1975 The sodium depletion induced by furosemide during continuous ACTH infusion increases plasma renin activity but does not change PA. Furosemide 32-42 renin Homo sapiens 92-97 1116335-4 1975 Secondly, renin activity was measured after frusemide stimualtion [0.42 mmol (140 mg) in 18 h] and 3 h ambulation. Furosemide 44-53 renin Homo sapiens 10-15 4443232-0 1974 Renin response to furosemide and hypertonic saline infusion. Furosemide 18-28 renin Homo sapiens 0-5 180717-0 1975 [Cyclic AMP and renin secretion following furosemide, beta-sympathicolysis and amitryptiline]. Furosemide 42-52 renin Homo sapiens 16-21 4821039-7 1974 Frusemide had no clear effect on the rate of beating of the controls, but it tended to reverse both the acceleration produced by 50 ng/ml prolactin and the slowing produced by the higher dose. Furosemide 0-9 prolactin Homo sapiens 138-147 4376467-0 1974 [Furosemide action on the liberation of renin in vitro]. Furosemide 1-11 renin Homo sapiens 40-45 4708961-0 1973 Renin output by diseased and contralateral normal dog kidneys following extracellular fluid volume expansion and furosemide. Furosemide 113-123 renin Canis lupus familiaris 0-5 4366973-4 1973 Activity of this enzyme in the presence of 0.1 muM cAMP was significantly inhibited by 100 muM mercuderamide, bumetanide and frusemide. Furosemide 125-134 latexin Homo sapiens 47-50 4366973-4 1973 Activity of this enzyme in the presence of 0.1 muM cAMP was significantly inhibited by 100 muM mercuderamide, bumetanide and frusemide. Furosemide 125-134 latexin Homo sapiens 91-94 4265384-12 1973 Furosemide at high concentrations inhibited ATPase, reducing both ouabain-sensitive and ouabain-insensitive enzyme at 1.0 mM concentration while showing no effect on ATPase at 0.05-0.1 mM concentration. Furosemide 0-10 dynein axonemal heavy chain 8 Homo sapiens 44-50 4265384-13 1973 The effects of furosemide on ATPase and on Na flux were dissociable on a dose-response curve. Furosemide 15-25 dynein axonemal heavy chain 8 Homo sapiens 29-35 4724467-0 1973 [The influence of mannitol and furosemide on plasma renin activity in dogs with expansion of the extracellular volume]. Furosemide 31-41 renin Canis lupus familiaris 52-57 4859545-0 1974 The nature of renin released in the dog followin haemorrhage and frusemide. Furosemide 65-74 renin Canis lupus familiaris 14-19 4454541-0 1974 [Effect of propranolol on the stimulation of renin secretion due to orthostasis and furosemide]. Furosemide 84-94 renin Homo sapiens 45-50 4354807-0 1973 Effect of propranolol and theophylline on renin release caused by furosemide in the cat. Furosemide 66-76 renin Homo sapiens 42-47 5074393-0 1972 Release of renin into the peripheral circulation of the ewe and foetus, following administration of frusemide, a natriuretic agent. Furosemide 100-109 renin Homo sapiens 11-16 5163370-1 1971 Effects of methylclothiazide and frusemide on blood pressure and plasma renin activity and electrolytes. Furosemide 33-42 renin Homo sapiens 72-77 4659318-0 1972 Effects of hemorrhage and furosemide on renin release in dogs. Furosemide 26-36 renin Canis lupus familiaris 40-45 4318270-0 1970 Effect of furosemide and hydrochlorothiazide on plasma renin activity in man. Furosemide 10-20 renin Homo sapiens 55-60 4996929-0 1970 [Glucagon test and electrolytes in long term administration of furosemide to insulin requiring diabetics]. Furosemide 63-73 insulin Homo sapiens 77-84 4308808-0 1969 Mechanism of the effects of furosemide on renin secretion in anesthetized dogs. Furosemide 28-38 renin Canis lupus familiaris 42-47 4976775-0 1969 [Action of furosemide on renin secretion in dogs]. Furosemide 11-21 renin Canis lupus familiaris 25-30 5642446-0 1968 Acute changes in plasma volume, renin activity, and free aldosterone levels in healthy subjects following Fursemide administration. Furosemide 106-115 renin Homo sapiens 32-37 5676393-0 1968 Mechanism of renin release following furosemide diuresis in rabbit. Furosemide 37-47 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 13-18 33969697-5 2021 Here we show that levels of Na+-K+-2Cl- cotransporter isoform 2 (NKCC2) and Na+/H+ exchanger isoform 3 (NHE3) are reduced at baseline in SMKOs, accompanied by attenuated natriuretic and diuretic responses to furosemide. Furosemide 208-218 solute carrier family 12, member 1 Mus musculus 28-63 6065850-0 1967 Frusemide induced diuresis as an aid to transfusion in severe anaemia. Furosemide 0-9 activation induced cytidine deaminase Homo sapiens 33-36 4159219-0 1965 Effect of angiotensin and of frusemide on plasma aldosterone, corticosterone, cortisol and renin in man. Furosemide 29-38 renin Homo sapiens 91-96 33988989-4 2021 The HD-CNTf rod mu-ES has been evaluated by electrochemical determination of biologically important analytes, i.e., dopamine (DA), beta-nicotinamide adenine dinucleotide (NADH), a diuretic drug, i.e., furosemide, and a heavy metal, i.e., lead ions (Pb2+). Furosemide 201-211 ciliary neurotrophic factor Homo sapiens 7-11 33969697-5 2021 Here we show that levels of Na+-K+-2Cl- cotransporter isoform 2 (NKCC2) and Na+/H+ exchanger isoform 3 (NHE3) are reduced at baseline in SMKOs, accompanied by attenuated natriuretic and diuretic responses to furosemide. Furosemide 208-218 solute carrier family 12, member 1 Mus musculus 65-70 33969697-5 2021 Here we show that levels of Na+-K+-2Cl- cotransporter isoform 2 (NKCC2) and Na+/H+ exchanger isoform 3 (NHE3) are reduced at baseline in SMKOs, accompanied by attenuated natriuretic and diuretic responses to furosemide. Furosemide 208-218 solute carrier family 9 (sodium/hydrogen exchanger), member 3 Mus musculus 76-102 33969697-5 2021 Here we show that levels of Na+-K+-2Cl- cotransporter isoform 2 (NKCC2) and Na+/H+ exchanger isoform 3 (NHE3) are reduced at baseline in SMKOs, accompanied by attenuated natriuretic and diuretic responses to furosemide. Furosemide 208-218 solute carrier family 9 (sodium/hydrogen exchanger), member 3 Mus musculus 104-108 33580790-0 2021 The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department. Furosemide 72-82 Fas activated serine/threonine kinase Homo sapiens 4-8 33828237-6 2021 Furthermore, the therapeutic effects of the diuretic furosemide on Abeta clearance via the kidney were assessed. Furosemide 53-63 amyloid beta (A4) precursor protein Mus musculus 67-72 33828237-9 2021 In addition, chronic furosemide treatment reduced blood and brain Abeta levels and attenuated AD pathologies and cognitive deficits in APP/PS1 mice. Furosemide 21-31 amyloid beta (A4) precursor protein Mus musculus 66-71 33828237-9 2021 In addition, chronic furosemide treatment reduced blood and brain Abeta levels and attenuated AD pathologies and cognitive deficits in APP/PS1 mice. Furosemide 21-31 presenilin 1 Mus musculus 139-142 33742787-6 2021 In Trial 2, 40 mg furosemide (OAT3 substrate) was administered alone and in presence of DM-4103. Furosemide 18-28 solute carrier family 22 member 8 Homo sapiens 30-34 33356948-6 2021 Two of the KCC2 screens identified new inhibitors that are 3-4 orders of magnitude more potent than furosemide. Furosemide 100-110 solute carrier family 12 member 5 Homo sapiens 11-15 33239392-7 2021 The kidney furosemide clearance correlated with iGFR (r=0.84) and the summary secretion score (r=0.86). Furosemide 11-21 insulin like growth factor 1 receptor Homo sapiens 48-52 33239392-8 2021 The mean proportionate error (MPE) between iGFR-predicted and measured furosemide clearance was 30.0%. Furosemide 71-81 insulin like growth factor 1 receptor Homo sapiens 43-47 33166587-6 2021 The blockade of ERK1/2 activation with icv injections of U0126 (MEK1/2 inhibitor, 2 mM; 2 mul) reduced 0.3 M NaCl induced by furosemide + captopril (5.0 +- 1.0, vs. vehicle: 7.3 +- 0.7 ml/120 min) or WD-PR (4.6 +- 1.3, vs. vehicle: 10.3 +- 1.4 ml/120 min). Furosemide 125-135 mitogen activated protein kinase 3 Rattus norvegicus 16-22 33166587-6 2021 The blockade of ERK1/2 activation with icv injections of U0126 (MEK1/2 inhibitor, 2 mM; 2 mul) reduced 0.3 M NaCl induced by furosemide + captopril (5.0 +- 1.0, vs. vehicle: 7.3 +- 0.7 ml/120 min) or WD-PR (4.6 +- 1.3, vs. vehicle: 10.3 +- 1.4 ml/120 min). Furosemide 125-135 mitogen activated protein kinase kinase 1 Rattus norvegicus 64-70 33647281-5 2021 Compared to euhydrated condition, the treatment with the diuretic furosemide + low dose of captopril (angiotensin converting enzyme blocker) increased the number of hedonic and reduced the number of aversive responses to intra-oral NaCl in normotensive rats, without changing the number of hedonic or aversive responses in SHRs. Furosemide 66-76 angiotensin I converting enzyme Rattus norvegicus 102-131 33514009-0 2021 Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs. Furosemide 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 58-72 33514009-1 2021 In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). Furosemide 263-273 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 33514009-1 2021 In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). Furosemide 275-278 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 33356004-1 2021 BACKGROUND: Furosemide inhibits the sodium potassium chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle and increases urinary water and sodium excretion. Furosemide 12-22 solute carrier family 12 member 1 Homo sapiens 77-82 33435470-4 2021 Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 muM, 1.52 muM, 74.8 muM, and 91.3 muM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration. Furosemide 329-339 solute carrier family 22 member 6 Homo sapiens 54-58 33410279-0 2021 ENaC expression correlates with the acute furosemide-induced K+ excretion. Furosemide 42-52 sodium channel, nonvoltage-gated 1 alpha Mus musculus 0-4 33410279-11 2021 In contrast, furosemide-induced kaliuresis was greatly enhanced in animals fed a high K+ or low Na+ diet, conditions with increased ENaC expression. Furosemide 13-23 sodium channel, nonvoltage-gated 1 alpha Mus musculus 132-136 33410279-13 2021 CONCLUSION: Acute furosemide-induced kaliuresis differs greatly and depends on the a priori molecular expression level of ENaC. Furosemide 18-28 sodium channel, nonvoltage-gated 1 alpha Mus musculus 122-126 33356004-7 2021 Urinary excretion of NKCC2 increased after furosemide and the increase in NKCC2 correlated with an increase in urine output and a decrease in ECW. Furosemide 43-53 solute carrier family 12 member 1 Homo sapiens 21-26 33356004-10 2021 Finally, urinary proteins from NKCC2 increases after furosemide with a good correlation with diuresis end the decrease in ECW. Furosemide 53-63 solute carrier family 12 member 1 Homo sapiens 31-36 32892950-11 2020 Further, pre-treatment with furosemide, a KCC2 inhibitor, during CTZ stimulation followed by washout significantly prevented convulsant stimulation-induced membrane KCC2 downregulation and significantly attenuated GABAAR downregulation concomitant with recovery of suppressed KCC2-independent GABAergic mIPSC amplitude. Furosemide 28-38 solute carrier family 12 member 5 Homo sapiens 42-46 33202945-4 2020 This work aimed to study the compatibility of furosemide and torsemide with PN used in clinical practice. Furosemide 46-56 U6 snRNA biogenesis phosphodiesterase 1 Homo sapiens 76-78 33225679-7 2020 Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase. Furosemide 26-36 tumor necrosis factor Homo sapiens 79-88 33225679-7 2020 Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase. Furosemide 26-36 interleukin 6 Homo sapiens 90-94 33225679-7 2020 Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase. Furosemide 26-36 CD86 molecule Homo sapiens 146-150 33225679-7 2020 Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase. Furosemide 26-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 181-186 33225679-7 2020 Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase. Furosemide 26-36 inositol-3-phosphate synthase 1 Homo sapiens 188-192 33225679-7 2020 Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase. Furosemide 26-36 interleukin 1 receptor antagonist Homo sapiens 273-279 33225679-8 2020 Our mechanism of action studies further demonstrate that furosemide reduces LPS-induced upregulation of endoplasmic reticulum (ER) stress marker genes, including Grp78, Atf4, Chop, tXbp1, and sXbp1. Furosemide 57-67 heat shock protein family A (Hsp70) member 5 Homo sapiens 162-167 33225679-8 2020 Our mechanism of action studies further demonstrate that furosemide reduces LPS-induced upregulation of endoplasmic reticulum (ER) stress marker genes, including Grp78, Atf4, Chop, tXbp1, and sXbp1. Furosemide 57-67 activating transcription factor 4 Homo sapiens 169-173 33225679-8 2020 Our mechanism of action studies further demonstrate that furosemide reduces LPS-induced upregulation of endoplasmic reticulum (ER) stress marker genes, including Grp78, Atf4, Chop, tXbp1, and sXbp1. Furosemide 57-67 DNA damage inducible transcript 3 Homo sapiens 175-179 33225679-8 2020 Our mechanism of action studies further demonstrate that furosemide reduces LPS-induced upregulation of endoplasmic reticulum (ER) stress marker genes, including Grp78, Atf4, Chop, tXbp1, and sXbp1. Furosemide 57-67 internexin neuronal intermediate filament protein alpha Homo sapiens 181-186 33369473-1 2020 OBJECTIVE: The aim of current study is to evaluate the role of diuretic assisted 68Ga-PSMA PET-CT, on image quality and clinical interpretation of indeterminate/equivocal lesions in pre-Lasix imaging of Prostate cancer. Furosemide 186-191 folate hydrolase 1 Homo sapiens 86-90 32892950-11 2020 Further, pre-treatment with furosemide, a KCC2 inhibitor, during CTZ stimulation followed by washout significantly prevented convulsant stimulation-induced membrane KCC2 downregulation and significantly attenuated GABAAR downregulation concomitant with recovery of suppressed KCC2-independent GABAergic mIPSC amplitude. Furosemide 28-38 solute carrier family 12 member 5 Homo sapiens 165-169 32892950-11 2020 Further, pre-treatment with furosemide, a KCC2 inhibitor, during CTZ stimulation followed by washout significantly prevented convulsant stimulation-induced membrane KCC2 downregulation and significantly attenuated GABAAR downregulation concomitant with recovery of suppressed KCC2-independent GABAergic mIPSC amplitude. Furosemide 28-38 solute carrier family 12 member 5 Homo sapiens 165-169 31422111-8 2020 Over 72h, the CA125-guided group received higher furosemide equivalent dose compared to usual care (p=0.011), which translated into higher urine volume (p=0.042). Furosemide 49-59 mucin 16, cell surface associated Homo sapiens 14-19 32799423-8 2020 The expression level of TMPRSS2 was increased with a number of medications, such as diclofenac, furosemide, and dexamethasone, whereas other medications, such as allopurinol, suppressed the expression of this gene. Furosemide 96-106 transmembrane serine protease 2 Rattus norvegicus 24-31 32622469-5 2020 Inhaled furosemide, a small molecule capable of inhibiting IL-6 and TNFalpha, may be an agent capable of treating the Coronavirus Disease 2019 cytokine storm in both resource-rich and developing countries. Furosemide 8-18 interleukin 6 Homo sapiens 59-63 32622469-5 2020 Inhaled furosemide, a small molecule capable of inhibiting IL-6 and TNFalpha, may be an agent capable of treating the Coronavirus Disease 2019 cytokine storm in both resource-rich and developing countries. Furosemide 8-18 tumor necrosis factor Homo sapiens 68-76 32743772-6 2020 Clearance of MDR1-mediated digoxin, OAT3-mediated furosemide, and OCT2-mediated metformin increased by 3.04-fold, 1.47-fold, and 1.26-fold, respectively. Furosemide 50-60 solute carrier family 22 (organic anion transporter), member 8 Mus musculus 36-40 32704455-10 2020 Upon treatment with furosemide, LPS-induced production of pro-inflammatory cytokines was reduced, indicating that furosemide suppresses the M1 polarization, including IL-6 and TNF-alpha release. Furosemide 20-30 interleukin 6 Homo sapiens 167-171 32704455-10 2020 Upon treatment with furosemide, LPS-induced production of pro-inflammatory cytokines was reduced, indicating that furosemide suppresses the M1 polarization, including IL-6 and TNF-alpha release. Furosemide 20-30 tumor necrosis factor Homo sapiens 176-185 32704455-10 2020 Upon treatment with furosemide, LPS-induced production of pro-inflammatory cytokines was reduced, indicating that furosemide suppresses the M1 polarization, including IL-6 and TNF-alpha release. Furosemide 114-124 interleukin 6 Homo sapiens 167-171 32704455-10 2020 Upon treatment with furosemide, LPS-induced production of pro-inflammatory cytokines was reduced, indicating that furosemide suppresses the M1 polarization, including IL-6 and TNF-alpha release. Furosemide 114-124 tumor necrosis factor Homo sapiens 176-185 32704455-11 2020 In addition, we found that furosemide promotes the production of anti-inflammatory cytokine products (IL-1RA, arginase), indicating M2 polarization. Furosemide 27-37 interleukin 1 receptor antagonist Homo sapiens 102-108 32704455-12 2020 Accordingly, we conclude that furosemide is a reasonably potent inhibitor of IL-6 and TNF-alpha that is also safe, inexpensive and well-studied. Furosemide 30-40 interleukin 6 Homo sapiens 77-81 32704455-12 2020 Accordingly, we conclude that furosemide is a reasonably potent inhibitor of IL-6 and TNF-alpha that is also safe, inexpensive and well-studied. Furosemide 30-40 tumor necrosis factor Homo sapiens 86-95 32105765-0 2020 miR-182 prevented ototoxic deafness induced by co-administration of kanamycin and furosemide in rats. Furosemide 82-92 microRNA 182 Rattus norvegicus 0-7 32105765-8 2020 miR-182 treatment also increased the level of phosphoinositide-3 kinase regulatory subunit p85alpha in the outer hair cells after co-administration of kanamycin and furosemide. Furosemide 165-175 microRNA 182 Rattus norvegicus 0-7 32905120-3 2020 The angiotensin-converting enzyme (ACE) is an important element for the cardiovascular system, through its actions on hydro-salin balance and vascular tone. Furosemide 118-123 angiotensin I converting enzyme Homo sapiens 4-33 32905120-3 2020 The angiotensin-converting enzyme (ACE) is an important element for the cardiovascular system, through its actions on hydro-salin balance and vascular tone. Furosemide 118-123 angiotensin I converting enzyme Homo sapiens 35-38 32647034-3 2020 METHOD: We initiated a community-based continuous subcutaneous infusion (CSCI) furosemide service for the treatment of advanced heart failure. Furosemide 79-89 CSCI Homo sapiens 73-77 32647034-8 2020 There was a reduction in mean hospital admission rates from 2.87 to 0.73 (p<0.001) in the 6-month periods either side of the first episode of CSCI furosemide. Furosemide 147-157 CSCI Homo sapiens 142-146 32426035-5 2020 In this model system and in the setting of furosemide-induced sodium excretion, alpha 2-AR activation inhibited adenylate cyclase, suppressed cAMP formation, and caused sodium retention. Furosemide 43-53 glycoprotein hormone subunit alpha 2 Homo sapiens 80-87 31928473-0 2020 Re: WNK4 Limits Distal Calcium Losses following Acute Furosemide Treatment. Furosemide 54-64 WNK lysine deficient protein kinase 4 Homo sapiens 4-8 31422111-9 2020 Moreover, patients in the active arm with CA125>35U/mL received the highest furosemide equivalent dose (p<0.001) and had higher diuresis (p=0.013). Furosemide 79-89 mucin 16, cell surface associated Homo sapiens 42-47 31985207-9 2020 Per-6-thiolated alpha-CD was not cytotoxic to Caco-2 cells in 0.5% (m/v) concentration within 24 h. It improved the solubility of FUR in the same manner as unmodified alpha-CD. Furosemide 130-133 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 16-24 29947262-3 2020 In this study, the effects of the antibiotics, furosemide, cefazolin, cefuroxime, gentamicin and clindamycin on rat erythrocyte G6PD enzyme was studied in in vitro conditions. Furosemide 47-57 glucose-6-phosphate dehydrogenase Rattus norvegicus 128-132 29947262-6 2020 The inhibition studies of these antibiotics were carried out on the enzyme revealing that gentamicin, clindamycin and furosemide inhibited the activity of the G6PD with an IC50 of 1.75, 34.65 and 0.526 mM, respectively with Ki of 0.7, 39.8 and 0.860 mM, respectively. Furosemide 118-128 glucose-6-phosphate dehydrogenase Rattus norvegicus 159-163 31985207-10 2020 The addition of per-6-thiolated alpha-CD (0.5% m/v) increased the mucus viscosity up to 5.8-fold at 37 C within 4 h. Because of the incorporation in per-6-thiolated alpha-CD, the apparent permeability coefficient (Papp) of FUR was 6.87-fold improved on the Caco-2 cell monolayer and 6.55-fold on the intestinal mucosa. Furosemide 224-227 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 32-40 31985207-11 2020 Moreover, in vivo studies showed a 4.9-fold improved oral bioavailability of FUR due to the incorporation in per-6-thiolated alpha-CD. Furosemide 77-80 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 125-133 31896111-2 2020 OBJECTIVE: This study tested the hypothesis that the fall in GFR with furosemide is due to volume depletion or activation of angiotensin type 1 (AT1) receptors or renal nerves. Furosemide 70-80 angiotensin II receptor, type 1a Rattus norvegicus 125-143 31760770-6 2020 In vivo, Sox6 expression is upregulated after a low-Na+ diet and furosemide. Furosemide 65-75 SRY-box transcription factor 6 Rattus norvegicus 9-13 31760770-7 2020 Importantly, knockout of Sox6 in Ren1d+ cells halts the increase in renin-expressing cells normally seen during a low-Na+ diet and furosemide as well as the typical increase in renin. Furosemide 131-141 SRY-box transcription factor 6 Rattus norvegicus 25-29 31896111-2 2020 OBJECTIVE: This study tested the hypothesis that the fall in GFR with furosemide is due to volume depletion or activation of angiotensin type 1 (AT1) receptors or renal nerves. Furosemide 70-80 angiotensin II receptor, type 1a Rattus norvegicus 145-148 31633875-0 2019 The displacement study of 99m Tc-DTPA-Human serum albumin binding in presence of furosemide and metformin by using equilibrium dialysis and molecular docking. Furosemide 81-91 albumin Homo sapiens 50-57 31724190-7 2020 Positive DAT occurred in 53 (30 3%) and was related to high MELD score (P = 0 048), HCV (P = 0 005) and furosemide use (P = 0 001). Furosemide 104-114 solute carrier family 6 member 3 Homo sapiens 9-12 32734228-7 2020 In our patient with long-term activated tubuloglomerular feedback due to SGLT-2 mutations, we show that the sensitivity of tubuloglomerular feedback is maintained, demonstrated by an increase in GFR measured using iohexol clearance following furosemide administration. Furosemide 242-252 solute carrier family 5 member 2 Homo sapiens 73-79 31809955-0 2019 Comparison between the effects of torsemide and furosemide on the renin-angiotensin-aldosterone system of normal dogs. Furosemide 48-58 renin Canis lupus familiaris 66-71 31809955-1 2019 INTRODUCTION/OBJECTIVES: We hypothesized that torsemide and furosemide, at approximately equipotent dosages (similar diuresis), would have comparable effects on the circulating renin-angiotensin-aldosterone system. Furosemide 60-70 renin Canis lupus familiaris 177-182 31809955-11 2019 CONCLUSIONS: At approximately equipotent dosages (20:1), torsemide and furosemide produced comparable renin-angiotensin-aldosterone system activation. Furosemide 71-81 renin Canis lupus familiaris 102-107 31496133-0 2019 WNK4 limits distal calcium losses following acute furosemide treatment. Furosemide 50-60 WNK lysine deficient protein kinase 4 Homo sapiens 0-4 31779627-8 2019 The degradation of furosemide and trimethoprim by soybean peroxidase and chloroperoxidase, respectively, was investigated in detail by examining the transformation products generated during their degradation. Furosemide 19-29 peroxidase Glycine max 58-68 31365295-1 2019 The Na+K+2Cl- cotransporter-2 (Nkcc2, Slc12a1) is abundantly expressed in the kidney and its inhibition with the loop-diuretics bumetanide and furosemide has been linked to transient or permanent hyperglycemia in mice and humans. Furosemide 143-153 solute carrier family 12, member 1 Mus musculus 4-29 31365295-1 2019 The Na+K+2Cl- cotransporter-2 (Nkcc2, Slc12a1) is abundantly expressed in the kidney and its inhibition with the loop-diuretics bumetanide and furosemide has been linked to transient or permanent hyperglycemia in mice and humans. Furosemide 143-153 solute carrier family 12, member 1 Mus musculus 31-36 31365295-1 2019 The Na+K+2Cl- cotransporter-2 (Nkcc2, Slc12a1) is abundantly expressed in the kidney and its inhibition with the loop-diuretics bumetanide and furosemide has been linked to transient or permanent hyperglycemia in mice and humans. Furosemide 143-153 solute carrier family 12, member 1 Mus musculus 38-45 30578654-9 2019 CONCLUSION: Sodium-glucose cotransporter 2 inhibitor DAPA predominantly decreased the ECW with a mild increase in urine volume, but the change in the ECW/total body water was smaller than that in patients treated with FR, and larger than that in patients treated with TLV, suggesting that the effects of SGLT2 inhibitors on fluid distribution may differ from those of conventional diuretics. Furosemide 218-220 solute carrier family 5 member 2 Homo sapiens 12-42 28358186-4 2019 After full body acquisition, 58 patients were administered 20 mg of furosemide 90 min post injection of FDG (P90). Furosemide 68-78 cellular inhibitor of PP2A Homo sapiens 109-112 28358186-5 2019 For 44 patients, 20 mg of furosemide was administered 30 min post injection of FDG (P30). Furosemide 26-36 centromere protein V Homo sapiens 84-87 31496133-7 2019 Following acute treatment with the loop diuretic, furosemide, which causes hypercalciuria through TAL inhibition, WNK4-/- animals demonstrated increased calcium wasting compared with wild-type controls. Furosemide 50-60 WNK lysine deficient protein kinase 4 Homo sapiens 114-118 31496133-11 2019 Our data show that WNK4, via regulation of TRPV5, limits distal calcium losses following acute treatment with furosemide; however, WNK4 deletion does not affect the chronic renal response to dietary calcium depletion. Furosemide 110-120 WNK lysine deficient protein kinase 4 Homo sapiens 19-23 31496133-11 2019 Our data show that WNK4, via regulation of TRPV5, limits distal calcium losses following acute treatment with furosemide; however, WNK4 deletion does not affect the chronic renal response to dietary calcium depletion. Furosemide 110-120 transient receptor potential cation channel subfamily V member 5 Homo sapiens 43-48 30992124-2 2019 An early study using furosemide to reversibly reduce EP showed that distortion product otoacoustic emissions (DPOAEs) recovered before EP. Furosemide 21-31 epiregulin Homo sapiens 53-55 31274842-6 2019 Furosemide dose-dependently induced plasma renin and angiotensin I levels, while an equiefficient diuretic BAY 1753011 dose did not activate the renin-angiotensin system. Furosemide 0-10 renin Homo sapiens 43-48 31274842-6 2019 Furosemide dose-dependently induced plasma renin and angiotensin I levels, while an equiefficient diuretic BAY 1753011 dose did not activate the renin-angiotensin system. Furosemide 0-10 angiotensinogen Homo sapiens 53-66 31053298-6 2019 Furosemide treatment dramatically decreased RNF183 expression in the renal medulla, consistent with the decrease in NFAT5 protein and target gene mRNA expression. Furosemide 0-10 ring finger protein 183 Mus musculus 44-50 31053298-6 2019 Furosemide treatment dramatically decreased RNF183 expression in the renal medulla, consistent with the decrease in NFAT5 protein and target gene mRNA expression. Furosemide 0-10 nuclear factor of activated T cells 5 Mus musculus 116-121 31053298-8 2019 These results indicated that RNF183 is predominantly expressed in the renal medullary collecting ducts, and that decreased renal medullary tonicity by furosemide treatment decreases RNF183 expression by NFAT5 downregulation. Furosemide 151-161 ring finger protein 183 Mus musculus 29-35 31053298-8 2019 These results indicated that RNF183 is predominantly expressed in the renal medullary collecting ducts, and that decreased renal medullary tonicity by furosemide treatment decreases RNF183 expression by NFAT5 downregulation. Furosemide 151-161 ring finger protein 183 Mus musculus 182-188 31053298-8 2019 These results indicated that RNF183 is predominantly expressed in the renal medullary collecting ducts, and that decreased renal medullary tonicity by furosemide treatment decreases RNF183 expression by NFAT5 downregulation. Furosemide 151-161 nuclear factor of activated T cells 5 Mus musculus 203-208 31316818-4 2019 To address this structural gap, the present work is primarily focused on sulfonamide-lactam and sulfonamide-syn-amide synthons with drugs such as celecoxib, hydro-chloro-thia-zide and furosemide. Furosemide 184-194 synemin Homo sapiens 108-111 31159750-8 2019 The increase in u-NGAL was absent when furosemide was given simultaneously, and the responses in u-NGAL were not significantly different from placebo control. Furosemide 39-49 lipocalin 2 Homo sapiens 18-22 31159750-9 2019 Furosemide changed responses in u-KIM-1 where a delayed increase was observed. Furosemide 0-10 hepatitis A virus cellular receptor 1 Homo sapiens 34-39 31159750-16 2019 p-AVP was increased by 3% saline, with a larger increase during furosemide. Furosemide 64-74 arginine vasopressin Homo sapiens 2-5 31159750-17 2019 CONCLUSION: This study shows minor increases in markers of kidney injury after 3% saline infusion Furosemide abolished the increase in NGAL and postponed the increase in u-KIM-1. Furosemide 98-108 lipocalin 2 Homo sapiens 135-139 31159750-17 2019 CONCLUSION: This study shows minor increases in markers of kidney injury after 3% saline infusion Furosemide abolished the increase in NGAL and postponed the increase in u-KIM-1. Furosemide 98-108 hepatitis A virus cellular receptor 1 Homo sapiens 172-177 30706760-4 2019 Here, we showed that in degenerated SGNs, induced by sensory epithelial cell loss in the cochlea of mice following kanamycin and furosemide administration, the lipofuscin area and oxidative stress level were increased, the nuclear-to-cytoplasmic TFEB ratio was decreased, and the late stage of autophagic flux was impaired. Furosemide 129-139 transcription factor EB Mus musculus 246-250 30839176-7 2019 Administering Ang-(1-7) decreased VO2 ; an effect prevented by dimethyl amiloride and furosemide, signifying that Ang-(1-7) inhibits transport-dependent VO2 in TAL. Furosemide 86-96 angiopoietin 1 Homo sapiens 14-22 30417726-4 2019 Furosemide, a recognized KCC2 antagonist in animals, blocks the formation of inhibitory post-synaptic potentials in spinal motoneurons without affecting excitatory post-synaptic potentials. Furosemide 0-10 solute carrier family 12 member 5 Homo sapiens 25-29 30417726-5 2019 Based on observations in animals studies, we hypothesized that furosemide may be used to unmask KCC2 downregulation after spinal cord injury in humans, which contributes to reflex hyperexcitability. Furosemide 63-73 solute carrier family 12 member 5 Homo sapiens 96-100 31086839-12 2019 Conclusion: Furosemide may influence the pharmacokinetics of P-gp-interfering drugs. Furosemide 12-22 phosphoglycolate phosphatase Homo sapiens 61-65 30892891-8 2019 Dihydrophenanthrene 1 markedly altered the pharmacokinetic parameters of the diuretic drug furosemide, a known substrate of both OAT1 and OAT3, in vivo. Furosemide 91-101 solute carrier family 22 member 6 Homo sapiens 129-133 30892891-8 2019 Dihydrophenanthrene 1 markedly altered the pharmacokinetic parameters of the diuretic drug furosemide, a known substrate of both OAT1 and OAT3, in vivo. Furosemide 91-101 solute carrier family 22 member 8 Homo sapiens 138-142 31001127-9 2019 Daily diuresis increased from 867 +- 413 to 1221 +- 680 ml; P = 0.25, while the dose of furosemide could be reduced from 620 +- 256 to 360 +- 110 mg/d; P = 0.0005, however, the kidney function deteriorated, with eGFR drop from 32 +- 11 to 25.6 +- 13 ml/min/1.73m2; P = 0.01). Furosemide 88-98 epidermal growth factor receptor Homo sapiens 212-216 30539654-4 2019 WT, UT-A3 KO, and UT-A1/A3 KO acutely respond to hydrochlorothiazide and furosemide; however, UT-A1/A3 KO fail to show a diuretic or natriuretic response following amiloride administration, indicating that baseline epithelial Na+ channel (ENaC) activity is impaired. Furosemide 73-83 solute carrier family 14 (urea transporter), member 2 Mus musculus 4-9 30539654-4 2019 WT, UT-A3 KO, and UT-A1/A3 KO acutely respond to hydrochlorothiazide and furosemide; however, UT-A1/A3 KO fail to show a diuretic or natriuretic response following amiloride administration, indicating that baseline epithelial Na+ channel (ENaC) activity is impaired. Furosemide 73-83 solute carrier family 14 (urea transporter), member 2 Mus musculus 18-29 30839176-7 2019 Administering Ang-(1-7) decreased VO2 ; an effect prevented by dimethyl amiloride and furosemide, signifying that Ang-(1-7) inhibits transport-dependent VO2 in TAL. Furosemide 86-96 angiopoietin 1 Homo sapiens 114-122 30839176-7 2019 Administering Ang-(1-7) decreased VO2 ; an effect prevented by dimethyl amiloride and furosemide, signifying that Ang-(1-7) inhibits transport-dependent VO2 in TAL. Furosemide 86-96 transaldolase 1 Homo sapiens 160-163 32382661-3 2019 Here we report the crystal structure of the soluble domain of human mitoNEET with a sulfonamide ligand, furosemide. Furosemide 104-114 CDGSH iron sulfur domain 1 Homo sapiens 68-76 30484346-3 2019 Furosemide acidifies the urine by increasing acid secretion via the Na+-H+ exchanger 3 (NHE3) in TAL and vacuolar H+-ATPase (V-ATPase) in the distal nephron. Furosemide 0-10 solute carrier family 9 (sodium/hydrogen exchanger), member 3 Mus musculus 68-86 30484346-3 2019 Furosemide acidifies the urine by increasing acid secretion via the Na+-H+ exchanger 3 (NHE3) in TAL and vacuolar H+-ATPase (V-ATPase) in the distal nephron. Furosemide 0-10 solute carrier family 9 (sodium/hydrogen exchanger), member 3 Mus musculus 88-92 30484346-3 2019 Furosemide acidifies the urine by increasing acid secretion via the Na+-H+ exchanger 3 (NHE3) in TAL and vacuolar H+-ATPase (V-ATPase) in the distal nephron. Furosemide 0-10 talipes Mus musculus 97-100 30484346-3 2019 Furosemide acidifies the urine by increasing acid secretion via the Na+-H+ exchanger 3 (NHE3) in TAL and vacuolar H+-ATPase (V-ATPase) in the distal nephron. Furosemide 0-10 ATPase, H+ transporting, lysosomal V0 subunit D2 Mus musculus 105-123 30484346-6 2019 Treating with furosemide (drinking water) for 11 days led to decreased urine pH in both wild-type (WT) and BK-beta4-knockout mice (BK-beta4-KO) with increased V-ATPase expression and elevated plasma aldosterone levels. Furosemide 14-24 potassium large conductance calcium-activated channel, subfamily M, beta member 4 Mus musculus 107-115 30484346-6 2019 Treating with furosemide (drinking water) for 11 days led to decreased urine pH in both wild-type (WT) and BK-beta4-knockout mice (BK-beta4-KO) with increased V-ATPase expression and elevated plasma aldosterone levels. Furosemide 14-24 ATPase, H+ transporting, lysosomal V0 subunit D2 Mus musculus 159-167 30484346-8 2019 Western blotting and immunofluorescence staining showed that furosemide treatment decreased cortical expression of BK-beta4 and reduced apical localization of BK-alpha in connecting tubules. Furosemide 61-71 potassium large conductance calcium-activated channel, subfamily M, beta member 4 Mus musculus 115-123 30484346-10 2019 Acetazolamide plus furosemide also restored the cortical expression of BK-beta4 and BK-alpha in connecting tubules. Furosemide 19-29 potassium large conductance calcium-activated channel, subfamily M, beta member 4 Mus musculus 71-79 30866733-6 2019 It is found that the Furosemide and Triamterene have significant cytotoxic effects on normal human astrocytes, in which the Triamterene can inhibit the neurokinase ROCK2, a representative of putative unexpected targets, with a high activity, which is comparable with the sophisticated ROCK2 inhibitor Fasudil. Furosemide 21-31 Rho associated coiled-coil containing protein kinase 2 Homo sapiens 164-169 30866733-6 2019 It is found that the Furosemide and Triamterene have significant cytotoxic effects on normal human astrocytes, in which the Triamterene can inhibit the neurokinase ROCK2, a representative of putative unexpected targets, with a high activity, which is comparable with the sophisticated ROCK2 inhibitor Fasudil. Furosemide 21-31 Rho associated coiled-coil containing protein kinase 2 Homo sapiens 285-290 29412704-8 2018 Although the initial response to furosemide was similar in wnk4-/- mice and controls, the response was lower in the knockout mice when reabsorption along the distal convoluted tubule was inhibited. Furosemide 33-43 WNK lysine deficient protein kinase 4 Mus musculus 59-63 30041982-7 2018 Our adjusted analysis suggests delaying furosemide administration until after serum creatinine results resulted in a 41% lower chance of successful discharge home relative to someone who had furosemide administered prior to creatinine results (aHR 1.41, 95%CI 1.07, 1,84). Furosemide 40-50 aryl hydrocarbon receptor Homo sapiens 244-247 31287791-8 2019 Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison. Furosemide 159-169 natriuretic peptide B Homo sapiens 123-148 31287791-8 2019 Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison. Furosemide 159-169 natriuretic peptide B Homo sapiens 150-153 31287791-8 2019 Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison. Furosemide 159-169 natriuretic peptide B Homo sapiens 123-148 31287791-8 2019 Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison. Furosemide 159-169 natriuretic peptide B Homo sapiens 150-153 31287791-8 2019 Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison. Furosemide 159-169 natriuretic peptide B Homo sapiens 123-148 31287791-8 2019 Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison. Furosemide 159-169 natriuretic peptide B Homo sapiens 150-153 30292441-3 2018 PATIENTS AND METHOD: We carried out a prospective inventory of the prescription of furosemide with the general practitioners of the universities of Bordeaux, between May 1, 2017 and July 30, 2017. Furosemide 83-93 protein kinase C delta Homo sapiens 166-171 30196524-9 2018 In addition, after drug exposure, the average hearing threshold of rats in the experimental group was significantly higher than that in the control group, with increased HSP60 expression level in response to kanamycin and furosemide treatments. Furosemide 222-232 heat shock protein family D (Hsp60) member 1 Rattus norvegicus 170-175 30332442-3 2018 Our main goal was to measure the effects of the combination of furosemide and hydration for reducing bladder signal directly on mouse bowel 18F-FDG-PET images. Furosemide 63-73 thyroid stimulating hormone receptor Mus musculus 148-151 30332442-12 2018 Our study shows the effect of furosemide on bladder spillover directly on 18F-FDG-PET images by measuring SUVmean in the bladder, colon, liver, muscle, and bone marrow. Furosemide 30-40 thyroid stimulating hormone receptor Mus musculus 82-85 29715039-9 2018 An optimized CNF-furosemide drug-delivery vehicle thus needs to have a maximized specific surface area irrespective of the surface charge with which it is achieved. Furosemide 17-27 NPHS1 adhesion molecule, nephrin Homo sapiens 13-16 30248150-6 2018 Results showed a significant increase in phosphorylation of the activating S130 site in NKCC2, the drug target for frusemide, in women with pre-eclampsia compared with normal pregnant women. Furosemide 115-124 solute carrier family 12 member 1 Homo sapiens 88-93 30007527-6 2018 By increasing the distal sodium chloride and calcium ion load with chronic furosemide administration, an intrinsic compensatory defect in the DCT from Umod-/- compared to wild type mice was found manifested as sodium wasting and hypercalciuria. Furosemide 75-85 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 Mus musculus 142-145 30007527-6 2018 By increasing the distal sodium chloride and calcium ion load with chronic furosemide administration, an intrinsic compensatory defect in the DCT from Umod-/- compared to wild type mice was found manifested as sodium wasting and hypercalciuria. Furosemide 75-85 uromodulin Mus musculus 151-155 30120768-2 2018 Simultaneously, drug-drug interactions (DDIs) mediated by OAT1 occur at high altitude, severely affecting furosemide pharmacokinetics. Furosemide 106-116 solute carrier family 22 member 6 Rattus norvegicus 58-62 30123180-1 2018 Objective: The peak-to-peak amplitude of the p13-n23 wave in cervical vestibular evoked myogenic potential can increase after furosemide administration in patients with Meniere"s disease [furosemide-loading VEMP (FVEMP) testing]. Furosemide 126-136 H3 histone pseudogene 6 Homo sapiens 45-48 30123180-1 2018 Objective: The peak-to-peak amplitude of the p13-n23 wave in cervical vestibular evoked myogenic potential can increase after furosemide administration in patients with Meniere"s disease [furosemide-loading VEMP (FVEMP) testing]. Furosemide 188-198 H3 histone pseudogene 6 Homo sapiens 45-48 29162614-4 2018 As expected, PROB increased the area under the plasma concentration-time curve (AUC) of coadministered furosemide, a known substrate of OAT1 and OAT3, by 4.1-fold, consistent with the values reported in humans (3.1- to 3.7-fold). Furosemide 103-113 solute carrier family 22 member 6 Homo sapiens 136-140 29527380-2 2018 It is caused by loss-of-function mutations of the SLC12A1 gene, encoding the furosemide-sensitive Na-K-Cl cotransporter. Furosemide 77-87 solute carrier family 12 member 1 Homo sapiens 50-57 29046296-10 2018 Consistent with the furosemide-like effect, in X. laevis oocytes, geraniin significantly reduced the activity of NKCC2, with no effect on NCC activity. Furosemide 20-30 solute carrier family 12 member 1 L homeolog Xenopus laevis 113-118 29682811-0 2018 Upregulation of hypothalamic arginine vasopressin by peripherally administered furosemide in transgenic rats expressing arginine vasopressin-enhanced green fluorescent protein. Furosemide 79-89 arginine vasopressin Rattus norvegicus 38-49 29682811-0 2018 Upregulation of hypothalamic arginine vasopressin by peripherally administered furosemide in transgenic rats expressing arginine vasopressin-enhanced green fluorescent protein. Furosemide 79-89 arginine vasopressin Rattus norvegicus 129-140 30119980-11 2018 Adding R-to-D<1.2 mg/40 mg furosemide to galectin-3>17.6 pg/mL and BNP>500 pg/mL the predictive value improved (log rank 23.59; p = 0.0001). Furosemide 30-40 galectin 3 Homo sapiens 44-54 29162614-4 2018 As expected, PROB increased the area under the plasma concentration-time curve (AUC) of coadministered furosemide, a known substrate of OAT1 and OAT3, by 4.1-fold, consistent with the values reported in humans (3.1- to 3.7-fold). Furosemide 103-113 solute carrier family 22 member 8 Homo sapiens 145-149 30193887-4 2018 OBJECTIVE: This study was planned to investigate whether the enhancing effect of furosemide for albuterol in ovalbumin-induced asthmatic BALB/c mice is diuretic-related or not. Furosemide 81-91 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 109-118 29344743-0 2018 Response to different furosemide doses predicts AKI progression in ICU patients with elevated plasma NGAL levels. Furosemide 22-32 lipocalin 2 Homo sapiens 101-105 30193887-15 2018 CONCLUSIONS: Inhaled subdiuretic dose of furosemide enhanced effects of albuterol more in ovalbumin-asthmatic mice rather than bumetanide, while oral diuretic doses of both drugs failed to improve asthma, indicating that this enhancing effect is not diuretic-related. Furosemide 41-51 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 90-99 31749411-9 2018 CONCLUSIONS: Both furosemide and scatter correction algorithm play a role in reducing scatter in PSMA PET. Furosemide 18-28 folate hydrolase 1 Homo sapiens 97-101 28980452-4 2017 METHODS AND RESULTS: This is a prospective, multicentre, randomized study that compares continuous infusion to intermittent infusion and a low vs. high diuretic dose of furosemide in patients with a diagnosis of acute heart failure, BNP >= 100 pg/mL, and specific chest X-ray signs. Furosemide 169-179 natriuretic peptide B Homo sapiens 233-236 29212491-5 2017 Load tests of captopril or furosemide in the standing position demonstrated autonomous aldosterone secretion and renin suppression. Furosemide 27-37 renin Homo sapiens 113-118 28623852-0 2017 Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer. Furosemide 0-9 folate hydrolase 1 Homo sapiens 50-54 28623852-3 2017 We evaluated if intravenous Frusemide at the time of 68 Ga-PSMA injection reduces excreted activity artefact and improves diagnostic certainty. Furosemide 28-37 folate hydrolase 1 Homo sapiens 59-63 28623852-13 2017 Reporter confidence on the presence/absence of PSMA avid disease in the prostate fossa improved from 63% (19/30) without Frusemide, to 91% (29/32) with Frusemide (P < 0.015). Furosemide 121-130 folate hydrolase 1 Homo sapiens 47-51 28623852-13 2017 Reporter confidence on the presence/absence of PSMA avid disease in the prostate fossa improved from 63% (19/30) without Frusemide, to 91% (29/32) with Frusemide (P < 0.015). Furosemide 152-161 folate hydrolase 1 Homo sapiens 47-51 28623852-14 2017 CONCLUSION: Intravenous Frusemide given with 68 Ga-PSMA reduces excretion artefact, and improves diagnostic certainty. Furosemide 24-33 folate hydrolase 1 Homo sapiens 51-55 28623852-15 2017 Frusemide should be considered for all 68 Ga-PSMA PET/CT imaging protocols. Furosemide 0-9 folate hydrolase 1 Homo sapiens 45-49 27282888-0 2017 Impact of the induced organic anion transporter 1 (Oat1) renal expression by furosemide on the pharmacokinetics of organic anions. Furosemide 77-87 solute carrier family 22 member 6 Rattus norvegicus 22-49 28598867-6 2017 We identified mutations in melanoma-associated antigen D2 in all study participants and showed, in vivo and in vitro, reduced expression of the furosemide and thiazide sensitive transporters sodium-potassium-2-chloride cotransporter and sodium chloride cotransporter, respectively. Furosemide 144-154 MAGE family member D2 Homo sapiens 27-57 28402032-0 2017 Furosemide loading test in a case of homozygous solute carrier family 12, member 1 (SLC12A1) mutation (g.62382825G>A, p.Pro372Leu) in Japanese Black cattle. Furosemide 0-10 solute carrier family 12 member 1 Bos taurus 48-82 28402032-0 2017 Furosemide loading test in a case of homozygous solute carrier family 12, member 1 (SLC12A1) mutation (g.62382825G>A, p.Pro372Leu) in Japanese Black cattle. Furosemide 0-10 solute carrier family 12 member 1 Bos taurus 84-91 28402032-5 2017 In order to validate these observations, we performed confirmation tests for the genotype and a diuretic loading test using furosemide, which inhibits the transporter activity of the SLC12A1 protein. Furosemide 124-134 solute carrier family 12 member 1 Bos taurus 183-190 28688582-11 2017 These results indicate mice on LNaHK exhibited furosemide-sensitive net K+ secretion in the TAL that is dependent on increased NKCC2 activity and mediated by ROMK. Furosemide 47-57 talipes Mus musculus 92-95 28688582-11 2017 These results indicate mice on LNaHK exhibited furosemide-sensitive net K+ secretion in the TAL that is dependent on increased NKCC2 activity and mediated by ROMK. Furosemide 47-57 solute carrier family 12, member 1 Mus musculus 127-132 28688582-11 2017 These results indicate mice on LNaHK exhibited furosemide-sensitive net K+ secretion in the TAL that is dependent on increased NKCC2 activity and mediated by ROMK. Furosemide 47-57 potassium inwardly-rectifying channel, subfamily J, member 1 Mus musculus 158-162 28688582-12 2017 We conclude that furosemide is a K-sparing diuretic by decreasing the TAL net K+ secretion in subjects on LNaHK. Furosemide 17-27 talipes Mus musculus 70-73 28951361-4 2017 In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats. Furosemide 39-49 carcinoembryonic antigen gene family 4 Rattus norvegicus 115-118 28951361-4 2017 In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats. Furosemide 39-49 carcinoembryonic antigen gene family 4 Rattus norvegicus 290-293 28951361-4 2017 In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats. Furosemide 39-49 carcinoembryonic antigen gene family 4 Rattus norvegicus 290-293 28951361-4 2017 In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats. Furosemide 51-55 carcinoembryonic antigen gene family 4 Rattus norvegicus 115-118 28951361-4 2017 In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats. Furosemide 88-93 carcinoembryonic antigen gene family 4 Rattus norvegicus 115-118 28583224-0 2017 Anti-parasitic effect of the diuretic and Na+-ATPAse inhibitor furosemide in cutaneous leishmaniasis. Furosemide 63-73 dynein, axonemal, heavy chain 8 Mus musculus 46-52 28583224-1 2017 Leishmania amazonensis promastigotes are known to express furosemide (Lasix )-sensitive P-type membrane Na+-ATPase. Furosemide 58-68 dynein, axonemal, heavy chain 8 Mus musculus 108-114 28583224-1 2017 Leishmania amazonensis promastigotes are known to express furosemide (Lasix )-sensitive P-type membrane Na+-ATPase. Furosemide 70-75 dynein, axonemal, heavy chain 8 Mus musculus 108-114 28583224-8 2017 To summarize, furosemide control of intracellular leishmanial growth by means of parasite Na+-ATPase inhibition, and macrophage ROS activation may help explain its sole and SSG-combined therapeutic effect against murine CL. Furosemide 14-24 dynein, axonemal, heavy chain 8 Mus musculus 94-100 27282888-0 2017 Impact of the induced organic anion transporter 1 (Oat1) renal expression by furosemide on the pharmacokinetics of organic anions. Furosemide 77-87 solute carrier family 22 member 6 Rattus norvegicus 51-55 27282888-3 2017 This study was undertaken to simultaneously evaluate the effects of furosemide pretreatment on organic anion transporter 1 (Oat1) and multidrug resistance protein 2 (Mrp2) renal expressions, on p-aminohippurate (PAH) pharmacokinetics and on renal and urinary PAH levels in rats. Furosemide 68-78 solute carrier family 22 member 6 Rattus norvegicus 95-122 27282888-3 2017 This study was undertaken to simultaneously evaluate the effects of furosemide pretreatment on organic anion transporter 1 (Oat1) and multidrug resistance protein 2 (Mrp2) renal expressions, on p-aminohippurate (PAH) pharmacokinetics and on renal and urinary PAH levels in rats. Furosemide 68-78 solute carrier family 22 member 6 Rattus norvegicus 124-128 27282888-3 2017 This study was undertaken to simultaneously evaluate the effects of furosemide pretreatment on organic anion transporter 1 (Oat1) and multidrug resistance protein 2 (Mrp2) renal expressions, on p-aminohippurate (PAH) pharmacokinetics and on renal and urinary PAH levels in rats. Furosemide 68-78 ATP binding cassette subfamily B member 4 Rattus norvegicus 134-164 27282888-3 2017 This study was undertaken to simultaneously evaluate the effects of furosemide pretreatment on organic anion transporter 1 (Oat1) and multidrug resistance protein 2 (Mrp2) renal expressions, on p-aminohippurate (PAH) pharmacokinetics and on renal and urinary PAH levels in rats. Furosemide 68-78 ATP binding cassette subfamily B member 4 Rattus norvegicus 166-170 27282888-8 2017 RESULTS: Furosemide pretreatment increased both the expression of Oat1 and Mrp2. Furosemide 9-19 solute carrier family 22 member 6 Rattus norvegicus 66-70 27282888-8 2017 RESULTS: Furosemide pretreatment increased both the expression of Oat1 and Mrp2. Furosemide 9-19 ATP binding cassette subfamily B member 4 Rattus norvegicus 75-79 28808364-0 2017 The Effect of Furosemide on the Level of Neutrophil Gelatinase-associated Lipocalin in Critically Hospitalized Patients with Acute Kidney Injury. Furosemide 14-24 lipocalin 2 Homo sapiens 41-83 29441935-10 2017 Based on cell culture studies, permeability of furosemide was low (Papp=1x10-5 cm/s) but increased when prepared in the ODT form (ODT1: Papp=2x10-5 cm/s; ODT2: Papp=3.6x10-5 cm/s). Furosemide 47-57 ectodysplasin A Homo sapiens 130-134 28105515-5 2017 The decrease in plasma BNP levels was larger in the azosemide group than in the furosemide group (p < 0.01). Furosemide 80-90 natriuretic peptide B Homo sapiens 23-26 28105515-7 2017 In conclusion, the decrease in plasma BNP levels was larger in the azosemide group than in the furosemide group. Furosemide 95-105 natriuretic peptide B Homo sapiens 38-41 28228405-1 2017 The Na+-K+-2Cl- cotransporter (NKCC2) on the loop of Henle is the site of action of furosemide. Furosemide 84-94 solute carrier family 12 member 1 Rattus norvegicus 31-36 28153413-4 2017 Exposure potential given by the ratio amount of the drug exported to the sea/amount emitted to the environment was higher than 50% for 7 drugs (Piperacillin, Lorazepam, Metformin, Hydroxycarbamide, Hydrochlorothiazide, Furosemide and Cetirizine), implying that a high proportion of them will reach the sea, and below 10% for 27 drugs, implying high catchment attenuation. Furosemide 219-229 S13 erythroblastosis (avian) oncogene homolog Homo sapiens 73-76 28488084-10 2017 The NKCC1 inhibitors furosemide and bumetanide concentration-dependently inhibit HlyA-induced lysis of human and murine erythrocytes. Furosemide 21-31 solute carrier family 12 member 2 Homo sapiens 4-9 28488084-10 2017 The NKCC1 inhibitors furosemide and bumetanide concentration-dependently inhibit HlyA-induced lysis of human and murine erythrocytes. Furosemide 21-31 hemolysin transport protein Escherichia coli 81-85 28560096-8 2017 The extract of Juncus effusus, a well-known traditional Chinese medicine, was assessed for its effect on the in vivo pharmacokinetic parameters of furosemide, a diuretic drug which is a known substrate of both OAT1 and OAT3. Furosemide 147-157 solute carrier family 22 member 6 Homo sapiens 210-214 28417963-4 2017 We investigated this issue using the NKCC1 inhibitors bumetanide and furosemide, which are commonly used loop diuretics. Furosemide 69-79 solute carrier family 12 member 2 Homo sapiens 37-42 28340405-8 2017 Analysis of covariates showed that CRCL was significantly influencing the clearance of furosemide. Furosemide 87-97 CRCL Homo sapiens 35-39 31994099-8 2017 Analysis of covariates showed that CRCL was significantly influencing the clearance of furosemide. Furosemide 87-97 CRCL Homo sapiens 35-39 28951782-2 2017 The aim of this study was to determine whether variation in SLC2A9 or SLC22A11 influences acute renal handling of uric acid in response to frusemide. Furosemide 139-148 solute carrier family 2 member 9 Homo sapiens 60-66 28951782-2 2017 The aim of this study was to determine whether variation in SLC2A9 or SLC22A11 influences acute renal handling of uric acid in response to frusemide. Furosemide 139-148 solute carrier family 22 member 11 Homo sapiens 70-78 28043731-3 2017 However, animal studies show that the simultaneous downregulation of pendrin with acetazolamide and inhibition of the sodium-chloride cotransporter with hydrochlorothiazide generates significant diuresis, and furosemide administration following a pendrin inhibitor potentiates furosemide"s diuretic effect. Furosemide 209-219 solute carrier family 26 member 4 Homo sapiens 69-76 28100655-10 2017 We conclude that furosemide decreases axonal excitability and prevents HFS-induced hyperexcitability via mechanisms downstream of blockage of anion transport, which could include hyperpolarization of axonal membranes.NEW & NOTEWORTHY This study shows that the anion transporter antagonists furosemide and DIDS cause a marked decrease of axonal excitability in rat hippocampal CA1 region and prevent the induction of activity-dependent hyperexcitability in Schaffer collateral axons. Furosemide 17-27 carbonic anhydrase 1 Rattus norvegicus 380-383 28043731-3 2017 However, animal studies show that the simultaneous downregulation of pendrin with acetazolamide and inhibition of the sodium-chloride cotransporter with hydrochlorothiazide generates significant diuresis, and furosemide administration following a pendrin inhibitor potentiates furosemide"s diuretic effect. Furosemide 277-287 solute carrier family 26 member 4 Homo sapiens 69-76 26927285-3 2017 Moreover, a common variant in the multidrug resistance protein-4 coding gene (ABCC4, rs17268282) was associated with weight loss with furosemide use (P=0.0001). Furosemide 134-144 ATP binding cassette subfamily C member 4 Homo sapiens 78-83 27335120-4 2017 Because inactivating mutations in ClC-Kb/K2 cause Bartter syndrome, a disease that mimics the effects of the loop diuretic furosemide, ClC-Kb/K2 is assumed to have a critical role in salt handling by the thick ascending limb. Furosemide 123-133 chloride channel, voltage-sensitive Kb Mus musculus 34-40 26879122-10 2017 During a second exposure to furosemide 24H after CYP injection, the micturition pattern returned to control, however, the micturition volume was still lower than in control. Furosemide 28-38 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 49-52 29430461-3 2017 We developed a mouse model with maximal increase in SDF-1 levels in the inner ear, according to the "one-shot" doses of kanamycin and furosemide. Furosemide 134-144 chemokine (C-X-C motif) ligand 12 Mus musculus 52-57 29430461-7 2017 Results: There were a significant reduction in hearing thresholds and a maximal increase of SDF-1 levels in the furosemide 130 mg/kg + kanamycin 550 mg/kg group, but severe hearing deterioration over time was observed in the furosemide 130 mg/kg + kanamycin 600 mg/kg group and four mice were dead. Furosemide 112-122 chemokine (C-X-C motif) ligand 12 Mus musculus 92-97 27335120-4 2017 Because inactivating mutations in ClC-Kb/K2 cause Bartter syndrome, a disease that mimics the effects of the loop diuretic furosemide, ClC-Kb/K2 is assumed to have a critical role in salt handling by the thick ascending limb. Furosemide 123-133 chloride channel, voltage-sensitive Kb Mus musculus 135-141 27302598-8 2017 Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system. Furosemide 18-28 renin Canis lupus familiaris 77-82 27166146-2 2016 While furosemide is a loop diuretic prescribed for the majority of CHF patients to reduce fluid retention, it also activates the renin-angiotensin aldosterone system (RAAS) which further contributes to the accelerated progression of heart failure. Furosemide 6-16 renin Canis lupus familiaris 129-134 29197870-8 2017 Furosemide led to a significant decrease in the medullary and cortical R2* of healthy subjects and NSS contralateral kidneys (p<0.05 each), whereas there was no significant change of R2* in ATN-induced AKI and the NSS-I/R kidneys (p>0.05 each). Furosemide 0-10 serine and arginine rich splicing factor 10 Homo sapiens 217-224 27821322-10 2016 We conclude that treatment with (higher total cumulative dose of) cisplatin, young age and furosemide co-medication independently are associated with an increased risk of ototoxicity in CCS. Furosemide 91-101 copper chaperone for superoxide dismutase Homo sapiens 186-189 27153921-0 2016 Small-Molecule Inhibitors of Pendrin Potentiate the Diuretic Action of Furosemide. Furosemide 71-81 solute carrier family 26, member 4 Mus musculus 29-36 27153921-8 2016 In mice treated long term with furosemide, in which renal pendrin is upregulated, PDSinh-C01 produced a 60% increase in urine output. Furosemide 31-41 solute carrier family 26, member 4 Mus musculus 58-65 27388150-4 2016 Furosemide, the selective antagonist of Gabra6-containing GABAARs, strongly increased peak amplitude of evoked IPSCs at CA3-CA1 synapses and the frequency of miniature IPSPs recorded from CA1 pyramidal cells in naive control animals, and this effect was occluded in MS animals. Furosemide 0-10 gamma-aminobutyric acid type A receptor subunit alpha6 Rattus norvegicus 40-46 27230512-10 2016 The significantly larger furosemide-induced decrease in medullary R2* levels in the healthy group and unaffected contralateral kidneys of the VUR group points towards more intense renal sodium transport in these kidneys. Furosemide 25-35 VUR Homo sapiens 142-145 27421685-12 2016 Clckb-/- mice showed a reduced sensitivity to furosemide and were completely resistant to thiazides. Furosemide 46-56 chloride channel, voltage-sensitive Kb Mus musculus 0-5 27388150-4 2016 Furosemide, the selective antagonist of Gabra6-containing GABAARs, strongly increased peak amplitude of evoked IPSCs at CA3-CA1 synapses and the frequency of miniature IPSPs recorded from CA1 pyramidal cells in naive control animals, and this effect was occluded in MS animals. Furosemide 0-10 carbonic anhydrase 3 Rattus norvegicus 120-127 27388150-5 2016 Knockdown of Gabra6 expression in hippocampus mimicked furosemide"s effect and was sufficient to produce similar depressive symptoms that were observed in MS animals. Furosemide 55-65 gamma-aminobutyric acid type A receptor subunit alpha6 Rattus norvegicus 13-19 27818782-10 2016 Although catecholamine improvements after treatment were not significantly different, plasma renin activity was enhanced in the furosemide group. Furosemide 128-138 renin Homo sapiens 93-98 27183025-12 2016 In addition to an altered pharmacokinetics (p < 0.01), a reduced pharmacodynamics response to furosemide also became important when creatinine clearance was reduced to less than 40 mL/min/1.73 m (p = 0.01). Furosemide 97-107 CD59 molecule (CD59 blood group) Homo sapiens 187-192 27404696-12 2016 This increase in lung congestion, myocardial remodeling, could be prevented by co-administration of furosemide, which resulted in normalized serum osmolality, neurohormonal activation, and renal aquaporin 1 expression, and hence decreased mortality post-MI. Furosemide 100-110 aquaporin 1 Mus musculus 195-206 29100270-6 2017 Interestingly, we discovered that albuminuria downregulated NKCC2 protein expression in murine kidney and impaired the renal response to loop diuretic furosemide. Furosemide 151-161 solute carrier family 12, member 1 Mus musculus 60-65 27338786-9 2016 Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system, evidenced from increased plasma renin activity and plasma aldosterone concentrations. Furosemide 18-28 renin Felis catus 77-82 27338786-9 2016 Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system, evidenced from increased plasma renin activity and plasma aldosterone concentrations. Furosemide 18-28 renin Felis catus 147-152 26911852-1 2016 Furosemide is a widely used, potent natriuretic drug, which inhibits the Na(+)-K(+)-2Cl(-) cotransporter (NKCC)-2 in the ascending limb of the loop of Henle applied to reduce extracellular fluid volume expansion in heart and kidney disease. Furosemide 0-10 solute carrier family 12 member 1 Homo sapiens 73-113 26550796-10 2016 The alterations in furosemide pharmacokinetics and pharmacodynamics were explained by changes in the expression of renal organic anion transporters 1 and 3, and sodium-potassium-chloride cotransporter-2. Furosemide 19-29 solute carrier family 22 member 6 Rattus norvegicus 115-155 26820767-0 2016 Purification and Characterization of Glucose 6-Phosphate Dehydrogenase, 6-Phosphogluconate Dehydrogenase, and Glutathione Reductase from Rat Heart and Inhibition Effects of Furosemide, Digoxin, and Dopamine on the Enzymes Activities. Furosemide 173-183 glucose-6-phosphate dehydrogenase Rattus norvegicus 37-70 27231243-3 2016 We sought to investigate, in CKD patients not on dialysis, the influence of either hydrochlorothiazide (Hydro) or furosemide (Furo) on circulating parathyroid hormone (PTH) and whether such actions are determined by the effects of these compounds on calcium excretion. Furosemide 114-124 parathyroid hormone Homo sapiens 147-166 26982381-1 2016 OBJECTIVE: Experiments were carried out to investigate whether diuretics (hydrochlorothiazide + furosemide) impact on the effects of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor on glucose metabolism and blood pressure (BP) in metabolic syndrome SHR/NDmcr-cp(+/+) rats (SHRcp). Furosemide 96-106 solute carrier family 5 member 2 Rattus norvegicus 135-175 26982381-1 2016 OBJECTIVE: Experiments were carried out to investigate whether diuretics (hydrochlorothiazide + furosemide) impact on the effects of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor on glucose metabolism and blood pressure (BP) in metabolic syndrome SHR/NDmcr-cp(+/+) rats (SHRcp). Furosemide 96-106 solute carrier family 5 member 2 Rattus norvegicus 177-182 26530829-7 2016 Na(+)-K(+)-Cl(-) co-transporter inhibitors (10 muM bumetanide, 30 muM furosemide) suppressed spontaneous Ca(2+) transients and vasoconstrictions. Furosemide 70-80 latexin Homo sapiens 66-69 27161422-5 2016 RESULTS: Pendrin activity was significantly hampered by 0.1 mM 5-nitro-2-[(3-phenylpropyl)amino]benzoic acid (NPPB), niflumic acid and tenidap, but was resistant to 0.1 mM 4, 4"-diisothiocyano-2, 2"-stilbene-disulfonic acid (DIDS), furosemide and probenecid. Furosemide 232-242 solute carrier family 26 member 4 Homo sapiens 9-16 26384643-5 2016 To estimate the competitive inhibition of tetraiodothyroacetic acid, diclofenac, genistein, ibuprofen, carbamazepine, and furosemide, reported to be competitive or noncompetitive pharmaceuticals for T4 binding to TTR or TBG, their 50% inhibition concentrations (IC50) (or 80% inhibition concentration, IC80) were calculated from the change of T4 responses in sensorgrams obtained with various concentrations of the pharmaceuticals. Furosemide 122-132 transthyretin Homo sapiens 213-216 26384643-5 2016 To estimate the competitive inhibition of tetraiodothyroacetic acid, diclofenac, genistein, ibuprofen, carbamazepine, and furosemide, reported to be competitive or noncompetitive pharmaceuticals for T4 binding to TTR or TBG, their 50% inhibition concentrations (IC50) (or 80% inhibition concentration, IC80) were calculated from the change of T4 responses in sensorgrams obtained with various concentrations of the pharmaceuticals. Furosemide 122-132 serpin family A member 7 Homo sapiens 220-223 26634699-14 2015 CONCLUSIONS: These data suggest that both COX-1 and COX-2 could generate the signal from the MD to the renin secreting cells in cats exposed to furosemide. Furosemide 144-154 cytochrome c oxidase subunit I Felis catus 42-47 25967121-1 2016 The furosemide-sensitive Na(+)-K(+)-2Cl(-)-cotransporter (NKCC2) is crucial for NaCl reabsorption in kidney thick ascending limb (TAL) and drives the urine concentrating mechanism. Furosemide 4-14 solute carrier family 12, member 1 Mus musculus 58-63 26715481-9 2015 IRRs during the first 14 days of treatment were for furosemide IRR 1.74 (95% CI 1.61 to 1.89) and for thiazides IRR 1.41 (1.28 to 1.55); IRR during the first 30 days of treatment with digoxin was 1.18 (1.02 to 1.37). Furosemide 52-62 insulin receptor related receptor Homo sapiens 0-3 26634699-0 2015 Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney. Furosemide 56-66 cytochrome c oxidase subunit II Felis catus 36-41 26634699-14 2015 CONCLUSIONS: These data suggest that both COX-1 and COX-2 could generate the signal from the MD to the renin secreting cells in cats exposed to furosemide. Furosemide 144-154 cytochrome c oxidase subunit II Felis catus 52-57 26634699-14 2015 CONCLUSIONS: These data suggest that both COX-1 and COX-2 could generate the signal from the MD to the renin secreting cells in cats exposed to furosemide. Furosemide 144-154 renin Felis catus 103-108 26344240-5 2015 The negative effect of muscimol on sodium and water intake could also be blocked by pretreatment with losartan microinjected into the CeA in rats given FURO (n=8 rats/group). Furosemide 152-156 carcinoembryonic antigen gene family 4 Rattus norvegicus 134-137 25555706-5 2015 Intense excitation is followed by extracellular K(+) undershoot which is decreased by furosemide, an NKCC1 inhibitor. Furosemide 86-96 solute carrier family 12 member 2 Homo sapiens 101-106 26089029-0 2015 Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system. Furosemide 0-10 renin Homo sapiens 95-100 26089029-2 2015 Parathyroid hormone (PTH) levels are increased shortly after furosemide treatment by an unknown mechanism, and this effect is blunted by the previous administration of a calcimimetic in animal studies. Furosemide 61-71 parathyroid hormone Homo sapiens 0-19 26089029-2 2015 Parathyroid hormone (PTH) levels are increased shortly after furosemide treatment by an unknown mechanism, and this effect is blunted by the previous administration of a calcimimetic in animal studies. Furosemide 61-71 parathyroid hormone Homo sapiens 21-24 26089029-7 2015 Subjects under placebo presented a sharp increase in PTH levels after furosemide injection. Furosemide 70-80 parathyroid hormone Homo sapiens 53-56 26089029-9 2015 No significant changes in electrolytes and urinary excretion were identified that could explain the furosemide-induced increase in PTH levels. Furosemide 100-110 parathyroid hormone Homo sapiens 131-134 26089029-12 2015 In conclusion, our results indicate that furosemide acutely stimulates PTH secretion in the absence of any detectable electrolyte changes in healthy adults. Furosemide 41-51 parathyroid hormone Homo sapiens 71-74 26301821-2 2015 The current study investigates the effect of furosemide on Cs-induced epileptiform activity (Cs-FP) evoked in area CA1 of rat hippocampal slices in the presence of Cs(+) (5mM) and ionotropic glutamatergic and GABAergic receptor antagonists. Furosemide 45-55 carbonic anhydrase 1 Rattus norvegicus 115-118 26301821-10 2015 Based on these results we propose that the anticonvulsant action of furosemide in the Cs(+)-model is exerted through blockade of the neuronal KCC2 and Na(+)-independent Cl(-)/HCO3(-)-exchanger (AE3) leading to stabilization of the activity-induced intracellular acidification in CA1 pyramidal neurons. Furosemide 68-78 solute carrier family 12 member 5 Rattus norvegicus 142-146 26301821-10 2015 Based on these results we propose that the anticonvulsant action of furosemide in the Cs(+)-model is exerted through blockade of the neuronal KCC2 and Na(+)-independent Cl(-)/HCO3(-)-exchanger (AE3) leading to stabilization of the activity-induced intracellular acidification in CA1 pyramidal neurons. Furosemide 68-78 carbonic anhydrase 1 Rattus norvegicus 279-282 26438710-10 2015 This hypothesis was confirmed by a video recording that revealed the administration by the mother of multiple drugs (insulin, glyburide, progesterone, and furosemide) that mimicked most of the features of Rabson-Mendenhall syndrome, including hirsutism and hypoglycemia with coincident, inappropriately normal c-peptide values due to the administration of the insulin secretagogue. Furosemide 155-165 insulin Homo sapiens 310-319 26438710-10 2015 This hypothesis was confirmed by a video recording that revealed the administration by the mother of multiple drugs (insulin, glyburide, progesterone, and furosemide) that mimicked most of the features of Rabson-Mendenhall syndrome, including hirsutism and hypoglycemia with coincident, inappropriately normal c-peptide values due to the administration of the insulin secretagogue. Furosemide 155-165 insulin Homo sapiens 360-367 26500550-13 2015 The potencies with which indomethacin, furosemide, cyclosporine A and cimetidine inhibited OAT2-tv1 are in good agreement with previous studies using this variant, but inconsistent with studies using OAT2 with an unidentified sequence. Furosemide 39-49 solute carrier family 22 member 7 Homo sapiens 91-95 26183401-11 2015 The administration of furosemide significantly increased the phosphorylated NKCC2 signal in wt but not in cGKIalpha-rescue mice. Furosemide 22-32 solute carrier family 12, member 1 Mus musculus 76-81 26035408-10 2015 Pharmacologic inhibition of sodium-potassium-chloride cotransporter by inhaled furosemide improved animal survival in WNK4(D561A/+) mice. Furosemide 79-89 WNK lysine deficient protein kinase 4 Mus musculus 118-122 26183401-0 2015 Regulation of the Na(+)-K(+)-2Cl(-) cotransporter by cGMP/cGMP-dependent protein kinase I after furosemide administration. Furosemide 96-106 protein kinase, cGMP-dependent, type I Mus musculus 58-89 26183401-15 2015 We hypothesize that furosemide administration activated cGKI, leading to NKCC2 phosphorylation and membrane translocation. Furosemide 20-30 protein kinase, cGMP-dependent, type I Mus musculus 56-60 26183401-2 2015 The loop diuretic furosemide is a potent inhibitor of NKCC2. Furosemide 18-28 solute carrier family 12, member 1 Mus musculus 54-59 26183401-15 2015 We hypothesize that furosemide administration activated cGKI, leading to NKCC2 phosphorylation and membrane translocation. Furosemide 20-30 solute carrier family 12, member 1 Mus musculus 73-78 26183401-16 2015 This cGKI-mediated pathway could be a mechanism to compensate for the inhibitory effect of furosemide on NKCC2. Furosemide 91-101 protein kinase, cGMP-dependent, type I Mus musculus 5-9 26183401-16 2015 This cGKI-mediated pathway could be a mechanism to compensate for the inhibitory effect of furosemide on NKCC2. Furosemide 91-101 solute carrier family 12, member 1 Mus musculus 105-110 25168165-3 2015 A mild NKCC2 inhibition was induced using a slow intravenous furosemide infusion. Furosemide 61-71 solute carrier family 12 member 1 Rattus norvegicus 7-12 25986441-7 2015 The inhibition by bumetanide (IC50=26.4 muM) and furosemide (IC50=315.4 muM) resembled the pharmacological fingerprint of the mammalian NKCC1 isoform. Furosemide 49-59 latexin Homo sapiens 72-75 25986441-7 2015 The inhibition by bumetanide (IC50=26.4 muM) and furosemide (IC50=315.4 muM) resembled the pharmacological fingerprint of the mammalian NKCC1 isoform. Furosemide 49-59 solute carrier family 12 member 2 Homo sapiens 136-141 25981193-4 2015 Furosemide was evaluated in vitro, and is a substrate of OAT1 and OAT3, with Km values of 38.9 and 21.5 muM, respectively. Furosemide 0-10 solute carrier family 22 member 6 Homo sapiens 57-61 25981193-4 2015 Furosemide was evaluated in vitro, and is a substrate of OAT1 and OAT3, with Km values of 38.9 and 21.5 muM, respectively. Furosemide 0-10 solute carrier family 22 member 8 Homo sapiens 66-70 25981193-4 2015 Furosemide was evaluated in vitro, and is a substrate of OAT1 and OAT3, with Km values of 38.9 and 21.5 muM, respectively. Furosemide 0-10 latexin Homo sapiens 104-107 25981193-5 2015 Furosemide was also identified as a substrate of BCRP, OATP1B1, and OATP1B3. Furosemide 0-10 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 49-53 25981193-5 2015 Furosemide was also identified as a substrate of BCRP, OATP1B1, and OATP1B3. Furosemide 0-10 solute carrier organic anion transporter family member 1B1 Homo sapiens 55-62 25981193-5 2015 Furosemide was also identified as a substrate of BCRP, OATP1B1, and OATP1B3. Furosemide 0-10 solute carrier organic anion transporter family member 1B3 Homo sapiens 68-75 25981193-6 2015 Furosemide inhibited BCRP (50% inhibition of drug transport: 170 muM), but did not inhibit OATP1B1, OATP1B3, OCT2, MATE1, and MATE2-K at concentrations below 300 muM, and P-gp at concentrations below 2000 muM. Furosemide 0-10 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 21-25 25981193-6 2015 Furosemide inhibited BCRP (50% inhibition of drug transport: 170 muM), but did not inhibit OATP1B1, OATP1B3, OCT2, MATE1, and MATE2-K at concentrations below 300 muM, and P-gp at concentrations below 2000 muM. Furosemide 0-10 latexin Homo sapiens 65-68 25995110-8 2015 These results suggest that the furosemide-induced H+ secretion is a consequence of a drop in intracellular Na+ concentration, increasing the driving force for NHE3. Furosemide 31-41 solute carrier family 9 (sodium/hydrogen exchanger), member 3 Mus musculus 159-163 25995110-9 2015 Intriguingly, in whole animal experiments, furosemide-induced urinary acidification and net acid excretion were markedly reduced by specific NHE3 inhibition. Furosemide 43-53 solute carrier family 9 (sodium/hydrogen exchanger), member 3 Mus musculus 141-145 26114157-3 2015 Both NKCC1 and NKCC2 are inhibited by furosemide and other high-ceiling diuretics widely used for attenuation of extracellular fluid volume. Furosemide 38-48 solute carrier family 12 member 2 Homo sapiens 5-10 26114157-3 2015 Both NKCC1 and NKCC2 are inhibited by furosemide and other high-ceiling diuretics widely used for attenuation of extracellular fluid volume. Furosemide 38-48 solute carrier family 12 member 1 Homo sapiens 15-20 25771846-0 2015 The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs. Furosemide 27-37 renin Canis lupus familiaris 48-53 25993027-7 2015 Renal hypoosmolality induced by furosemide (NKCC2 inhibitor) inhibited Prox1 expression and delayed maturation of the ascending limb of Henle"s loop. Furosemide 32-42 solute carrier family 12, member 1 Mus musculus 44-49 25837675-7 2015 The MAP17-induced sensitivity to bortezomib is dependent on the oxidative status of the cells and the activity of Na(+)-coupled transporters because treatment with antioxidants or the inhibitor furosemide restores the cytoprotective activity induced by bortezomib. Furosemide 194-204 PDZK1 interacting protein 1 Homo sapiens 4-9 26019342-3 2015 However, the widely used KCC2 inhibitor furosemide is nonselective with antiseizure efficacy in slices and in vivo, leading to a conflicting scheme of how KCC2 influences GABAergic control of neuronal synchronization. Furosemide 40-50 solute carrier family 12, member 5 Mus musculus 25-29 26019342-3 2015 However, the widely used KCC2 inhibitor furosemide is nonselective with antiseizure efficacy in slices and in vivo, leading to a conflicting scheme of how KCC2 influences GABAergic control of neuronal synchronization. Furosemide 40-50 solute carrier family 12, member 5 Mus musculus 155-159 25993027-7 2015 Renal hypoosmolality induced by furosemide (NKCC2 inhibitor) inhibited Prox1 expression and delayed maturation of the ascending limb of Henle"s loop. Furosemide 32-42 prospero homeobox 1 Mus musculus 71-76 25715987-11 2015 With furosemide and NHE inhibitor, dimethylamiloride (DMA), increase in tubular flow increased PSF (furosemide+DMA: 2.7 +- 0.5 mmHg, n = 6), and benzamil blocked this (furosemide+DMA+benzamil: -1.1 +- 0.2 mmHg; P < 0.01, n = 6). Furosemide 100-110 solute carrier family 9 member C1 Homo sapiens 20-23 25715987-3 2015 Furosemide inhibits NKCC2 and TGF. Furosemide 0-10 solute carrier family 12 member 1 Homo sapiens 20-25 25627679-7 2015 Plasma renin activity also increased appropriately when the patient was upright and after furosemide-induced volume depletion. Furosemide 90-100 renin Homo sapiens 7-12 25715987-11 2015 With furosemide and NHE inhibitor, dimethylamiloride (DMA), increase in tubular flow increased PSF (furosemide+DMA: 2.7 +- 0.5 mmHg, n = 6), and benzamil blocked this (furosemide+DMA+benzamil: -1.1 +- 0.2 mmHg; P < 0.01, n = 6). Furosemide 5-15 insulin like growth factor binding protein 7 Homo sapiens 95-98 25715987-11 2015 With furosemide and NHE inhibitor, dimethylamiloride (DMA), increase in tubular flow increased PSF (furosemide+DMA: 2.7 +- 0.5 mmHg, n = 6), and benzamil blocked this (furosemide+DMA+benzamil: -1.1 +- 0.2 mmHg; P < 0.01, n = 6). Furosemide 100-110 solute carrier family 9 member C1 Homo sapiens 20-23 25834041-6 2015 Since NKCC2 is the molecular target of the loop diuretics bumetanide and furosemide, we asked about their effects on HNS function following disturbed water balance. Furosemide 73-83 solute carrier family 12 member 1 Rattus norvegicus 6-11 25644429-2 2015 METHODS: Using solubility, dissolution kinetics, gastrointestinal (GI) parameters and disposition parameters, a PBPK model for furosemide was developed with STELLA software. Furosemide 127-137 developmental pluripotency associated 3 Homo sapiens 157-163 25423287-0 2015 The role of the c-Jun N-terminal kinases 1/2 and receptor-interacting protein kinase 3 in furosemide-induced liver injury. Furosemide 90-100 mitogen-activated protein kinase 8 Mus musculus 16-86 25362991-12 2015 This intracellular alkalization is mediated through an increased apical NHE3 activity, similar to what we previously observed when tubular transport is inhibited with furosemide. Furosemide 167-177 solute carrier family 9 (sodium/hydrogen exchanger), member 3 Mus musculus 72-76 25653502-4 2015 The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3). Furosemide 179-189 solute carrier family 22 member 8 Homo sapiens 44-48 25653502-4 2015 The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3). Furosemide 179-189 solute carrier organic anion transporter family member 1B1 Homo sapiens 50-57 25653502-4 2015 The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3). Furosemide 179-189 solute carrier organic anion transporter family member 1B3 Homo sapiens 63-70 25653502-4 2015 The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3). Furosemide 179-189 solute carrier family 22 member 8 Homo sapiens 211-215 25653502-4 2015 The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3). Furosemide 179-189 solute carrier organic anion transporter family member 1B1 Homo sapiens 267-274 25653502-4 2015 The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3). Furosemide 179-189 solute carrier organic anion transporter family member 1B3 Homo sapiens 279-286 26411965-5 2015 The selective inhibitors of NKCC1 including bumetanide and furosemide are conventionally employed as diuretics. Furosemide 59-69 solute carrier family 12 member 2 Homo sapiens 28-33 24813929-0 2014 Nrf2 protects against furosemide-induced hepatotoxicity. Furosemide 22-32 nuclear factor, erythroid derived 2, like 2 Mus musculus 0-4 25710042-9 2015 However, OAT2-dependent uptake of cGMP was inhibited by furosemide. Furosemide 56-66 solute carrier organic anion transporter family, member 1a4 Rattus norvegicus 9-13 25710042-10 2015 The strongly decreased expression of Oat2 and other transporters in female diabetic ZSF1 rats could possibly impair renal drug excretion, for example, of furosemide. Furosemide 154-164 solute carrier organic anion transporter family, member 1a4 Rattus norvegicus 37-41 25598374-0 2014 [The spiral ganglion degeneration and the expression of EFR3A in the cochlea of the deaf mice induced by co-administration of kanamycin and furosemide]. Furosemide 140-150 EFR3 homolog A Mus musculus 56-61 25598374-1 2014 OBJECTIVE: To investigate the spiral ganglion degeneration and the expression of EFR3A in the cochlea of the deaf mice induced by co-administration of kanamycin and furosemide. Furosemide 165-175 EFR3 homolog A Mus musculus 81-86 24813929-6 2014 The two genotypes of over-expressed Nrf2 mice had increased expression of the Nrf2 target genes Gclm, Gclc and Nqo1 prior to furosemide administration, and the expressions of these genes were increased further after furosemide administration. Furosemide 125-135 nuclear factor, erythroid derived 2, like 2 Mus musculus 36-40 24813929-6 2014 The two genotypes of over-expressed Nrf2 mice had increased expression of the Nrf2 target genes Gclm, Gclc and Nqo1 prior to furosemide administration, and the expressions of these genes were increased further after furosemide administration. Furosemide 125-135 nuclear factor, erythroid derived 2, like 2 Mus musculus 78-82 24813929-6 2014 The two genotypes of over-expressed Nrf2 mice had increased expression of the Nrf2 target genes Gclm, Gclc and Nqo1 prior to furosemide administration, and the expressions of these genes were increased further after furosemide administration. Furosemide 125-135 glutamate-cysteine ligase, modifier subunit Mus musculus 96-100 24813929-6 2014 The two genotypes of over-expressed Nrf2 mice had increased expression of the Nrf2 target genes Gclm, Gclc and Nqo1 prior to furosemide administration, and the expressions of these genes were increased further after furosemide administration. Furosemide 216-226 nuclear factor, erythroid derived 2, like 2 Mus musculus 36-40 24813929-7 2014 Thus, our findings provide strong evidence that over-expression of Nrf2 in Keap1-KD and Keap1-HKO mice and the increases in mRNA of a number of genes involved in anti-oxidative stress, anti-inflammation, anti-ER stress and anti-apoptosis protect against furosemide-induced hepatotoxicity. Furosemide 254-264 nuclear factor, erythroid derived 2, like 2 Mus musculus 67-71 24526686-1 2014 The furosemide-sensitive Na(+)-K(+)-2Cl(-) cotransporter (NKCC2) is responsible for urine concentration and helps maintain systemic salt homeostasis. Furosemide 4-14 solute carrier family 12 member 1 Homo sapiens 58-63 24845846-6 2014 A slight increase in GPx and GR activities and GSH level was observed with propranolol and furosemide treatment alone, while the two drugs together caused a significant increase in GPx and GR activities (35% and 42%, respectively) and GSH content (35%) in ACHN cell lysates (p < 0.05). Furosemide 91-101 glutathione-disulfide reductase Homo sapiens 29-31 24845846-6 2014 A slight increase in GPx and GR activities and GSH level was observed with propranolol and furosemide treatment alone, while the two drugs together caused a significant increase in GPx and GR activities (35% and 42%, respectively) and GSH content (35%) in ACHN cell lysates (p < 0.05). Furosemide 91-101 glutathione-disulfide reductase Homo sapiens 189-191 24845404-4 2014 In this study, we found that lipopolysaccharide (LPS), an important component of bacterial endotoxin, when given in combination with kanamycin and furosemide, augmented the inflammatory response to hair cell injury and exacerbated hearing loss and hair cell injury. Furosemide 147-157 toll-like receptor 4 Mus musculus 49-52 24940940-10 2014 In addition, our data suggested the severity of RIFLE classification and pathological injury of glomerular basement membrane was higher in large-dosage furosemide group (>=120 mg/d) than in low-dosage group (<120 mg/d). Furosemide 152-162 leucine rich repeat and sterile alpha motif containing 1 Homo sapiens 48-53 25087413-2 2014 It was shown that the regular annual systematic spa and resort-based treatment with the strict compliance to the proposed balneotherapeutic modality and basal medicamental therapy enhances the effectiveness of rehabilitation of these patients, promotes the steady progress in the clinical and instrumental manifestations of decompensation, optimizes effects of ACE inhibitors and diuretic furosemide, improves exercise tolerance and quality of life. Furosemide 389-399 surfactant protein A2 Homo sapiens 48-51 24498157-7 2014 Furosemide (10(-4) M), an inhibitor of Na(+)-K(+)-2Cl(-) co-transporter, also inhibited the increased ISC response to CQ, whereas another Cl(-) channel inhibitor, CFTR(inh)-172(10(-5) M), had no effect. Furosemide 0-10 CF transmembrane conductance regulator Rattus norvegicus 163-167 24772088-4 2014 Osmotic stress induced time-dependent activation of FAK as evidenced by phosphorylation at Tyr-397, and furosemide reduces FAK Tyr-397 phosphorylation in the rat renal medulla. Furosemide 104-114 protein tyrosine kinase 2 Rattus norvegicus 123-126 23847084-5 2013 Microinjection of brain-derived neurotrophic factor (BDNF) into the NRM inhibited the KCC2 protein level in the NRM, and both BDNF administration and KCC2 inhibition by furosemide mimicked the pain-induced effects on EIPSC and excitability in MOR-expressing neurons. Furosemide 169-179 brain-derived neurotrophic factor Rattus norvegicus 18-51 23986517-10 2013 When furosemide (1.1 mg kg(-1) day(-1)) was coinfused with ANG II, no increase in plasma membrane Na pump activity was observed. Furosemide 5-15 angiotensinogen Rattus norvegicus 59-65 23839288-7 2013 furosemide dose (slow diuretic response, SDR). Furosemide 0-10 caveolae associated protein 2 Homo sapiens 41-44 24117047-8 2014 Consistent with these data, furosemide blocked individual CFTR Cl(-) channels with "very fast" speed and drug-induced blocking events overlapped brief channel closures, whereas piretanide inhibited individual channels with "intermediate" speed and drug-induced blocking events were distinct from channel closures. Furosemide 28-38 CF transmembrane conductance regulator Homo sapiens 58-62 23946287-6 2013 This shift from NKCC2A to NKCC2B during a low-salt diet could be mimicked by furosemide in vivo and in cultured kidney slices. Furosemide 77-87 solute carrier family 12, member 1 Mus musculus 16-21 23847084-5 2013 Microinjection of brain-derived neurotrophic factor (BDNF) into the NRM inhibited the KCC2 protein level in the NRM, and both BDNF administration and KCC2 inhibition by furosemide mimicked the pain-induced effects on EIPSC and excitability in MOR-expressing neurons. Furosemide 169-179 brain-derived neurotrophic factor Rattus norvegicus 53-57 23847084-5 2013 Microinjection of brain-derived neurotrophic factor (BDNF) into the NRM inhibited the KCC2 protein level in the NRM, and both BDNF administration and KCC2 inhibition by furosemide mimicked the pain-induced effects on EIPSC and excitability in MOR-expressing neurons. Furosemide 169-179 brain-derived neurotrophic factor Rattus norvegicus 126-130 23847084-5 2013 Microinjection of brain-derived neurotrophic factor (BDNF) into the NRM inhibited the KCC2 protein level in the NRM, and both BDNF administration and KCC2 inhibition by furosemide mimicked the pain-induced effects on EIPSC and excitability in MOR-expressing neurons. Furosemide 169-179 solute carrier family 12 member 5 Rattus norvegicus 150-154 23847084-6 2013 Furthermore, inhibiting BDNF signaling by NRM infusion of tyrosine receptor kinase B-IgG or blocking KCC2 with furosemide prevented these pain effects in MOR-expressing neurons. Furosemide 111-121 solute carrier family 12 member 5 Rattus norvegicus 101-105 23457060-6 2013 Furthermore, we have found that probenecid, furosemide, and diclofenac inhibit chlorothiazide transport by OAT1 and OAT3, of which the probenecide-mediated inhibition may be of clinical importance. Furosemide 44-54 solute carrier family 22 member 6 Homo sapiens 107-111 25505556-6 2013 Furosemide acyl-glucuronidation was sigmoidal and best fitted to the Hill equation in hUGT1 mice and human liver microsomes, while it was fitted to the substrate inhibition equation in mouse liver microsomes. Furosemide 0-10 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 86-91 25505556-7 2013 Kinetic parameters of furosemide glucuronidation were very similar between hUGT1 mice and human liver microsomes. Furosemide 22-32 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 75-80 25505556-8 2013 The kinetics of S-naproxen acyl-glucuronidation and inhibitory effects of compounds on furosemide glucuronidation in hUGT1 liver microsomes were also slightly, but similar to those in human liver microsomes, rather than in wild-type mice. Furosemide 87-97 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 117-122 23986689-7 2013 Hypertonicity stimulates NKCC1, which, aided by beta-adrenergic stimulation of the Na(+),K(+)-ATPase, causes regulatory volume increase, furosemide-inhibited undershoot in [K(+)]e and perhaps facilitation of the termination of slow neuronal hyperpolarization (sAHP), with behavioral consequences. Furosemide 137-147 solute carrier family 12 member 2 Homo sapiens 25-30 23565710-7 2013 On the other hand, pre-treatment with furosemide (a KCC2 inhibitor) suppressed the enhancing effects of zolpidem on morphine-induced hyperlocomotion. Furosemide 38-48 solute carrier family 12 member 5 Homo sapiens 52-56 23448699-11 2013 Cox model"s multivariate analysis showed that administration of furosemide and doxapram significantly increased the occurrence of severe hypokalaemia with relative risks of 4.9 (95% CI 1.9 to 12.5) and 8.2 (95% CI 3.1 to 21.7), respectively. Furosemide 64-74 cytochrome c oxidase subunit 8A Homo sapiens 0-3 23952288-8 2013 Plasma renin activity and plasma aldosterone were significantly lower after the administration of carperitide than after the administration of furosemide (P < .05, respectively). Furosemide 143-153 renin Canis lupus familiaris 7-12 23457060-6 2013 Furthermore, we have found that probenecid, furosemide, and diclofenac inhibit chlorothiazide transport by OAT1 and OAT3, of which the probenecide-mediated inhibition may be of clinical importance. Furosemide 44-54 solute carrier family 22 member 8 Homo sapiens 116-120 26069797-0 2012 Increased expression of renal TRPM6 compensates for Mg(2+) wasting during furosemide treatment. Furosemide 74-84 transient receptor potential cation channel, subfamily M, member 6 Mus musculus 30-35 23438181-0 2013 Biophysical insight into furosemide binding to human serum albumin: a study to unveil its impaired albumin binding in uremia. Furosemide 25-35 albumin Homo sapiens 53-66 22913624-5 2013 Animals were given a combined treatment of furosemide and a low dose of captopril (furo/cap), comprising a diuretic and an angiotensin-converting enzyme inhibitor, respectively, to elevate endogenous AngII levels in the brain. Furosemide 43-53 angiotensinogen Rattus norvegicus 200-205 23483451-1 2013 OBJECTIVES/HYPOTHESIS: To evaluate the ability of the Ad28.gfap.atoh1 to promote hair cell regeneration and hearing recovery in cochlea injured with kanamycin and furosemide. Furosemide 163-173 atonal bHLH transcription factor 1 Mus musculus 64-69 23483451-16 2013 CONCLUSIONS: Ad28.gfap.atoh1 promotes hair cell regeneration in cochlea ablated with kanamycin and furosemide resulting in moderate hearing recovery. Furosemide 99-109 atonal bHLH transcription factor 1 Mus musculus 23-28 24695967-13 2013 Interestingly, Smad3/4 signaling was reduced by all compounds except furosemide, which even enhanced this profibrotic signaling. Furosemide 69-79 SMAD family member 3 Homo sapiens 15-20 23269645-3 2013 Since furosemide attenuated the increase in TNF levels, we hypothesized that hypertonic NaCl intake increases renal TNF production by a pathway involving the Na(+)-K(+)-2Cl(-) cotransporter (NKCC2). Furosemide 6-16 tumor necrosis factor Mus musculus 44-47 23766851-3 2013 Graded activation of Nrf2 offered a Nrf2-dependent protection against the hepatotoxicity produced by carbon tetrachloride, acetaminophen, microcystin, phalloidin, furosemide, cadmium, and lithocholic acid, as evidenced by serum alanine aminotransferase (ALT) activities and by histopathology. Furosemide 163-173 nuclear factor, erythroid derived 2, like 2 Mus musculus 21-25 23766851-3 2013 Graded activation of Nrf2 offered a Nrf2-dependent protection against the hepatotoxicity produced by carbon tetrachloride, acetaminophen, microcystin, phalloidin, furosemide, cadmium, and lithocholic acid, as evidenced by serum alanine aminotransferase (ALT) activities and by histopathology. Furosemide 163-173 nuclear factor, erythroid derived 2, like 2 Mus musculus 36-40 22997204-7 2012 MEASUREMENTS AND MAIN RESULTS: In the BNP-driven group, furosemide and acetazolamide were given more often and in higher doses than in the control group, resulting in a more negative median (interquartile range) fluid balance during weaning (-2,320 [-4,735, 738] vs. -180 [-2,556, 2,832] ml; P < 0.0001). Furosemide 56-66 natriuretic peptide B Homo sapiens 38-41 26069797-1 2012 BACKGROUND: Furosemide is a loop diuretic, which blocks the Na(+), K(+), 2Cl(-) cotransporter (NKCC2) in the thick ascending limb of Henle (TAL). Furosemide 12-22 solute carrier family 12, member 1 Mus musculus 95-100 26069797-1 2012 BACKGROUND: Furosemide is a loop diuretic, which blocks the Na(+), K(+), 2Cl(-) cotransporter (NKCC2) in the thick ascending limb of Henle (TAL). Furosemide 12-22 talipes Mus musculus 140-143 26069797-13 2012 CONCLUSIONS: During chronic furosemide treatment, enhanced active reabsorption of Mg(2+) via the epithelial channel TRPM6 in DCT compensates for the reduced reabsorption of Mg(2+) in TAL. Furosemide 28-38 transient receptor potential cation channel, subfamily M, member 6 Mus musculus 116-121 26069797-13 2012 CONCLUSIONS: During chronic furosemide treatment, enhanced active reabsorption of Mg(2+) via the epithelial channel TRPM6 in DCT compensates for the reduced reabsorption of Mg(2+) in TAL. Furosemide 28-38 talipes Mus musculus 183-186 22946656-6 2012 Exposure to caspase inhibitors, Fas-antagonistic antibody, DR4 antagonist, and furosemide (a blocker of Bax translocation) effectively abolished ar-turmerone-triggered apoptosis. Furosemide 79-89 BCL2 associated X, apoptosis regulator Homo sapiens 104-107 22846885-4 2012 Results showed that sodium depletion induced by Furo+low-Cap increased taste preference for hypertonic NaCl solution with amplified brain action of ANG II but without peripheral action, while Furosemide combined with a high dose of captopril can partially inhibit the formation of brain ANG II, with parallel decreased effects on salty taste changes. Furosemide 48-53 angiotensinogen Rattus norvegicus 148-154 22846885-4 2012 Results showed that sodium depletion induced by Furo+low-Cap increased taste preference for hypertonic NaCl solution with amplified brain action of ANG II but without peripheral action, while Furosemide combined with a high dose of captopril can partially inhibit the formation of brain ANG II, with parallel decreased effects on salty taste changes. Furosemide 192-202 angiotensinogen Rattus norvegicus 287-293 22846885-5 2012 And the resulting elevating forebrain ANG II may activate a variety of brain areas including SFO, PVN, SON and OVLT in sodium depleted rats injected with Furo+low-Cap, which underlines salty taste function and sodium intake behavioral changes. Furosemide 154-159 angiotensinogen Rattus norvegicus 38-44 22791335-8 2012 Furosemide-sensitive Na(+) reabsorption in cTAL was higher in KS-WNK1-knockout (KO) mice than in wild-type. Furosemide 0-10 WNK lysine deficient protein kinase 1 Mus musculus 65-69 22791338-6 2012 Furosemide, an established stimulus for COX-2 induction, caused enhanced expression of both ANXA1 and COX-2 with maintained colocalization (99%). Furosemide 0-10 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 40-45 22791338-6 2012 Furosemide, an established stimulus for COX-2 induction, caused enhanced expression of both ANXA1 and COX-2 with maintained colocalization (99%). Furosemide 0-10 annexin A1 Rattus norvegicus 92-97 22791338-6 2012 Furosemide, an established stimulus for COX-2 induction, caused enhanced expression of both ANXA1 and COX-2 with maintained colocalization (99%). Furosemide 0-10 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 102-107 22648948-1 2012 The oxidative stress-responsive kinase 1 (OSR1) is activated by WNK (with no K kinases) and in turn stimulates the thiazide-sensitive Na-Cl cotransporter (NCC) and the furosemide-sensitive Na-K-2Cl cotransporter (NKCC), thus contributing to transport and cell volume regulation. Furosemide 168-178 odd-skipped related transcription factor 1 Mus musculus 42-46 22648948-13 2012 Na(+)/H(+) exchanger activity in osr(WT) DCs was increased by the NKCC1 inhibitor furosemide (100 nM) to values similar to those in osr(KI) DCs. Furosemide 82-92 solute carrier family 12, member 2 Mus musculus 66-71 22873416-5 2012 PAL-treatment combines high levels of positive end-expiratory pressure, small volume resuscitation with hyperoncotic albumin, and fluid removal with furosemide (Lasix ) or ultrafiltration. Furosemide 149-159 SHC binding and spindle associated 1 Homo sapiens 0-3 22873416-5 2012 PAL-treatment combines high levels of positive end-expiratory pressure, small volume resuscitation with hyperoncotic albumin, and fluid removal with furosemide (Lasix ) or ultrafiltration. Furosemide 161-166 SHC binding and spindle associated 1 Homo sapiens 0-3 22751371-0 2012 Effect of albumin on diuretic response to furosemide in patients with hypoalbuminemia. Furosemide 42-52 albumin Homo sapiens 10-17 22612805-6 2012 In support of this hypothesis is an accumulation of data from a number of studies suggesting that furosemide and bumetanide mediate antiepileptic effects through their blockade of cell swelling, dependent on their antagonism of the glial Na+-K-2Cl cotransporter (NKCC1). Furosemide 98-108 solute carrier family 12 member 2 Homo sapiens 263-268 22496496-9 2012 CONCLUSION: The IGF-I-mediated and PTH-independent increase in calcitriol synthesis in acromegaly is responsible for both absorptive hypercalciuria and increased fasting plasma calcium linked to enhanced distal tubular calcium reabsorption, as shown by the selectively diminished calciuric response to furosemide. Furosemide 302-312 insulin like growth factor 1 Homo sapiens 16-21 21352352-6 2012 The results clearly demonstrate that FS produced toxic responses in the hepatocytes as evident from increased ALT/AST level, DNA damage, TUNEL positive cells and increased DNA fragmentation in mice in vivo. Furosemide 37-39 glutamic pyruvic transaminase, soluble Mus musculus 110-113 21352352-6 2012 The results clearly demonstrate that FS produced toxic responses in the hepatocytes as evident from increased ALT/AST level, DNA damage, TUNEL positive cells and increased DNA fragmentation in mice in vivo. Furosemide 37-39 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 114-117 22496496-9 2012 CONCLUSION: The IGF-I-mediated and PTH-independent increase in calcitriol synthesis in acromegaly is responsible for both absorptive hypercalciuria and increased fasting plasma calcium linked to enhanced distal tubular calcium reabsorption, as shown by the selectively diminished calciuric response to furosemide. Furosemide 302-312 parathyroid hormone Homo sapiens 35-38 22266263-10 2012 The physicochemical characterization of Furosemide:crospovidone SDs (1:1 and 1:2 w/w, respectively) generated by SAS revealed the presence of the drug amorphously dispersed in the 1:2 w/w sample at 100bar still remaining stable after 6months. Furosemide 40-50 CUP2Q35 Homo sapiens 64-78 22441041-7 2012 We then measured KCC2 activity by monitoring both the rate and relative amount of furosemide-sensitive NH(4)(+) influx through the co-transporter using an intracellular pH-sensitive fluorescent indicator. Furosemide 82-92 solute carrier family 12 member 5 Rattus norvegicus 17-21 22343084-0 2012 Spectroscopic characterization of furosemide binding to human carbonic anhydrase II. Furosemide 34-44 carbonic anhydrase 2 Homo sapiens 62-83 22343084-1 2012 This study reports the interaction between furosemide and human carbonic anhydrase II (hCA II) using fluorescence, UV-vis and circular dichroism (CD) spectroscopy. Furosemide 43-53 carbonic anhydrase 2 Homo sapiens 64-85 22343084-1 2012 This study reports the interaction between furosemide and human carbonic anhydrase II (hCA II) using fluorescence, UV-vis and circular dichroism (CD) spectroscopy. Furosemide 43-53 carbonic anhydrase 2 Homo sapiens 87-93 22343084-3 2012 The binding average distance between furosemide and hCA II was estimated on the basis of the theory of Forster energy transfer. Furosemide 37-47 carbonic anhydrase 2 Homo sapiens 52-58 22343084-5 2012 Chemical modification of hCA II using N-bromosuccinimide indicated decrease of the number of accessible tryptophans in the presence of furosemide. Furosemide 135-145 carbonic anhydrase 2 Homo sapiens 25-31 22203737-8 2012 The PKC inhibitor calphostin C (1 mumol/L) or the PKCalpha/beta inhibitor Go6976 (1 mumol/L) decreased furosemide-sensitive O(2) consumption in both groups, achieving values that did not differ between sham and diabetic. Furosemide 103-113 protein kinase C, alpha Rattus norvegicus 50-58 22133520-7 2012 With regard to brain Fos immunoreactivity, we observed that Furosemide-sodium depletion in the PM-Na group induced a higher number of activated cells in the subfornical organ, ventral subdivision of the paraventricular nucleus and vasopressinergic neurons of the supraoptic nucleus than in the PM-Ctrol animals. Furosemide 60-70 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 21-24 22203737-11 2012 We conclude that NADPH oxidase and PKC (primarily PKCalpha) contribute to an increase in O(2) consumption by the mTAL during type 1 diabetes through effects on the ouabain-sensitive Na(+)-K(+)-ATPase and furosemide-sensitive Na(+)-K(+)-2Cl(-) cotransporter that are primarily responsible for active transport Na(+) reabsorption by this nephron segment. Furosemide 204-214 protein kinase C, alpha Rattus norvegicus 50-58 23235437-1 2012 BACKGROUND: The WNK-dependent STE20/SPS1-related proline/alanine-rich kinase (SPAK) regulates the renal thiazide sensitive NaCl cotransporter (NCC) and the renal furosemide sensitive Na+, K+, 2Cl- cotransporter (NKCC2) and thus participates in the regulation of renal salt excretion, extracellular fluid volume and blood pressure. Furosemide 162-172 serine/threonine kinase 24 Mus musculus 30-35 22081478-2 2012 Eight novel equimolar cocrystals of furosemide were obtained by liquid-assisted grinding with (i) caffeine, (ii) urea, (iii) p-aminobenzoic acid, (iv) acetamide, (v) nicotinamide, (vi) isonicotinamide, (vii) adenine, and (viii) cytosine. Furosemide 36-46 cytochrome c oxidase subunit 8A Homo sapiens 222-226 21863227-9 2012 These differences were abolished by the administration of AM + BF (equivalent to the outflow from the TAL) and AM + BF + FUR (equivalent to the outflow from the proximal tubule), suggesting that the increase in NKCC2 expression was not functional. Furosemide 121-124 solute carrier family 12 member 1 Rattus norvegicus 211-216 22591021-1 2012 We wanted to test the hypothesis that treatment with amiloride or spironolactone reduced ambulatory (ABP) and central blood pressure (CBP) and that tubular transport via ENaCgamma and AQP2 was increased after furosemide treatment. Furosemide 209-219 sodium channel epithelial 1 subunit gamma Homo sapiens 170-179 22591021-1 2012 We wanted to test the hypothesis that treatment with amiloride or spironolactone reduced ambulatory (ABP) and central blood pressure (CBP) and that tubular transport via ENaCgamma and AQP2 was increased after furosemide treatment. Furosemide 209-219 aquaporin 2 Homo sapiens 184-188 22591021-4 2012 The increases in water and sodium absorption via AQP2 and ENaC after furosemide treatment most likely are compensatory phenomena to antagonize water and sodium depletion. Furosemide 69-79 aquaporin 2 Homo sapiens 49-53 22080226-6 2012 A comparable reduction of SBP was observed in rats after MT-189, RT-93 or furosemide administration. Furosemide 74-84 spermine binding protein Rattus norvegicus 26-29 23235437-1 2012 BACKGROUND: The WNK-dependent STE20/SPS1-related proline/alanine-rich kinase (SPAK) regulates the renal thiazide sensitive NaCl cotransporter (NCC) and the renal furosemide sensitive Na+, K+, 2Cl- cotransporter (NKCC2) and thus participates in the regulation of renal salt excretion, extracellular fluid volume and blood pressure. Furosemide 162-172 serine/threonine kinase 39 Mus musculus 78-82 23235437-1 2012 BACKGROUND: The WNK-dependent STE20/SPS1-related proline/alanine-rich kinase (SPAK) regulates the renal thiazide sensitive NaCl cotransporter (NCC) and the renal furosemide sensitive Na+, K+, 2Cl- cotransporter (NKCC2) and thus participates in the regulation of renal salt excretion, extracellular fluid volume and blood pressure. Furosemide 162-172 solute carrier family 12, member 3 Mus musculus 143-146 23235437-1 2012 BACKGROUND: The WNK-dependent STE20/SPS1-related proline/alanine-rich kinase (SPAK) regulates the renal thiazide sensitive NaCl cotransporter (NCC) and the renal furosemide sensitive Na+, K+, 2Cl- cotransporter (NKCC2) and thus participates in the regulation of renal salt excretion, extracellular fluid volume and blood pressure. Furosemide 162-172 solute carrier family 12, member 1 Mus musculus 212-217 22139699-2 2011 The first objective was the evaluation of a possible role of intestinal P-gp in the kinetic absorption of a model drug: furosemide. Furosemide 120-130 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 72-76 23548701-1 2012 BACKGROUND/AIMS: Since furosemide (FS) inhibits active Na(+) reabsorption by medullary thick ascending limb (mTAL) in the renal outer medulla, it may decrease its work during periods of low O2 supply to deep in the renal outer medulla. Furosemide 23-33 talipes Mus musculus 109-113 23548701-1 2012 BACKGROUND/AIMS: Since furosemide (FS) inhibits active Na(+) reabsorption by medullary thick ascending limb (mTAL) in the renal outer medulla, it may decrease its work during periods of low O2 supply to deep in the renal outer medulla. Furosemide 35-37 talipes Mus musculus 109-113 22236570-0 2012 GPR35 is a target of the loop diuretic drugs bumetanide and furosemide. Furosemide 60-70 G protein-coupled receptor 35 Homo sapiens 0-5 22236570-1 2012 We report that the loop diuretic drugs bumetanide and furosemide used in the treatment of hypertension are GPR35 agonists. Furosemide 54-64 G protein-coupled receptor 35 Homo sapiens 107-112 22120095-10 2011 However, furosemide also decreased serum potassium concentration and increased plasma arginine vasopressin concentrations and plasma renin activity. Furosemide 9-19 renin Canis lupus familiaris 133-138 22139699-6 2011 The results indicated that verapamil at various drug concentrations (5-100 mug/mL) significantly decreased the B A (2-3 fold) and increased the A B (1.5-2 fold) permeability of furosemide, which showed that this drug could be a P-gp substrate. Furosemide 181-191 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 232-236 21317676-16 2011 Logistic regression identified cyanosis, coadministration of furosemide, and baseline estimated creatinine clearance as independent risk factors for any degree of angiotensin-converting enzyme inhibitor-associated acute kidney injury (p < .05). Furosemide 61-71 angiotensin I converting enzyme Homo sapiens 163-192 21972418-6 2011 KSP-OSR1(-/-) mice exhibited impaired Na(+) reabsorption in the thick ascending loop on a low-Na(+) diet accompanied by remarkably decreased expression of p-NKCC2 and a blunted response to furosemide, an NKCC2 inhibitor. Furosemide 189-199 odd-skipped related transcription factor 1 Mus musculus 0-8 21938673-4 2011 In addition, changes in HSP70 immunolocalization following the infusion of furosemide were investigated. Furosemide 75-85 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 24-29 21938673-10 2011 However, furosemide infusion resulted in significantly reduced HSP70 immunolocalization in the IMCD and ATL. Furosemide 9-19 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 63-68 21317676-19 2011 The presence of cyanosis and coadministration of furosemide are independent risk factors for acute kidney injury in patients receiving angiotensin-converting enzyme inhibitor. Furosemide 49-59 angiotensin I converting enzyme Homo sapiens 135-164 21553016-5 2011 Moreover, the administration of furosemide in vivo decreased the blood pressure and increased the urine output and natriuresis in MHS rats demonstrating the actual involvement of NKCC2 activity in the pathogenesis of hypertension in this strain of rats. Furosemide 32-42 solute carrier family 12 member 1 Rattus norvegicus 179-184 21733846-4 2011 WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs. Furosemide 151-161 WNK lysine deficient protein kinase 1 Homo sapiens 0-4 21733846-4 2011 WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs. Furosemide 151-161 WNK lysine deficient protein kinase 4 Homo sapiens 9-13 21733846-4 2011 WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs. Furosemide 151-161 serine/threonine kinase 39 Homo sapiens 108-112 21733846-4 2011 WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs. Furosemide 151-161 odd-skipped related transcription factor 1 Homo sapiens 113-117 21733846-4 2011 WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs. Furosemide 151-161 serine/threonine kinase 24 Homo sapiens 118-123 21733846-4 2011 WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs. Furosemide 151-161 solute carrier family 12 member 1 Homo sapiens 172-177 21849545-6 2011 Moreover, furosemide and bumetanide, two inhibitors of sodium-coupled and/or potassium-coupled chloride movement strongly modified the phase shift, suggesting an involvement of two neuronal cotransporters, NKCC1 (Na-K-Cl) and KCC2 (K-Cl) in the genesis of the optical signal. Furosemide 10-20 solute carrier family 12, member 2 Mus musculus 206-211 21849545-6 2011 Moreover, furosemide and bumetanide, two inhibitors of sodium-coupled and/or potassium-coupled chloride movement strongly modified the phase shift, suggesting an involvement of two neuronal cotransporters, NKCC1 (Na-K-Cl) and KCC2 (K-Cl) in the genesis of the optical signal. Furosemide 10-20 solute carrier family 12, member 5 Mus musculus 226-230 21118399-2 2011 Astrocytic swelling also occurs following brain trauma or ischemia, together with an increase in extracellular K(+) ([K(+)](o)), stimulating a bumetanide/furosemide/ethacrynic acid-inhibitable cotransporter, NKCC1, that accumulates Na(+) and K(+) together with 2 Cl(-) and osmotically obliged water. Furosemide 154-164 solute carrier family 12, member 2 Mus musculus 208-213 21414853-9 2011 All 3 patients received intravenous treatment with serum, furosemide and corticoids and in one case with subcutaneous calcitonine as well. Furosemide 58-68 paired box 5 Homo sapiens 0-5 21373963-0 2011 Water flux through human aquaporin 1: inhibition by intracellular furosemide and maximal response with high osmotic gradients. Furosemide 66-76 aquaporin 1 (Colton blood group) Homo sapiens 25-36 21373963-3 2011 In this way, the specific intracellular inhibition of hAQP1 by the diuretic drug furosemide was demonstrated. Furosemide 81-91 aquaporin 1 (Colton blood group) Homo sapiens 54-59 21325280-2 2011 To investigate how these changes are transmitted to the hormone-binding site, we developed a sensitive assay using a synthesized thyroxine fluorophore and solved the crystal structures of reactive loop cleaved TBG together with its complexes with thyroxine, the thyroxine fluorophores, furosemide, and mefenamic acid. Furosemide 286-296 serpin family A member 7 Homo sapiens 210-213 21616283-10 2011 After reinitiation of furosemide, both urinary KIM-1 and NAG concentrations returned to baseline (both p < 0.05), but NGAL values were unaffected. Furosemide 22-32 hepatitis A virus cellular receptor 1 Homo sapiens 47-52 21616283-10 2011 After reinitiation of furosemide, both urinary KIM-1 and NAG concentrations returned to baseline (both p < 0.05), but NGAL values were unaffected. Furosemide 22-32 O-GlcNAcase Homo sapiens 57-60 21893990-2 2011 It is second only to the collecting duct as a source of renal endothelin (ET)-1, which inhibits NaCl reabsorption in the thick ascending limb by reducing NaCl entry into the cell via the furosemide-sensitive Na(+)/K(+)/2 Cl(-) cotransporter. Furosemide 187-197 endothelin 1 Homo sapiens 62-79 21177779-5 2011 Acute furosemide infusion increased urinary ET-1 excretion in anesthetized rats. Furosemide 6-16 endothelin 1 Rattus norvegicus 44-48 21414921-5 2011 Moreover, pretreatment with furosemide, a blocker of Bax translocation to mitochondria, significantly protected rat and mouse oligodendrocytes from AMPA- and kainate-induced damage; in contrast, bongkrekic acid, a blocker of the mitochondrial permeability transition pore, had no effect. Furosemide 28-38 BCL2 associated X, apoptosis regulator Rattus norvegicus 53-56 20810575-7 2010 This study revealed the following characteristics of these disorders: 1) subjects with CLCNKB mutations showed one or more biochemical features of Gitelman syndrome (including hypomagnesemia, hypocalciuria, and fractional chloride excretion insensitivity to thiazide administration); and 2) subjects with KCNJ1 mutations appeared to show normal fractional chloride excretion sensitivity to furosemide and thiazide administration. Furosemide 390-400 chloride voltage-gated channel Kb Homo sapiens 87-93 21112289-7 2010 The furosemide or DIOA (dihydroindenyl-oxy-alkanoic acid)-sensitive water flux was much larger than expected when water passively followed the KCC1-mediated ion flow. Furosemide 4-14 solute carrier family 12 member 4 Homo sapiens 143-147 20146722-9 2010 All NKCC2 isoforms were more efficiently inhibited by bumetanide than by furosemide. Furosemide 73-83 solute carrier family 12 member 1 Homo sapiens 4-9 20810651-9 2010 Furthermore, loop diuretics, such as furosemide and bumetanide, substantially interacted with hNPT4. Furosemide 37-47 solute carrier family 17 member 3 Homo sapiens 94-99 20813865-7 2010 We observed a blunted response to thiazide but normal response to furosemide in SPAK(-/-) mice. Furosemide 66-76 serine/threonine kinase 39 Mus musculus 80-84 20660105-8 2010 Likewise, cinacalcet decreased furosemide-stimulated renin from 30.6 +- 2.3 to 21.3 +- 2.3 ng ANG I ml(-1) h(-1) (P < 0.001). Furosemide 31-41 renin Rattus norvegicus 53-58 19729213-10 2010 Sex, left cardiac work index, stroke index, hemoglobin, renal failure and discharge furosemide and lisinopril doses were associated to BNP only in univariate analysis. Furosemide 84-94 natriuretic peptide B Homo sapiens 135-138 20516068-9 2010 Dose-response curves of wild-type and chimeric KCCs revealed that the LEL contributes to the different sensitivity to loop diuretics; a KCC2 chimera containing the KCC4 LEL displayed an IC(50) of 396.5 mum for furosemide, which was closer to KCC4 (548.8 mum) than to KCC2 (184.4 mum). Furosemide 210-220 solute carrier family 12 member 5 Homo sapiens 136-140 20516068-9 2010 Dose-response curves of wild-type and chimeric KCCs revealed that the LEL contributes to the different sensitivity to loop diuretics; a KCC2 chimera containing the KCC4 LEL displayed an IC(50) of 396.5 mum for furosemide, which was closer to KCC4 (548.8 mum) than to KCC2 (184.4 mum). Furosemide 210-220 solute carrier family 12 member 7 Homo sapiens 164-168 20308015-0 2010 Influence of myristic acid on furosemide binding to bovine serum albumin. Furosemide 30-40 albumin Homo sapiens 59-72 20219947-8 2010 In vivo, osmoresponsiveness of Cln3 was demonstrated by reduction of medullary Cln3 transcript abundance after furosemide administration. Furosemide 111-121 ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease) Mus musculus 31-35 20410470-5 2010 Ussing chamber experiments demonstrated that the NKCC inhibitors (bumetanide and furosemide) were ineffective at blocking the cotransporter under basal conditions, as well as under pharmacologically stimulated Cl(-)-secreting conditions (forskolin and chlorzoxazone application). Furosemide 81-91 solute carrier family 12 member 1 L homeolog Xenopus laevis 49-53 20413337-12 2010 CONCLUSION: Furosemide is physically compatible with bicarbonate solution, heparin, insulin, morphine and nitroglycerin and incompatible with amiodarone, cisatracurium, haloperidol, midazolam and urapidil. Furosemide 12-22 insulin Homo sapiens 84-91 20308015-1 2010 Comparison with furosemide-human serum albumin complex. Furosemide 16-26 albumin Homo sapiens 33-46 20308015-2 2010 Fluorescence studies on furosemide (FUR) binding to bovine serum albumin (BSA) showed the existence of three or four binding sites in the tertiary structure of the protein. Furosemide 24-34 albumin Homo sapiens 59-72 20308015-2 2010 Fluorescence studies on furosemide (FUR) binding to bovine serum albumin (BSA) showed the existence of three or four binding sites in the tertiary structure of the protein. Furosemide 36-39 albumin Homo sapiens 59-72 19919977-0 2009 Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. Furosemide 21-31 renin Ovis aries 54-59 20597365-4 2010 These data for the first time show that furosemide not only decreases sodium reabsorption, but also blocks some componentin molecular mechanism of vasopressin-dependent increase of the osmotic permeability of water. Furosemide 40-50 arginine vasopressin Rattus norvegicus 147-158 20181798-10 2010 Ang II also increased type-1 Ang II receptor-mediated BDNF expression in vivo in furosemide-treated rats. Furosemide 81-91 angiotensinogen Rattus norvegicus 0-6 20181798-10 2010 Ang II also increased type-1 Ang II receptor-mediated BDNF expression in vivo in furosemide-treated rats. Furosemide 81-91 angiotensinogen Homo sapiens 29-35 20181798-10 2010 Ang II also increased type-1 Ang II receptor-mediated BDNF expression in vivo in furosemide-treated rats. Furosemide 81-91 brain-derived neurotrophic factor Rattus norvegicus 54-58 19835936-10 2010 Interestingly, egr-1 mRNA levels were significantly higher only in the furosemide-treated group compared with controls. Furosemide 71-81 early growth response 1 Rattus norvegicus 15-20 19919977-5 2009 Compared with furosemide treatment alone, Ucn2+furosemide produced a further diuresis (P<0.05), natriuresis (P<0.05), and a sustained increase in creatinine excretion (P<0.05) and clearance (P<0.05), without additional potassium elimination. Furosemide 14-24 urocortin-2 Ovis aries 42-46 23960725-3 2010 This study was done due to the great disagreement between what is published in the literature regarding the influence of P-gp on furosemide and at the same time due to the importance of this drug in the treatment of different conditions as described above. Furosemide 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 23960725-5 2010 METHODS: The study utilized the everted intestinal sacs technique to investigate both the effect of the efflux transporter (P-gp) on furosemide absorption and also the effect of the chosen excipients. Furosemide 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 23960725-6 2010 RESULTS: The absorption of furosemide was significantly influenced by the P-gp as confirmed by the everted vis the non-everted sacs together with the verapamil study in which the transport of furosemide was inhibited by verapamil. Furosemide 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 23960725-6 2010 RESULTS: The absorption of furosemide was significantly influenced by the P-gp as confirmed by the everted vis the non-everted sacs together with the verapamil study in which the transport of furosemide was inhibited by verapamil. Furosemide 192-202 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 23960725-8 2010 CONCLUSIONS: P-glycoprotein and some of the used excipients in the formulation play a very important role in the transport of furosemide and other drugs. Furosemide 126-136 ATP binding cassette subfamily B member 1 Homo sapiens 13-27 20035777-1 2010 We investigated if a history of FURO/CAP, a protocol that increases brain angiotensin II (ANG II), sensitizes or enhances sodium intake. Furosemide 32-36 angiotensinogen Homo sapiens 74-88 20035777-1 2010 We investigated if a history of FURO/CAP, a protocol that increases brain angiotensin II (ANG II), sensitizes or enhances sodium intake. Furosemide 32-36 angiotensinogen Homo sapiens 90-96 20035777-10 2010 The results suggest that a history of FURO/CAP enhances stimulated and spontaneous sodium intake, as well as water deprivation-induced sodium appetite, and reinforce the role of ANG II as a peptide that mediates long-term effects on behavior. Furosemide 38-42 angiotensinogen Homo sapiens 178-184 19789943-16 2010 Renal cortical Cox-2 protein expressions due to furosemide and rofecoxib with or without furosemide were similar and significantly increased compared with controls. Furosemide 48-58 cytochrome c oxidase II, mitochondrial Rattus norvegicus 15-20 19789943-16 2010 Renal cortical Cox-2 protein expressions due to furosemide and rofecoxib with or without furosemide were similar and significantly increased compared with controls. Furosemide 89-99 cytochrome c oxidase II, mitochondrial Rattus norvegicus 15-20 19709838-0 2010 Alterations of furosemide binding to serum albumin induced by increased level of fatty acid. Furosemide 15-25 albumin Homo sapiens 43-50 19709838-1 2010 Localization of high and low affinity binding sites of furosemide in human serum albumin (HSA) as well as the influence of myristic acid on the drug binding to the albumin using fluorescence quenching method was investigated. Furosemide 55-65 albumin Homo sapiens 81-88 19709838-4 2010 It was concluded that association of myristic acid in its low affinity binding sites which corresponds to elevated fatty acid level in vivo, significantly decreases albumin affinity towards furosemide. Furosemide 190-200 albumin Homo sapiens 165-172 20234144-10 2010 Compared with the control group, serum creatinine and cystatin C levels and fractional excretion of sodium were significantly increased in the furosemide group for 24-36 h after indomethacin therapy (p < 0.01). Furosemide 143-153 cystatin C Homo sapiens 54-64 19919977-0 2009 Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. Furosemide 21-31 urocortin-2 Ovis aries 0-11 19919977-7 2009 In contrast to the increase in plasma renin activity elicited by furosemide alone, Ucn2 and Ucn2+furosemide markedly reduced plasma renin activity. Furosemide 65-75 renin Ovis aries 38-43 19919977-7 2009 In contrast to the increase in plasma renin activity elicited by furosemide alone, Ucn2 and Ucn2+furosemide markedly reduced plasma renin activity. Furosemide 97-107 renin Ovis aries 132-137 19919977-9 2009 CONCLUSIONS: Ucn2 cotreatment with furosemide enhanced hemodynamic and renal function and diuretic responsiveness (without additional potassium depletion) in experimental heart failure. Furosemide 35-45 urocortin-2 Ovis aries 13-17 19919977-10 2009 Furthermore, Ucn2 reversed furosemide-induced increases in plasma renin activity and induced greater decreases in plasma aldosterone and vasopressin. Furosemide 27-37 urocortin-2 Ovis aries 13-17 19919977-10 2009 Furthermore, Ucn2 reversed furosemide-induced increases in plasma renin activity and induced greater decreases in plasma aldosterone and vasopressin. Furosemide 27-37 renin Ovis aries 66-71 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 55-65 urocortin-2 Ovis aries 133-137 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 55-65 urocortin-2 Ovis aries 133-137 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 55-65 urocortin-2 Ovis aries 133-137 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 55-65 urocortin-2 Ovis aries 133-137 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 55-65 urocortin-2 Ovis aries 133-137 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 119-129 urocortin-2 Ovis aries 46-50 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 119-129 urocortin-2 Ovis aries 46-50 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 119-129 urocortin-2 Ovis aries 46-50 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 119-129 urocortin-2 Ovis aries 46-50 19919977-4 2009 Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Furosemide 119-129 urocortin-2 Ovis aries 46-50 19052532-8 2009 As expected, the expression of TonEBP target genes in the renal medulla also decreased in response to furosemide. Furosemide 102-112 nuclear factor of activated T-cells 5 Rattus norvegicus 31-37 19428648-4 2009 The impairment of LTP maintenance was significantly reversed by picrotoxinin, a specific GABA(A) receptor-chloride channel blocker and furosemide, a K+-Cl- cotransporter 2 (KCC2) blocker, respectively. Furosemide 135-145 solute carrier family 12 member 5 Rattus norvegicus 149-171 19428648-4 2009 The impairment of LTP maintenance was significantly reversed by picrotoxinin, a specific GABA(A) receptor-chloride channel blocker and furosemide, a K+-Cl- cotransporter 2 (KCC2) blocker, respectively. Furosemide 135-145 solute carrier family 12 member 5 Rattus norvegicus 173-177 19340543-7 2009 Furosemide- and low Cl(-)-induced NO generation was completely inhibited by 50 microM 7-nitroindasole (7-NI), a nNOS inhibitor. Furosemide 0-10 nitric oxide synthase 1, neuronal Mus musculus 112-116 19675228-3 2009 Functional analysis indicates that, like mammalian KCCs, C. elegans KCC-2 transports chloride, is activated by hypotonic conditions, and is inhibited by the loop diuretic furosemide. Furosemide 171-181 K+/Cl- Cotransporter Caenorhabditis elegans 68-73 19119014-3 2009 Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM). Furosemide 160-170 carbonic anhydrase 2 Homo sapiens 107-112 19119014-3 2009 Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM). Furosemide 160-170 carbonic anhydrase 2 Homo sapiens 206-211 19119014-5 2009 Examining the four X-ray crystal structures of their CA II adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, trichloromethiazide, and furosemide scaffolds which may be responsible for this important difference of activity. Furosemide 184-194 carbonic anhydrase 2 Homo sapiens 53-58 19007810-11 2009 The Gd3+ action was blocked by furosemide, a blocker of both KCC and Na+-K+-Cl- co-transporter (NKCC), but not bumetanide, a specific blocker of NKCC. Furosemide 31-41 GRDX Homo sapiens 4-7 19075089-2 2009 We analyzed the degree of cross-linking and the expression of the enzyme lysyl oxidase, which regulates cross-linking, in the myocardium of patients with chronic heart failure at baseline and after 8 months of treatment with either torasemide or furosemide in addition to their standard heart failure therapy. Furosemide 246-256 lysyl oxidase Homo sapiens 73-86 19126296-0 2009 Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. Furosemide 90-100 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 11-26 19126296-5 2009 After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2. Furosemide 20-30 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 81-88 19126296-5 2009 After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2. Furosemide 20-30 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 138-145 19126296-5 2009 After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2. Furosemide 107-117 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 81-88 19126296-5 2009 After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2. Furosemide 107-117 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 138-145 19126296-6 2009 CONCLUSIONS: These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug-drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2). Furosemide 83-93 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 131-138 19126296-6 2009 CONCLUSIONS: These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug-drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2). Furosemide 83-93 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 156-162 19126296-6 2009 CONCLUSIONS: These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug-drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2). Furosemide 83-93 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 262-269 18843255-2 2009 Here we found that mRNA expression by the PGE(2)-activated G-protein-coupled receptors, EP3 and EP4 in the renal medulla was decreased by furosemide treatment, a procedure that reduces medullary hypertonicity. Furosemide 138-148 prostaglandin E receptor 3 Homo sapiens 88-91 18843255-2 2009 Here we found that mRNA expression by the PGE(2)-activated G-protein-coupled receptors, EP3 and EP4 in the renal medulla was decreased by furosemide treatment, a procedure that reduces medullary hypertonicity. Furosemide 138-148 prostaglandin E receptor 4 Homo sapiens 96-99 19001187-5 2008 Ang II-dependent hypertension increased furosemide-sensitive oxygen consumption (26.2+/-1.0% versus 36.6+/-1.2% of total oxygen consumption; P<0.01). Furosemide 40-50 angiotensinogen Rattus norvegicus 0-6 18724382-9 2008 CONCLUSIONS AND IMPLICATIONS: These data suggest that inhibition of MRP4-mediated urate efflux by furosemide and thiazide diuretics could have an important function in their hyperuricaemic mechanisms. Furosemide 98-108 ATP binding cassette subfamily C member 4 Homo sapiens 68-72 19001187-11 2008 Unilateral renal infusion of the PKCalpha inhibitor Go6976 reduced furosemide-sensitive oxygen consumption (37.4+/-1.5% versus 25.1+/-1.0% of total oxygen consumption; P<0.01) in hypertensive rats. Furosemide 67-77 protein kinase C, alpha Rattus norvegicus 33-41 18753266-5 2008 Activation of endogenous ANG II production by sodium depletion (10 days low-sodium diet followed by furosemide, 1 mg sc) enhanced NaCl intake in NSE-AT(1A) mice compared with wild types. Furosemide 100-110 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 25-31 18840481-7 2008 The E(Cl)-sustained was blocked by furosemide, a blocker of both KCC2 and NKCC1, but not bumetanide, a blocker of NKCC1. Furosemide 35-45 solute carrier family 12 member 5 Homo sapiens 65-69 18840481-7 2008 The E(Cl)-sustained was blocked by furosemide, a blocker of both KCC2 and NKCC1, but not bumetanide, a blocker of NKCC1. Furosemide 35-45 solute carrier family 12 member 2 Homo sapiens 74-79 18546202-2 2008 The chloride channel inhibitor furosemide prevented the intracellular acidification, the translocation of Bax and the cell death. Furosemide 31-41 BCL2 associated X, apoptosis regulator Homo sapiens 106-109 18216144-3 2008 Previous experiments in Oat1 knockout (-/-) mice revealed an almost complete loss of renal secretion of the prototypic organic anion p-aminohippurate (PAH) and a role of OAT1 in tubular secretion of furosemide (Eraly SA, Vallon V, Vaughn D, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK. Furosemide 199-209 solute carrier family 22 (organic anion transporter), member 6 Mus musculus 24-28 18759624-6 2008 Bumetanide, a furosemide-related diuretic already used to treat volume overload in neonates, is a specific inhibitor of NKCC1 at low doses, can switch the GABA equilibrium potential of immature neurons from depolarizing to hyperpolarizing, and has recently been shown to inhibit epileptic activity in vitro and in vivo in animal models of neonatal seizures. Furosemide 14-24 solute carrier family 12 member 2 Homo sapiens 120-125 18385266-6 2008 Furosemide-induced increments in the fractional excretion rate of Na(+) and K(+) and absolute excretion of Na(+) and K(+) were significantly blunted in Romk(-/-) mice, consistent with a major salt transport defect in the TAL. Furosemide 0-10 potassium inwardly-rectifying channel, subfamily J, member 1 Mus musculus 152-156 18385266-6 2008 Furosemide-induced increments in the fractional excretion rate of Na(+) and K(+) and absolute excretion of Na(+) and K(+) were significantly blunted in Romk(-/-) mice, consistent with a major salt transport defect in the TAL. Furosemide 0-10 talipes Mus musculus 221-224 18216144-3 2008 Previous experiments in Oat1 knockout (-/-) mice revealed an almost complete loss of renal secretion of the prototypic organic anion p-aminohippurate (PAH) and a role of OAT1 in tubular secretion of furosemide (Eraly SA, Vallon V, Vaughn D, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK. Furosemide 199-209 solute carrier family 22 (organic anion transporter), member 6 Mus musculus 170-174 18216144-5 2008 In this study we found that both furosemide and bendroflumethiazide inhibited mOat1- and mOat3-mediated uptake of a labeled tracer in Xenopus oocytes injected with cRNA, consistent with their being substrates for mouse OAT1 and OAT3. Furosemide 33-43 solute carrier family 22 (organic anion transporter), member 6 Mus musculus 78-83 18216144-5 2008 In this study we found that both furosemide and bendroflumethiazide inhibited mOat1- and mOat3-mediated uptake of a labeled tracer in Xenopus oocytes injected with cRNA, consistent with their being substrates for mouse OAT1 and OAT3. Furosemide 33-43 solute carrier family 22 (organic anion transporter), member 8 Mus musculus 89-94 18216144-5 2008 In this study we found that both furosemide and bendroflumethiazide inhibited mOat1- and mOat3-mediated uptake of a labeled tracer in Xenopus oocytes injected with cRNA, consistent with their being substrates for mouse OAT1 and OAT3. Furosemide 33-43 solute carrier family 22 (organic anion transporter), member 6 Mus musculus 219-223 18216144-5 2008 In this study we found that both furosemide and bendroflumethiazide inhibited mOat1- and mOat3-mediated uptake of a labeled tracer in Xenopus oocytes injected with cRNA, consistent with their being substrates for mouse OAT1 and OAT3. Furosemide 33-43 solute carrier family 22 (organic anion transporter), member 8 Mus musculus 228-232 18216144-7 2008 Thus, whereas OAT1 (in contrast to OAT3) is the classic basolateral PAH transporter of the proximal tubule, both OAT1 and OAT3 contribute similarly to normal renal secretion of furosemide and bendroflumethiazide, and a lack of either one is not fully compensated by the other. Furosemide 177-187 solute carrier family 22 (organic anion transporter), member 6 Mus musculus 113-117 18216144-7 2008 Thus, whereas OAT1 (in contrast to OAT3) is the classic basolateral PAH transporter of the proximal tubule, both OAT1 and OAT3 contribute similarly to normal renal secretion of furosemide and bendroflumethiazide, and a lack of either one is not fully compensated by the other. Furosemide 177-187 solute carrier family 22 (organic anion transporter), member 8 Mus musculus 122-126 18179782-13 2008 Furosemide significantly elevated plasma renin activity and aldosterone concentration. Furosemide 0-10 renin Rattus norvegicus 41-46 18059056-0 2008 Interaction of glycyrrhetinic acid, furosemide and hydrochlorothiazide with bovine serum albumin and their displacement interactions: capillary electrophoresis and fluorescence quenching study. Furosemide 36-46 albumin Homo sapiens 83-96 18059056-3 2008 In this work, capillary electrophoresis-frontal analysis (CE-FA) was applied to study the binding of bovine serum albumin with GA and two diuretics: furosemide (FU) and hydrochlorothiazide (HZ). Furosemide 149-159 albumin Homo sapiens 108-121 17728380-8 2007 In A1AR-/-, furosemide did not further impair autoregulation at 5-25 s, but eliminated the third mechanism and enhanced MR. Furosemide 12-22 adenosine A1 receptor Mus musculus 3-7 18081357-6 2008 In the furosemide group, a significant increase in arterial angiotensin-II (AT-II) plasma levels was observed compared with the torasemide group (relative treatment effect over time between groups; p = 0.031). Furosemide 7-17 angiotensinogen Homo sapiens 60-74 18081357-6 2008 In the furosemide group, a significant increase in arterial angiotensin-II (AT-II) plasma levels was observed compared with the torasemide group (relative treatment effect over time between groups; p = 0.031). Furosemide 7-17 angiotensinogen Homo sapiens 76-81 18081357-7 2008 CONCLUSION: Torasemide increased cardiac output (relative treatment effect over the time), whereas treatment with furosemide significantly increased arterial AT-II plasma levels. Furosemide 114-124 angiotensinogen Homo sapiens 158-163 18081357-8 2008 A possible explanation for these findings might be activation of the renin-angiotensin system by furosemide. Furosemide 97-107 renin Homo sapiens 69-74 18081357-9 2008 However, the underlying pathomechanism remains to be established and evidence from an adequately powered trial is needed to determine if furosemide aggravates cardiac function by increasing AT-II plasma levels. Furosemide 137-147 angiotensinogen Homo sapiens 190-195 17719021-5 2007 cDNA-expressed and reconstituted Oat3 transported both GSH and p-aminohippurate (PAH) in exchange for 2-oxoglutarate (2-OG) and 2-OG and PAH in exchange for GSH, and PAH uptake was inhibited by both probenecid and furosemide, consistent with function of Oat3. Furosemide 214-224 solute carrier family 22 member 8 Rattus norvegicus 33-37 18078705-6 2008 Each compound elicited significant serum ALT increases after 24h (ALT U/L: APAP, 3036+/-1462; BB, 5308+/-2210; CCl4, 5089+/-1665; FS, 2301+/-1053), accompanied by centrilobular damage as assessed by histopathology. Furosemide 130-132 glutamic pyruvic transaminase, soluble Mus musculus 41-44 18078705-15 2008 In summary, we have demonstrated that the hepatotoxins BB, CCl4 and FS can induce a small but significant increase in Nrf2 accumulation in hepatic nuclei. Furosemide 68-70 nuclear factor, erythroid derived 2, like 2 Mus musculus 118-122 18178800-3 2008 To answer this question, CCD from furosemide-treated mice were perfused in vitro, and the subcellular distributions of pendrin and the H(+)-ATPase were quantified using immunogold cytochemistry and morphometric analysis. Furosemide 34-44 solute carrier family 26, member 4 Mus musculus 119-126 18094726-4 2008 Expression of ClC-K1 is upregulated by dehydration and downregulated by the diuretic furosemide, whereas expression of ClC-K2 is upregulated by furosemide and downregulated by high salt levels. Furosemide 85-95 chloride voltage-gated channel Ka Homo sapiens 14-20 18094726-4 2008 Expression of ClC-K1 is upregulated by dehydration and downregulated by the diuretic furosemide, whereas expression of ClC-K2 is upregulated by furosemide and downregulated by high salt levels. Furosemide 144-154 chloride voltage-gated channel Kb Homo sapiens 119-125 18094240-10 2007 Application of the KCC2 blocker, furosemide, to control neurons mimicked E(GABA) shifts evident in granule cells post-STEP. Furosemide 33-43 solute carrier family 12 member 5 Rattus norvegicus 19-23 17670898-4 2007 Western blot analysis of NKCC2 expression using two different antibodies revealed a band of approximately 160 kDa, and RT-PCR analysis demonstrated the presence of NKCC2 isoforms A and F, which was confirmed by DNA sequencing; transport of Cl(-) into raTAL cells was inhibited by furosemide. Furosemide 280-290 solute carrier family 12 member 1 Rattus norvegicus 164-169 17652376-6 2007 Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6). Furosemide 47-57 transient receptor potential cation channel, subfamily V, member 5 Mus musculus 161-166 17652376-6 2007 Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6). Furosemide 47-57 transient receptor potential cation channel, subfamily V, member 6 Mus musculus 168-173 17652376-6 2007 Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6). Furosemide 47-57 calbindin 1 Mus musculus 179-193 17652376-6 2007 Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6). Furosemide 47-57 transient receptor potential cation channel, subfamily V, member 5 Mus musculus 246-251 17652376-6 2007 Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6). Furosemide 47-57 transient receptor potential cation channel, subfamily V, member 6 Mus musculus 256-261 17652376-7 2007 Chronic furosemide administration induced three- to fourfold increases in urinary calcium excretion and elevated mRNA levels of TRPV5, TRPV6, calbindin-D28k, and calbindin-D9k without or with salt supplement. Furosemide 8-18 transient receptor potential cation channel, subfamily V, member 5 Mus musculus 128-133 17652376-7 2007 Chronic furosemide administration induced three- to fourfold increases in urinary calcium excretion and elevated mRNA levels of TRPV5, TRPV6, calbindin-D28k, and calbindin-D9k without or with salt supplement. Furosemide 8-18 transient receptor potential cation channel, subfamily V, member 6 Mus musculus 135-140 17652376-7 2007 Chronic furosemide administration induced three- to fourfold increases in urinary calcium excretion and elevated mRNA levels of TRPV5, TRPV6, calbindin-D28k, and calbindin-D9k without or with salt supplement. Furosemide 8-18 calbindin 1 Mus musculus 142-156 17652376-7 2007 Chronic furosemide administration induced three- to fourfold increases in urinary calcium excretion and elevated mRNA levels of TRPV5, TRPV6, calbindin-D28k, and calbindin-D9k without or with salt supplement. Furosemide 8-18 S100 calcium binding protein G Mus musculus 162-175 17596413-7 2007 Interruption of the Cl(-) extrusion by [(dihydroindenyl)oxy] alkanoic acid or furosemide gradually shifted E(GABA) in positive direction with increasing maturity, suggesting that KCC2 could be involved in maintaining low [Cl(-)]i after the postnatal day 7 thereby providing the hyperpolarizing Cl(-)-mediated inhibition in SBC. Furosemide 78-88 solute carrier family 12 member 5 Homo sapiens 179-183 17804801-7 2007 NaCl supplementation of Pvalb(-/-) mice increased calciuria at baseline and after furosemide. Furosemide 82-92 parvalbumin Mus musculus 24-29 17494095-2 2007 In isolated perfused afferent arterioles preconstricted with angiotensin II or N(G)-nitro-L-arginine methyl ester, furosemide caused a dose-dependent increase of vascular diameter, but it was without effect in vessels from NKCC1-/- mice suggesting that inhibition of NKCC1 mediates dilatation in afferent arterioles. Furosemide 115-125 solute carrier family 12, member 2 Mus musculus 223-228 17556636-3 2007 To define the nature of the toxic metabolite, we examined the relationship between furosemide metabolism in CD-1 mice and Wistar rats. Furosemide 83-93 CD1 antigen complex Mus musculus 108-112 17703139-9 2007 At 24 hours postdose, plasma renin activity was increased after furosemide or HCTZ administered alone or with tolvaptan, but it was unchanged after tolvaptan alone. Furosemide 64-74 renin Homo sapiens 29-34 17555702-10 2007 Km of 14C-tetraethylammonium and 3H-estrone-3-sulfate uptake and hOAT3 inhibition by ibuprofen and furosemide were similar to conventional dish uptake studies. Furosemide 99-109 solute carrier family 22 member 8 Homo sapiens 65-70 17494095-2 2007 In isolated perfused afferent arterioles preconstricted with angiotensin II or N(G)-nitro-L-arginine methyl ester, furosemide caused a dose-dependent increase of vascular diameter, but it was without effect in vessels from NKCC1-/- mice suggesting that inhibition of NKCC1 mediates dilatation in afferent arterioles. Furosemide 115-125 solute carrier family 12, member 2 Mus musculus 267-272 17494095-5 2007 Similarly, NKCC1-/- mice responded to furosemide with a 45.4% decrease of RBF and a 29% decrease of SBF. Furosemide 38-48 solute carrier family 12, member 2 Mus musculus 11-16 17584643-0 2007 [Effects of furosemide, antisterone and hydrochlorothiazide on expression of kidney aquaporin-2 gene and urine aquaporin-2 excretion in rats]. Furosemide 12-22 aquaporin 2 Rattus norvegicus 84-95 17587708-2 2007 METHODS AND RESULTS: The first protocol was to examine if an infusion of human ANP (carperitide) changed serum levels of TRX (thioredoxin) during the treatment of patients with heart failure compared with conventional therapy using furosemide. Furosemide 232-242 natriuretic peptide A Homo sapiens 79-82 17587708-4 2007 In Protocol 1, 8 patients were treated with only an intravenous bolus of furosemide and 11 patients with only an intravenous infusion of carperitide for 24 h. Serum TRX levels significantly decreased at 4 h (p<0.03) and at 24 h (p<0.05) in the carperitide group, whereas they decreased slightly but were not significantly different in the furosemide group. Furosemide 345-355 thioredoxin Homo sapiens 165-168 17515456-7 2007 Acute stimulation of renin release by furosemide, quinaprilat, captopril, or candesartan caused significant increases of plasma renin concentration in both beta1/beta2ADR(-/-) and WT mice, but again the absolute changes were greater in WT mice. Furosemide 38-48 hemoglobin, beta adult major chain Mus musculus 156-161 17584643-1 2007 OBJECTIVE: To investigate effects of the furosemide, antisterone and hydrochlorothiazide on expression of kidney aquaporin-2 (AQP(2)) gene and urine aquaporin-2 excretion in rats. Furosemide 41-51 aquaporin 2 Rattus norvegicus 113-124 17584643-1 2007 OBJECTIVE: To investigate effects of the furosemide, antisterone and hydrochlorothiazide on expression of kidney aquaporin-2 (AQP(2)) gene and urine aquaporin-2 excretion in rats. Furosemide 41-51 aquaporin 2 Rattus norvegicus 126-132 17584643-9 2007 The kidney inner medullary AQP(2) mRNA, V(2)-R mRNA and AQP(2) protein expression of furosemide group increased in comparison with that of the control group (Plt;0.05). Furosemide 85-95 aquaporin 2 Rattus norvegicus 27-33 17584643-9 2007 The kidney inner medullary AQP(2) mRNA, V(2)-R mRNA and AQP(2) protein expression of furosemide group increased in comparison with that of the control group (Plt;0.05). Furosemide 85-95 aquaporin 2 Rattus norvegicus 56-62 17584643-12 2007 Hydrochlorothiazide reduces kidney AQP(2) mRNA and protein expression, while furosemide increased kidney AQP(2) gene expression. Furosemide 77-87 aquaporin 2 Rattus norvegicus 105-111 17464433-9 2007 The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide. Furosemide 206-216 angiotensin II receptor, type 1a Rattus norvegicus 143-147 19086502-10 2007 Captopril (3, 1, 0.3 microg mL(-1)) and Furosemide (5, 2.5, 1.25 microg mL(-1)) caused a dose dependent inhibition in TNF-alpha compared with control (329 +/- 23, 427 +/- 15, 519 +/- 19 and 343 +/- 19, 430 +/- 14, respectively vs. 562 +/- 24 pg mL(-1) p < 0.05). Furosemide 40-50 tumor necrosis factor Homo sapiens 118-127 19086502-11 2007 Furosemide caused a dose dependent decrease in IL-6 (421 +/- 31, 534 +/- 33 vs. 662 +/- 41 pg mL(-1) p < 0.05). Furosemide 0-10 interleukin 6 Homo sapiens 47-51 17464433-9 2007 The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide. Furosemide 206-216 angiotensin II receptor, type 2 Rattus norvegicus 152-156 17464433-9 2007 The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide. Furosemide 206-216 angiotensin II receptor, type 1a Rattus norvegicus 143-147 17464433-9 2007 The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide. Furosemide 206-216 angiotensin II receptor, type 1a Rattus norvegicus 143-147 17464433-9 2007 The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide. Furosemide 206-216 angiotensin II receptor, type 2 Rattus norvegicus 152-156 17464433-9 2007 The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide. Furosemide 206-216 angiotensin II receptor, type 1a Rattus norvegicus 143-147 17172466-4 2007 Inhibition of Bax translocation using furosemide, as well as Bax gene deletion, afforded significant protection against malonate-induced apoptosis. Furosemide 38-48 BCL2 associated X, apoptosis regulator Homo sapiens 14-17 17077386-5 2007 Thus further experiments employed mice given the high-NaCl diet and furosemide to upregulate renal pendrin expression. Furosemide 68-78 solute carrier family 26, member 4 Mus musculus 99-106 17077386-8 2007 In contrast, in CCDs from furosemide-treated Slc26a4 null mice, Cl(-) secretion and a V(T) of approximately 0 were observed, neither of which changed with angiotensin II application. Furosemide 26-36 solute carrier family 26, member 4 Mus musculus 45-52 17442791-9 2007 The furosemide-induced increase in urinary PGE(2) excretion that was seen in wild-type mice was attenuated in mPGES1-deficient mice. Furosemide 4-14 prostaglandin E synthase Mus musculus 110-116 17442791-10 2007 However, furosemide-associated diuresis was reduced only in male, not female, mPGES1-deficient mice. Furosemide 9-19 prostaglandin E synthase Mus musculus 78-84 17314201-5 2007 hOAT3-mediated sitagliptin uptake was inhibited by probenecid, ibuprofen, furosemide, fenofibric acid, quinapril, indapamide, and cimetidine with IC50 values of 5.6, 3.7, 1.7, 2.2, 6.2, 11, and 79 microM, respectively. Furosemide 74-84 solute carrier family 22 member 8 Homo sapiens 0-5 16954339-7 2007 Urinary K(+) excretion was significantly smaller in TRPV4(-/-) than in TRPV4(+/+) mice when urine production was stimulated by a venous application of furosemide. Furosemide 151-161 transient receptor potential cation channel, subfamily V, member 4 Mus musculus 52-57 16954339-7 2007 Urinary K(+) excretion was significantly smaller in TRPV4(-/-) than in TRPV4(+/+) mice when urine production was stimulated by a venous application of furosemide. Furosemide 151-161 transient receptor potential cation channel, subfamily V, member 4 Mus musculus 71-76 16926446-11 2007 Treatment of neonatal animals with furosemide dramatically reduced expression of TonEBP, AR, and UT-A1. Furosemide 35-45 nuclear factor of activated T cells 5 Mus musculus 81-87 16926446-11 2007 Treatment of neonatal animals with furosemide dramatically reduced expression of TonEBP, AR, and UT-A1. Furosemide 35-45 aldo-keto reductase family 1, member B3 (aldose reductase) Mus musculus 89-91 16926446-11 2007 Treatment of neonatal animals with furosemide dramatically reduced expression of TonEBP, AR, and UT-A1. Furosemide 35-45 solute carrier family 14 (urea transporter), member 2 Mus musculus 97-102 16926446-12 2007 Furosemide also prevented the disappearance of NKCC2-expressing TALs in the papilla. Furosemide 0-10 solute carrier family 12, member 1 Mus musculus 47-52 16926446-13 2007 The sequential expression of NKCC2, TonEBP, and its targets AR and UT-A and the reduced expression TonEBP and its targets in response to furosemide treatment support the hypothesis that local hypertonicity produced by the activity of NKCC2 activates TonEBP during development. Furosemide 137-147 nuclear factor of activated T cells 5 Mus musculus 99-105 16926446-13 2007 The sequential expression of NKCC2, TonEBP, and its targets AR and UT-A and the reduced expression TonEBP and its targets in response to furosemide treatment support the hypothesis that local hypertonicity produced by the activity of NKCC2 activates TonEBP during development. Furosemide 137-147 solute carrier family 12, member 1 Mus musculus 234-239 16926446-13 2007 The sequential expression of NKCC2, TonEBP, and its targets AR and UT-A and the reduced expression TonEBP and its targets in response to furosemide treatment support the hypothesis that local hypertonicity produced by the activity of NKCC2 activates TonEBP during development. Furosemide 137-147 nuclear factor of activated T cells 5 Mus musculus 99-105 17710582-9 2007 IL-10, TNF-alpha, and IL-6 production from preeclamptic placenta and PBMCs were inhibited by diazoxide and furosemide. Furosemide 107-117 interleukin 10 Homo sapiens 0-5 16965835-10 2007 Thus, an overnight infusion of ANG II is sufficient to mimic the robust expression of salt appetite as observed after furosemide and overnight sodium depletion. Furosemide 118-128 angiotensinogen Rattus norvegicus 31-37 17710582-9 2007 IL-10, TNF-alpha, and IL-6 production from preeclamptic placenta and PBMCs were inhibited by diazoxide and furosemide. Furosemide 107-117 tumor necrosis factor Homo sapiens 7-16 17710582-9 2007 IL-10, TNF-alpha, and IL-6 production from preeclamptic placenta and PBMCs were inhibited by diazoxide and furosemide. Furosemide 107-117 interleukin 6 Homo sapiens 22-26 17497460-12 2007 Compared to the I/R group, furosemide significantly (p < 0.01) upregulated the phosphorylation of Akt. Furosemide 27-37 AKT serine/threonine kinase 1 Rattus norvegicus 101-104 17483578-2 2007 Recent evidence suggests that acute furosemide decreases both dopamine uptake and striatal dopamine transporter density and increases enkephalin mRNA levels in the nucleus accumbens (Acb). Furosemide 36-46 proenkephalin Rattus norvegicus 134-144 17483578-8 2007 Additionally, in rats previously primed with furosemide to crave salt in a "need-free" manner, salt intake was augmented in the VTA and reduced in the AcbSh after infusion of [D-Ser(2),Leu(5),Thr(6)]-enkephalin. Furosemide 45-55 proenkephalin Rattus norvegicus 200-210 17135398-0 2007 Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. Furosemide 106-116 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mus musculus 0-41 17135398-2 2007 Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP). Furosemide 66-76 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mus musculus 126-167 17135398-2 2007 Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP). Furosemide 66-76 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mus musculus 169-173 17135398-2 2007 Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP). Furosemide 66-76 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 179-211 17135398-2 2007 Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP). Furosemide 66-76 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 213-217 17135398-4 2007 The functional importance of MRP4 and BCRP in the urinary excretion of HCT and furosemide was investigated using gene knockout mice. Furosemide 79-89 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mus musculus 29-33 17135398-4 2007 The functional importance of MRP4 and BCRP in the urinary excretion of HCT and furosemide was investigated using gene knockout mice. Furosemide 79-89 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 38-42 17135398-7 2007 Our results suggest that Mrp4, together with other unknown transporters, accounts for the luminal efflux of HCT and furosemide from proximal tubular epithelial cells. Furosemide 116-126 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mus musculus 25-29 17052386-1 2006 Furosemide, a blocker of Na(+)/K(+)/2Cl(-) cotransporter (NKCC), is often used as a diuretic to improve edema, ascites, and pleural effusion of patients with cancers. Furosemide 0-10 solute carrier family 12 member 1 Homo sapiens 25-56 17052386-1 2006 Furosemide, a blocker of Na(+)/K(+)/2Cl(-) cotransporter (NKCC), is often used as a diuretic to improve edema, ascites, and pleural effusion of patients with cancers. Furosemide 0-10 solute carrier family 12 member 1 Homo sapiens 58-62 17052386-7 2006 Based on these observations, we indicate that furosemide diminishes cell growth by delaying the G(1)-S phase progression in poorly differentiated gastric adenocarcinoma cells, which show high expression and activity of NKCC, but not in moderately differentiated gastric adenocarcinoma cells with low expression and NKCC activity. Furosemide 46-56 solute carrier family 12 member 1 Homo sapiens 219-223 17052386-7 2006 Based on these observations, we indicate that furosemide diminishes cell growth by delaying the G(1)-S phase progression in poorly differentiated gastric adenocarcinoma cells, which show high expression and activity of NKCC, but not in moderately differentiated gastric adenocarcinoma cells with low expression and NKCC activity. Furosemide 46-56 solute carrier family 12 member 1 Homo sapiens 315-319 16985514-6 2006 This effect of furosemide was abolished with amiloride or benzamil blocking ENaC action. Furosemide 15-25 sodium channel, nonvoltage-gated 1 alpha Mus musculus 76-80 16985514-8 2006 In contrast, in mice with a kidney-specific inactivation of the alpha subunit of ENaC in the CCD and MCD, but not in the CNT, furosemide alone and in combination with hydrochlorothiazide induced normal urinary acidification. Furosemide 126-136 sodium channel, nonvoltage-gated 1 alpha Mus musculus 81-85 16985514-11 2006 Thus, functional expression of ENaC channels in the CNT is sufficient for furosemide-stimulated urinary acidification and identifies the CNT as a major segment in electrogenic urinary acidification. Furosemide 74-84 sodium channel, nonvoltage-gated 1 alpha Mus musculus 31-35 17111813-4 2006 Furosemide and ouabain were applied to block the two channels in Castel mice line which can long-time maintain normal auditory function and then their auditory function was detected by ABR to authenticate the mode of potassium recycling in vivo and the relationship between cochlear potassium recycling and NKCC1(+/-) and alpha2 Na, K-ATPase. Furosemide 0-10 solute carrier family 12, member 2 Mus musculus 307-312 16571595-5 2006 Increasing angiotensin II concentration restored autoregulation and increased renal vascular resistance (RVR) in B60 kidneys; this facilitated autoregulation, and the increase in RVR was abolished by 100 microM furosemide. Furosemide 211-221 angiotensinogen Rattus norvegicus 11-25 17015841-10 2006 Further, the lower renal inner medullary interstitial NaCl concentration that occurs chronically in ClCK1-/- mice and acutely in normal mice given furosemide is associated with lower NTE mRNA and protein. Furosemide 147-157 patatin-like phospholipase domain containing 6 Mus musculus 183-186 16905250-4 2006 Our results showed that inhibition of KCC2 with furosemide, as well as blockade of GABA(A)R with bicuculline, significantly enhanced circuit activity. Furosemide 48-58 solute carrier family 12 member 5 Homo sapiens 38-42 16712968-3 2006 The present studies examined expression of the immediate early gene Fos in the nucleus accumbens (NAc) as a marker of neuronal activation following the induction and expression of furosemide-induced sodium appetite. Furosemide 180-190 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 68-71 16418303-8 2006 Renal clearance studies revealed that IROA normalized the increased natriuretic efficacy of furosemide found in CBL rats. Furosemide 92-102 Cbl proto-oncogene Rattus norvegicus 112-115 16418303-10 2006 Finally, Western blot analyses of outer medullary homogenates showed increased abundance of the furosemide-sensitive Na-K-2Cl (NKCC2) cotransporter. Furosemide 96-106 solute carrier family 12 member 1 Rattus norvegicus 127-132 16609147-5 2006 The loop diuretic furosemide 2-fold diluted and increased approximately 10-fold the volume of distal tubular fluid, while also causing the release of 20% of juxtaglomerular renin content. Furosemide 18-28 renin Homo sapiens 173-178